VIOLIN: Vaccine Investigation and Online Information Network

Human Immunodeficiency Virus

Table of Contents

General Information
Vaccine Related Pathogen Genes
1. HIV complete genome (Other)
2. nef from subtype B (Other)
3. Nef SIV (Other)
4. pol from subtype B (Other)
5. Pol SIV (Other)
6. Polymerase protein (Other)
7. pro (Other)
8. rev MN isolate (Other)
9. vif (Other)
10. vpr (Other)
11. vpu (Other)
12. env (Protective antigen)
13. env (Protective antigen)
14. env (Protective antigen)
15. env (Protective antigen)
16. env (Protective antigen)
17. env (Protective antigen)
18. env (Protective antigen)
19. env (Protective antigen)
20. env (Protective antigen)
21. env (Protective antigen)
22. env (Protective antigen)
23. env (Protective antigen)
24. env (Protective antigen)
25. env (Protective antigen)
26. env from SIV (Protective antigen)
27. Envelope polyprotein from HXB2 (Protective antigen)
28. gag (Protective antigen)
29. gag (Protective antigen)
30. gag (Protective antigen)
31. gag (Protective antigen)
32. Gag from HIV 1 (Protective antigen)
33. gag from HIV-1 vector pNL4-3 (Protective antigen)
34. gag from HXB2 (Protective antigen)
35. Gag protein from SIV-mnd 2 (Protective antigen)
36. gag-pol (Protective antigen)
37. gag-pol SIV (Protective antigen)
38. gp120 (Protective antigen)
39. gp120 (Protective antigen)
40. HIV1 ENV (Protective antigen)
41. Nef (Protective antigen)
42. nef (Protective antigen)
43. pol (Protective antigen)
44. pol (Protective antigen)
45. rev (Protective antigen)
46. rev from HIV 1 (Protective antigen)
47. Tat (Protective antigen)
48. tat (Protective antigen)
49. tat (Protective antigen)
50. vif (Protective antigen)
51. vpr (Protective antigen)
52. vpu (Protective antigen)
Vaccine Related Host Genes
1. ANXI
2. human IFNG
3. IFNG
4. Ifng (Interferon gamma)
5. IFNG from Macaca nemestrina
6. IgA
7. IgA Fc fragment
8. IgG
9. IgG Fc fragment
10. IgG2b
11. Ighg1
12. Ighv1-9
13. IL-6
14. Il12a
15. Il2
16. IL2
17. IL2
18. IL4
19. Il4 (interleukin 4)
20. Il5
21. TNF
22. TNF-a from Papio anubis
23. TNF-alpha
Vaccine Information
References

I. General Information

1. NCBI Taxonomy ID:

12721

2. Disease:

Acquired Immunodeficiency Syndrome (AIDS)

3. Introduction

Human immunodeficiency virus (HIV) is the retrovirus that causes acquired immunodeficiency syndrome (AIDS). Within bodily fluids, HIV is present as both free virus particles and as virus within infected immune cells. So far, AIDS has killed more than 25 million people since it was first recognized in 1981, making it one of the most destructive pandemics in recorded history. Antiretroviral treatment reduces both the mortality and the morbidity of HIV infection, but routine access to antiretroviral medication is not available in all countries. Most HIV-infected individuals develop AIDS and die; however, about 10% remains healthy for many years, with no noticeable symptoms. Treatment with anti-retrovirals increases the life expectancy of people infected with HIV (Palella et al., 1998; Buchbinder et al., 1994).

4. Microbial Pathogenesis

The 3 major routes of HIV transmission are sexual intercourse, contaminated needles, and transmission from an infected mother to her baby at birth, or through breast milk. HIV primarily infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages, and dendritic cells. This decreases CD4+ T cells through direct viral killing of infected cells, increased rates of apoptosis in infected cells, and killing of infected CD4+ T cells by CD8 cytotoxic lymphocytes that recognize infected cells. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity (CMI) is lost, and the body becomes progressively more susceptible to opportunistic infections (Chan et al., 1997).

5. Host Ranges and Animal Models

AIDS has killed more than 25 million people since it was first recognized in 1981. Globally, ~40 million people currently live with HIV. Sub-Saharan Africa remains by far the worst-affected region. More than 64% of all people living with HIV are in sub-Saharan Africa, as are more than three quarters of all women living with HIV. Two-thirds of HIV/AIDS infections in Asia occur in India, with an estimated 6 million infections, surpassing South Africa's 5.5 million infections, making India the country with the highest number of HIV infections in the world (Palella et al., 1998).

6. Host Protective Immunity

HIV can infect a variety of immune cells such as CD4+ T cells, macrophages, and microglial cells. HIV-1 entry to macrophages and T cells is mediated through interaction of the virion envelope glycoproteins (gp120) with the CD4 molecule on target cells and also with chemokine coreceptors. Macrophages play a key role in several critical aspects of HIV infection. They appear to be the first cells infected by HIV and perhaps the source of HIV production when CD4+ cells become depleted in the patient. T-tropic isolates, or syncitia-inducing (SI) strains replicate in primary CD4+ T cells as well as in macrophages. Dual-tropic HIV-1 strains are thought to be transitional strains of the HIV-1 virus. HIV can also infect a subtype of myeloid dendritic cells, which probably constitute a reservoir that maintains infection when CD4+ T cell numbers have declined to extremely low levels (Chan et al., 1997; Coakley et al., 2005; Deng et al., 1996; Knight et al., 1990).

II. Vaccine Related Pathogen Genes

1. env

Gene Name : env
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
VO ID : VO_0010937
NCBI Protein GI : 8218033
Other Database IDs : CDD:278917
CDD:295533
CDD:197369
GOA:Q9IBN3
HSSP: 1MEQ
InterPro: IPR000328
InterPro: IPR000777
UniProtKB/TrEMBL: Q9IBN3
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein Name : ENV (gp160)
Protein pI : 8.84
Protein Weight : 92355.68
Protein Length : 920
Protein Note : HIV-1 GB8 isolated into the cell line JM and the provirus clone was derived by PCR off extracted high molecular weight DNA

DNA Sequence : Show Sequence

>gi|8218025:6237-8786 Human immunodeficiency virus type 1 proviral genome, isolate GB8, clone 46R
ATGAAAGCGAAGGGGACCAGGAAGAATTATCAGCACTTGTGGAAATGGGGCATCATGCTCCTTGGGATGT
TGATGATCTGTAGTGCTACAGAAAAATTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAAGAAGC
AACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGACACAGAAAAACATAATGTTTGGGCCACA
CATGCCTGTGTACCCACAGACCCCAACCCACAAGAGGTAGTATTGGGAAATGTGACAGAAAATTTTAACA
TGTGGAAAAATAACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCC
ATGTGTAAAATTAACCCCACTCTGTGTTACTTTAAATTGCACTGATTTGAGGAATGATACTAATACCGAT
AATAGTATAATGGAGGGAGGAGAAATGAAAAACTGCTCTTTCAATATCACCACAAGCATAAGGGATAAGA
TGCAGAAAGAATATGCACTTTTGTATAAACTTGATATAGTATCAATAGGTAGTGATAATACTAGCTATAT
ATTGACAAAGTGTGACGCCTCAGTCATTACACAGGCCTGTCCAAAGATATCCTTTGAGCCAATTCCCATA
CATTTTTGTGCCCCGGCTGGTTTTGCGATTCTAAAGTGTAACAATAAGACATTCGATGGAAAAGGACCAT
GTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTGTCAACTCAACTGCTGTTAAA
TGGCAGTCTAGCAGAAGAAAAGGTAGTAATTAGATCTGACAATTTCATGGACAATACTAAAACCATAATA
GTACAGCTGAAAGAAGCTGTAGAAATTAATTGTACAAGACCCAACAACAATACAAGAAAAGGTATATACA
TAGGACCAGGGAGAAGATTTTATACAACAGGAAGAATAATAGGAGATATAAGACAAGCACATTGTAACAT
TAGTAAAGAAAAATGGAATAATACTTTACACCAGATAGTTATAGAATTGAGGAAACAATTTAGGAATAAA
ACAATAGTCTTTAATCAATCCTCAGGAGGGGACCCAGAAATTGTAATGCACAGTTTTAATTGTGGAGGGG
AATTTTTCTACTGTAAGACAGCACAACTGTTTAATAGTACTTGGAATAGTACTGGAAATGGTACTATAAA
GTCAAATACCACTGAAATTATCACACTCCCATGTAGAATAAAACAAATTGTAAACATGTGGCAGGAAGTA
GGAAAAGCAATGTATGCCCCTCCCATCACAGGACAAATTAGATGTGCATCACATATTACAGGGCTACTAT
TAACAAGAGATGGAGGTAGGGAGAACAATACCAACGAGACCGAGACCTTCAGACCTGGAGGAGGAGATAT
GAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCC
ACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATGATAGGAGCTATGTTCCTTG
GGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCACTGACGCTGACGGTACAGGCCAGACTATT
ATTGTCTGGTATAGTGCAACAGCAAAATAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCGA
CTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAGTCCTGGCTGTGGAAAGATACCTAAAGGATCAAC
AGCTCCTAGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTACTGTGCCTTGGAATGTTAGTTG
GAGTAATAAATCTCTGGATAAGATTTGGAATAACATGACCTGGATGGAGTGGGAAAGAGAAATTGACAAT
TACACAAACACAATATACACCTTAATTGAAGAATCGCAGAACCAACAAGAAAAGAATGAACAAGAATTAT
TGGAATTGGATAAGTGGGCAAATTTGTGGAATTGGTTTGACATAACAAACTGGCTGTGGTATATAAAAAT
ATTCATAATGATAATAGGAGGCTTAATAGGTTTAAGAATAATTTTTGCTGTAATTTCTATAGTGAATAGA
GTTAGGCGGGGATACTCACCATTATCATTGCAGACCCACCTCCCAACCCCAAGGGGACCCGACAGGCCCG
AAGGAATCGAAGAAGAAGGTGGAGAGCAAGACAGAGACAGATCCATCAGATTGGTGAATGGATTCTTAGC
GCTTTTCTGGGACGACCTGCGGAGCCTGTGCCTCTTCAGCTACCACCGATTGAGAGACTTACTCTTGATT
GTGACGAGGATTGTGGGACTTCTGGGACGCAGGGGGTGGGAAGCCCTCAAGTATTGGTGGAATCTCCTGC
AGTATTGGATCCAGGAACTAAAGAATAGTGCTATTAGCTTGCTTAATACCACAGCTATAGCAGTAGCTGA
GGGGACAGATAGGGTTATAGAAGTAGTACAAAGAGCTTATAGAGCTATTCTCCACATACCTACAAGAATA
AGACAGGGCTTAGAAAGGGCTTTGCAATAA

Protein Sequence : Show Sequence

>CAB92793.1 ENV (gp160) [Human immunodeficiency virus 1]
MKAKGTRKNYQHLWKWGIMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEKHNVWAT
HACVPTDPNPQEVVLGNVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNCTDLRNDTNTD
NSIMEGGEMKNCSFNITTSIRDKMQKEYALLYKLDIVSIGSDNTSYILTKCDASVITQACPKISFEPIPI
HFCAPAGFAILKCNNKTFDGKGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEKVVIRSDNFMDNTKTII
VQLKEAVEINCTRPNNNTRKGIYIGPGRRFYTTGRIIGDIRQAHCNISKEKWNNTLHQIVIELRKQFRNK
TIVFNQSSGGDPEIVMHSFNCGGEFFYCKTAQLFNSTWNSTGNGTIKSNTTEIITLPCRIKQIVNMWQEV
GKAMYAPPITGQIRCASHITGLLLTRDGGRENNTNETETFRPGGGDMRDNWRSELYKYKVVKIEPLGVAP
TKAKRRVVQREKRAVGMIGAMFLGFLGAAGSTMGAASLTLTVQARLLLSGIVQQQNNLLRAIEAQQHLLR
LTVWGIKQLQARVLAVERYLKDQQLLGIWGCSGKLICTTTVPWNVSWSNKSLDKIWNNMTWMEWEREIDN
YTNTIYTLIEESQNQQEKNEQELLELDKWANLWNWFDITNWLWYIKIFIMIIGGLIGLRIIFAVISIVNR
VRRGYSPLSLQTHLPTPRGPDRPEGIEEEGGEQDRDRSIRLVNGFLALFWDDLRSLCLFSYHRLRDLLLI
VTRIVGLLGRRGWEALKYWWNLLQYWIQELKNSAISLLNTTAIAVAEGTDRVIEVVQRAYRAILHIPTRI
RQGLERALQ

Molecule Role : Protective antigen
Related Vaccine(s): DNA vaccine expressing multiple HIV epitopes , HIV priming with DNA vaccine expressing HIV gp160 protein and boosted with Ad5/35 vector expressing the same protein

2. env

Gene Name : env
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
NCBI Gene ID : 155971
NCBI Protein GI : 9629363
Locus Tag : HIV1gp8
Genbank Accession : AF033819
Protein Accession : NP_057856
Taxonomy ID : 11676
Gene Starting Position : 5770
Gene Ending Position : 8340
Gene Strand (Orientation) : +
Protein Name : Envelope surface glycoprotein gp160, precursor
Protein pI : 9.19
Protein Weight : 91753.45
Protein Length : 856

DNA Sequence : Show Sequence

>NC_001802.1:5770-8340 Human immunodeficiency virus 1, complete genome
AATGAGAGTGAAGGAGAAATATCAGCACTTGTGGAGATGGGGGTGGAGATGGGGCACCATGCTCCTTGGG
ATGTTGATGATCTGTAGTGCTACAGAAAAATTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAGG
AAGCAACCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGC
CACACATGCCTGTGTACCCACAGACCCCAACCCACAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTT
AACATGTGGAAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAA
AGCCATGTGTAAAATTAACCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATAC
CAATAGTAGTAGCGGGAGAATGATAATGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCACA
AGCATAAGAGGTAAGGTGCAGAAAGAATATGCATTTTTTTATAAACTTGATATAATACCAATAGATAATG
ATACTACCAGCTATAAGTTGACAAGTTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCCTT
TGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACGTTC
AATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTATCAA
CTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACGGACAA
TGCTAAAACCATAATAGTACAGCTGAACACATCTGTAGAAATTAATTGTACAAGACCCAACAACAATACA
AGAAAAAGAATCCGTATCCAGAGAGGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGAAATATGA
GACAAGCACATTGTAACATTAGTAGAGCAAAATGGAATAACACTTTAAAACAGATAGCTAGCAAATTAAG
AGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAAATTGTAACG
CACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGTACTTGGTTTA
ATAGTACTTGGAGTACTGAAGGGTCAAATAACACTGAAGGAAGTGACACAATCACCCTCCCATGCAGAAT
AAAACAAATTATAAACATGTGGCAGAAAGTAGGAAAAGCAATGTATGCCCCTCCCATCAGTGGACAAATT
AGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAGCAACAATGAGTCCGAGA
TCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAA
AATTGAACCATTAGGAGTAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTG
GGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCCTCAATGACGC
TGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGA
GGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTG
GAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTG
CTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGA
GTGGGACAGAGAAATTAACAATTACACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAA
GAAAAGAATGAACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAA
ATTGGCTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTTGC
TGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTCAGACCCACCTCCCAACC
CCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTC
GATTAGTGAACGGATCCTTGGCACTTATCTGGGACGATCTGCGGAGCCTGTGCCTCTTCAGCTACCACCG
CTTGAGAGACTTACTCTTGATTGTAACGAGGATTGTGGAACTTCTGGGACGCAGGGGGTGGGAAGCCCTC
AAATATTGGTGGAATCTCCTACAGTATTGGAGTCAGGAACTAAAGAATAGTGCTGTTAGCTTGCTCAATG
CCACAGCCATAGCAGTAGCTGAGGGGACAGATAGGGTTATAGAAGTAGTACAAGGAGCTTGTAGAGCTAT
TCGCCACATACCTAGAAGAATAAGACAGGGCTTGGAAAGGATTTTGCTATA

Protein Sequence : Show Sequence

>NP_057856.1 Envelope surface glycoprotein gp160, precursor [Human immunodeficiency virus 1]
MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWA
THACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNT
NSSSGRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSVITQACPKVSF
EPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDN
AKTIIVQLNTSVEINCTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLR
EQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRI
KQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVK
IEPLGVAPTKAKRRVVQREKRAVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQQQNNLLRAIE
AQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNHTTWME
WDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFA
VLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCLFSYHR
LRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAI
RHIPRRIRQGLERILL

Molecule Role : Protective antigen
Related Vaccine(s): ALVAC-HIV-2- env/gag/pol , HIV DNA vaccine Ad26/Ad5HVR48 encoding HIV or SIV env or gag , HIV DNA vaccine pHIS-SHIV-B , HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6) , HIV priming with DNA vaccine expressing HIV gp160 protein and boosted with Ad5/35 vector expressing the same protein , HIV recombinant vector vaccine MVA.HIVA encoding env and rev , NYVAC-HIV-2

3. env

Gene Name : env
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
NCBI Protein GI : 169641099
Other Database IDs : CDD:278917
CDD:295533
CDD:197369
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein Name : envelope glycoprotein
Protein pI : 8.37
Protein Weight : 86073.29
Protein Length : 888
Protein Note : subtype: C

Protein Sequence : Show Sequence

>ACA61283.1 envelope glycoprotein, partial [Human immunodeficiency virus 1]
VPVWKEAKTTLFCASDAKAYETEVHNVWATHACVPTDPNPQEMLMGNVTKNFNMWKNDMVEQMHEDVISL
WDQSLKPCVKLTPLCVTLECREVNSTNRNVTVDAKEEIKNCSFNATTEIRDKQKKVHALFYKLDIVPLDN
KTSSNHTNYRLINCNTSAITQACPKINFDPIPIHYCAPAGFAILKCNNDTFNGTGPCTNVSTVQCTHGIK
PVVSTQLLLNGSLAEKEIIIRSANLTDNAKTIIVHLNQSVEIVCTRPNNNTRDSIRIGPGQTFYATGDII
GDIRQAHCNISEAAWNKTLYEVSKKLEEHYNKTIKFNASSGGDLEITTHSFNCRGEFFYCNTSKLFNGTY
MNMNGTNSSSDSIITIPCRIKQFINMWQEVGRAMYAPPIAGNITCKSNITGLLLVRDGGPGNGTNNTETF
RPGGGDMRDNWRSELYKYKVVEIKPLGVAPTEAKRRVVERQKRAVGLGAMFLGFLGAAGSTMGAASMTLT
VQARQLLSGIVQQQSNLLRAIEAQQHLLQLTVWGIKQLQARVLAIERYLREQQLLGLWGCSEKLICPTTV
PWNDSWSNKSLDIIWGNMTWMEWDKEISNYTQTIFNLLEDSQIQQEKNEKDLLELDSWKNLWNWFNISNW
LWYIKIFIMIVGGLIGLRIIFAVLSVVNRVRQGYSPLSFQTLTPHPREPDRLRGIEEEGGEQDKGRSIRL
VNGFLALAWDDLRSLCLFLYHRLRDFISVTARAVDILGRRGWEALKYLKSIVQYWLLELKKSAISLLDTI
AIAVAEGTDRIIELIQRVFRAIINRPTRI

Molecule Role : Protective antigen

4. env

Gene Name : env
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1 MN
NCBI Protein GI : 3342812
Other Database IDs : CDD:278917
CDD:295533
CDD:197369
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein Name : envelope glycoprotein
Protein pI : 8.75
Protein Weight : 92117.65
Protein Length : 938
Protein Note : MN neutralization phenotype variant clone

Protein Sequence : Show Sequence

>AAC31819.1 envelope glycoprotein [Human immunodeficiency virus 1]
MRVKGIRRNYQHWWGWGTMLLGLLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEAHNVWAT
HACVPTDPNPQEVELVNVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNCTDLRNTTNTN
NSTDNNNSNSEGTIKGGEMKNCSFNITTSIGDKVQKEYALLYKLDIESIDNDSTSYRLISCNTSVITQAC
PKISFEPIPIHYCAPAGFAILKCNDKKFSGKGSCKNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSE
DFTDNAKTIIVHLKESVQINCTRPNYNKRKRIHIGPGRAFYTTKNIKGTIRQAHCIISRAKWNDTLRQIV
SKLKEQFKNKTIVFNPSSGGDPEIVMHSFNCGGEFFYCNTSPLFNSTWNGNNTWNNTTGSNNNITLQCKI
KQIINMWQKVGKAMYAPPIEGQIRCSSNITGLLLTRDGGIDTDTNDTEIFRPGGGDMRDNWRSELYKYKV
VTIEPLGVAPTKAKRRVVQREKRAAIGALFLGFLGAAGSTMGAASVTLTVQARPLLSGIVQQQNNLLRAI
ESQQHMLQLTVWGIKQLQARVLAVERYLKDQQLLGFWGCSGKLICTTTVPWNASWSNKSLDDIWNNMTWM
QWEREIDNYTSLIYSLLEKSQTQQEKNEQELLELDKWASLWNWFDITNWLWYIKIFIMIVGGLVGLRIVF
AVLSIVNRVRQGYSPLSLQTRPPVPRGPDRPEGIEEEGGERDRDTSGRLVHGFLAIIWVDLRSLFLLSYH
HLRDLLLIAARIVELLGRRGWEVLKYWWNLLQYWSQELKSSAVSLLNAAAIAVAEGTDRVIEVLQRAGRA
ILHIPTRIRQGLERALL

Molecule Role : Protective antigen
Related Vaccine(s): HIV DNA vaccine pCMN160

5. env

Gene Name : env
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
NCBI Protein GI : 58043865
Other Database IDs : CDD:278917
CDD:295533
CDD:197369
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein Name : envelope glycoprotein
Protein pI : 7.78
Protein Weight : 91300.9
Protein Length : 933
Protein Note : clone can be used to generate pseudotyed infectious virions that use the CCR5 coreceptor;
subtype: B

Protein Sequence : Show Sequence

>AAW64267.1 envelope glycoprotein [Human immunodeficiency virus 1]
MRVKEIRKNYRHLWKWGIMLLGMLMICSATENLWVTVYYGVPVWKEATTTLFCASDAKGYEKEVHNVWAT
HACVPTDPNPQEVVLENVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNCSDVNTTSVNT
TASSMEGGEIKNCSFNTTTSMSDKMQKEYALFYTLDVVPIVKENNTYRLISCNTSVITQACPKVSFEPIP
IHYCAPAGFAILMCNNKTFDGKGPCNNVSTVQCTHGIKPVVSTQLLLNGSLAEEEVVIRSDNFTDNAKTI
IVHLNESIEITCTRPNNNTSKSITIGPGRAFYATGRIIGDIRKAHCNISGEKWHNALEQIVKKLGEKFEN
ATTIRFNQSSGGDQEIVMHTFNCGGEFFYCNSTQLFNSTWWPNGTTTEWSNETSNGTITLPCRIKQIINM
WQEVGKAMYAPPISGPISCSSNITGLLLVRDGGNDNETNGTETFRPGGGDMRDNWRSELYKYKVVKIEPL
GVAPTKAKRRVVQREKRAVGLGAMFLGFLGAAGSTMGAASITLTVQARLLLSGIVQQQNNLLRAIEAQQH
LLQLTVWGIKQLQARVLAIERYLKDQQLLGIWGCSGKLICTTAVPWNSSWSNKSLKWIWDNMTWMEWEKE
IDNYTGIIYNLLEESQNQQDKNEKELLELDKWASLWTWFDITNWLWYIKIFIMIVGGLVGLRIVFAVLSI
VNRVRQGYSPLSFQTRLPAPRGLDRPEGTEEEGGDRDKDRSIRLVDGFLALIWDDLRSLCLFSYHRLRDL
LLIVARVVEILGHRGWEILKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRIIEVLQRIGRAILHIP
TRIRQGLERALL

Molecule Role : Protective antigen

6. env

Gene Name : env
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
NCBI Protein GI : 1129018
Other Database IDs : CDD:278917
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein Name : envelope glycoprotein gp120
Protein pI : 10.41
Protein Weight : 10151.67
Protein Length : 175
Protein Note : Envelope glycoprotein GP120; pfam00516

Protein Sequence : Show Sequence

>AAC37905.1 envelope glycoprotein gp120, partial [Human immunodeficiency virus 1]
VVIRSENFTNNAKTIIVHLNKSVEIDCIRPNNNTRRSIHIGPGRAFYGTDIIGDIRQAHCNISRKEWNDT
LTKIVSKLKEQFKNKTIVFN

Molecule Role : Protective antigen

7. env

Gene Name : env
Sequence Strain (Species/Organism) : Simian-Human immunodeficiency virus strain SHIV89.6P
NCBI Protein GI : 72398919
Other Database IDs : CDD:278917
Taxonomy ID : 57667
Gene Strand (Orientation) : ?
Protein Name : envelope protein
Protein pI : 9.92
Protein Weight : 40473.44
Protein Length : 461
Protein Note : Envelope glycoprotein GP120; pfam00516

Protein Sequence : Show Sequence

>AAZ72871.1 envelope protein, partial [Simian-Human immunodeficiency virus]
LNCTNLNITKNTTNPTSSSWGMMEEGEIKNCSFYITTSIRDKVKKEYALFNRLDVVPVENTSYRLISCNT
SVITQACPKVSFQPIPIHYCVPAGFAILKCNNKTFNGSGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEE
DIVIRSENFTNNVKNIIVQLNESVVINCTRPNNNTRERLSIGPGRAFYARRNIIGDIRQAHCNISRAKWN
NTLQQIVIKLREKYRNKTIAFNQSSGGDPEIVMHSFNCGGEFFYCNTAQLFNSTWNVTGGTNGTKGSDII
TLQCRIKQIINMWQKVGKAMYAPPIKGQIRCSSNITGLLLTRDGGSSTETEPEIFRPGGGDMRDNWRSEL
YKYKVVRIEPIGVAPTRAKRRTVQREKR

Molecule Role : Protective antigen
Related Vaccine(s): DNA and poxvirus priming-boosting SHIV vaccine , HIV DNA vaccine SIVmac239 Gag-Pol-Nef and mock Env with rAd5 boost

8. env

Gene Name : env
Sequence Strain (Species/Organism) : Simian-Human immunodeficiency virus strain SHIV-89.6
NCBI Protein GI : 2828045
Other Database IDs : CDD:278917
CDD:295533
CDD:197369
Taxonomy ID : 57667
Gene Strand (Orientation) : ?
Protein Name : env
Protein pI : 9.04
Protein Weight : 91775.38
Protein Length : 922
Protein Note : Envelope glycoprotein GP120; pfam00516

Protein Sequence : Show Sequence

>AAB99966.1 env [Simian-Human immunodeficiency virus]
MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWREATTTLFCASDAKAYDTEVHNVWA
THACVPTDPNPQEVVLGNVTENFNMWKNNMVDQMHEDIISLWDESLKPCVKLTPLCVTLNCTNLNITKNT
TNPTSSSWGMMEKGEIKNCSFYITTSIRNKVKKEYALFNRLDVVPIENTNNTKYRLISCNTSVITQACPK
VSFQPIPIHYCVPAGFAMLKCNNKTFNGSGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEDIVIRSENF
TDNAKTIIVQLNESVVINCTRPNNNTRRRLSIGPGRAFYARRNIIGDIRQAHCNISRAKWNNTLQQIVIK
LREKFRNKTIAFNQSSGGDPEIVMHSFNCGGEFFYCNTAQLFNSTWNVTGGTNGTEGNDIITLQCRIKQI
INMWQKVGKAMYAPPITGQIRCSSNITGLLLTRDGGNSTETETEIFRPGGGDMRDNWRSELYKYKVVRIE
PIGVAPTRAKRRTVQREKRAVGIGAVFLGFLGAAGSTMGAASVTLTVQARLLLSGIVQQQNNLLRAIEAQ
QHMLQLTVWGIKQLQARVLALERYLRDQQLMGIWGCSGKLICTTSVPWNVSWSNKSVDDIWNNMTWMEWE
REIDNYTDYIYDLLEKSQTQQEKNEKELLELDKWASLWNWFDITNWLWYIRLFIMIVGGLIGLRIVFAVL
SIVNRVRQGYSPLSFQTLLPASRGPDRPEGTEEEGGERDRDRSGPLVNGSLALIWDDLRSLCLFSYHRLR
DLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAIRH
IPRRIRQGLERILL

Molecule Role : Protective antigen
Related Vaccine(s): HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)

9. env

Gene Name : env
Sequence Strain (Species/Organism) : Human immunodeficiency virus 2
NCBI Protein GI : 1845209
Other Database IDs : CDD:278917
CDD:278918
CDD:197369
Taxonomy ID : 11709
Gene Strand (Orientation) : ?
Protein Name : envelope polyprotein
Protein pI : 8.65
Protein Weight : 93936.04
Protein Length : 945
Protein Note : similar to HIV2BEN, GenBank Accession Number M30502, and to HIV2D194, GenBank Accession Number J04542

Protein Sequence : Show Sequence

>AAB47784.1 envelope polyprotein [Human immunodeficiency virus 2]
MEPGRNQLLAVILLTSACLIYCKQYVTVFYGVPVWRNASIPLFCATKNRDTWGTIQCLPDNDDYQEIPLN
VTEAFDAWDNTVTEQAIEDVWRLFETSIKPCVKLTPLCVAMNCNPVTGNNTNATAKPTAARPTTNPSYLT
IINESSTCVGADNCTGLGDEGMVNCKFNMTGLEQDKIKGYTDTWYSDDVVCDSTNKTGTNTTCYMRHCNT
SVIKESCDKHYWDSMKFRYCTPPGYALLRCNDTNYSGFAPNCPKVVAASCTRMMETQTSTWFGFNGTRAE
NRTYIYWHGRDNRTIISLNKHYNLTMHCKRPGNKTVVPITLMSGHRFHSQAVINKKPRQAWCWFKGNWKG
AMQEVKQTLAGHPRYKGTNDTSKINFVKPGVGSDPEVTYMWTNCRGEFFYCNMTWFLNWVENRTSQKQRN
YAPCHIRQIINTWHKVGQYVYLPPREGELTCNSTVTSIIANIDTDGNQTNITFSAEVAELYRLELGDYKL
IEITPIGFAPTSEKRYSSAPARNKRGVFVLGLLGFLATAGSAMGAASLTLSAQSRTLLAGIVQQQQQLLD
IVKRQQELLRLTVWGTKNLQARVTAIEKYLKDQAQLNSWGCTFRQVCHTTVPWVNDSLTPRWNNMTWQEW
EKQVRYLEANISQSLEEAQIQQEKNMYELQKLNSWDVFGNWFDLTSWIKYIQYGVYIVVGIIALRIAIYV
VQLLSRFRKGYRPVFSSPPGYLQQIHIHTDRGQPANEETEGDAGDASGYDFWPWPINYIQLLIHLLTRLL
TGLYSICRDLLSANSPTRRLISQNLTAIRDWLRLKAAYLQYGCEWIQEAFQAIARTARETLAGAWRGLCK
AVQRIGRGILAVPRRIRQGAEIALL

Molecule Role : Protective antigen
Related Vaccine(s): ALVAC-HIV-2 , HIV-2 DNA vaccine , NYVAC-HIV-1

10. env

Gene Name : env
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1 isolate 715 from Baltimore clone 6
NCBI Protein GI : 475647
Other Database IDs : CDD:278917
CDD:295533
CDD:197369
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein Name : envelope glycoprotein
Protein pI : 8.4
Protein Weight : 91460.08
Protein Length : 942
Protein Note : Envelope glycoprotein GP120; pfam00516

Protein Sequence : Show Sequence

>AAB04079.1 envelope glycoprotein, partial [Human immunodeficiency virus 1]
VTGIRKNCQHWWKWGIMLLGILMICNATEKLWVTVYYGVPVWKEANTTLFCASDAKAYDTEVHNVWATHA
CVPTDPDPQEVELENVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNCTNLRNDTNTTRN
ATNTTSSETMMEEGEIKNCSFNITTSIRDKVQKEFALFYKLDVVPIENDTTSYRLISCNTSVLTQACPKV
SFEPIPIHFCAPAGFAILKCKDKKFNGTGPCTNVSTVQCTHGIKPVVSTQLLLNGSLAEEEVVIRSANLS
DNAKTIIVQLNESVQMNCTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHCNLSRTKWNETLKRIVIKL
REQYENKTIVFNQSSGGDPEIVMLSFNCGGEFFYCNSTKLFNSTWNGTESNNTGDDPIVLPCRIKQVINM
WQEVGKAMYAPPIRGQIRCSSNITGLLLTRDGGNSNETNTTEIFRPGGGNMKDNWRSELYKYKVVRIEPL
GIAPTRAKRRVVQREKRAAGLGVMFLGFLGAAGSTMGAASIALTVQARQLLSGIVQQQNNLLRAIEAQQH
MLQLTVWGIKQLQARVLAVERYLRDQQLLGIWGCSGKLICTTTVPWNASWSNKSHDQIWQNMTWMQWEKE
IDNYTSLIYNLIEVSQNQQEKNEQELLELDKWASLWNWFDITNWLWYIKIFIMIVGGLIGLRIVFIVLSI
VNRVRQGYSPLSFQTHLPARRGPDRPEGIEEEGGERDRDRSGQLVTGFLAIIWVDLRSLCLFSYHRLRDL
LLIVARIVELLGRRGWEILKYWWNLLQYWSQELKSGAVSLLNATAIAVAEGTDRVIEVLQRAGRAILHIP
RRIRQGFERALL

Molecule Role : Protective antigen
Related Vaccine(s): SHIV DNA vaccine encoding env and gag , SHIV(Ba-L) DNA vaccine encoding env and gag

11. env

Gene Name : env
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1 strain Ba-L subtype B
NCBI Nucleotide GI : 326367
NCBI Protein GI : 326371
Other Database IDs : CDD:278917
CDD:295533
CDD:197369
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein pI : 8.87
Protein Weight : 91185.73
Protein Length : 918
Protein Note : Envelope glycoprotein GP120; pfam00516

Protein Sequence : Show Sequence

>AAA44191.1 env [Human immunodeficiency virus 1]
MRVTEIRKSYQHWWRWGIMLLGILMICNAEEKLWVTVYYGVPVWKEATTTLFCASDRKAYDTEVHNVWAT
HACVPTDPNPQEVELKNVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNCTDLRNATNGN
DTNTTSSSRGMVGGGEMKNCSFNITTNIRGKVQKEYALFYKLDIAPIDNNSNNRYRLISCNTSVITQACP
KVSFEPIPIHYCAPAGFAILKCKDKKFNGKGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSAN
FADNAKVIIVQLNESVEINCTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHCNLSRAKWNDTLNKIVI
KLREQFGNKTIVFKHSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWNVTEESNNTVENNTITLPCRIKQ
IINMWQEVGRAMYAPPIRGQIRCSSNITGLLLTRDGGPEDNKTEVFRPGGGDMRDNWRSELYKYKVVKIE
PLGVAPTKAKRRVVQREKRAVGIGAVFLGFLGAAGSTMGAAAMTLTVQARLLLSGIVQQQNNLLRAIEAQ
QHLLQLTVWGIKQLQARVLAVERYLRDQQLLGIWGCSGKLICTTAVPWNASWSNKSLNKIWDNMTWIEWD
REINNYTSIIYSLIEESQNQQEKNEQELLELDKWASLWNWFDITKWLWYIKIFIMIVGGLIGLRIVFSVL
SIVNRVRQGYSPLSFQTHLPSSRGPDRPGGIEEEGGERDRDRSGPLVNGFLALIWVDLRSLFLFSYHRLR
DLLLIVMRIVELLGLAGGWEVLKYWWNLLQYWSQELKNSAVSLLNATAVAVAEGTDRVIEVLQRAVRAIL
HIPRRIRQGLERALL

Molecule Role : Protective antigen
Related Vaccine(s): SHIV DNA vaccine encoding env and gag , SHIV(Ba-L) DNA vaccine encoding env and gag

12. env

Gene Name : env
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1 strain 96ZM651
NCBI Protein GI : 13569225
Other Database IDs : CDD:278917
CDD:197369
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein Name : envelope glycoprotein
Protein pI : 8.71
Protein Weight : 93508.85
Protein Length : 949
Protein Note : isolated in 1996

Protein Sequence : Show Sequence

>AAK30970.1 envelope glycoprotein [Human immunodeficiency virus 1]
MRVREILRNWQRWWTWGILGFWMLMICNVWGNLWVTVYYGVPVWKEAKTTLFCASDAKSYEKEVHNVWAT
HACVPTDPNPQEIVLGNVTENFNMWKNDMVDQMHEDIISLWDQSLKPCVKLTPLCVTLNCTEVNVTRNVN
NSVVNNTTNVNNSMNGDMKNCSFNITTELKDKKKNVYALFYKLDIVSLNETDDSETGNSSKYYRLINCNT
SALTQACPKVSFDPIPIHYCAPAGYAILKCNNKTFNGTGPCHNVSTVQCTHGIKPVVSTQLLLNGSLAEE
GIIIRSENLTNNVKTIIVHLNRSIEIVCVRPNNNTRQSIRIGPGQTFYATGDIIGDIRQAHCNISRTNWT
KTLREVRNKLREHFPNKNITFKPSSGGDLEITTHSFNCRGEFFYCNTSGLFSINYTENNTDGTPITLPCR
IRQIINMWQEVGRAMYAPPIEGNIACKSDITGLLLVRDGGSTNDSTNNNTEIFRPAGGDMRDNWRSELYK
YKVVEIKPLGIAPTEAKRRVVEREKRAVGIGAVFLGFLGAAGSTMGAASITLTAQARQVLSGIVQQQSNL
LRAIEAQQHLLQLTVWGIKQLQTRVLAIERYLKDQQLLGLWGCSGKLICTTAVPWNISWSNKSKTDIWDN
MTWMQWDREISNYTNTIYRLLEDSQSQQEQNEKDLLALDSWNNLWNWFDITKWLWYIKIFIMIVGGLIGL
RIIFAVLSIVNRVRQGYSPLSFQTLIPNPREPDRPGRIEEEGGEQDKERSVRLVSGFLALAWDDLRSLCL
FSYHRLRDFILVTARAVELLRRSSLKGLQRGWEALKYLGSLVQYWGLELKKSAISLLDTIAIAVAEGTDR
IIELIQGICRAIRNVPRRIRQGFETALL

Molecule Role : Protective antigen
Related Vaccine(s): SHIV DNA vaccine encoding env and gag , SHIV(Ba-L) DNA vaccine encoding env and gag

13. env

Gene Name : env
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1 strain 976 clone 17
NCBI Protein GI : 475668
Other Database IDs : CDD:278917
CDD:295533
CDD:197369
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein Name : envelope glycoprotein
Protein pI : 8.59
Protein Weight : 92331.19
Protein Length : 944
Protein Note : Envelope glycoprotein GP120; pfam00516

Protein Sequence : Show Sequence

>AAB04093.1 envelope glycoprotein, partial [Human immunodeficiency virus 1]
VKETQMNWPNLWKWGTLILGLVIICSASDNLWVTVYYGVPVWKDADTTLFCASDAKAHETEVHNVWATHA
CVPTDPNPQEIHLENVTENFNMWKNKMVEQMQEDVISLWDQSLKPCVKLTPLCVTLTCTNATLNCTNLTN
GNKTTNVSNIIGNLTDEVRNCSFHMTTELRDKKQKVYALFYKLDIVQINSSEYRLINCNTSVIKQACPKI
SFDPIPIHYCTPAGYAILKCNDKNFNGTGPCKNVSSVQCTHGIKPVVSTQLLLNGSLAEEEIIISSENLT
NNAKTIIVHLNKSVEISCTRPSTNTRTSIRIGPGQVFYRTGDITGDIRKAYCEINETKWNEALKQVAGKL
KEHFNKTIIFQPPSGGDLEITMHHFNCRGEFFYCDTTQLFNRTWGENETREGRNITLPCKIKQIVNMWQG
AGQAMYAPPISGIIKCVSNITGILLTRDGGANNSASETFRPGGGNIKDNWRSELYKYKVVQIEPLGIAPT
RAKRRVVEREKRAVGIGAMIFGFLGAAGSTMGAASITLTVQARQLLSGIVQQQSNLLRAIEAQQHLLQLT
VWGIKQLQARVLAVERYLKDQKFLGLWGCSGKIICTTAVPWNSTWSNKSYEEIWNNMTWIEWEREISNYT
NQIYEILTESQDQQDRNEKDLLELDKWASLWNWFDITNWLWYIKIFIMIVGGLIGLRIIFAVLSIVNRVR
QGYSPLSFQIPFHHQREPDRPERIEEGGGEQGRDRSVRLVSGFLALAWDDLRSLCLFLYHRLRDLLLIAT
RTVEILGHSSLKGLRRGWEGLKYLGNLLIYWGQELRISAISLLNATAIAVGGWTDRIIEVAQRAWRAILR
IPRRIRQGLERSLL

Molecule Role : Protective antigen
Related Vaccine(s): SHIV DNA vaccine encoding env and gag , SHIV(Ba-L) DNA vaccine encoding env and gag

14. env

Gene Name : env
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1 isolate 037 clone 08
NCBI Protein GI : 487257
Other Database IDs : CDD:278917
CDD:295533
CDD:197369
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein Name : envelope glycoprotein
Protein pI : 8.4
Protein Weight : 91749
Protein Length : 946
Protein Note : Envelope glycoprotein GP120; pfam00516

Protein Sequence : Show Sequence

>AAB05027.1 envelope glycoprotein, partial [Human immunodeficiency virus 1]
VMGIERNYPCWWTWGIMILGMIIICNTAENLWVTVYYGVPVWKDAETTLFCASDAKAYDTEVHNVWATHA
CVPTDPNPQEIYMENVTEEFNMWKNNMVEQMHTDIISLWDQSLKPCVQLTPLCVTLDCSYNITNNITNSI
TNSSVNMREEIKNCSFNMTTELRDKNRKVYSLFYKLDVVQINNGNNSSNLYRLINCNTSALTQACPKVTF
EPIPIRYCAPAGYAILKCNDKEFNGTGLCKNVSTVQCTHGIRPVVSTQLLLNGSLAEGKVMIRSENITNN
VKNIIVQLNETVTINCTRPNNNTRKSVRIGPGQTFYATGDIIGDIRQAHCNVSGSQWNRALHQVVGQLRE
YWNTTIIFKNSSGGDLEITTHSFNCGGEFFYCNTSGLFNSNWTHNDTASMKPNDTITLPCRIKQIINMWQ
RVGQAIYAPPIQGVIRCESNITGLILTRDGGGNINESQIFRPGGGDMRDNWRSELYKYKVVRIEPLGVAP
TKAKRRVVEREKRAVVELGAVFIGFLGTAGSTMGAASITLTVQVRKLLSGIVQQQSNLLRAIEAQQHLLK
LTVWGIKQLQARVLAVERYLRDQQLLGIWGCSGKLICTTNVPWNSSWSNKSEREIWENMTWLQWDKEISN
YTHIIYELIEESQKQQEKNEQELLELDKWANLWNWFDISNWLWYIKIFIMIVGGLIGLRIVFAVLSVINR
VRQGYSPLSFQTLTPNPRDPDRPGRIEGEGGEQDRGRSIRLVSGFLALAWDDLRNLCLSSYHQLRDFILI
VARTVELLGHSSLKGLRLGWEGLKYLGNLLLYWGRELKTSAINLFDTIAIVVAGWTDRVIEVGQRLGRAI
LNIPRRIRQGLERALL

Molecule Role : Protective antigen
Related Vaccine(s): SHIV(Ba-L) DNA vaccine encoding env and gag

15. env from SIV

Gene Name : env from SIV
Sequence Strain (Species/Organism) : Simian immunodeficiency virus
NCBI Gene ID : 1490007
NCBI Protein GI : 9627208
Locus Tag : SIVgp6
Genbank Accession : M58410
Protein Accession : NP_054372
Taxonomy ID : 11723
Gene Starting Position : 6201
Gene Ending Position : 8765
Gene Strand (Orientation) : ?
Protein Name : envelope protein
Protein pI : 8.73
Protein Weight : 91594.7
Protein Length : 854

DNA Sequence : Show Sequence

>NC_001549.1:6201-8765 Simian immunodeficiency virus, complete genome
TATGGGGAGATTGCTTATAAAAATACTAATAATAGCAATAGGGATAAGTATAGGAATAGGTAACCTGTAT
GTGACAGTGTTTTATGGAATCCCAGTATGGAAAAATTCAACAGTTCAGGCATTTTGCATGACGCCCAATA
CCAATATGTGGGCAACCACCAACTGCATACCAGATGATCATGATAATACAGAGGTGCCTCTAAACATTAC
AGAAGCTTTCGAGGCTTGGGATAATCCGCTGGTAAAACAAGCAGAGAGTAATATACATCTACTCTTTGAA
CAAACGATGAGGCCTTGTGTTAAGCTCTCCCCCATATGTATTAAAATGTCCTGTGTAGAGCTGAATGGTA
CAGCCACGACAAAGGCCACCACTACTGCAACTACAACAATGACTACCCCCTGTCAGAATTGCAGTACAGA
GCAGATAGAAGGAGAAATGGCAGAGGAACCAGCATCCAACTGCACTTTTGCAATTGCAGGATATCAAAGA
GATGTAAAAAAGAATTATAGCATGACCTGGTATGATCAGGAGTTAGTCTGCAATAATAAAACAGGAAGTG
AAAAGGGAAGTAAGGATTGTTACATGATACATTGTAATGATTCAGTGATAAAAGAAGCTTGTGATAAAAC
ATATTGGGATACTTTAAGAGTAAGATACTGTGCACCAGCAGGGTATGCTTTGCTAAAATGTAATGATAAG
GATTATAGAGGCTTTGCTCCAAAGTGCAAGAATGTTTCAGTAGTGCATTGTACTAGATTAATCAATACTA
CTATAACTACAGGGATAGGATTAAATGGTAGTAGATCAGAAAATAGAACAGAGATATGGCAGAAAGGAGG
AAATGATAATGATACAGTTATAATAAAGTTGAATAAGTTTTACAACTTGACAGTGAGATGCCGAAGACCT
GGTAATAAAACAGTGTTGCCAGTAACAATCATGGCAGGGTTAGTATTTCACTCTCAGAAATATAATACCA
GGTTAAAACAAGCGTGGTGCCACTTCCAAGGAGATTGGAAAGGGGCATGGAAAGAAGTCAGAGAAGAAGT
AAAGAAAGTGAAAAATCTTACAGAAGTAAGCATAGAAAATATACATCTGAGAAGGATATGGGGAGATCCA
GAATCAGCGAATTTTTGGTTCAATTGTCAAGGTGAATTTTTCTATTGTAAGATGGACTGGTTTATCAATT
ATCTAAACAATCGAACAGAAGATGCAGAAGGTACTAATAGGACCTGTGACAAAGGGAAGCCAGGACCAGG
ACCATGTGTTCAGAGAACTTATGTTGCCTGCCATATACGACAAGTAGTAAATGATTGGTACACTGTCTCT
AAAAAGGTATATGCTCCACCAAGGGAAGGTCATTTGGAGTGTAACTCATCAGTCACGGCACTATACGTGG
CAATAGATTATAACAACAAGTCTGGCCCAATAAATGTGACCCTAAGTCCTCAGGTACGCAGCATATGGGC
GTACGAACTGGGAGACTATAAATTAGTAGAGATAACACCAATTGGCTTTGCTCCTACAGATGTAAGAAGA
TATACTGGCCCCACAAGAGAAAAAAGGGTGCCATTCGTGCTAGGGTTTCTAGGCTTCTTGGGAGCTGCTG
GAACTGCAATGGGCGCAGCGGCAACAACGCTGACAGTCCAGTCTCGGCATTTGCTTGCTGGGATATTGCA
GCAGCAGAAGAACTTGCTGGCGGCTGTGGAACAGCAACAACAGTTGTTGAAGCTGACCATTTGGGGTGTG
AAAAACCTCAATGCCCGCGTCACAGCTCTCGAGAAGTACCTAGAGGATCAGGCACGGCTAAATTCATGGG
GATGTGCGTGGAAACAAGTATGTCACACCACAGTGCCATGGAAGTATAATAACACTCCTAAGTGGGACAA
TATGACTTGGTTGGAGTGGGAGAGACAAATTAATGCCTTGGAAGGCAACATAACTCAACTATTGGAAGAA
GCACAAAATCAGGAATCAAAGAATCTGGATCTGTACCAGAAATTGGATGATTGGTCAGGGTTCTGGTCAT
GGTTCTCACTGTCAACTTGGTTAGGCTATGTTAAAATAGGATTTTTAGTGATAGTGATTATTCTAGGATT
AAGATTTGCATGGGTATTATGGGGATGTATCAGAAATATTAGGCAGGGATATAATCCTCTCCCCCAGATC
CATATCCACAGTTCAGCGGAACGGCCAGACAACGGAGGAGGGCAAGACAGAGGTGGAGAAAGCAGCAGCA
GCAAATTGATAAGATTGCAGGAAGAGTCCTCAACACCTTCGAGGATCAACAACTGGTGGCTCAACTTCAA
GAGCTGCAGCTTGAGAATAAGGACTTGGTGTTACAACATCTGCCTGACCCTCCTCATATTCATCAGGACA
GCAGTGGGATACCTGCAGTATGGGCTCCAGCAACTCCAAGAGGCAGCAACAGGGCTTGCTCAAGCTCTGG
CGAGGGCTGCGAGGGAAGCCTGGGGCAGACTGGGTGCTATTGTCCGATCCGCTTATCGGGCAGTCATCAA
CAGTCCAAGAAGAGTGCGGCAAGGCCTTGAAAAAGTCCTGGGGTA

Protein Sequence : Show Sequence

>NP_054372.1 envelope protein [Simian immunodeficiency virus]
MGRLLIKILIIAIGISIGIGNLYVTVFYGIPVWKNSTVQAFCMTPNTNMWATTNCIPDDHDNTEVPLNIT
EAFEAWDNPLVKQAESNIHLLFEQTMRPCVKLSPICIKMSCVELNGTATTKATTTATTTMTTPCQNCSTE
QIEGEMAEEPASNCTFAIAGYQRDVKKNYSMTWYDQELVCNNKTGSEKGSKDCYMIHCNDSVIKEACDKT
YWDTLRVRYCAPAGYALLKCNDKDYRGFAPKCKNVSVVHCTRLINTTITTGIGLNGSRSENRTEIWQKGG
NDNDTVIIKLNKFYNLTVRCRRPGNKTVLPVTIMAGLVFHSQKYNTRLKQAWCHFQGDWKGAWKEVREEV
KKVKNLTEVSIENIHLRRIWGDPESANFWFNCQGEFFYCKMDWFINYLNNRTEDAEGTNRTCDKGKPGPG
PCVQRTYVACHIRQVVNDWYTVSKKVYAPPREGHLECNSSVTALYVAIDYNNKSGPINVTLSPQVRSIWA
YELGDYKLVEITPIGFAPTDVRRYTGPTREKRVPFVLGFLGFLGAAGTAMGAAATTLTVQSRHLLAGILQ
QQKNLLAAVEQQQQLLKLTIWGVKNLNARVTALEKYLEDQARLNSWGCAWKQVCHTTVPWKYNNTPKWDN
MTWLEWERQINALEGNITQLLEEAQNQESKNLDLYQKLDDWSGFWSWFSLSTWLGYVKIGFLVIVIILGL
RFAWVLWGCIRNIRQGYNPLPQIHIHSSAERPDNGGGQDRGGESSSSKLIRLQEESSTPSRINNWWLNFK
SCSLRIRTWCYNICLTLLIFIRTAVGYLQYGLQQLQEAATGLAQALARAAREAWGRLGAIVRSAYRAVIN
SPRRVRQGLEKVLG

Molecule Role : Protective antigen
Related Vaccine(s): HIV DNA vaccine Ad26/Ad5HVR48 encoding HIV or SIV env or gag , NYVAC-SIV , rMVTT-SIV-gpe

16. Envelope polyprotein from HXB2

Gene Name : Envelope polyprotein from HXB2
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
NCBI Protein GI : 1906385
Other Database IDs : CDD:278917
CDD:278918
CDD:197369
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein pI : 9.19
Protein Weight : 92032.73
Protein Length : 936
Protein Note : HTLV-III/LAV

Protein Sequence : Show Sequence

>AAB50262.1 envelope polyprotein [Human immunodeficiency virus 1]
MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWA
THACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNT
NSSSGRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPIDNDTTSYKLTSCNTSVITQACPKVSF
EPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDN
AKTIIVQLNTSVEINCTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLR
EQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRI
KQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVK
IEPLGVAPTKAKRRVVQREKRAVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQQQNNLLRAIE
AQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNHTTWME
WDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFA
VLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCLFSYHR
LRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAI
RHIPRRIRQGLERILL

Molecule Role : Protective antigen

17. gag

Gene Name : gag
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
NCBI Protein GI : 5081475
Other Database IDs : CDD:249943
CDD:279002
CDD:197667
CDD:285867
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein Name : gag
Protein pI : 9.19
Protein Weight : 54682.29
Protein Length : 566
Protein Note : isolated from patient SC49 PBMC; infection was aquired in Sydney, Australia 1998; this patient registered low levels of viral RNA in plasma by RT-PCR (Amplicor 1.0) and low levels of P24 (gag) antigen by monoclonal ELISA despite symptomatic seroconversion; HIV RNA quantitation by an alternative method (bDNA, Chiron 3.0) on the same sample yielded a level of >500,000 copies/ml; subtyping in envelope and P17 gag by sequencing and phylogenetic analysis revealed subtype B; the entire gag gene was then sequenced to search for mutations to account for the failure of detection methods directed to this genomic area;
subtype: B

Protein Sequence : Show Sequence

>AAD39400.1 gag [Human immunodeficiency virus 1]
MGARASVLSGGKLDKWEKIRLRPGGKKTYQLKHIVWASRELERFAVNPGLLETGGGCKQILVQLQPSLQT
GSEELKSLYNAVATLYCVHQGIEVRDTKEALDKIEEEQNKSKKKAQQAAADTGNSSQVSQNYPIVQNLQG
QMVHQAISPRTLNAWVKVIEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAA
EWDRLHPAHAGPNAPGQMREPRGSDIAGTTSTLQEQIGWMTSNPPVPVGEIYKRWIILGLNKIVRMYSPV
SILDIRQGPKEPFRDYVDRFYKTLRAEQASQDVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTAC
QGVGGPSHKARILAEAMSQVTSPANIMMQRGNFRNQRKTIKCFNCGKEGHLARHCRAPRKKGCWKCGREG
HQMKDCTERQANFLGKIWPSHKGRPGNFLQSRPEPTAPPEESFRFGEETTTPPQKQEPLPSQKQETIDKD
LYPLASLKSLFGNDPSLQ

Molecule Role : Protective antigen

18. gag

Gene Name : gag
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
NCBI Protein GI : 1537051
Other Database IDs : CDD:249943
CDD:279002
CDD:278525
CDD:197667
CDD:285867
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein Name : gag
Protein pI : 9.26
Protein Weight : 54190.94
Protein Length : 561
Protein Note : gag gene protein p17 (matrix protein); pfam00540

Protein Sequence : Show Sequence

>AAC55459.1 gag [Human immunodeficiency virus 1]
MGARASVLSGGKLDAWEKIRLRPGGRKKYRLKHLVWASRELERFALNPSFLETAEGCQQIIEQLQSTLKT
GLEELKSLFNTVATLWCVHQRIEVKDTKEALDKIEEVQNKSQRKTQQAAAGTGSSSKVSQNYPIVQNAQG
QMAHQPLSPRTLNAWVKVVEEKGFNPEVIPMFSALSEGATPQDLNMMLNIVGGHQAAMQMLKETINEEPA
EWDRVHPVHAGPIPPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGDIYKRWIILGLNKIVRMYSPV
SILDIRQGPKEPFRDYVDRFYKTLRAEQATQEVKNWMTETLLVQNANPDCKSILKALGTGATLEEMMTAC
QGVGGPSHKARVLAEAMSHAQHATIMMQRGNFKGQKRIKCFNCGREGHLARNCRAPRKQGCWKCGKEGHQ
MKDCTERQANFLGKIWPSNKGRPGNFPQSRPEPTAPPAENWGMGEEITGEEITSLPKQEQKDKEHPPPLV
SLKSLFGNDPLSQ

Molecule Role : Protective antigen

19. gag

Gene Name : gag
Sequence Strain (Species/Organism) : Simian-Human immunodeficiency virus strain SHIV-89.6
NCBI Protein GI : 2828037
Other Database IDs : CDD:249943
CDD:279002
CDD:331526
Taxonomy ID : 57667
Gene Strand (Orientation) : ?
Protein Name : gag
Protein pI : 9.12
Protein Weight : 54236.02
Protein Length : 573
Protein Note : gag gene protein p17 (matrix protein); pfam00540

Protein Sequence : Show Sequence

>AAB99958.1 gag [Simian-Human immunodeficiency virus]
MGVRNSVLSGKKADELEKIRLRPNGKKKYMLKHVVWAANELDRFGLAESLLENKEGCQKILSVLAPLVPT
GSENLKSLYNTVCVIWCIHAEEKVKHTEEAKQIVQRHLVVETGTTETMPKTSRPTAPSSGRGGNYPVQQI
GGNYVHLPLSPRTLNAWVKLIEEKKFGAEVVPGFQALSEGCTPYDINQMLNCVGDHQAAMQIIRDIINEE
AADWDLQHPQPAPQQGQLREPSGSDIAGTTSSVDEQIQWMYRQQNPIPVGNIYRRWIQLGLQKCVRMYNP
TNILDVKQGPKEPFQSYVDRFYKSLRAEQTDAAVKNWMTQTLLIQNANPDCKLVLKGLGVNPTLEEMLTA
CQGVGGPGQKARLMAEALKEALAPVPIPFAAAQQRGPRKPIKCWNCGKEGHSARQCRAPRRQGCWKCGKM
DHVMAKCPDRQAGFLGLGPWGKKPRNFPMAQVHQGLMPTAPPEDPAVDLLKNYMQLGKQQREKQRESREK
PYKEVTEDLLHLNSLFGGDQ

Molecule Role : Protective antigen
Related Vaccine(s): HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6) , rBCG-SIVgag and rDIsSIVgag Prime-boost SHIV vaccine

20. gag

Gene Name : gag
Sequence Strain (Species/Organism) : Human immunodeficiency virus 2
NCBI Protein GI : 1845205
Other Database IDs : CDD:249943
CDD:279002
CDD:197667
Taxonomy ID : 11709
Gene Strand (Orientation) : ?
Protein Name : gag polyprotein
Protein pI : 9.25
Protein Weight : 55390.11
Protein Length : 591
Protein Note : similar to HIV2BEN, GenBank Accession Number M30502, and to HIV2D194, GenBank Accession Number J04542

Protein Sequence : Show Sequence

>AAB47780.1 gag polyprotein [Human immunodeficiency virus 2]
MGARNSVLRGKKADELEKIRLRPGGKKKYRLKHIVWAANELDRFRLAENLLESKEGCQKILTVLDPLVPT
GSENLKSLFNTVCVIWCLHAEEKVKDTEEAKKLVQRHLVAETGTAEKMPNTSRPTAPPSGKGGNFPVQQA
GGNYVHVPLSPRTLNAWVKLVEEKKFGAEVVPGFQALSEGCTPYDINQMLNCVGDQQAAMQIIREIINEE
AADWDAQHPIPGPLPAGQLRDPRGSDIAGTTSTVDEQIQWMYRQQNPVPVGNIYRRWIQIGLQKCVRMYN
PTNVLDVKQGPKESFQSYVDRFYKSLRAEQADPAVKNWMTQTLLVQNANPDCKLVLKGLGMNPTLEEMLT
ACQGVGGPGQKARLMAEALKEALTPPPIPFAAAQQRRTIRCWNCGKEGHSAKQCRAPRRQGCWKCGKPGH
IMANCPDRQAGFLGMGSRGKKPRNFPVAQAPQGLIPTAPPADPAADLLEKYLQQGRKQREQRERPYKEVT
EDLLHLEQGETPRREATEDLLHLNSLFGKDQ

Molecule Role : Protective antigen
Related Vaccine(s): ALVAC-HIV-2 , ALVAC-HIV-2- env/gag/pol , HIV-2 DNA vaccine

21. Gag from HIV 1

Gene Name : Gag from HIV 1
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
VO ID : VO_0011263
NCBI Gene ID : 155030
NCBI Protein GI : 9629360
Locus Tag : HIV1gp2
Genbank Accession : AF033819
Protein Accession : NP_057850
Taxonomy ID : 11676
Gene Starting Position : 335
Gene Ending Position : 1837
Gene Strand (Orientation) : +
Protein Name : Pr55(Gag)
Protein pI : 9.42
Protein Weight : 53447.94
Protein Length : 500

DNA Sequence : Show Sequence

>NC_001802.1:335-1837 Human immunodeficiency virus 1, complete genome
GATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGAAAAAATTCGGTTAAGGCCA
GGGGGAAAGAAAAAATATAAATTAAAACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTA
ATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGAC
AGGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAG
ATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGAAAAAAGCACAGC
AAGCAGCAGCTGACACAGGACACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGG
GCAAATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAGTAGAAGAGAAGGCT
TTCAGCCCAGAAGTGATACCCATGTTTTCAGCATTATCAGAAGGAGCCACCCCACAAGATTTAAACACCA
TGCTAAACACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGC
AGAATGGGATAGAGTGCATCCAGTGCATGCAGGGCCTATTGCACCAGGCCAGATGAGAGAACCAAGGGGA
AGTGACATAGCAGGAACTACTAGTACCCTTCAGGAACAAATAGGATGGATGACAAATAATCCACCTATCC
CAGTAGGAGAAATTTATAAAAGATGGATAATCCTGGGATTAAATAAAATAGTAAGAATGTATAGCCCTAC
CAGCATTCTGGACATAAGACAAGGACCAAAGGAACCCTTTAGAGACTATGTAGACCGGTTCTATAAAACT
CTAAGAGCCGAGCAAGCTTCACAGGAGGTAAAAAATTGGATGACAGAAACCTTGTTGGTCCAAAATGCGA
ACCCAGATTGTAAGACTATTTTAAAAGCATTGGGACCAGCGGCTACACTAGAAGAAATGATGACAGCATG
TCAGGGAGTAGGAGGACCCGGCCATAAGGCAAGAGTTTTGGCTGAAGCAATGAGCCAAGTAACAAATTCA
GCTACCATAATGATGCAGAGAGGCAATTTTAGGAACCAAAGAAAGATTGTTAAGTGTTTCAATTGTGGCA
AAGAAGGGCACACAGCCAGAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGAAAGGAAGG
ACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTTTTTAGGGAAGATCTGGCCTTCCTACAAGGGA
AGGCCAGGGAATTTTCTTCAGAGCAGACCAGAGCCAACAGCCCCACCAGAAGAGAGCTTCAGGTCTGGGG
TAGAGACAACAACTCCCCCTCAGAAGCAGGAGCCGATAGACAAGGAACTGTATCCTTTAACTTCCCTCAG
GTCACTCTTTGGCAACGACCCCTCGTCACAATA

Protein Sequence : Show Sequence

>NP_057850.1 Pr55(Gag) [Human immunodeficiency virus 1]
MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQT
GSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAADTGHSNQVSQNYPIVQNIQG
QMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAA
EWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPT
SILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTAC
QGVGGPGHKARVLAEAMSQVTNSATIMMQRGNFRNQRKIVKCFNCGKEGHTARNCRAPRKKGCWKCGKEG
HQMKDCTERQANFLGKIWPSYKGRPGNFLQSRPEPTAPPEESFRSGVETTTPPQKQEPIDKELYPLTSLR
SLFGNDPSSQ

Molecule Role : Protective antigen
Molecule Role Annotation : HIV-1 DNA plasmids expressing Env, Gag and Tat, either alone or combined with the corresponding protein immunogens formulated in the MF59 adjuvant, resulted in protection against an experimental HIV-1 infection in C57Bl/6 mice (Bråve et al., 2007).
Related Vaccine(s): DNA vaccine expressing multiple HIV epitopes , HIV DNA vaccine Ad26/Ad5HVR48 encoding HIV or SIV env or gag , HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6) , HIV recombinant vector vaccine MVA-gag encoding gag , L. T -HIV-1 Gag

22. gag from HIV-1 vector pNL4-3

Gene Name : gag from HIV-1 vector pNL4-3
Sequence Strain (Species/Organism) : HIV-1 vector pNL4-3
NCBI Protein GI : 12831136
Other Database IDs : CDD:249943
CDD:279002
CDD:331526
CDD:312289
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein Name : gag polyprotein
Protein pI : 9.31
Protein Weight : 54183.8
Protein Length : 569
Protein Note : from sequence deposited in GenBank Accession Number M19921

Protein Sequence : Show Sequence

>AAK08483.1 gag polyprotein (plasmid) [HIV-1 vector pNL4-3]
MGARASVLSGGELDKWEKIRLRPGGKKQYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQT
GSEELRSLYNTIAVLYCVHQRIDVKDTKEALDKIEEEQNKSKKKAQQAAADTGNNSQVSQNYPIVQNLQG
QMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAA
EWDRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTHNPPIPVGEIYKRWIILGLNKIVRMYSPT
SILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPGATLEEMMTAC
QGVGGPGHKARVLAEAMSQVTNPATIMIQKGNFRNQRKTVKCFNCGKEGHIAKNCRAPRKKGCWKCGKEG
HQMKDCTERQANFLGKIWPSHKGRPGNFLQSRPEPTAPPEESFRFGEETTTPSQKQEPIDKELYPLASLR
SLFGSDPSSQ

Molecule Role : Protective antigen
Related Vaccine(s): SHIV DNA vaccine encoding env and gag , SHIV(Ba-L) DNA vaccine encoding env and gag

23. gag from HXB2

Gene Name : gag from HXB2
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1 HXB2
NCBI Protein GI : 328450
Other Database IDs : CDD:249943
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein Name : gag protein
Protein pI : 9.72
Protein Weight : 14664.54
Protein Length : 201
Protein Note : gag gene protein p17 (matrix protein); pfam00540

Protein Sequence : Show Sequence

>AAA44995.1 gag protein, partial [Human immunodeficiency virus 1]
MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQT
GSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAADTGHSNQVSQNY

Molecule Role : Protective antigen
Related Vaccine(s): CVB4/p24(73(3))

24. Gag protein from SIV-mnd 2

Gene Name : Gag protein from SIV-mnd 2
Sequence Strain (Species/Organism) : Simian immunodeficiency virus SIV-mnd 2
VO ID : VO_0010949
NCBI Gene ID : 956108
NCBI Protein GI : 27311167
Locus Tag : Siv2gp1
Genbank Accession : AF367411
Protein Accession : NP_758886
Taxonomy ID : 159122
Gene Starting Position : 736
Gene Ending Position : 2289
Gene Strand (Orientation) : +
Protein Name : gag protein
Protein pI : 8.78
Protein Weight : 55072.29
Protein Length : 517

DNA Sequence : Show Sequence

>NC_004455.1:736-2289 Simian immunodeficiency virus 2 isolate SIVmnd-2, complete genome
AATGGGCGCGAGCGCGTCAGGTCTTAGGGGAGAAAAATTGGACGAGCTGGAAAAGATTAGGTTACGGCCC
TCCGGAAAAAAGAAATACCAGCTGAAACACATAATATGGGTAAGCAAGGAACTAGACAGATTTGGCCTTC
ATGAAAAGCTGTTAGAAAGTAAGGAAGGATGCGAGAAAATTCTTAGCGTACTCTTTCCACTAGTTCCTAC
AGGGTCAGAAAATTTAATCTCGCTGTACAACACCTGCTGCTGCGTATGGTGCGTACATGCGAAAGAGAAA
GTAACAGATACAGAGGAAGCGAAAGAGAAAGTAAAACAAAAGCTCCATCTAGTGGCCGAAAAGGAAAATG
CAGCATCAGAAAAAGAACAAAGAGCAATAGTGACACCTAGTGGCCGCTCAAAAAATTACCCAATACAGAT
AATAAATCAGACCCCAGTCCATCAGGGAATTTCACCGCGCACGCTGAATGCGTGGGTAAAATGCATAGAA
GAGAAGAAGTTTAGCCCAGAAATAGTGCCCATGTTCATAGCCTTGTCTGAAGGGTGCCTCCCCTATGATC
TCAATGGCATGCTCAATGCTATTGGAGACCATCAGGGAGCGCTTCAAATAGTGAAGGATGTCATCAATGA
GGAAGCTGCAGACTGGAACTTGAGACACCCACAAGTGGGTCCTATGCCCCAAGGTGTCTTGAGAAACCCA
ACGGGCAGTGATATTGCTGGAACAACAAGCTCCATAGAAGAGCAGATAGAATGGACTACAAGGGAGCAAG
ATGCAGTAAATGTGGGAGGAATATATAAACAATGGATAGTTTTAGGGCTTCAGAAGTGTGTAAGCATGTA
TAATCCAGTAAACATCCTGGACATAAAGCAAGGACCAAAGGAGCCGTTCAAGGACTATGTGGACAGGTTT
TACAAAGCTCTGCGGGCGGAGCGGACTGATCCACAAGTCAAAACCTGGATGACACAAACTTTGCTCATCC
AGAATGCTAACCCAGATTGTAAATCCATCCTTAAAGGGCTAGGCATGAATCCCTCTTTAGAAGAGATGCC
GCTAGCCTGCCAAGGGGTAGGAGGCCCTAAATATAAAGCACAAATGATGGCAGAGGCTATGAAGGAAGCC
CAGTCAGCTGTAATGATGCAGAATTCGGGAGGGCCACCGCGGGGCCCCCCGAGACAACCTCCTAGAAACA
TCAGATGCCCTAACTGTGGAAAATTTGGTCATGGGCTGAGGGACTGTATAAGCCCTCGAAAAAAGGGATG
CTTCAAGTGTGGAGATCTAGGACACATAATGAGAAATTGCCCAAAGATGGTGAATTTTTTAGGGAATACC
CCCTGGGGCAGTGGCAAACCCAGGAACTTCCCGGCGATGCCATTGACCCCAACGGCCCCTCCAATGCCAG
GGATGGAAGACCCAGCAGAGAGAATGCTGTTAGATTACATGAAGAAAGGGCAACAGCAGAAAGCGGAAAG
CAAACAGGAAAAGAAAGAGAGGGGTCCATACGAGGCAGCTTACAACTCCCTCAGTTCTCTCTTTGGAACA
GACCAACTACAGTA

Protein Sequence : Show Sequence

>NP_758886.1 gag protein [Simian immunodeficiency virus SIV-mnd 2]
MGASASGLRGEKLDELEKIRLRPSGKKKYQLKHIIWVSKELDRFGLHEKLLESKEGCEKILSVLFPLVPT
GSENLISLYNTCCCVWCVHAKEKVTDTEEAKEKVKQKLHLVAEKENAASEKEQRAIVTPSGRSKNYPIQI
INQTPVHQGISPRTLNAWVKCIEEKKFSPEIVPMFIALSEGCLPYDLNGMLNAIGDHQGALQIVKDVINE
EAADWNLRHPQVGPMPQGVLRNPTGSDIAGTTSSIEEQIEWTTREQDAVNVGGIYKQWIVLGLQKCVSMY
NPVNILDIKQGPKEPFKDYVDRFYKALRAERTDPQVKTWMTQTLLIQNANPDCKSILKGLGMNPSLEEMP
LACQGVGGPKYKAQMMAEAMKEAQSAVMMQNSGGPPRGPPRQPPRNIRCPNCGKFGHGLRDCISPRKKGC
FKCGDLGHIMRNCPKMVNFLGNTPWGSGKPRNFPAMPLTPTAPPMPGMEDPAERMLLDYMKKGQQQKAES
KQEKKERGPYEAAYNSLSSLFGTDQLQ

Molecule Role : Protective antigen
Molecule Role Annotation : A novel primate lentivirus was identified in Mandrillus sphinx. One of the newly isolated SIV strains was intravenously inoculated into two rhesus macaques and resulted in chronic infection. These SIVs do not cluster with SIVmndGB1, the former representative strain of SIVmnd, but form a new, independent lineage. These results indicate that these SIVmnds are a novel type of SIVmnd and have infected Cameroonian mandrills for a long time. To date, M. sphinx is the only primate species other than humans that is naturally infected with two different types of SIV (Takehisa et al., 2001).
Related Vaccine(s): Adenoviral vector Ad5 expressing SIV gag protein , DNA and poxvirus priming-boosting SHIV vaccine , HIV DNA and adenoviral vector Ad5 expressing SIV gag protein , HIV DNA vaccine Ad26/Ad5HVR48 encoding HIV or SIV env or gag , HIV DNA vaccine pHIS-SHIV-B , HIV DNA vaccine SIVmac239 Gag-Pol-Nef and mock Env with rAd5 boost

25. gag-pol

Gene Name : gag-pol
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
NCBI Gene ID : 155348
NCBI Protein GI : 28872819
Locus Tag : HIV1gp1
Genbank Accession : AF033819
Protein Accession : NP_057849
Taxonomy ID : 11676
Gene Starting Position : 335
Gene Ending Position : 4641
Gene Strand (Orientation) : +
Protein Name : Gag-Pol
Protein pI : 9.02
Protein Weight : 152515.27
Protein Length : 1435
Protein Note : Pr160

DNA Sequence : Show Sequence

>NC_001802.1:335-4641 Human immunodeficiency virus 1, complete genome
GATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGAAAAAATTCGGTTAAGGCCA
GGGGGAAAGAAAAAATATAAATTAAAACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTA
ATCCTGGCCTGTTAGAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGAC
AGGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAG
ATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGAAAAAAGCACAGC
AAGCAGCAGCTGACACAGGACACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGG
GCAAATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAGTAGAAGAGAAGGCT
TTCAGCCCAGAAGTGATACCCATGTTTTCAGCATTATCAGAAGGAGCCACCCCACAAGATTTAAACACCA
TGCTAAACACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGC
AGAATGGGATAGAGTGCATCCAGTGCATGCAGGGCCTATTGCACCAGGCCAGATGAGAGAACCAAGGGGA
AGTGACATAGCAGGAACTACTAGTACCCTTCAGGAACAAATAGGATGGATGACAAATAATCCACCTATCC
CAGTAGGAGAAATTTATAAAAGATGGATAATCCTGGGATTAAATAAAATAGTAAGAATGTATAGCCCTAC
CAGCATTCTGGACATAAGACAAGGACCAAAGGAACCCTTTAGAGACTATGTAGACCGGTTCTATAAAACT
CTAAGAGCCGAGCAAGCTTCACAGGAGGTAAAAAATTGGATGACAGAAACCTTGTTGGTCCAAAATGCGA
ACCCAGATTGTAAGACTATTTTAAAAGCATTGGGACCAGCGGCTACACTAGAAGAAATGATGACAGCATG
TCAGGGAGTAGGAGGACCCGGCCATAAGGCAAGAGTTTTGGCTGAAGCAATGAGCCAAGTAACAAATTCA
GCTACCATAATGATGCAGAGAGGCAATTTTAGGAACCAAAGAAAGATTGTTAAGTGTTTCAATTGTGGCA
AAGAAGGGCACACAGCCAGAAATTGCAGGGCCCCTAGGAAAAAGGGCTGTTGGAAATGTGGAAAGGAAGG
ACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTTTTTAGGGAAGATCTGGCCTTCCTACAAGGGA
AGGCCAGGGAATTTTCTTCAGAGCAGACCAGAGCCAACAGCCCCACCAGAAGAGAGCTTCAGGTCTGGGG
TAGAGACAACAACTCCCCCTCAGAAGCAGGAGCCGATAGACAAGGAACTGTATCCTTTAACTTCCCTCAG
GTCACTCTTTGGCAACGACCCCTCGTCACAATAAAGATAGGGGGGCAACTAAAGGAAGCTCTATTAGATA
CAGGAGCAGATGATACAGTATTAGAAGAAATGAGTTTGCCAGGAAGATGGAAACCAAAAATGATAGGGGG
AATTGGAGGTTTTATCAAAGTAAGACAGTATGATCAGATACTCATAGAAATCTGTGGACATAAAGCTATA
GGTACAGTATTAGTAGGACCTACACCTGTCAACATAATTGGAAGAAATCTGTTGACTCAGATTGGTTGCA
CTTTAAATTTTCCCATTAGCCCTATTGAGACTGTACCAGTAAAATTAAAGCCAGGAATGGATGGCCCAAA
AGTTAAACAATGGCCATTGACAGAAGAAAAAATAAAAGCATTAGTAGAAATTTGTACAGAGATGGAAAAG
GAAGGGAAAATTTCAAAAATTGGGCCTGAAAATCCATACAATACTCCAGTATTTGCCATAAAGAAAAAAG
ACAGTACTAAATGGAGAAAATTAGTAGATTTCAGAGAACTTAATAAGAGAACTCAAGACTTCTGGGAAGT
TCAATTAGGAATACCACATCCCGCAGGGTTAAAAAAGAAAAAATCAGTAACAGTACTGGATGTGGGTGAT
GCATATTTTTCAGTTCCCTTAGATGAAGACTTCAGGAAGTATACTGCATTTACCATACCTAGTATAAACA
ATGAGACACCAGGGATTAGATATCAGTACAATGTGCTTCCACAGGGATGGAAAGGATCACCAGCAATATT
CCAAAGTAGCATGACAAAAATCTTAGAGCCTTTTAGAAAACAAAATCCAGACATAGTTATCTATCAATAC
ATGGATGATTTGTATGTAGGATCTGACTTAGAAATAGGGCAGCATAGAACAAAAATAGAGGAGCTGAGAC
AACATCTGTTGAGGTGGGGACTTACCACACCAGACAAAAAACATCAGAAAGAACCTCCATTCCTTTGGAT
GGGTTATGAACTCCATCCTGATAAATGGACAGTACAGCCTATAGTGCTGCCAGAAAAAGACAGCTGGACT
GTCAATGACATACAGAAGTTAGTGGGGAAATTGAATTGGGCAAGTCAGATTTACCCAGGGATTAAAGTAA
GGCAATTATGTAAACTCCTTAGAGGAACCAAAGCACTAACAGAAGTAATACCACTAACAGAAGAAGCAGA
GCTAGAACTGGCAGAAAACAGAGAGATTCTAAAAGAACCAGTACATGGAGTGTATTATGACCCATCAAAA
GACTTAATAGCAGAAATACAGAAGCAGGGGCAAGGCCAATGGACATATCAAATTTATCAAGAGCCATTTA
AAAATCTGAAAACAGGAAAATATGCAAGAATGAGGGGTGCCCACACTAATGATGTAAAACAATTAACAGA
GGCAGTGCAAAAAATAACCACAGAAAGCATAGTAATATGGGGAAAGACTCCTAAATTTAAACTGCCCATA
CAAAAGGAAACATGGGAAACATGGTGGACAGAGTATTGGCAAGCCACCTGGATTCCTGAGTGGGAGTTTG
TTAATACCCCTCCCTTAGTGAAATTATGGTACCAGTTAGAGAAAGAACCCATAGTAGGAGCAGAAACCTT
CTATGTAGATGGGGCAGCTAACAGGGAGACTAAATTAGGAAAAGCAGGATATGTTACTAATAGAGGAAGA
CAAAAAGTTGTCACCCTAACTGACACAACAAATCAGAAGACTGAGTTACAAGCAATTTATCTAGCTTTGC
AGGATTCGGGATTAGAAGTAAACATAGTAACAGACTCACAATATGCATTAGGAATCATTCAAGCACAACC
AGATCAAAGTGAATCAGAGTTAGTCAATCAAATAATAGAGCAGTTAATAAAAAAGGAAAAGGTCTATCTG
GCATGGGTACCAGCACACAAAGGAATTGGAGGAAATGAACAAGTAGATAAATTAGTCAGTGCTGGAATCA
GGAAAGTACTATTTTTAGATGGAATAGATAAGGCCCAAGATGAACATGAGAAATATCACAGTAATTGGAG
AGCAATGGCTAGTGATTTTAACCTGCCACCTGTAGTAGCAAAAGAAATAGTAGCCAGCTGTGATAAATGT
CAGCTAAAAGGAGAAGCCATGCATGGACAAGTAGACTGTAGTCCAGGAATATGGCAACTAGATTGTACAC
ATTTAGAAGGAAAAGTTATCCTGGTAGCAGTTCATGTAGCCAGTGGATATATAGAAGCAGAAGTTATTCC
AGCAGAAACAGGGCAGGAAACAGCATATTTTCTTTTAAAATTAGCAGGAAGATGGCCAGTAAAAACAATA
CATACTGACAATGGCAGCAATTTCACCGGTGCTACGGTTAGGGCCGCCTGTTGGTGGGCGGGAATCAAGC
AGGAATTTGGAATTCCCTACAATCCCCAAAGTCAAGGAGTAGTAGAATCTATGAATAAAGAATTAAAGAA
AATTATAGGACAGGTAAGAGATCAGGCTGAACATCTTAAGACAGCAGTACAAATGGCAGTATTCATCCAC
AATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAG
ACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCGGGTTTATTACAGGGACAG
CAGAAATCCACTTTGGAAAGGACCAGCAAAGCTCCTCTGGAAAGGTGAAGGGGCAGTAGTAATACAAGAT
AATAGTGACATAAAAGTAGTGCCAAGAAGAAAAGCAAAGATCATTAGGGATTATGGAAAACAGATGGCAG
GTGATGATTGTGTGGCAAGTAGACAGGATGAGGATTA

Protein Sequence : Show Sequence

>NP_057849.4 Gag-Pol [Human immunodeficiency virus 1]
MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQT
GSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAADTGHSNQVSQNYPIVQNIQG
QMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINEEAA
EWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTNNPPIPVGEIYKRWIILGLNKIVRMYSPT
SILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTAC
QGVGGPGHKARVLAEAMSQVTNSATIMMQRGNFRNQRKIVKCFNCGKEGHTARNCRAPRKKGCWKCGKEG
HQMKDCTERQANFLREDLAFLQGKAREFSSEQTRANSPTRRELQVWGRDNNSPSEAGADRQGTVSFNFPQ
VTLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAI
GTVLVGPTPVNIIGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEK
EGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGD
AYFSVPLDEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQY
MDDLYVGSDLEIGQHRTKIEELRQHLLRWGLTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWT
VNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSK
DLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKITTESIVIWGKTPKFKLPI
QKETWETWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTNRGR
QKVVTLTDTTNQKTELQAIYLALQDSGLEVNIVTDSQYALGIIQAQPDQSESELVNQIIEQLIKKEKVYL
AWVPAHKGIGGNEQVDKLVSAGIRKVLFLDGIDKAQDEHEKYHSNWRAMASDFNLPPVVAKEIVASCDKC
QLKGEAMHGQVDCSPGIWQLDCTHLEGKVILVAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKTI
HTDNGSNFTGATVRAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIH
NFKRKGGIGGYSAGERIVDIIATDIQTKELQKQITKIQNFRVYYRDSRNPLWKGPAKLLWKGEGAVVIQD
NSDIKVVPRRKAKIIRDYGKQMAGDDCVASRQDED

Molecule Role : Protective antigen
Related Vaccine(s): HIV DNA vaccine pCMN160 , NYVAC-HIV-1 , NYVAC-HIV-2

26. gag-pol SIV

Gene Name : gag-pol SIV
Sequence Strain (Species/Organism) : Simian immunodeficiency virus
NCBI Gene ID : 1490009
NCBI Protein GI : 22535297
Locus Tag : SIVgp1
Genbank Accession : M29973
Protein Accession : NP_687035
Taxonomy ID : 11723
Gene Starting Position : 896
Gene Ending Position : 5313
Gene Strand (Orientation) : +
Protein Name : Gag-Pol
Protein pI : 8.66
Protein Weight : 157171.22
Protein Length : 1472

DNA Sequence : Show Sequence

>NC_001549.1:896-5313 Simian immunodeficiency virus, complete genome
AATGGGCGGGGGTCACTCAGCACTGTCAGGGAGAAGCCTCGACACGTTCGAGAAGATTAGGCTACGTCCG
AACGGGAAAAAGAAGTACCAAATTAAACATTTAATATGGGCAGGAAAAGAAATGGAACGATTTGGGTTAC
ATGAGAAACTTTTAGAAACAAAAGAAGGCTGTCAAAAAATCATAGAAGTTTTAACCCCGTTGGAACCGAC
AGGCTCCGAGGGGCTAAAAGCTCTGTTTAATTTGTGCTGCGTCATTTGGTGCATTCACGCAGAACAGAAA
GTGAAAGACACAGAGGAAGCTGTAGTAACAGTTAAGCAACACTACCATCTAGTGGACAAAAATGAGAAAG
CAGCTAAAAAGAAAAATGAGACAACAGCGCCACCTGGTGGCGAATCAAGAAATTACCCAGTAGTAAATCA
GAATAATGCCTGGGTACACCAGCCTTTGTCTCCGCGCACGTTAAATGCGTGGGTCAAATGCGTGGAGGAA
AAAAGGTGGGGAGCAGAAGTAGTCCCCATGTTCCAAGCACTCTCAGAGGGATGTCTCTCCTATGATGTAA
ATCAGATGCTCAATGTAATAGGAGACCATCAGGGGGCATTACAAATTCTTAAGGAAGTCATTAATGAAGA
AGCAGCAGAGTGGGACAGGACACACAGACCACCAGCTGGCCCGTTACCAGCAGGGCAGCTAAGAGACCCG
ACAGGGTCAGATATAGCAGGAACTACCAGCTCAATTCAGGAACAAATAGAGTGGACCTTCAATGCCAATC
CAAGAATAGACGTAGGGGCACAATACAGAAAATGGGTTATTTTGGGCTTACAAAAGGTAGTGCAGATGTA
CAATCCCCAAAAGGTCCTAGACATTCGACAGGGACCTAAAGAACCCTTCCAGGACTATGTAGACAGATTC
TATAAAGCCCTGAGAGCAGAACAAGCACCACAGGATGTTAAAAATTGGATGACACAAACTTTGCTTATCC
AGAATGCCAATCCGGATTGTAAATTGATTCTGAAAGGATTGGGAATGAATCCAACCTTGGAGGAAATGCT
AATAGCTTGCCAGGGAGTAGGAGGGCCACAACATAAGGCTAAGCTAATGGTAGAAATGATGAGTAATGGA
CAGAATATGGTCCAAGTGGGACCTCAGAAAAAGGGCCCCCGAGGGCCGCTAAAATGCTTTAATTGTGGCA
AATTTGGACATATGCAAAGGGAATGCAAGGCACCAAGACAGATCAAATGCTTTAAGTGCGGCAAAATTGG
CCATATGGCAAAAGACTGCAAGAATGGACAGGCAAATTTTTTAGGGTATGGCCATTGGGGAGGAGCGAAA
CCAAGAAATTTTGTGCAATACAGAGGAGACACAGTTGGTCTGGAACCAACAGCCCCCCCAATGGAAACAG
CTTACGATCCAGCAAAGAAGCTCCTCCAGCAGTATGCAGAGAAGGGACAGCGCCTGAGAGAGGAGAGAGA
ACAGACAAGGAAACAGAAGGAGAAAGAAGTGGAGGATGTTTCCTTGAGCTCCCTCTTTGGAGGAGACCAA
TGAAACGAGTCATCATAGAAGGAACGCCAGTGCAAGCCTTGTTAGATACAGGAGCAGATGACACTATAAT
TCAAGAAAAGGACTTGCACTTTCCCCCACATAAACCATGGCGTTCCAAGGTAGTAGGAGGTATAGGAGGA
GGGATTCATGTCAAAGAATATCAGGGGGTACAAGTACAATTGGAGGATAAAATCATCACCGGCTCAATTC
TAATAGGAAGTACACCAATCAATATTATAGGAAGAAATATTTTAGCTCAGGCAGGCATGAAATTAGTTAT
GGGAGTTCTATCTAGTCAGATTGAGGAAACAAAAGTACAACTAAAAGAAGGGAAAGATGGACCTAAATTG
AAACAATGGCCCTTATCAAGAGAAAAAATTGAAGCTTTAACAGAAATATGCAAACAAATGGAAGAGGAGG
GAAAATTATCTAGGATAGGAGGAGAAAATCCTTATAATACACCAGTGTTTGCCATAAAGAAAAAGGATAA
AACACAATGGAGAATGCTTGTAGATTTCAGGGAACTAAACAAAGCTACTCAAGACTTTTTTGAGGTTCAG
CTGGGAATTCCTCACCCAGCGGGCCTTCAGAAAAAGAAGCAAATCACAGTAATAGACATAGGGGATGCCT
ATTATTCAATACCATTATGCAAGGAATTCAGAAAATATACAGCATTTACCATCCCCTCAGTAAATAATAC
AGGGCCAGGGATAAGGTATCAGTTCAATTGTCTGCCTCAGGGATGGAAAGGATCTCCTACAATTTTCCAG
AATACGGCAGCAAACATTTTAGAGGAGATCAAAAGGCACACTCCTGGGTTAGAAATTGTCCAATACATGG
ACGATTTGTGGTTGGCGTCAGACCATGATGAGACTAGACATAATCAACAGGTAGACATAGTAAGAAAGAT
GCTGCTAGAAAAAGGTCTAGAAACCCCAGACAAGAAAGTCCAAAGAGAACCGCCATGGGAATGGATGGGG
TATAAATTGCATCCGAATAAATGGACCATTAACAAAATAGAATTACCCCCCTTAGAAGGAGAATGGACAG
TAAACAAAATACAGAAGGTAGTAGGAGTTCTAAATTGGGCAAGTCAAATTTATCCAGGAATTAAAACCAA
ACATACCTGTGCCATGTTGAGAGGGAAAAAGAACCTCCTAGAAGAAATAGTATGGACAGAAGAGGCAGAG
GCAGAATATAAGAACAATCAAGGGATAGTGCAGGAAACACAAGAAGGAACATACTATGACCCTCTCAAAG
AATTAATAGCAACAGTTCAAAAGCAAGGAGAAGGGCAATGGACATACCAATTCACCCAAGAAGGGGCAGT
ATTAAAGGTGGGAAGATATGCCAAGCAAAGAGAAACTCATACTAATGATCTAAGGACTCTAGCACACCTT
GTCCAAAAAATCTGTAAGGAAGCACTTACCATTTGGGGAAGACTTCCACGAGTACAACTCCCAGTAGACA
AGAAAACATGGGATATGTGGTGGCAGGACTATTGGCAAGTATCCTGGATACCAGAATGGGAGTTTGTTAG
CACACCACTCCTAGTAAAACTGTGGTATTCCTTAGTAAAAGAACCAATCAAAGGAGAAGATGTTTATTAT
GTGGATGGGGCAGCATCCAAAGTGACCAAATTAGGTAAGGCAGGATATCTGTCAGAGAGAGGAAAAAGTA
GAATTAGGGAATTAGAAAACACCACTAACCAACAAGCAGAATTAACAGCAGTTAAGATGGCATTGGAGGA
CAGTGGAGAAAATGTAAATATAGTCACAGATTCTCAATATGTAATGAACATCTTGACAGCATGTCCACAG
GAAAGTAACTCACCCTTAGTGGAACAGATAATACAAGCCCTAATGAAAAAGAGGCAGGTCTACTTACAAT
GGGTACCAGCTCATAAGGGGATAGGAGGCAATACAGAAATAGATAAATTAGTAAGCAAAGGAATAAGACA
GATCCTCTTCTTAGATAGAATAGAAGAAGCACAAGATGACCATGCAAAGTACCATAACAATTGGAGAAGT
ATGGTACAGGAATTTGGATTACCTAATATAGTAGCAAAAGAGATAGTAGCGGCATGTCCCAAATGCCAAA
TAAGAGGAGAACCTAAGCATGGACAGGTAGACGCCTCCATTGAAACTTGGCAGATGGACTGCACCCATTT
AGAAGGAAAAGTTATAATAGTAGCAGTACATGTAGCCAGTGGATTCATAGAAGCAGAGGTGATCCCAAGA
GAAACTGGGAAGGAGACAGCACACTTTCTGCTGAAACTGTTAGCAAGATGGCCAGTGAAACATCTACACA
CTGATAATGGCCCAAACTTTACCTCTCAGAATGTGGCAGCGGTGTGCTGGTGGGGTAATATAGAGCACAC
CACTGGAATACCTTATAACCCACAGTCACAGGGTAGTGTAGAAAGCATGAACAGACAGCTCAAGGAAATC
ATCTCTCAAATAAGAGATGATTGTGAGAGATTGGAGACAGCAGTGCAAATGGCTACGCATATCCACAATT
TTAAAAGAAAGGGAGGAATAGGGGGTATCTCTAGTGCAGAAAGATTGGTTAATATGCTAACAACACAACT
AGAACTAAATACTCTACAAAACCAAATCCAAAAAATTTTGAATTTTAAGGTCTACTACAGAGAAGGTAGA
GATCCAGTGTGGAAAGGACCAGCGCGACTCATCTGGAAAGGAGAAGGCGCGGTGGTAATTAAAGAGGGGG
AAGACATCAAGGTAGTCCCCAGGAGAAAGGCTAAGATTATCAAAGATTATGGAGAGAGAAAAACAATGGA
TAGTGAGGGTAGTATGGAGGGTGTCAGAGAGGCAAATAAGCAGATGGAGGGGGATAGTGACTTACAAGAT
CAGGAATA

Protein Sequence : Show Sequence

>NP_687035.1 Gag-Pol [Simian immunodeficiency virus]
MGGGHSALSGRSLDTFEKIRLRPNGKKKYQIKHLIWAGKEMERFGLHEKLLETKEGCQKIIEVLTPLEPT
GSEGLKALFNLCCVIWCIHAEQKVKDTEEAVVTVKQHYHLVDKNEKAAKKKNETTAPPGGESRNYPVVNQ
NNAWVHQPLSPRTLNAWVKCVEEKRWGAEVVPMFQALSEGCLSYDVNQMLNVIGDHQGALQILKEVINEE
AAEWDRTHRPPAGPLPAGQLRDPTGSDIAGTTSSIQEQIEWTFNANPRIDVGAQYRKWVILGLQKVVQMY
NPQKVLDIRQGPKEPFQDYVDRFYKALRAEQAPQDVKNWMTQTLLIQNANPDCKLILKGLGMNPTLEEML
IACQGVGGPQHKAKLMVEMMSNGQNMVQVGPQKKGPRGPLKCFNCGKFGHMQRECKAPRQIKCFKCGKIG
HMAKDCKNGQANFFRVWPLGRSETKKFCAIQRRHSWSGTNSPPNGNSLRSSKEAPPAVCREGTAPERGER
TDKETEGERSGGCFLELPLWRRPMKRVIIEGTPVQALLDTGADDTIIQEKDLHFPPHKPWRSKVVGGIGG
GIHVKEYQGVQVQLEDKIITGSILIGSTPINIIGRNILAQAGMKLVMGVLSSQIEETKVQLKEGKDGPKL
KQWPLSREKIEALTEICKQMEEEGKLSRIGGENPYNTPVFAIKKKDKTQWRMLVDFRELNKATQDFFEVQ
LGIPHPAGLQKKKQITVIDIGDAYYSIPLCKEFRKYTAFTIPSVNNTGPGIRYQFNCLPQGWKGSPTIFQ
NTAANILEEIKRHTPGLEIVQYMDDLWLASDHDETRHNQQVDIVRKMLLEKGLETPDKKVQREPPWEWMG
YKLHPNKWTINKIELPPLEGEWTVNKIQKVVGVLNWASQIYPGIKTKHTCAMLRGKKNLLEEIVWTEEAE
AEYKNNQGIVQETQEGTYYDPLKELIATVQKQGEGQWTYQFTQEGAVLKVGRYAKQRETHTNDLRTLAHL
VQKICKEALTIWGRLPRVQLPVDKKTWDMWWQDYWQVSWIPEWEFVSTPLLVKLWYSLVKEPIKGEDVYY
VDGAASKVTKLGKAGYLSERGKSRIRELENTTNQQAELTAVKMALEDSGENVNIVTDSQYVMNILTACPQ
ESNSPLVEQIIQALMKKRQVYLQWVPAHKGIGGNTEIDKLVSKGIRQILFLDRIEEAQDDHAKYHNNWRS
MVQEFGLPNIVAKEIVAACPKCQIRGEPKHGQVDASIETWQMDCTHLEGKVIIVAVHVASGFIEAEVIPR
ETGKETAHFLLKLLARWPVKHLHTDNGPNFTSQNVAAVCWWGNIEHTTGIPYNPQSQGSVESMNRQLKEI
ISQIRDDCERLETAVQMATHIHNFKRKGGIGGISSAERLVNMLTTQLELNTLQNQIQKILNFKVYYREGR
DPVWKGPARLIWKGEGAVVIKEGEDIKVVPRRKAKIIKDYGERKTMDSEGSMEGVREANKQMEGDSDLQD
QE

Molecule Role : Protective antigen
Related Vaccine(s): NYVAC-SIV

27. gp120

Gene Name : gp120
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
NCBI Protein GI : 2326505
Other Database IDs : CDD:278917
GOA:O40515
InterPro: IPR000777
UniProtKB/TrEMBL: O40515
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein pI : 9.81
Protein Weight : 11668
Protein Length : 172
Protein Note : Envelope glycoprotein GP120; pfam00516

Protein Sequence : Show Sequence

>CAA74764.1 gp120, partial [Human immunodeficiency virus 1]
NGSLAEGEVVIRSENFTDNAKTIIVQLNESVVINCTRPNNNTRKNIHLGRGRSVYATEKIIGNVKQAHCN
ISRAKWNDTLKQIVEKLREQFGKNKTIVFNQSSGGDPEI

Molecule Role : Protective antigen
Related Vaccine(s): HIV DNA vaccine VlJns-tPA-gp120

28. gp120

Gene Name : gp120
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
NCBI Protein GI : 7769646
Other Database IDs : CDD:278917
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein Name : gp120
Protein pI : 5.17
Protein Weight : 14848.42
Protein Length : 201
Protein Note : isolated from a 37 year old injecting drug user; HIV-1 RNA was extracted from plasma; RNA was reverse transcribed and the gp120 region was amplified using nested PCR; sequence was obtained bi-directionally from cloned DNA

Protein Sequence : Show Sequence

>AAF69493.1 gp120, partial [Human immunodeficiency virus 1]
VPVWKDAETTLFCASDAKAHETEVHNVWATHACVPTDPNPQEIQLKNVTENFNMWKNNMVEQMQEDVISL
WDQSLKPCVKLTPLCVTLNCTDATLTNSTYITNVSKIIGDITEEVRNCSFNMTTELRDKKQKVHALFL

Molecule Role : Protective antigen

29. HIV complete genome

Gene Name : HIV complete genome
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
NCBI Nucleotide GI : 388332048
NCBI Protein GI : 388332049
Protein Accession : AFK29870.1
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein Name : gag protein
Protein Note : subtype: B

DNA Sequence : Show Sequence

>gi|388332048|gb|JN860769.1| HIV-1 isolate MERLBDTRC10 from Thailand, complete genome
GATGGGTGCGAGAGCGTCAGTATTAAGCGGCGGAAAATTAGATCAATGGGAAAAAATTCGGTTAAGACCA
GGAGGAAAGAAAAAATATAAATTAAAACATATAGTATGGGCAAGCAGGGAGCTAGAAAGATTTGCAGTTA
ATCCTGGCCTTTTAGAAACAGCAGAAGGCTGTAGACAAATACTGGGACAGCTACAGCCATCCCTTCAGAC
AGGGTCAGAAGAACTTAAATCATTATTTAATACAGTGGCAACCCTCTATTGTGTGCATCAAAGGATAGAG
ATAAAAGACACCAAAGAAGCTCTAGACAGGATAGAGGAAGAACAAAATAAAAGTAAGCAAAAAGCACAGC
CAGCGGCAGCTGACACAGGAAACAACAGCCAGGTCAGCCAAAATTACCCTATAGTACAGAACCTGCAGGG
GCAAATGGTACATCAGCCCATATCACCTAGAACTCTAAATGCATGGGTGAAAGTAGTAGAAGAGAAGGCT
TTCAGCCCAGAAGTAATACCCATGTTTTCAGCYTTATCAGAAGGAGCCACCCCACAAGATTTAAACACCA
TGCTAAACACAGTGGGGGGACATCAAGCAGCCATGCAAATGTTAAAAGAGACTATAAATGAAGAAGCTGC
AGAATGGGATAGAGTGCATCCAGTACATGCAGGGCCTATTGCACCAGGCCAGATGAGGGAACCAAGGGGA
AGTGACATAGCAGGAACCACTAGCACCCTTCAGGAACAAATAGCATGGATGACAAATAATCCACCTATCC
CAGTAGGAGACATCTATAAAAGATGGATAATCCTGGGGCTAAATAAAATAGTAAGAATGTACAGCCCTAC
TAGCATTCTGGACATAAAACAAGGACCAAAAGAGCCCTTTAGAGATTATGTAGATCGGTTCTATAGAACC
CTAAGAGCCGAGCAAGCTTCACAGGATGTAAAAAATTGGATGACAGAAACCTTGTTGGTCCAAAATTCGA
ACCCAGATTGTAAAACTATTTTAAAAGCATTGGGACCAGCAGCTACACTAGAAGAAATGATGACAGCATG
TCAAGGAGTGGGGGGACCCAGCCATAAAGCAAGAGTCTTGGCTGAAGCAATGAGCCAAGCAACAAATTCA
GCTGCTGCCATAATGATGCAGAGAAACAATTTTAAGCAGAGAGGCAATTTTAAGGGCCAAAGGAGAGTCG
TTAAATGTTTCAACTGTGGCAAGGAAGGGCACATAGCCAAAAATTGCAGGGCCCCTAGAAAAAAGGGTTG
TTGGAAATGTGGACAGGAAGGACACCAAATGAAAGATTGTACTGAGAGACAGGCTAATTTTTTAGGGAAA
ATCTGGCCCTCCCACAAGGGAAGGCCAGGAAACTTTCTTCAGAACAGACCAGAGCCAACAGCCCCTCCAG
AAGAGAGCTTCAGGTTTGGGGAAGAGACAACAACTCCCCCTCAGAAACAGGAACCAATAGACAAGGAACT
ATATCCCTTAGCTTCCCTCAGATCACTCTTTGGCAACGACCCCTTGTCGCAATAAAGATAGGGGGGCAGT
TAAGGGAAGCTCTATTAGACACAGGAGCAGATGATACAGTATTAGAAGAAATGAATTTACCAGGAAAATG
GAAACCAAAAATGATAGGGGGAATTGGAGGTTTTATCAAAGTAAGGCAATATGAGCAAATACCTATAGAA
ATCTGTGGACATAAAGCTATAGGTACAGTATTAATAGGACCTACACCTGTAAACATAATTGGAAGAAATT
TGTTGACTCAGCTTGGTTGCACTCTAAATTTTCCCATTAGTCCTATTGAAACTGTACCAGTAAAATTAAA
GCCAGGAATGGATGGCCCAAAAGTTAAACAATGGCCATTGACAGAAGAAAAAATAAAAGCATTAGTAGAA
ATTTGTACAGAAATGGAAAAGGAAGGAAAGATTTCAAAAATTGGGCCTGAAAATCCATACAATACTCCAA
TATTTGCCATAAAGAAAAAAGACAGTACTAAATGGAGAAAATTAGTAGATTTCAGAGAACTCAATAAGAG
AACTCAAGACTTCTGGGAAGTTCAATTAGGAATACCACATCCTGCAGGGTTAAAACAGAAAAAATCAGTA
ACAGTACTGGATGTGGGTGATGCATACTTCTCAGTTCCTTTGGATAAAGAATTCAGGAAGTATACTGCAT
TTACCATACCTAGTGTAAACAATGAGACACCAGGGGTTAGATATCAGTACAATGTGCTTCCACAGGGATG
GAAAGGATCACCAGCAATATTTCAAAGTAGCATGACAAGAATTTTAGAGCCTTTTAGAAAACAAAATCCA
GACATAGTTATCTATCAATACATGGATGATCTGTATGTAGGGTCTGACTTAGAAATAGAGCAGCATAGAA
CAAAAATAGAGGAGCTGAGACAACATCTGTTGAGGTGGGGATTTACCACACCAGACAAAAAACATCAGAA
GGAACCTCCATTCCTTTGGATGGGTTATGAACTCCATCCTGATAAATGGACAGTACAGCCTATAAGGTTG
CCAGAAAAAGACAGCTGGACTGTCAATGATATACAAAAGTTAGTGGGAAAATTGAATTGGGCAAGCCAGA
TTTATCCAGGGATTAAAATAAAGCAATTATGTAAACTCCTTAGGGGAACCAAAGCACTAACAGAAATAGT
ATCACTAACAGAAGAAGCAGAGTTAGAACTAGCAGAAAACAGGGAGATTCTAAGAGAACCAGTACATGGA
GTGTATTATGACCCATCAAAAGACTTAATAGCAGAAATACAGAAGCAGGGGCAAGGCCAATGGACATATC
AAATTTATCAAGAGCCATTTAAAAACCTGAAAACAGGAAAGTACGCAAGAATGAGGGGCACCCATACTAA
TGATGTAAAACAATTAACCGAGGCAGTACAAAAAATAGCCACAGAAAGCATAGTAATATGGGGAAAGACC
CCCAAATTTAAACTACCCATACAAAAAGAAGCATGGGAAGCATGGTGGACAGATTATTGGCAAGCCACCT
GGATCCCTGAATGGGAGTTTGTCAATACCCCTCCTTTAGTGAAATTATGGTACCAGTTAGAGAAAGAACC
CATAGAAGGAGCAGAAACTTTCTATGTAGATGGGGCAGCTAATAGGGAGACTAAAATAGGAAAAGCAGGA
TATGTTACTAACAAAGGAAGACAAAAAGTTGTCACCCTACCTGACACAACAAATCAGAAGACTGAGTTAC
AAGCAATTAATCTAGCTTTACAAGATTCTGGATTAGAAGTAAACATAGTAACAGACTCACAATATGCATT
AGGAATCATTCAAGCACAACCAGATAAGAGTGAATCAGAGTTAGTCAGTCAAATAATAGAGCAGTTAATA
AAAAAGGAAAAAGTCTACCTGGCATGGGTGCCAGCACACAAAGGAATTGGAGGAAATGAACAAATAGATA
AATTAGTTAGTGCTGGAATCAGGAAAGTACTATTTTTAGATGGAATAGATAAGGCCCAAGAAGAACATGA
GAAATATCACAATAACTGGAGAGCAATGGCTAGTGATTTTAACCTGCCACCTATAGTAGCAAAAGAAATA
GTAGCCAGCTGTGATAAATGTCAGCTAAAAGGAGAAGCCATGCATGGACAAGTAGACTGTAGTCCAGGAA
TATGGCAACTAGACTGTACCCATTTAGAAGGAAAAATTATCCTGGTGGCAGTACATGTGGCCAGTGGCTA
TATAGAAGCAGAAGTTATTCCAGCAGAAACAGGACAGGAAACAGCATACTTTCTCTTAAAGTTAGCAGGA
AGATGGCCAGTAAAAACAATACATACAGACAATGGCAGCAATTTCACCAGTAATACGGTTAAGGCCGCCT
GTTGGTGGGCGGGGATCAAGCAGGAATTTGGCATTCCCTACAATCCCCAAAGCCAAGGAGTAGTAGAATC
TATGAATAAAGAATTAAAGAAAATTATAGAACAGGTAAGAGATCAAGCTGAACATCTTAAGACAGCAGTA
CAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAA
TAGTAGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAACATATTACAAAAATGCAAAATTT
TCGGGTTTATTACAGGGACAACAGAGATCCACTTTGGAAAGGACCAGCAAAGCTCCTTTGGAAAGGTGAA
GGGGCAGTAGTAATACAAGAAAATAGTGACATAAAAGTAGTGCCAAGAAGAAAAGCAAAGATCATTAGGG
ATTATGGAAAACAGATGGCAGGTGATGATTGTGTGGCAAGTAGACAGGATGAGGATTAACACCTGGAAAA
GTTTGGTAAAATACCATATGCATGTTTCAAAGAAAGCTAGGGGATGGTTTTATAGACATCACTATGAAAG
CACTCACCCTAGAATAAGTTCAGAAGTACACATCCCACTAGGGGATGCTGAATTGGTAGTAATAACATAT
TGGGGTCTAAATACAGGAGAAAGAGAGTGGCATTTAGGTCAAGGAGCCTCCATAGAATGGAGAAAAAAGA
GGTACAGCACACAAGTAGACCCTAATGTAGCAGACCAACTAATTCATCTGTATTACTTTGATTGTTTTTC
AGAATCTGCTATAAGAAAGGCCATATTAGGAAGTAGAGTTAGACCTAGGTGTGAATATCAAGCAGGACAT
AACAAGGTAGGATCTCTACAGTACTTGGCACTAACAGCATTACTAACACCAAAAAAGATAAAGCCACCTT
TGCCTAGTGTTAGGAAACTGACAGAGGATAGATGGAACAAGCCCCGGAAGACCAAGGGCCACAGAGGGAG
CCAAACAACGAATGGACATTAGAGCTTTTAGAGGAACTGAAGAGTGAAGCAGTTAGACACTTCCCTAGGC
CATGGCTCCATAGCTTAGGACAATATATCTATAGAACTTATGGAGATACTTGGACGGGAGTGGAAGCTCT
AATAAGAATGCTGCAACAACTGCTGTTTATTCATTTCAGAATTGGGTGTCAACATAGCAGAATAGGCATT
ACTCCAACGAGAAGAGCAAGAAATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGT
CAGCCTAGGACTACTTGTACCAATTGTTATTGTAAAAAGTGCTGCTTTCATTGCCAAGTTTGCTTCATAA
AAAAAGGCTTAGGCATCTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAGGACCTCCTCAAGACAGTCA
GACTCATCAAGCTTCTCTATCAAAGCAGTAAGTAGTAAATGTGATGCAAGCTTTATACATTTTAGCAATA
GTAGCTTTAGTAATAGCAGCAATAATAGCAATAGTTGTATGGACCATAGTAATTATAGAATATAGGAAAA
TATTAAGACAGAAAAAAATAGATAGATTAATTGATAGAATAAGAGAAAGAGCAGAAGACAGTGGCAATGA
AAGCGAAGGGGATCAGGAAGAATTATCAGCACTTGTGGTGGAAATGGGGCACGATGCTCCTTGGGATGTT
GATGATCTGTAGTGCAACAAAACAATTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAAGATGCA
TCCACCACTCTATTTTGTGCATCAGATGCTAAAGCATATGATACAGAGGCACATAATGTTTGGGCCACGC
ATGCCTGTGTACCCACAGACCCTAACCCACAAGAAATAGCATTGGGAAATGTGACAGAAAAGTTTAACAT
GTGGGAAAATAACATGGTAGATCAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCCA
TGTGTAAGATTAACCCCACTCTGTGTCACTTTAAATTGCACTGATGTGTGGAGAAATACTACTAATACTA
CTAGTGGTGGGGAGGAAGTGATGGAGAGCGGAGAAATAAAAAACTGCTCTTTCAATATCACCACAAGCAC
AAAAGATAAGAAGAACACATATGCACTTTTTTATAAACTTGATGTAACACCAATGGATAATGAAGTATCA
AGAAATAATATTACAAATGATACCAATTATAGTAGGTATAGGTTGTTAAATTGTAACACCTCAGTCATTA
CACAGGCCTGTCCAAAGGTATCCTTTGAACCAATTCCTATACATTATTGCACCCCGGCTGGTTTTGCGAT
TATACAGTGTAATGATAAGAAGTTCAATGGAACAGGACCATGTAAAAATGTCAGCACAGTACAATGTACA
CATGGAATTAGACCAGTAGTGTCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAGGAGATAGTAA
TTAGATCTAAAAATTTTACAAACAATGCTAACACCATAATAGTACAGCTGAATAAATCTGTAACAATTGA
TTGTATAAGACCCAACAACAATACAAGGAAAAGTATACATATGGGGCCAGGGAAAGCATTTTATACAACA
GGAGACATAATAGGAGATATAAGAAAAGCACATTGCAGCATTAATAGAACAGATTGGGAAAACACTTTAA
AACAGGTAGCTAACAAATTAATGGAACAATTTGGGAATAAAACAATAGTCTTTAAGAACTCCTCAGGAGG
GGACCCAGAAATTACAACACACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATACATCAGCACTG
TTTAATCATACGTTTAATAATACTGAAGGCGAAAATATAACTGAAAGCATAAATACAACAATTATCAAGC
TCCCATGCAGAATAAAACAAATTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCAT
CAGTGGACAAATTAGCTGTTCATCAAATATTACAGGAATACTATTAACAAGAGATGGTGGTGGTAATAAT
ACGGGAAATGAGACCTTCAGACCTGGGGGAGGAAATATGAAAGACAATTGGAGAAGTGAATTATATAAAT
ATAAAGTAGTAAAAATTGAGCCATTAGGAATAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGA
AAAAAGAGCAGTGGGAGTGATAGGAGCTATGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC
GCAGCGTCACTGACGCTGACGGTACAGGCCAGACAATTGTTGTCTGGTATAGTGCAACAGCAGAACAATT
TGCTGAGAGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGC
AAGAGTCCTGGCTGTGGAGAGATACCTAAAGGACCAACAGCTCCTAGGGATTTGGGGTTGCTCTGGAAAA
CTCATTTGCACCACTGCTGTACCTTGGAATGATAGTTGGAGTAATAAATCTCTGACTGAGATTTGGAATA
ACATGACCTGGATGGAGTGGGAAAGAGAAATTAACAATTATACAGGCATAATATACTCCTTAATTGAGGA
ATCGCAGAACCAGCGGGAAAAGAATGAACTAGAATTATTGGAATTGGATAAGTGGGCAAGTTTGTGGAAT
TGGTTTGACATAACAAAATGGCTGTGGTATATAAAAATATTCATAATGATAGTAGGAGGCTTGGTAGGTT
TAAGAATAGTTTTTGCTGTACTTTCTATAGTAAATAGAGTTAGGCAGGGATACTCACCATTGTCATTACA
GACCCGCTTCCCAGCCCCGAGGGGACCCGGAGGGCCCGAAGGAATCGAAGAAGAAGGTGGAGAGAGAGAC
AGAGACAGATCCGGGACATTAGTGAACGGATTCTTGACACTTATCTGGGACGACCTCCAGAACCTGTGCC
TCTTCAGTTACCGCCGATTGAGAGACTTACTCTTGATTGTAGTGAGGATTGTGGAACTTCTGGGACGCAG
GGGGTGGGAGGCCCTCAAGTATTGGTGGAACCTCCTGCAGTATTGGGGTCAGGAACTAAAGAATAGTGCT
GTTAGCTTGCTCAATGTCACAGCCATAGCAGTAGCTGAGGGGACAGATAGGGTTATAGAAGTAGTACAAA
GAGCCTATAGAGCTATTATCCACATACCTAGAAGAATAAGACAGGGCTTAGAAAGGACTTTAGTATAAAA
TAAAAATAAGACAGGGCTTAGAAAGGACTTTAGTATAAAATGGGTGGCAAGTGGTCAAAAAGTAGTCTGG
TTGGATGGCCTGCTATAAGGGAAAGAATGAAACGAGCTGAGCCAGCAGCAGATGGGGTGGGAGCAGTATC
TCGAGACCTGGAAAGACATGGAGCAATCACAAATAACAATACACCAGCTAATAATGCTGATTGTGCCTGG
CTGGAAGCACAAGAAGAGGAGGAGGAGGTGGGTTTTCCAGTCAAACCCCAGGTACCTTTAAGGCCAATGA
CTTACAAGGGAGCTCTGGATCTGAGCCACTTTTTAAGAGAAAAGGGGGGACTGGAAGGGTTAGTTTACTC
CCAGAAAAGACAAGACATTCTTGATCTGTGGATCTATCACACACAAGGCTTCTTCCCTGACTGGCAGAAC
TACACACCAGGGCCAGGGACCAGATTTCCACTGACCTTTGGATGGTGCTTCAAGCTAGTACCAGTAGAGC
CAGAGGAGGTAGAAAAGGCCAATGAAGGGGAGAATAACTGCTTGTTGCATCCTATGAGCCAACATGGAAT
GGAAGACCCGGAGAGAGAAGTGTTAAAGTGGAAGTTTGACAGCAGCCTAGCATATCATCACAGGGCCCGA
GAGCTGCATCCGGAGTTCTACAAAGACTGCTGACACCGAGCTTTCTACAAGGGACTTTCCGCTGGGGACT
TTCCAGGGGAGGTGTGGCCTGGGCGGGACCGGGGAGTGGCGAG

Molecule Role : Other

30. HIV1 ENV

Gene Name : HIV1 ENV
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
NCBI Protein GI : 1490266
Other Database IDs : CDD:197369
GOA:Q76270
InterPro: IPR000328
PDB: 1I5X
PDB: 1I5Y
PDB: 1QR8
PDB: 1QR9
UniProtKB/TrEMBL: Q76270
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein Name : GP41
Protein pI : 6.77
Protein Weight : 13958.9
Protein Length : 186
Protein Note : heptad repeat 1-heptad repeat 2 region (ectodomain) of the gp41 subunit of human immunodeficiency virus (HIV-1), and related domains; cd09909

Protein Sequence : Show Sequence

>CAA58216.1 GP41, partial [Human immunodeficiency virus 1]
FLGFLGAAGSTMGAASITLTVQARTLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARVLAVERYLQ
DQQLLGIWGCSGKHICTTTVPWNSSWSNKSLEEIWQNMTWMEWEREIDNYTGLI

Molecule Role : Protective antigen

31. Nef

Gene Name : Nef
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
VO ID : VO_0011261
NCBI Gene ID : 156110
NCBI Protein GI : 28872818
Locus Tag : HIV1gp9
Genbank Accession : AF033819
Protein Accession : NP_057857
Taxonomy ID : 11676
Gene Starting Position : 8342
Gene Ending Position : 8962
Gene Strand (Orientation) : +
Protein Name : Nef
Protein pI : 6.42
Protein Weight : 22179.3
Protein Length : 206
Protein Note : This particular nucleotide sequence has a premature stop codon in place of a well-conserved tryptophan codon at position 8712-8714 that truncates the HIV1 Nef protein sequence to a 123 amino acids-long N-terminal portion (not shown).

DNA Sequence : Show Sequence

>NC_001802.1:8342-8962 Human immunodeficiency virus 1, complete genome
GATGGGTGGCAAGTGGTCAAAAAGTAGTGTGATTGGATGGCCTACTGTAAGGGAAAGAATGAGACGAGCT
GAGCCAGCAGCAGATAGGGTGGGAGCAGCATCTCGAGACCTGGAAAAACATGGAGCAATCACAAGTAGCA
ATACAGCAGCTACCAATGCTGCTTGTGCCTGGCTAGAAGCACAAGAGGAGGAGGAGGTGGGTTTTCCAGT
CACACCTCAGGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAA
AAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATATCCTTGATCTGTGGATCTACCACA
CACAAGGCTACTTCCCTGATTAGCAGAACTACACACCAGGGCCAGGGGTCAGATATCCACTGACCTTTGG
ATGGTGCTACAAGCTAGTACCAGTTGAGCCAGATAAGATAGAAGAGGCCAATAAAGGAGAGAACACCAGC
TTGTTACACCCTGTGAGCCTGCATGGGATGGATGACCCGGAGAGAGAAGTGTTAGAGTGGAGGTTTGACA
GCCGCCTAGCATTTCATCACGTGGCCCGAGAGCTGCATCCGGAGTACTTCAAGAACTGCTG

Protein Sequence : Show Sequence

>NP_057857.2 Nef [Human immunodeficiency virus 1]
MGGKWSKSSVIGWPTVRERMRRAEPAADRVGAASRDLEKHGAITSSNTAATNAACAWLEAQEEEEVGFPV
TPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDILDLWIYHTQGYFPDWQNYTPGPGVRYPLTFG
WCYKLVPVEPDKIEEANKGENTSLLHPVSLHGMDDPEREVLEWRFDSRLAFHHVARELHPEYFKNC

Molecule Role : Protective antigen
Molecule Role Annotation : Study compared the handling of overlapping 24-mer peptides from HIV Nef either mixed or covalently linked in tandem in one protein. With adjuvant, overlapping peptides were capable of protecting Balb/c mice against lethal viral challenge with 3 × 108 plaque forming units of vv-nef, whereas the intact protein was less protective (Zhang et al., 2009).
Related Vaccine(s): DNA vaccine expressing multiple HIV epitopes

32. nef

Gene Name : nef
Sequence Strain (Species/Organism) : Human immunodeficiency virus 2
NCBI Protein GI : 1845210
Other Database IDs : CDD:249884
Taxonomy ID : 11709
Gene Strand (Orientation) : ?
Protein Name : nef protein
Protein pI : 6.88
Protein Weight : 28422.79
Protein Length : 319
Protein Note : similar to HIV2BEN, GenBank Accession Number M30502, and to HIV2D194, GenBank Accession Number J04542

Protein Sequence : Show Sequence

>AAB47785.1 nef protein [Human immunodeficiency virus 2]
MGASGSKKLSKQSQGLRERLLRARGGGYVRQCSASGGESSQSQGGSGREQKSPSCEGQQYRQGDYMNTPW
RTPAMEGQKESYKQQNMDDVDSDDNDQVGVSVTSRVPLRPMTYKLAVDMSHFIKEKGGLEGMFYSRDRHR
ILDLYLEKEEGVIPDWQNYTHGPGVRYPMCFGWLWKLVPVNMSQEAEDDETNCLMHPAQTSRYDDIHGET
LVWRFNSMLAYEYKAFTLYPEEFGHKSGLPEKEWKAKLKARGIPYSE

Molecule Role : Protective antigen
Related Vaccine(s): HIV-2 DNA vaccine

33. nef from subtype B

Gene Name : nef from subtype B
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
NCBI Protein GI : 108860393
Other Database IDs : CDD:109523
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein Name : Nef
Protein Length : 207
Protein Note : Vector:p04JPDR6075B-50; subtype B

Protein Sequence : Show Sequence

>gi|108860393|dbj|BAE95916.1| Nef [Human immunodeficiency virus 1]
MGGKWSKFSGWPAVRERIRRTEPAADPPADGVGAASRDLGAHGAITSSNTAATNADCAWLEAQEEEEVGF
PVRPQVPLRPMTYKGAVDLSHFLKEKGGLEGLIYSQKRKDILDLWVYHTQGYFPDWHNYTPGPGTRFPLT
FGWCFKLVPVDQEQVEKANEGENNALLHPMHLHGMDDPEREVLQWKFDSRLAFRHVAREMHPDFYKD

Molecule Role : Other

34. Nef SIV

Gene Name : Nef SIV
Sequence Strain (Species/Organism) : Simian immunodeficiency virus
NCBI Gene ID : 1490008
NCBI Protein GI : 9627209
Locus Tag : SIVgp7
Genbank Accession : M66437
Protein Accession : NP_054373
Taxonomy ID : 11723
Gene Starting Position : 8599
Gene Ending Position : 9270
Gene Strand (Orientation) : ?
Protein Name : nef protein
Protein pI : 6.4
Protein Weight : 24504.09
Protein Length : 223

DNA Sequence : Show Sequence

>gi|9627204:8599-9270 Simian immunodeficiency virus, complete genome
TATGGGCTCCAGCAACTCCAAGAGGCAGCAACAGGGCTTGCTCAAGCTCTGGCGAGGGCTGCGAGGGAAG
CCTGGGGCAGACTGGGTGCTATTGTCCGATCCGCTTATCGGGCAGTCATCAACAGTCCAAGAAGAGTGCG
GCAAGGCCTTGAAAAAGTCCTGGGGTAAAGGTAAAATGACTCCAGACGGCCGCCGCCTGCAAGAAGGAGA
CACCTTTGATGAGTGGGATGATGATGAAGAAGAAGTAGGCTTCCCTGTGCAACCTCGAGTCCCCTTAAGA
CAGATGACCTATAAATTAGCAGTGGACTTTTCCCACTTTTTAAAATCAAAGGGGGGACTGGATGGGATAT
ATTACTCTGAAAGAAGAGAAAAGATCCTGAATTTGTATGCCTTGAACGAGTGGGGAATAATAGATGATTG
GCAAGCTTACTCACCAGGCCCGGGGATAAGGTACCCGAGAGTCTTTGGCTTCTGCTTTAAGCTAGTCCCA
GTGGACCTGCATGAGGAGGCACGCAACTGTGAGAGACACTGTCTGATGCATCCAGCACAGATGGGGGAAG
ATCCTGATGGAATAGATCATGGAGAAGTCTTGGTCTGGAAGTTTGACCCGAAGTTGGCGGTGGAGTACCG
CCCGGACATGTTTAAGGACATGCACGAACATGCAAAGCGCTA

Protein Sequence : Show Sequence

>gi|9627209|ref|NP_054373.1| nef protein [Simian immunodeficiency virus]
MGSSNSKRQQQGLLKLWRGLRGKPGADWVLLSDPLIGQSSTVQEECGKALKKSWGKGKMTPDGRRLQEGD
TFDEWDDDEEEVGFPVQPRVPLRQMTYKLAVDFSHFLKSKGGLDGIYYSERREKILNLYALNEWGIIDDW
QAYSPGPGIRYPRVFGFCFKLVPVDLHEEARNCERHCLMHPAQMGEDPDGIDHGEVLVWKFDPKLAVEYR
PDMFKDMHEHAKR

Molecule Role : Other
Related Vaccine(s): HIV DNA vaccine SIVmac239 Gag-Pol-Nef and mock Env with rAd5 boost

35. pol

Gene Name : pol
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
NCBI Protein GI : 7021456
Other Database IDs : CDD:278505
CDD:133149
CDD:238823
CDD:278506
CDD:284283
CDD:284281
CDD:278503
CDD:259998
CDD:280240
CDD:279057
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein Name : pol
Protein pI : 7.77
Protein Weight : 90126.73
Protein Length : 918
Protein Note : long-term nonprogressor

Protein Sequence : Show Sequence

>AAF35355.1 pol, partial [Human immunodeficiency virus 1]
FFREDLAFPQGKAREFPSEQTRAISPARRELQVWGRDNNSLSEAGANRQGTVSFSFPQITLWQRPLVAIK
IGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQVAIEICGHKAIGTVLIGPTPVNI
IGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENP
YNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFR
KYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEI
GQHRIKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIVLPEKDSWTVNDIQKLVGKLN
WASQIYAGIKVKQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGVYYDPAKDLIAEIQKQGQG
QWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKVAIESIVIWGKTPKFKLPIQKETWEAWWTEY
WQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTDRGRQKVVPLTDTTNQ
KTELQAIHLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVSQIIEQLIKKEKVYLAWVPAHKGIGGN
EQVDKLVSAGIRKVLFLDGIDKAQEEHEKYHSNWRAMAGDFNLPPVVAKEIVACCDKCQLKGEAMHGQVD
CSPGIWQLDCTHLEGKVILVAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKTIHTDNGSNFTSNT
VKAACW

Molecule Role : Protective antigen
Related Vaccine(s): DNA vaccine expressing multiple HIV epitopes , HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)

36. pol

Gene Name : pol
Sequence Strain (Species/Organism) : Simian-Human immunodeficiency virus strain SHIV-89.6
NCBI Protein GI : 2828038
Other Database IDs : CDD:133149
CDD:295487
CDD:278506
CDD:238185
CDD:284283
CDD:284281
CDD:278503
CDD:259998
CDD:280240
CDD:279057
CDD:278951
Taxonomy ID : 57667
Gene Strand (Orientation) : ?
Protein Name : pol
Protein pI : 7.9
Protein Weight : 113326.45
Protein Length : 1139
Protein Note : Retropepsins, pepsin-like aspartate proteases; cd05482

Protein Sequence : Show Sequence

>AAB99959.1 pol, partial [Simian-Human immunodeficiency virus]
LELWERGTLCKAMQSPKKTGMLEMWKNGPCYGQMPRQTGGFFRPWSMGKEAPQFPHGSSASGADANCSPR
GPSCGSAKELHAVGQAAERKAERKQREALQGGDRGFAAPQFSLWRRPVVTAHIEGQPVEVLLDTGADDSI
VTGIELGPHYTPKIVGGIGGFINTKEYKNVEIEVLGKRIKGTIMTGDTPINIFGRNLLTALGMSLNFPIA
KVEPVKVALKPGKDGPKLKQWPLSKEKIVALREICEKMEKDGQLEEAPPTNPYNTPTFAIKKKDKNKWRM
LIDFRELNRVTQDFTEVQLGIPHPAGLAKRKRITVLDIGDAYFSIPLDEEFRQYTAFTLPSVNNAEPGKR
YIYKVLPQGWKGSPAIFQYTMRHVLEPFRKANPDVTLVQYMDDILIASDRTDLEHDRVVLQSKELLNSIG
FSTPEEKFQKDPPFQWMGYELWPTKWKLQKIELPQRETWTVNDIQKLVGVLNWAAQIYPGIKTKHLCRLI
RGKMTLTEEVQWTEMAEAEYEENKIILSQEQEGCYYQEGKPLEATVIKSQDNQWSYKIHQEDKILKVGKF
AKIKNTHTNGVRLLAHVIQKIGKEAIVIWGQVPKFHLPVEKDVWEQWWTDYWQVTWIPEWDFISTPPLVR
LVFNLVKDPIEGEETYYTDGSCNKQSKEGKAGYITDRGKDKVKVLEQTTNQQAELEAFLMALTDSGPKAN
IIVDSQYVMGIITGCPTESESRLVNQIIEEMIKKSEIYVAWVPAHKGIGGNQEIDHLVSQGIRQVLFLEK
IEPAQEEHDKYHSNVKELVFKFGLPRIVARQIVDTCDKCHQKGEAIHGQANSDLGTWQMDCTHLEGKIII
VAVHVASGFIEAEVIPQETGRQTALFLLKLAGRWPITHLHTDNGANFASQEVKMVAWWAGIEHTFGVPYN
PQSQGVVEAMNHHLKNQIDRIREQANSVETIVLMAVHCMNFKRRGGIGDMTPAERLINMITTEQEIQFQQ
SKNSKFKNFRVYYREGRDQLWKGPGELLWKGEGAVILKVGTDIKVVPRRKAKIIKDYGGGKEVDSSSHME
DTGEAREVA

Molecule Role : Protective antigen
Related Vaccine(s): HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)

37. pol from subtype B

Gene Name : pol from subtype B
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
NCBI Protein GI : 108860386
Other Database IDs : CDD:133149
CDD:73152
CDD:200982
CDD:115473
CDD:203523
CDD:209893
CDD:187690
CDD:202092
CDD:207376
CDD:144223
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein Name : Pol
Protein Length : 1003
Protein Note : Vector:p04JPDR6075B-50; subtype B

Protein Sequence : Show Sequence

>gi|108860386|dbj|BAE95909.1| Pol [Human immunodeficiency virus 1]
FFRENLAFQQGEAREFPSEQTRANSPTRRELQVWGEDNNSLSEAGADRRGTISFSFPQITLWQRPLVTVK
IGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVRQYDQVPIEICEHKVIGTVLIGPTPVNI
IGRNLLTQLGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENP
YNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDKDFR
KYTAFTIPSTNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDDLYVGSDLEI
GQHREKVEDLRQHLLKWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIMLPEKDSWTVNDIQKLVGKLN
WASQIYPGIRIKQLCKLLRGTKALTEVVPLTEEAELELAENREILKEPVHGAYYDPSKDLIAEIQKQGYG
QWTYQIYQEPFKNLKTGKYARMRGAHTNDVKQLTEAVQKIATESIVIWGKIPKFKLPIQKETWEAWWLEY
WQATWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRDTKLGKAGYVTDRGRQKVVTLTDTTNQ
KTELQAIYLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVSQIIEQLIKKEKIYLAWVPAHKGIGGN
EQVDKLVSNGIRKVLFLDGIDKAQEEHEKYHSNWRAMVSDFNLPPVVAKEIVANCDKCQLKGEAMHGQVD
CSPGIWQLDCTHLEGKIILVAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKTIHTDNGGNFISTA
VKAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQAEHLKTAVQMAVFIHNFKRKGGIGGYS
AGERIIDIIATDIQTKELQNQITKISKFRVYYRDSRDPLWKGPAKLLWKGEGAVVIQDNSEIKVVPRRKA
KIIKDYGKQMAGGDCVASGQDED

Molecule Role : Other

38. Pol SIV

Gene Name : Pol SIV
Sequence Strain (Species/Organism) : Simian immunodeficiency virus SIV-mnd 2
NCBI Gene ID : 956107
NCBI Protein GI : 27311168
Locus Tag : Siv2gp2
Genbank Accession : AF367411
Protein Accession : NP_758887
Taxonomy ID : 159122
Gene Starting Position : 2049
Gene Ending Position : 5081
Gene Strand (Orientation) : +
Protein Name : pol protein
Protein pI : 7.91
Protein Weight : 106929.88
Protein Length : 1010

DNA Sequence : Show Sequence

>gi|27311166:2049-5081 Simian immunodeficiency virus SIV-mnd 2, complete genome
ATTTTTTAGGGAATACCCCCTGGGGCAGTGGCAAACCCAGGAACTTCCCGGCGATGCCATTGACCCCAAC
GGCCCCTCCAATGCCAGGGATGGAAGACCCAGCAGAGAGAATGCTGTTAGATTACATGAAGAAAGGGCAA
CAGCAGAAAGCGGAAAGCAAACAGGAAAAGAAAGAGAGGGGTCCATACGAGGCAGCTTACAACTCCCTCA
GTTCTCTCTTTGGAACAGACCAACTACAGTAGTAGAGATAGAAGGGCAAAAAGTGGAGGCCTTACTGGAC
ACAGGAGCTGATGATACAGTAATCAAAGATCTAGATTTAAAAGGTAATTGGAAACCACAGATTATTGGAG
GAATTGGAGGATCAATCAATGTAAAACAGTTTTTCAATTGTAAAGTAACAATAGCAGGCAAAACTACACA
CGCTTCAGTCCTAGTGGGCCCCACACCTGTAAATATTGTAGGTAGAAATGTGCTGAAGAAATTAGGATGT
ACACTAAATTTTCCAGTTAGTAAAGTAGAAACAGTAAAGGTAACACTAAAACCAGGAACTGACGGACCTA
AAATAAAACAATGGCCATTGTCTAAGGAAAAGATTTTAGCCTTACAAGAAATATGTAGTCAAATGGAGAA
GGAAGGCCAGATCTCTAAGATAGGTCCAGAAAATCCTTACAACACACCGGTGTTTTGCATCAAAAAGAAA
GATGGAACCAGCTGGAGAAAATTGGTAGATTTTAGACAGTTAAACAAAGTAACTCAGGACTTCTTTGAGG
TGCAGTTGGGAATCCCACACCCTGGAGGTCTCAAACAATGTGAGCAAATTACAGTACTGGACATAGGGGA
TGCCTATTTCTCATGTCCTTTGGATGAGGACTTTAGAAAGTACACTGCATTCACCATTCCATCGGTGAAT
AATCAGGGCCCAGGAATCAGGTACCAGTATAATGTCCTACCACAGGGATGGAAGGGCTCCCCAGCCATTT
TCCAGGCAACAGCAGATAAAATCTTACAGCCCTTCAGAGAGAGACATCCAGATGTAGTGATCTATCAATA
TATGGATGATCTCTTTGTTGGGAGTGATAGAGTTGCCCCAGAACACAGCAGAATGATTCAAGAGTTAAGA
GACCACCTCTTGTTTTGGGGGCTCGAGACCCCAGACAAGAAGTTTCAAAAGGAACCACCCTTTGAGTGGA
TGGGATACATACTGCACCCTAAGAAATGGACAGTGCAGAAAGTACAGCTTCCAGAGAAAGAAGAATGGAC
AGTAAATGACATCCAAAAGTTGGTAGGGAAACTTAATTGGGCAAGTCAGATTTATTCCGGAATTAAAACA
AAAGAGCTCTGTAGACTAATTAGAGGGGCAAAACCCCTAGATGAAAAAGTAGAATGGACTAGAGAAGCAG
AATTAGAATATGAAGAAAACAAACTCATAGTGCAGGAGGAAGTGCATGGAGTATACTATCAACCAGAGAA
GCCTTTAATGGCAAAGGTTCAAAAATTGACACAAGGGCAATGGAGTTACCAAATAGAGCAGGAGGATAAT
AAGCCGCTGAAGGTAGGGAAATATGCCAGAACAAAGAATGCTCATACAAATGAGCTTAGAGTGCTTGCAG
GACTAGTACAGAAGATTGCAAAAGAAGCTTTAGTGATCTGGGGAAAACTCCCTAAGTTTTATCTGCCAAT
AGAAAGAGAAGTCTGGGACCAGTGGTGGCCAGAATATTGGCAAGCCACATGGATTCCCGAATGGGAATTT
GTATCCACTCCACACCTTATCGGGTTGTGGTATAACCTGTTGAGAGAACCTGTGCCAGGAGAAGATGTGT
ATTATGTGGATGGAGCAGCTAACAGAAACTCCAAAGAAGGGAAAGCAGGATATGTAACAGCTAGAAATAA
ATCCAGAGTAATAGCCCTAGAGAATACCACAAACCAAAAAGCAGAATTGGAGGCAATAAAAATGGCATTA
CAAGACTCAGGACCAAAAGTAAATATAGTGACAGATTCACAGTATGCTATGGGTATCCTATCGGCAGCAC
CCGACCAATCAGACAACCCCATAGTAAGAGAAATTATAGAACTCATGATCCACAAGGAAGCAGTATACCT
AGCTTGGGTACCAGCACACAAAGGCATAGGAGGGAATGAGCAAGTAGATAAACTAGTGAGCAGAGGAGTA
AGGCAAGTACTGTTTTTAGAAGGCATAGATAAAGCACAAGAAGAGCATGATAAATATCACAATAATTGGA
GGGCATTAGCACAAGACTTCTGTATACCAAACATAGTGGCAAAAGAAATAGTAGCCCAGTGTCCAAAGTG
TCAAACAAAAGGAGAGCCAATACATGGCCAGGTAGATACATCCCCAGGAACCTGGCAAATGGACTGCACA
CATATGGAAGGAAAAGTAATCATAGCAGCAGTCCATGTAGCAAGTAGGTATCTAGAAGCAGAAGTAATAC
CCACAGAAACAGGAAAAGAAACAGCACACTTCCTGTTAAAATTAGCAGGTAGATGGCCAGTAAAACATCT
ACACACAGATAATGGCCCTAATTTCACCAGTGAAAAAGTAGCCACAGTCTGTTGGTGGGCTCAAATAGAG
CACACTACAGGAATTCCCTACAATCCTCAGAGTCAAGGAGTAATAGAGGCAAAAAACCATCATCTCAAAC
AAATCATAGGGCAAGTTAGAGACCAAGCAGAGAAACTAGAAACAGCAGTTCAAATGGCAGTATTAATTCA
CAATTTTAAAAGAAAAGGGGGGATAGGGGAATACAGTCCAGGAGAAAGAATAGTAGACATTATAGCAACA
GACCTCCTAACAACTAAATTACAACACAATATTCAAAAAATTCAAAATTTTCGGGTTTATTACAGAGAAG
GAAGGGACCAACAGTGGAAAGGACCAGCAGAACTCATTTGGAAAGGAGAAGGAGCGGTGGTAATCAAAGA
GGGGACAGACTTGAAGGTAGTACCAAGGAGAAAAGCAAAAATCATCAGAGATTATGGAAAAACAGTGGAT
AGTGATCCCAACGTGGAAGCTTG

Protein Sequence : Show Sequence

>gi|27311168|ref|NP_758887.1| pol protein [Simian immunodeficiency virus SIV-mnd 2]
FFREYPLGQWQTQELPGDAIDPNGPSNARDGRPSRENAVRLHEERATAESGKQTGKEREGSIRGSLQLPQ
FSLWNRPTTVVEIEGQKVEALLDTGADDTVIKDLDLKGNWKPQIIGGIGGSINVKQFFNCKVTIAGKTTH
ASVLVGPTPVNIVGRNVLKKLGCTLNFPVSKVETVKVTLKPGTDGPKIKQWPLSKEKILALQEICSQMEK
EGQISKIGPENPYNTPVFCIKKKDGTSWRKLVDFRQLNKVTQDFFEVQLGIPHPGGLKQCEQITVLDIGD
AYFSCPLDEDFRKYTAFTIPSVNNQGPGIRYQYNVLPQGWKGSPAIFQATADKILQPFRERHPDVVIYQY
MDDLFVGSDRVAPEHSRMIQELRDHLLFWGLETPDKKFQKEPPFEWMGYILHPKKWTVQKVQLPEKEEWT
VNDIQKLVGKLNWASQIYSGIKTKELCRLIRGAKPLDEKVEWTREAELEYEENKLIVQEEVHGVYYQPEK
PLMAKVQKLTQGQWSYQIEQEDNKPLKVGKYARTKNAHTNELRVLAGLVQKIAKEALVIWGKLPKFYLPI
EREVWDQWWPEYWQATWIPEWEFVSTPHLIGLWYNLLREPVPGEDVYYVDGAANRNSKEGKAGYVTARNK
SRVIALENTTNQKAELEAIKMALQDSGPKVNIVTDSQYAMGILSAAPDQSDNPIVREIIELMIHKEAVYL
AWVPAHKGIGGNEQVDKLVSRGVRQVLFLEGIDKAQEEHDKYHNNWRALAQDFCIPNIVAKEIVAQCPKC
QTKGEPIHGQVDTSPGTWQMDCTHMEGKVIIAAVHVASRYLEAEVIPTETGKETAHFLLKLAGRWPVKHL
HTDNGPNFTSEKVATVCWWAQIEHTTGIPYNPQSQGVIEAKNHHLKQIIGQVRDQAEKLETAVQMAVLIH
NFKRKGGIGEYSPGERIVDIIATDLLTTKLQHNIQKIQNFRVYYREGRDQQWKGPAELIWKGEGAVVIKE
GTDLKVVPRRKAKIIRDYGKTVDSDPNVEA

Molecule Role : Other
Related Vaccine(s): HIV DNA vaccine pHIS-SHIV-B , HIV DNA vaccine SIVmac239 Gag-Pol-Nef and mock Env with rAd5 boost , rMVTT-SIV-gpe

39. Polymerase protein

Gene Name : Polymerase protein
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
NCBI Protein GI : 6715123
Other Database IDs : CDD:133149
CDD:207741
CDD:200982
CDD:73150
CDD:115473
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein Name : polymerase
Protein Length : 420
Protein Note : Retropepsins, pepsin-like aspartate proteases; cd05482

Protein Sequence : Show Sequence

>gi|6715123|gb|AAF26291.1| polymerase [Human immunodeficiency virus 1]
PQITLWQRPLVTVKIGGQLKEALLDTGADDTVLEDINLPGKWKPRMIGGIGGFIKVRQYDQILIEICGKK
AIGTVLVGPTPVNIIGRNMLTQIGCTLNLPISPIDTVPVKLKPGMDGPKVKQWPLTEEKIKALTEICKEM
EEEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDV
GDAYFSVPLDESFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRIKNPEIDIY
QYMDDLYVGSDLEIGQHRTKIEELRAHLLSWGFTTPDKKHQKEPPFLWMGYELHPDKWTVQPIELPEKDS
WTVNDIQKLVGKLNWASQIYPGIKIKQLCKLLRGAKALTDIVPLTEEAELELEENREILKTPVHGVYYDP

Molecule Role : Other

40. pro

Gene Name : pro
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
NCBI Protein GI : 19911446
Other Database IDs : CDD:133149
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein Name : protease
Protein Length : 99
Protein Note : HIV-1; subtype C; synonym: Human immunodeficiency virus type 1

Protein Sequence : Show Sequence

>gi|19911446|dbj|BAB88039.1| protease [Human immunodeficiency virus 1]
PQITLWQRPLVTIKVEGQVKEALLDTGADDTVLEDMNLPGRWKPKMIGGIGGFIKVRQYDQITLEICGKK
AIGTVLVGPTPVNIIGRNMLTQLGCTLNF

Molecule Role : Other

41. rev

Gene Name : rev
Sequence Strain (Species/Organism) : Simian-Human immunodeficiency virus strain SHIV-89.6
NCBI Protein GI : 2828043
Other Database IDs : CDD:278833
Taxonomy ID : 57667
Gene Strand (Orientation) : ?
Protein Name : rev
Protein pI : 9.94
Protein Weight : 12952.65
Protein Length : 173
Protein Note : REV protein (anti-repression trans-activator protein); pfam00424

Protein Sequence : Show Sequence

>AAB99964.1 rev [Simian-Human immunodeficiency virus]
MAGRSGDSDEELIRTVRLIKLLYQSNPPPSLEGTRQARRNRRRRWRERQRQIRSISERILGTYLGRSAEP
VPLQLPPLERLTLDCNEDCGTSGTQGVGSPQILVESPTVLESGTKE

Molecule Role : Protective antigen
Related Vaccine(s): HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)

42. rev from HIV 1

Gene Name : rev from HIV 1
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
NCBI Gene ID : 155908
NCBI Protein GI : 9629359
Locus Tag : HIV1gp6
Genbank Accession : AF033819
Protein Accession : NP_057854
Taxonomy ID : 11676
Gene Starting Position : 5515
Gene Ending Position : 8198
Gene Strand (Orientation) : +
Protein Name : Rev
Protein pI : 9.36
Protein Weight : 12578.23
Protein Length : 116

DNA Sequence : Show Sequence

>NC_001802.1:5515-8198 Human immunodeficiency virus 1, complete genome
TATGGCAGGAAGAAGCGGAGACAGCGACGAAGAGCTCATCAGAACAGTCAGACTCATCAAGCTTCTCTAT
CAAAGCAGTAAGTAGTACATGTAATGCAACCTATACCAATAGTAGCAATAGTAGCATTAGTAGTAGCAAT
AATAATAGCAATAGTTGTGTGGTCCATAGTAATCATAGAATATAGGAAAATATTAAGACAAAGAAAAATA
GACAGGTTAATTGATAGACTAATAGAAAGAGCAGAAGACAGTGGCAATGAGAGTGAAGGAGAAATATCAG
CACTTGTGGAGATGGGGGTGGAGATGGGGCACCATGCTCCTTGGGATGTTGATGATCTGTAGTGCTACAG
AAAAATTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAGGAAGCAACCACCACTCTATTTTGTGC
ATCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACACATGCCTGTGTACCCACAGAC
CCCAACCCACAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTAACATGTGGAAAAATGACATGGTAG
AACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCCATGTGTAAAATTAACCCCACT
CTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACCAATAGTAGTAGCGGGAGAATGATA
ATGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCACAAGCATAAGAGGTAAGGTGCAGAAAG
AATATGCATTTTTTTATAAACTTGATATAATACCAATAGATAATGATACTACCAGCTATAAGTTGACAAG
TTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCCTTTGAGCCAATTCCCATACATTATTGT
GCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACGTTCAATGGAACAGGACCATGTACAAATG
TCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTATCAACTCAACTGCTGTTAAATGGCAGTCT
AGCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACGGACAATGCTAAAACCATAATAGTACAGCTG
AACACATCTGTAGAAATTAATTGTACAAGACCCAACAACAATACAAGAAAAAGAATCCGTATCCAGAGAG
GACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGAAATATGAGACAAGCACATTGTAACATTAGTAG
AGCAAAATGGAATAACACTTTAAAACAGATAGCTAGCAAATTAAGAGAACAATTTGGAAATAATAAAACA
ATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAAATTGTAACGCACAGTTTTAATTGTGGAGGGGAAT
TTTTCTACTGTAATTCAACACAACTGTTTAATAGTACTTGGTTTAATAGTACTTGGAGTACTGAAGGGTC
AAATAACACTGAAGGAAGTGACACAATCACCCTCCCATGCAGAATAAAACAAATTATAAACATGTGGCAG
AAAGTAGGAAAAGCAATGTATGCCCCTCCCATCAGTGGACAAATTAGATGTTCATCAAATATTACAGGGC
TGCTATTAACAAGAGATGGTGGTAATAGCAACAATGAGTCCGAGATCTTCAGACCTGGAGGAGGAGATAT
GAGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCC
ACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGT
TCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCCTCAATGACGCTGACGGTACAGGCCAGACAATTATT
GTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTC
ACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGC
TCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAG
TAATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTAC
ACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAGAATTATTGG
AATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGCTGTGGTATATAAAATTATT
CATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTTGCTGTACTTTCTATAGTGAATAGAGTT
AGGCAGGGATATTCACCATTATCGTTTCAGACCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAG
GAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCCTTGGCACT
TATCTGGGACGATCTGCGGAGCCTGTGCCTCTTCAGCTACCACCGCTTGAGAGACTTACTCTTGATTGTA
ACGAGGATTGTGGAACTTCTGGGACGCAGGGGGTGGGAAGCCCTCAAATATTGGTGGAATCTCCTACAGT
ATTGGAGTCAGGAACTAAAGAATA

Protein Sequence : Show Sequence

>NP_057854.1 Rev [Human immunodeficiency virus 1]
MAGRSGDSDEELIRTVRLIKLLYQSNPPPNPEGTRQARRNRRRRWRERQRQIHSISERILGTYLGRSAEP
VPLQLPPLERLTLDCNEDCGTSGTQGVGSPQILVESPTVLESGTKE

Molecule Role : Protective antigen
Related Vaccine(s): DNA vaccine expressing multiple HIV epitopes , HIV DNA vaccine pHIS-SHIV-B , HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6) , HIV priming with DNA vaccine expressing HIV gp160 protein and boosted with Ad5/35 vector expressing the same protein , HIV recombinant vector vaccine MVA.HIVA encoding env and rev

43. rev MN isolate

Gene Name : rev MN isolate
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1 MN
NCBI Protein GI : 3511264
Other Database IDs : CDD:189539
Taxonomy ID : 11676
Gene Strand (Orientation) : ?
Protein Name : rev protein
Protein Length : 116
Protein Note : neutralization phenotype variant molecular clone

Protein Sequence : Show Sequence

>gi|3511264|gb|AAC33786.1| rev protein [Human immunodeficiency virus 1]
MAGRNGDSDEELLKTVRLIKFLHQSNPPPSSEGTRQARRNRRRRWRERQRHIRSISAWILSNYLGRPAEP
VPPQLPPLERLTLDCSEDCGTSGTQGVGSPQILVESPTVLESGTKE

Molecule Role : Other
Related Vaccine(s): HIV DNA vaccine pCMN160

44. Tat

Gene Name : Tat
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
VO ID : VO_0011262
NCBI Gene ID : 155871
NCBI Protein GI : 9629358
Locus Tag : HIV1gp5
Genbank Accession : AF033819
Protein Accession : NP_057853
Taxonomy ID : 11676
Gene Starting Position : 5376
Gene Ending Position : 7969
Gene Strand (Orientation) : +
Protein Name : Tat
Protein pI : 10.43
Protein Weight : 9638.3
Protein Length : 86
Protein Note : the length of Tat varies depending on virus strain or clade

DNA Sequence : Show Sequence

>NC_001802.1:5376-7969 Human immunodeficiency virus 1, complete genome
AATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGTCAGCCTAAAACTGCTTGTACC
AATTGCTATTGTAAAAAGTGTTGCTTTCATTGCCAAGTTTGTTTCATAACAAAAGCCTTAGGCATCTCCT
ATGGCAGGAAGAAGCGGAGACAGCGACGAAGAGCTCATCAGAACAGTCAGACTCATCAAGCTTCTCTATC
AAAGCAGTAAGTAGTACATGTAATGCAACCTATACCAATAGTAGCAATAGTAGCATTAGTAGTAGCAATA
ATAATAGCAATAGTTGTGTGGTCCATAGTAATCATAGAATATAGGAAAATATTAAGACAAAGAAAAATAG
ACAGGTTAATTGATAGACTAATAGAAAGAGCAGAAGACAGTGGCAATGAGAGTGAAGGAGAAATATCAGC
ACTTGTGGAGATGGGGGTGGAGATGGGGCACCATGCTCCTTGGGATGTTGATGATCTGTAGTGCTACAGA
AAAATTGTGGGTCACAGTCTATTATGGGGTACCTGTGTGGAAGGAAGCAACCACCACTCTATTTTGTGCA
TCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACACATGCCTGTGTACCCACAGACC
CCAACCCACAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTAACATGTGGAAAAATGACATGGTAGA
ACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAGCCATGTGTAAAATTAACCCCACTC
TGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACCAATAGTAGTAGCGGGAGAATGATAA
TGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCACAAGCATAAGAGGTAAGGTGCAGAAAGA
ATATGCATTTTTTTATAAACTTGATATAATACCAATAGATAATGATACTACCAGCTATAAGTTGACAAGT
TGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCCTTTGAGCCAATTCCCATACATTATTGTG
CCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACGTTCAATGGAACAGGACCATGTACAAATGT
CAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTATCAACTCAACTGCTGTTAAATGGCAGTCTA
GCAGAAGAAGAGGTAGTAATTAGATCTGTCAATTTCACGGACAATGCTAAAACCATAATAGTACAGCTGA
ACACATCTGTAGAAATTAATTGTACAAGACCCAACAACAATACAAGAAAAAGAATCCGTATCCAGAGAGG
ACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGAAATATGAGACAAGCACATTGTAACATTAGTAGA
GCAAAATGGAATAACACTTTAAAACAGATAGCTAGCAAATTAAGAGAACAATTTGGAAATAATAAAACAA
TAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAAATTGTAACGCACAGTTTTAATTGTGGAGGGGAATT
TTTCTACTGTAATTCAACACAACTGTTTAATAGTACTTGGTTTAATAGTACTTGGAGTACTGAAGGGTCA
AATAACACTGAAGGAAGTGACACAATCACCCTCCCATGCAGAATAAAACAAATTATAAACATGTGGCAGA
AAGTAGGAAAAGCAATGTATGCCCCTCCCATCAGTGGACAAATTAGATGTTCATCAAATATTACAGGGCT
GCTATTAACAAGAGATGGTGGTAATAGCAACAATGAGTCCGAGATCTTCAGACCTGGAGGAGGAGATATG
AGGGACAATTGGAGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCA
CCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTT
CTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCCTCAATGACGCTGACGGTACAGGCCAGACAATTATTG
TCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCA
CAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCT
CCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGT
AATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGAAATTAACAATTACA
CAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAGAATTATTGGA
ATTAGATAAATGGGCAAGTTTGTGGAATTGGTTTAACATAACAAATTGGCTGTGGTATATAAAATTATTC
ATAATGATAGTAGGAGGCTTGGTAGGTTTAAGAATAGTTTTTGCTGTACTTTCTATAGTGAATAGAGTTA
GGCAGGGATATTCACCATTATCGTTTCAGACCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGG
AATA

Protein Sequence : Show Sequence

>NP_057853.1 Tat [Human immunodeficiency virus 1]
MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRAHQNSQTHQASLS
KQPTSQPRGDPTGPKE

Molecule Role : Protective antigen
Molecule Role Annotation : HIV-1 DNA plasmids expressing Env, Gag and Tat, either alone or combined with the corresponding protein immunogens formulated in the MF59 adjuvant, resulted in protection against an experimental HIV-1 infection in C57Bl/6 mice (Bråve et al., 2007).
Related Vaccine(s): DNA vaccine expressing multiple HIV epitopes , HIV DNA vaccine pHIS-SHIV-B , HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)

45. tat

Gene Name : tat
Sequence Strain (Species/Organism) : Simian-Human immunodeficiency virus strain SHIV-89.6
NCBI Protein GI : 2828042
Other Database IDs : CDD:278940
Taxonomy ID : 57667
Gene Strand (Orientation) : ?
Protein Name : tat
Protein pI : 10.4
Protein Weight : 11598.34
Protein Length : 158
Protein Note : Transactivating regulatory protein (Tat); pfam00539

Protein Sequence : Show Sequence

>AAB99963.1 tat [Simian-Human immunodeficiency virus]
MEPVDPRLEPWKHPGSKPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRAHQNSQTHQASLS
KQPSSQPRGDPTGPKEQKKKVERETETDPVH

Molecule Role : Protective antigen
Related Vaccine(s): HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)

46. tat

Gene Name : tat
Sequence Strain (Species/Organism) : Human immunodeficiency virus 2
NCBI Protein GI : 1845211
Other Database IDs : CDD:278940
Taxonomy ID : 11709
Gene Strand (Orientation) : ?
Protein Name : tat protein
Protein pI : 9.61
Protein Weight : 14481.48
Protein Length : 190
Protein Note : similar to HIV2BEN, GenBank Accession Number M30502, and to HIV2D194, GenBank Accession Number J04542

Protein Sequence : Show Sequence

>AAB47786.1 tat protein [Human immunodeficiency virus 2]
METPLKAPESSLKSYNEPSPCTSEWEVAAQELAKQGEELLAQLHRPLEACTNPCYCKKCSFHCQLCFLKK
GLGIWYVRKGGRRRTPKRTKTHPPSTPDKSISIQTGDSRPTKKQKETPETPVATTSGLGR

Molecule Role : Protective antigen
Related Vaccine(s): HIV-2 DNA vaccine

47. vif

Gene Name : vif
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
NCBI Gene ID : 155459
NCBI Protein GI : 9629361
Locus Tag : HIV1gp3
Genbank Accession : AF033819
Protein Accession : NP_057851
Taxonomy ID : 11676
Gene Starting Position : 4586
Gene Ending Position : 5164
Gene Strand (Orientation) : +
Protein Name : Vif
Protein pI : 10.39
Protein Weight : 21322.07
Protein Length : 192

DNA Sequence : Show Sequence

>gi|9629357:4586-5164 Human immunodeficiency virus 1, complete genome
TATGGAAAACAGATGGCAGGTGATGATTGTGTGGCAAGTAGACAGGATGAGGATTAGAACATGGAAAAGT
TTAGTAAAACACCATATGTATGTTTCAGGGAAAGCTAGGGGATGGTTTTATAGACATCACTATGAAAGCC
CTCATCCAAGAATAAGTTCAGAAGTACACATCCCACTAGGGGATGCTAGATTGGTAATAACAACATATTG
GGGTCTGCATACAGGAGAAAGAGACTGGCATTTGGGTCAGGGAGTCTCCATAGAATGGAGGAAAAAGAGA
TATAGCACACAAGTAGACCCTGAACTAGCAGACCAACTAATTCATCTGTATTACTTTGACTGTTTTTCAG
ACTCTGCTATAAGAAAGGCCTTATTAGGACACATAGTTAGCCCTAGGTGTGAATATCAAGCAGGACATAA
CAAGGTAGGATCTCTACAATACTTGGCACTAGCAGCATTAATAACACCAAAAAAGATAAAGCCACCTTTG
CCTAGTGTTACGAAACTGACAGAGGATAGATGGAACAAGCCCCAGAAGACCAAGGGCCACAGAGGGAGCC
ACACAATGAATGGACACTA

Protein Sequence : Show Sequence

>gi|9629361|ref|NP_057851.1| Vif [Human immunodeficiency virus 1]
MENRWQVMIVWQVDRMRIRTWKSLVKHHMYVSGKARGWFYRHHYESPHPRISSEVHIPLGDARLVITTYW
GLHTGERDWHLGQGVSIEWRKKRYSTQVDPELADQLIHLYYFDCFSDSAIRKALLGHIVSPRCEYQAGHN
KVGSLQYLALAALITPKKIKPPLPSVTKLTEDRWNKPQKTKGHRGSHTMNGH

Molecule Role : Other
Related Vaccine(s): HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)

48. vif

Gene Name : vif
Sequence Strain (Species/Organism) : Simian-Human immunodeficiency virus strain SHIV-89.6
NCBI Protein GI : 2828039
Other Database IDs : CDD:278957
Taxonomy ID : 57667
Gene Strand (Orientation) : ?
Protein Name : vif
Protein pI : 10.5
Protein Weight : 24244.15
Protein Length : 273
Protein Note : Retroviral Vif (Viral infectivity) protein; pfam00559

Protein Sequence : Show Sequence

>AAB99960.1 vif [Simian-Human immunodeficiency virus]
MEEEKRWIAVPTWRIPERLERWHSLIKYLKYKTKDLQKVCYVPHFKVGWAWWTCSRVIFPLQEGSHLEVQ
GYWHLTPEKGWLSTYAVRITWYSKNFWTDVTPNYADILLHSTYFPCFTAGEVRRAIRGEQLLSCCRFPRA
HKYQVPSLQYLALKVVSDVRSQGENPTWKQWRRDNRRGLRMAKQNSRGDKQRGGKPPTKGANFPGLAKVL
GILA

Molecule Role : Protective antigen
Related Vaccine(s): HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)

49. vpr

Gene Name : vpr
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
NCBI Gene ID : 155807
NCBI Protein GI : 28872817
Locus Tag : HIV1gp4
Genbank Accession : AF033819
Protein Accession : NP_057852
Taxonomy ID : 11676
Gene Starting Position : 5104
Gene Ending Position : 5395
Gene Strand (Orientation) : +
Protein Name : Vpr
Protein pI : 8.54
Protein Weight : 11024.76
Protein Length : 96
Protein Note : An artificial frameshift eliminating the orf-disrupting nucleotide at position 5320 is introduced to obtain the typical HIV-1 Vpr protein sequence. For this particular HIV-1 strain, HXB2, only a short (78 amino acid long) variant of the Vpr sequence can be obtained by translation of nucleotides 5105 through 5341 without the frameshift

DNA Sequence : Show Sequence

>gi|9629357:5104-5395 Human immunodeficiency virus 1, complete genome
GATGGAACAAGCCCCAGAAGACCAAGGGCCACAGAGGGAGCCACACAATGAATGGACACTAGAGCTTTTA
GAGGAGCTTAAGAATGAAGCTGTTAGACATTTTCCTAGGATTTGGCTCCATGGCTTAGGGCAACATATCT
ATGAAACTTATGGGGATACTTGGGCAGGAGTGGAAGCCATAATAAGAATTCTGCAACAACTGCTGTTTAT
CCATTTTCAGAATTGGGTGTCGACATAGCAGAATAGGCGTTACTCGACAGAGGAGAGCAAGAAATGGAGC
CAGTAGATCCTA

Protein Sequence : Show Sequence

>gi|28872817|ref|NP_057852.2| Vpr [Human immunodeficiency virus 1]
MEQAPEDQGPQREPHNEWTLELLEELKNEAVRHFPRIWLHGLGQHIYETYGDTWAGVEAIIRILQQLLFI
HFRIGCRHSRIGVTRQRRARNGASRS

Molecule Role : Other
Related Vaccine(s): HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)

50. vpr

Gene Name : vpr
Sequence Strain (Species/Organism) : Simian-Human immunodeficiency virus strain SHIV-89.6
NCBI Protein GI : 2828041
Other Database IDs : CDD:278923
Taxonomy ID : 57667
Gene Strand (Orientation) : ?
Protein Name : vpr
Protein pI : 5.91
Protein Weight : 11514.23
Protein Length : 158
Protein Note : VPR/VPX protein; pfam00522

Protein Sequence : Show Sequence

>AAB99962.1 vpr [Simian-Human immunodeficiency virus]
MEERPPENEGPQREPWDEWVVEVLEELKEEALKHFDPRLLTALGNHIYNRHGDTLEGAGELIRILQRALF
MHFRGGCIHSRIGQPGGGNPLSAIPPSRSML

Molecule Role : Protective antigen
Related Vaccine(s): HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)

51. vpu

Gene Name : vpu
Sequence Strain (Species/Organism) : Human immunodeficiency virus 1
NCBI Gene ID : 155945
NCBI Protein GI : 9629366
Locus Tag : HIV1gp7
Genbank Accession : AF033819
Protein Accession : NP_057855
Taxonomy ID : 11676
Gene Starting Position : 5607
Gene Ending Position : 5855
Gene Strand (Orientation) : +
Protein Name : Vpu
Protein pI : 4.43
Protein Weight : 8250.01
Protein Length : 82
Protein Note : Vpu and gp160 are translated from different reading frames of the same bicistronic mRNA

DNA Sequence : Show Sequence

>gi|9629357:5607-5855 Human immunodeficiency virus 1, complete genome
AATGCAACCTATACCAATAGTAGCAATAGTAGCATTAGTAGTAGCAATAATAATAGCAATAGTTGTGTGG
TCCATAGTAATCATAGAATATAGGAAAATATTAAGACAAAGAAAAATAGACAGGTTAATTGATAGACTAA
TAGAAAGAGCAGAAGACAGTGGCAATGAGAGTGAAGGAGAAATATCAGCACTTGTGGAGATGGGGGTGGA
GATGGGGCACCATGCTCCTTGGGATGTTGATGATCTGTA

Protein Sequence : Show Sequence

>gi|9629366|ref|NP_057855.1| Vpu [Human immunodeficiency virus 1]
MQPIPIVAIVALVVAIIIAIVVWSIVIIEYRKILRQRKIDRLIDRLIERAEDSGNESEGEISALVEMGVE
MGHHAPWDVDDL

Molecule Role : Other
Related Vaccine(s): HIV DNA vaccine pHIS-SHIV-B , HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)

52. vpu

Gene Name : vpu
Sequence Strain (Species/Organism) : Simian-Human immunodeficiency virus strain SHIV-89.6
NCBI Protein GI : 2828044
Other Database IDs : CDD:109608
Taxonomy ID : 57667
Gene Strand (Orientation) : ?
Protein Name : vpu
Protein pI : 4.6
Protein Weight : 8647.38
Protein Length : 138
Protein Note : Vpu protein; pfam00558

Protein Sequence : Show Sequence

>AAB99965.1 vpu [Simian-Human immunodeficiency virus]
MQPIQIAIVALVVAIIIAIVVWSIVIIEYRKILRQRKIDRLIDRLIERAEDSGNESEGEISALVEMGVEM
GHHAPWDVDDL

Molecule Role : Protective antigen
Related Vaccine(s): HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)

III. Vaccine Related Host Genes

1. ANXI

Gene Name : ANXI
Sequence Strain (Species/Organism) : Ovis aries
NCBI Gene ID : 100302599
Taxonomy ID : 9940
Gene Strand (Orientation) : ?
Protein Name : annexin I
Molecule Role : Vaximmutor

2. human IFNG

Gene Name : human IFNG
Sequence Strain (Species/Organism) : Homo sapiens
NCBI Gene ID : 3458
NCBI Protein GI : 56786138
Genbank Accession : AC007458
Protein Accession : NP_000610
Taxonomy ID : 9606
Chromosome No : 12
Gene Starting Position : 68548549
Gene Ending Position : 68553520
Gene Strand (Orientation) : -
Protein Name : interferon, gamma
Protein pI : 10.01
Protein Weight : 18454.87
Protein Length : 166
Protein Note : Also known as IFG; IFI

DNA Sequence : Show Sequence

>gi|224589803:68548549-68553520 Homo sapiens chromosome 12, GRCh37.p5 Primary Assembly
AGTTGTGAACTTACACTTTATTCATATATATTAGATATTGATAATTTTAACAAATGAGTTACTTTCCATT
TGGGTACAGTCACAGTTGTCAACAATATTTGGAAGCACCAGGCATGAAATCTCCTGAGATGCTATGTTTT
CATCAGGGTCACCTGACACATTCAAGTTCTGTCTGACATGCCATTAAAGCACTGGCTCAGATTGCAGGCA
TATTTTCAAACCGGCAGTAACTGGATAGTATCACTTCACTTATAAGTGTTCATTGTATCATCAAGTGAAA
TAAACACACAACCCATGGGATCTTGCTTAGGTTGGCTGCCTAGTTGGCCCCTGAGATAAAGCCTTGTAAT
CACATAGCCTTGCCTAATTAGTCAGAAAACAAAGGATTAAGTGAGACAGTCACAGGATATAGGAATTATA
AATAATACATATATTAATAGATATTCATTTTCATTACACAAAAGTTGCTATTATAAATACTTATTTGATT
GATGAGTCTAAAAATATATTCCCCATATAAATAATGTTAAATATTAATAAATAGATTTAGATTTAAAATT
CAAATATTGCAGGCAGGACAACCATTACTGGGATGCTCTTCGACCTCGAAACAGCATCTGACTCCTTTTT
CGCTTCCCTGTTTTAGCTGCTGGCGACAGTTCAGCCATCACTTGGATGAGTTCATGTATTGCTTTGCGTT
GGACATTCAAGTCAGTTACCTATCGGGAAAGAAAAGAGCAAAATTAATTTCAGGCATATAAGCCATCAGG
ATATTCTGCTAATGTCATGATGGTCAGTGAAAATAAAAGTATTCCTTTAAAAAATGGACCGTATTACCTT
AATATACAATATTTACTTCTTCAGCAGTTGAAGCTAAAAATTACAATTACATTTCTAGTTGTGCTATAAT
GTGGTGGAGTCCATCACATATCTTTAAATCTACTTCTATAGAATTCTTGAAATTATATAGTGAAAAGACT
CCTGGTTGTGGAGTCAGCATAAAAAGGTGGGTTTGAATCTCATGCATGCAATAATTCTGACCTTGAGCCA
GCTACTTAACCTCTCTGAACTTCTATTTTCTCATCTAAAGGAGGATGAGACTGTTTCTATGACCTCTCTA
TCATCAATCTACCAATTATATCACTTTATACTTCAGTCTTTCCTGTATGCATCAAATGAGTAACTATAGG
TCAATGATTCTCACTGTTGTGCATAGCAGATTAATCCGGAAACCTGTCAAAGACCTCAGAGATCCAGGTG
CATGAAGTGGAAGGACTGTGCCCTGTGCATTCACTAAGCTCCCCAGGTGATTCTGACATCCACCTAAGTT
TGAGAACCACTGATCTAGGTTAGGTACCCTAGAAAACACCAAATCCAAAACGAGTGAAAACTGTAATTTT
TAATTTCTCCCAGATTAGGTCAGTCTCTCAATTTCCATAATAGATTTTAAAATAAACACCCCCAATCATA
TTTATATATGGCTTACTGATATATAAAGTTTAAAATTAAGAATTGCAACAACTTTTCCAGTACCCTGCCT
TCTAGGCAAGCAAATTGAACTACTTGCATCTCCTCACTCTAACCAATAGGGCCATTTAGATGATGCTTCA
TAAAATGTGGACCATTTACCTTCCTCTTGGCTCTGCCATTACATTTTTTCTAATCTTGGGAACACTATGG
CTACTCACCACATTTCTGAGGATGGCTGGGGGATTACAGCTAAAGACTAATTGTCAAAGGGCATAACATG
CATAAAATAGCTTAGCAACTGAGCCAAAGAGAATAATAATTAATAGAGCTCACTCAAGATTGCCCATCAA
GAAACAGGAGGTTTGTAGCTTCCAGAAGGAAGAAACCACAGATTTTTTTTCATTTTTTTAAGGCCCAGTT
CCTGCAGAGTAGAAAAAATTTTCGACAAGCTGTGTGTTTGCAAGTGACAGATTTTACTTTCCAATGTTCA
AATCATCACCAAGAAACTAAGAGACTTATCCAGGACTGAACAGTAAGCCAGGGGCACCACTGGATTAGAA
ACAAGTGCTGAGTGTCTAGTTTATAACCAAAGGAGACCTGTTGCCATGTCTCTCCTTTCTGTTTCTGGGG
GCTTACATGAGAGGAGTGAGAGGCAGGCCCAGCAATAGTGAAAGCTGAGCACATATCCTAAGAACACAAA
TGCTAGCTTGAAGACCCTGGTCCCTCTCATTTGAGCCCATTTATATCAAAGTCAACCCCAAAGGAATCTA
GAGGCCTTTGTCTTCTAGAAAACATTTTGAAAAACATGATTTGTCTTTATGCCTCAACGTTATCTTTCTG
TTTATAGAAGCCATAACTTAAAGATACAAGTTCATGAGGTAAGACTTAGGAGTCTAAGGAGTTCTCCAGC
TGAGATATTCTGAAAGTTGATAGAGAGTTGATAGAACAATCTTTTCATAAGGTATAAATTCTATCTATTT
TTCCCTAAAAACAAACAAACAGCAACCATTCTTGCTTCTAATTGGGCAGTACAATCTGATAGGTTGGCTA
GAGACTTGCAGTGGGGTGTCCCTGGTACCTATTCAAAGACTGTAGCTTTCTTCTATCTCATTCTCATTTT
CTATTCTTTGCATTGTAGAGTTTTGGAGCAAAGAAGGTCATCAAACTTATACAGTGAGCCTAACAGTTTC
CTTTTAAGATGAGGAAACTGAGCCCCAGCCAGCCATGTGATTCATCACAGTTCCTTGGTGGCTGAGTTGG
GAGGAGAACACACATCTTCTCAGCTCCTCCCACTGCTCTTTCCATTAAGACAGACAGCCTCTCATTCAAA
GTAAGAGAATTTCCATCATATGAGCAAGGGACAATGAGAGAACTGCTTCTCAGTACTCCCCGCTTCTTCC
TCACCTACTTCCTCTTCACTGGATTTGTCAACTCACCTGTCTTTACGCAATAGTTACAATGCCAGCATTT
CTCTACATTACATACTTCAGCGATTCTCTTACTGGCTTTGCAAAGTCACCCAAACACGAATGGAAATAGT
AAGGTAGAGTTTCAGCCATGAGTTGAGTTCATAGCTTTAGCAACTGTTAAATAGCTAATGTCTACTTTCT
GGAGAATAAATGCTTTGCAAGACCCTCGGCAATGAAACCAAAGAAAGAATTTAAATAGCCTCACCGAATA
ATTAGTCAGCTTTTCGAAGTCATCTCGTTTCTTTTTGTTGCTATTGAAAAACTTGACATTCATGTCTTCC
TTGATGGTCTCCACACTCTTTTGGATGCTCTGGTCATCTTTAAAGTTTTTAAAAAGTTTGAAGTAAAAGG
AGACAATTTGGCTCTGCATTATTTTTCTGTCACTCTCCTTGGAAGGAAAGAGCACAAACAGAGGATGATG
TGAATTTATCCATCAGAAAGCAAGCAACAGGAAAATTAGCCAAATGGGAATATTCAGCTTACCTCTTTCC
AATTCTTCAAAATGCCTAAGAAAAGAGTTCCATTATCCGCTACATCTGAATGACCTGCATTCTAAAAAAA
AAAAAAGAAAAAATTGGTTTACAATTAGCCCATAAATTGCCTTAAAAATATATTTCAAGTTTCATTGAAC
TCAGATGTGACAATATTCACTGATTTCCTTTTCAACTCTTCTGCTTAGTTCTAACAATAAGTATTCCCAA
AAGGCTTATGTGAGATATAGACAAAGACTATTATGTTCTTTTAGCTTTTTTATTTCCCAATATAACCATT
AAATTGCAATGTCACAAATGAGCTCAACAAAGCTGATACTCCAAAGGTCCCAAAAACTATAGTAAGCTAA
AGAAAGTATTTTCAAGCTAGGCTAAAAAATACAAAAACAAAAAACAGCAAAGCCACCCCACTATAAAATA
CTGCCCCCCAATGGTACAGGTTTCTATTACATCTACTGTGCCTTCCTGTAGGGTATTATTATACGAGCTT
TAAAAGATAGTTCCAAACATGTGCGAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGATTTGATTTTGTGTT
GTAAGAATAAAATCAATTGTGAATGTCTGAATATTATTATGACAGCTATAATTATAACAGCTAAGTTTTA
AACAAATAATGAAATATTTAAAATGTAAAAACTTTTCATTAACCATCAATAAAATTTTAAAAGAAACTCA
AAAAATTCACTTAAAATTTTTAAACATTCCTTAGCCAGAATCATAATTCTTCCAAAATCCCAGTGAGCAA
CGAAGTTCCGGAATACTTCACAAGTAATATAGATAGAGAAGCAGAATGTTGAAATCACTTTTTGGAGAAA
ATCACCTATCAGTTATTTTTTTAAGCCAAAGCTTTAAGGACCTTTTTGACTTTAATTTGTAAACATTTCC
TATTACCTTTTTAATGCTAATCTTGACCTTAGAGTCTGAGAAGTCAAAAACTAATAACCAATCATTTTTT
TCAATCTGCATACTCCTTGACTATCACAACTGAATGAGTTCCCACCACAAAATTATTAACATCATTATGC
TTCATACCCATATTATGCCCATCTTTTGGAAAATTCATAAATCCCTTTTAAGTCTCTATACAAACTGAGC
AGAAGGTTAAAACAATATCTAGATTATTTAGTCAAGGAACTCATCTAGTCAATAATTAACAAAATAACAC
CAAATCTCAAAATGACTGCCTACAAGAGATGACAGCCTATCAGAGATGCTACAGCAAGTCGATATTCAGT
CATTTTCAACCACAAACAAGTACTATTAAAAAGTCATACTTACAAAATATTTCTTAAGGTTTTCTGCTTC
TTTTACATATGGGTCCTGGCAGTAACAGCCAAGAGAACCCAAAACGATGCAGAGCTGAAAAGCCAAGATA
TAACTTGTATATTTCATCGTTTCCGAGAGAATTAAGCCAAAGAAGTTGAAATCAGTAGTTCTTGTATCAA
GCTGATCAGGTCCAAAGGACTTAACTGATCTTTCTCTTCTAATAGCTGATCTTCAGATGATCAGAACAAT
GT

Protein Sequence : Show Sequence

>gi|56786138|ref|NP_000610.2| interferon gamma precursor [Homo sapiens]
MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWKEESDRKIMQS
QIVSFYFKLFKNFKDDQSIQKSVETIKEDMNVKFFNSNKKKRDDFEKLTNYSVTDLNVQRKAIHELIQVM
AELSPAAKTGKRKRSQMLFRGRRASQ

Molecule Role : Vaximmutor

3. IFNG

Gene Name : IFNG
Sequence Strain (Species/Organism) : Macaca mulatta
NCBI Gene ID : 574282
NCBI Protein GI : 74136365
Locus Tag : EGK_03901
Genbank Accession : CM001263
Protein Accession : NP_001028077
Taxonomy ID : 9544
Chromosome No : 11
Gene Starting Position : 65143979
Gene Ending Position : 65148219
Gene Strand (Orientation) : -
Protein Name : interferon-gamma
Protein pI : 9.92
Protein Weight : 18339.63
Protein Length : 165
Protein Note : Also known as IFN-gamma

DNA Sequence : Show Sequence

>gi|109156580:65143979-65148219 Macaca mulatta chromosome 11, Mmul_051212, whole genome shotgun sequence
ATTATTGGGATGCTCTTCGACCTCGAAACATCTGACTCCTTTTTCGCTTCCCTATTTTAGCTGCTGGCGA
CAGTTCAGCCATCACTTGGATGAGTTCATGTACTGCTTTGCGTTGGACATTTGAGTCAGTTACCTATTGG
GAAAGAAAAGAGCAAAATTAATTTCAGGCATATAAGCCATCAGGATATTCAGTTAATGGCATGATGGTCA
GTGAAAATAAAACTATTCCTTTAAAAAAATGGACCATATTACCTTAATATACAATATTTACTTCTTCAGC
AGTTGAGGCTAAAAATTACAATTACATTACTAGTTGTGCAATGATGTGGTGGAGTCCGTCACATATCTTT
AAATCTACTCCCATAGAATTCTTGAAATCATATAGTGAAAAGACCCCTGGTGTGGAGTCAATGTAAAAAG
GTGGATCTGAATCTCATGCGTGCAATAATTCTGACCTTGAGCCAGCTACTTAACCTTTTGGAACCTCTAT
TTTCTCATCTAAAGGAAGAGAAGACTGTTTCTATGACCTCTCTATCATCAATCTACCAATTATATCACTT
TATACTTTAGTCTCTCCTGTATGTATCAAACGAGTAACTATAGGTCAATGATTCTCACTGTTGTGCATAG
CAGATTAACCTGGAAACCTAATAAAGACCTCAGAGATCCAGGGGCACGAATTGGAAGGACTGTGCCCTGT
GCATTCACTAAGCTCCCCAGGTGATTCTGACATCCACCTAAGTTTGAGAACCACTGATCTAGGTTAGGTA
CCCTAGAAAACATCAAATCCAAAACAAGTGAAAACTGTAATTTTTAATTTCTCCCAGATTAGATCAGTCT
CTCAATTTCCATAATAGGTTTTAAAATAACCACCAATCATATTTATATATGGCTTACTGATATATAAAGT
TTAAAATTAGGAATTGCAACAACTTTTTCAGTACCCTACCTTCTAGGCCAGCAAATTGAACTACTTGCAT
TTCCTCACTCTAACTAATAGGGCCATTTAGGTGATTTCATTCTTCCTAAAATGTGGACCATTTACTTTCC
TCTTGACTCTGCCATTATATTTTTTCTAATCTTGGGAACACTATGGCTACCTCGCCACATTTCTGAGGAT
GGCTGGGGGATTACAGGCTACAGAGCTAATTATGAAAGGGCATAACATACCTCAGCTTAGCAACTGAGCC
AAAGAGAACAATAATTAATAGAGCTCACTCAAGATTGCCCATCAAGAAACAGGAGGTTTGTAGCTTCCAG
AAGGAAGAAACCCACAGATTTTTTTTTCACTTTTTTAAGGCCCAGTTCCTGCGGAGTAGAAAAAGTTTTC
TACAAGCTGTGTGTTTGCAAGTGACAGATTTTACTTTCCAGTGTTCAAATCATCACCAAGAAACTAAGAG
ACTTATCCAGGACGGAACAGTAAGCCAGGGGCACCACTGGGTTGGTGGCAAGTGCTGAGTGTCTAGTTTC
TAACCAAAGGAGACCTGTTGCCATGTCCCTCCTTTCAGTTTCTGGGGGTTCACATGAGAGGAGTGAGAGG
CAGGCCCGGCAATAGTGAAAGCTGAGCACAAATCCTAAGAGCACAAATGCCAGCTTGAGCTCTCATTTGA
GCCCATTTATATCAAAGCCAATCCCAAAGGAATCTAGAGGTCTTTGTCTTCTAGATAAAATTTTGAAAAA
CGTGTTTTGTCTTTATGCCTCAATGTTATCTTTCTGTTTATAGAAGGCATAATTTAAAGATAATTTAAAG
ATACAAGTTCATGAGGTATGACTTAGGAGTCTAAGGAGTTCTCCAGCTGAGATATTCTGAAAGTTGATAG
AGACTTGATAGAACAATGTTTTCATAAGCTATAAATTCTACCTATTTTTCCCTAAAAACAAACAGCAACC
ATTCTTGCTTCTAATTAGGCAGTACAATCTGATAGGTTGGCTAGAGAATTGCAGTGGGGTGCACTGGTAC
CTACTCAAAGGCTGTAGCTTTCTTCTATCTCATTCTCATTTTCTATTCTTGGCATTGTAGAGTTTTGGAG
CAAAGAATGTCATCAAACTTATGCAGTGAACCTAACAGTTTCCTTTTAAGATGAGGGCACTGAGCCCCAG
CCAGCCATGTGATTCATCACAGTTCCCTGGTGGCTGAGATGGGAGGAGAACACACATCTTCTCAGCTCCT
CCCACTGCTCTTTCCATTAAGACAGACAGCCTCTCATTCAAAGTAAGAGAATTTCCATCATATGAGCAAA
GGACAATGAGAGAATTGCTTCTCAGTACTCCCCACTACTTCCTCACCTACTTCCTCTTCATTGGATTTGT
CAATTCACCTGTCTTTACACAATAGTTACAATGCCAGCACTTTTCCTACATTACATACTTCAGTGATTCC
CATACTGGCTTTGCAAAGTCATCCAAACACAAATAGAATTAGTAAGAGTTTCAGCTACGGGTTGAGTTCA
TAGCTTTAGCAACTGTTAAATAGCTAATGTCTACTTTCTGGAGAACAAATGCTTTGCAAGACCTTCCGCA
ATGAAACCAAAGAAAGAATTTAAAGAGCCTTACCGAATAATTGGTCAGCTTTTCAAAGTCATCCCGTTTC
TTTTTGTTGCTATTGAAAAACTTGACATTAATGTCTTCCTTGATGGTCTCCACACTCTTTTGGATCCTCT
GGTCATCTTTGAAGTTTTTAAAAAGTTTGAAGTAAAAGGAGACAATTTGGCTCTGCATTATTTTTCTGTC
ACTCTCCTTGGAAGGAAAGAACACAAACAGAGGATGATGTGTATTTATCCATCAGAAAGCAAGCAACAGG
AAAATTAGCCAAATGGGAATATTCAGCTTACCTCTTTCCAATTCCTCAAGATGTCTAAGAAAAGAGTTCC
ATTATCTGCTACATCTGGATCACCTGCATTCTGGGGGAAAAAAAAGGGTTTACAATTAGCCCATAAATTG
TCTTAAAAATATATTTCAAGTTTCATTAAACTCAGATGTGACAATATTCACTGATTTCCTTTTCAATTCT
TCTGCTTAGTTCTAACAATAAGTGTTCACAAAATGTTTATGTGAGATATAGCCAAAGACTACTATGCTCT
TTTAGCTTTTTTATTTTCCAACATAACCATTAAATTGCAATGTCACAAAGGAGTTAAACAAAGCTGATGA
TACTCCAAGGGTCTCAAAAACTATAGTAGGCTAAAGAAAGTATTTTCAAGCTAGGCTAAAAAATACAGAA
CAAAAAACAGCAAAGCCACCCCACTATAAAATACTGCCCCCCAATGGCACAGGTTTCTATTACATCTACT
ATGCCTTCCTGTAGGGTATTATGTCAACTTTAAAAGATAGTTCCAAACGTGTGCGTGCGTGTGTGTGTGT
GTGTGTGTGTGTGGTCTGATTTTGTGTTGTAGGAATAAAATTAATTGTGAATGTCTGAATATTAGTATGA
CAGCTATAATTATAACTAAGTTTTAAATAAATAATGAAATATTTAAAATGTAAAAACTTTTCATTAACCA
TCAATAAAATTTTAAAAGAAACTCAAAAAACTCACTTAAAATTTTTAAACATTCCATAGCCAGAATCATA
ATTCCTACAAAATCCCAGTGAGCAACTAAGTTCAGGAGTAATTCACAAGGAATATAGATAGAGCAGCAGA
ATGTTGAAATAACTTTTTGGAGAAAATCACCTATCAGTGATTTTTTTTAAGCCAAAACTTTAAGGACCTT
TTTTACTTTAATTTGTAAACGTTTCCTATTAACTTTTGAATGCTAATCTTGACCTTAGAGTCTGAGAAGT
CAAAAACTAATAGCCAATCATTTTTTTCAATATGCATACTCCTTGACTTATCACATCTGAATGAGTTCTC
ACCACAAAATTATTAACATCATTATGCTTCATATCCATATTATGCCCATCTTTGGGAAGATTCATAAATC
CCTTTTAAGTCTCTATACAAACTGAGCAGAAGGTTAAAACAATATCTAGATTATGTAGTCAAGAAACTCA
TCCAGTCAATAATTAACAAAATAAAACCAGATCTCAAAATGACTGCGTACGAGAGGACAGTCTATCAGAG
ATGCTACAGCAAGTCAATATTCAGACATTTTCAACCACAAAAAAGTACTATTAAAAAGCCATACTTACAA
AATATTTCTTAAGGTTTTCTGCTTCTTTTACATATGGGTCCTGGCAGTAACAGCCAAGAGAACCCAAAAC
AATGCAGAGCTGAAAAGCCAAGATATAACTTGTGTATTTCA

Protein Sequence : Show Sequence

>gi|74136365|ref|NP_001028077.1| interferon gamma precursor [Macaca mulatta]
MKYTSYILAFQLCIVLGSLGCYCQDPYVKEAENLKKYFNAGDPDVADNGTLFLDILRNWKEESDRKIMQS
QIVSFYFKLFKNFKDDQRIQKSVETIKEDINVKFFNSNKKKRDDFEKLTNYSVTDSNVQRKAVHELIQVM
AELSPAAKIGKRKRSQMFRGRRASQ

Molecule Role : Vaximmutor
Related Vaccine(s): DNA and poxvirus priming-boosting SHIV vaccine , HIV DNA and adenoviral vector Ad5 expressing SIV gag protein

4. Ifng (Interferon gamma)

Gene Name : Ifng (Interferon gamma)
Sequence Strain (Species/Organism) : Mouse
NCBI Gene ID : 15978
NCBI Protein GI : 33468859
Genbank Accession : NM_008337
Protein Accession : NP_032363.1
Other Database IDs : MGI:107656; UniProt: P01580
Taxonomy ID : 10090
Gene Strand (Orientation) : ?

DNA Sequence : Show Sequence

>gi|145966741|ref|NM_008337.3| Mus musculus interferon gamma (Ifng), mRNA
ATAGCTGCCATCGGCTGACCTAGAGAAGACACATCAGCTGATCCTTTGGACCCTCTGACTTGAGACAGAA
GTTCTGGGCTTCTCCTCCTGCGGCCTAGCTCTGAGACAATGAACGCTACACACTGCATCTTGGCTTTGCA
GCTCTTCCTCATGGCTGTTTCTGGCTGTTACTGCCACGGCACAGTCATTGAAAGCCTAGAAAGTCTGAAT
AACTATTTTAACTCAAGTGGCATAGATGTGGAAGAAAAGAGTCTCTTCTTGGATATCTGGAGGAACTGGC
AAAAGGATGGTGACATGAAAATCCTGCAGAGCCAGATTATCTCTTTCTACCTCAGACTCTTTGAAGTCTT
GAAAGACAATCAGGCCATCAGCAACAACATAAGCGTCATTGAATCACACCTGATTACTACCTTCTTCAGC
AACAGCAAGGCGAAAAAGGATGCATTCATGAGTATTGCCAAGTTTGAGGTCAACAACCCACAGGTCCAGC
GCCAAGCATTCAATGAGCTCATCCGAGTGGTCCACCAGCTGTTGCCGGAATCCAGCCTCAGGAAGCGGAA
AAGGAGTCGCTGCTGATTCGGGGTGGGGAAGAGATTGTCCCAATAAGAATAATTCTGCCAGCACTATTTG
AATTTTTAAATCTAAACCTATTTATTAATATTTAAAACTATTTATATGGAGAATCTATTTTAGATGCATC
AACCAAAGAAGTATTTATAGTAACAACTTATATGTGATAAGAGTGAATTCCTATTAATATATGTGTTATT
TATAATTTCTGTCTCCTCAACTATTTCTCTTTGACCAATTAATTATTCTTTCTGACTAATTAGCCAAGAC
TGTGATTGCGGGGTTGTATCTGGGGGTGGGGGACAGCCAAGCGGCTGACTGAACTCAGATTGTAGCTTGT
ACCTTTACTTCACTGACCAATAAGAAACATTCAGAGCTGCAGTGACCCCGGGAGGTGCTGCTGATGGGAG
GAGATGTCTACACTCCGGGCCAGCGCTTTAACAGCAGGCCAGACAGCACTCGAATGTGTCAGGTAGTAAC
AGGCTGTCCCTGAAAGAAAGCAGTGTCTCAAGAGACTTGACACCTGGTGCTTCCCTATACAGCTGAAAAC
TGTGACTACACCCGAATGACAAATAACTCGCTCATTTATAGTTTATCACTGTCTAATTGCATATGAATAA
AGTATACCTTTGCAACC

Protein Sequence : Show Sequence

>gi|33468859|ref|NP_032363.1| interferon gamma [Mus musculus]
MNATHCILALQLFLMAVSGCYCHGTVIESLESLNNYFNSSGIDVEEKSLFLDIWRNWQKDGDMKILQSQI
ISFYLRLFEVLKDNQAISNNISVIESHLITTFFSNSKAKKDAFMSIAKFEVNNPQVQRQAFNELIRVVHQ
LLPESSLRKRKRSRC

Molecule Role Annotation : IFN-gamma plays a critical role in Th1 type immune response. It is important for protection against infections by various viruses and intracellular bacteria.
Additional Molecule Role : Vaximmutor
Additional Molecule Role Annotation : The experimental data demonstrated that three time vaccinations with BCG in BALB/c mice induced strong TB Ag-specific IFN-gamma immune responses in splenocytes (Wang et al., 2009).
Related Vaccine(s): DNA vaccine expressing multiple HIV epitopes , HIV DNA vaccine VlJns-tPA-gp120 , HIV priming with DNA vaccine expressing HIV gp160 protein and boosted with Ad5/35 vector expressing the same protein

5. IFNG from Macaca nemestrina

Gene Name : IFNG from Macaca nemestrina
Related Vaccine(s): HIV DNA vaccine pHIS-SHIV-B

6. IgA

Gene Name : IgA
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 238447
Genbank Accession : AC160982
Taxonomy ID : 10090
Chromosome No : 12
Gene Starting Position : 8607
Gene Ending Position : 12639
Gene Strand (Orientation) : -
Protein Name : immunoglobulin heavy constant alpha
Protein Note : Also known as IgA; Igh-2

DNA Sequence : Show Sequence

>gi|121699722:8607-12639 Mus musculus immunoglobulin heavy chain complex (Igh) on chromosome 12
AGTACTGGGGGACCTCTTTGCTGCCAAACGGGCCTCGAACAGTTGTAACAGTGAGTGCTGTGCTGTAGAA
CAAGCTCAGTAGGAAGAGGGTGAGGAAGGTCACAGTGGTGGGCCACAGGCTGGCACCTGGGGCCTCTTCC
TCCAGGATGTCTTCTGACTGGTCCAGTAGCACATAGGAAAGTGGCTCTTGACGTTCTGTAAGACATAGAT
GACCTTCTAGATCCAAACCCATGGGGATGGGGGCTCAGACTTAAGGTTTCTGCTTCTATGCCTCCTTGGG
CTTTGGGGACAGTGGTGGTAGGGGTCCCTTATTCCCGGGAAGGGACTTGTTCAGGGATAATGAGGAGGCA
GGGTCCCAGGTAAGGGACTGGAATCCCAGCAGTTCTTGAGATGGCCCCAAGACCCATCTCTCTCTCTTAG
GGAAACCTTAATTAGAGACCTGTCATGGTAAGAGAGTTGTTTCTGTCAAACTCTGAGAAGAGTTTGAACC
CAAGGCTCCTTAGGTCTCAGTCCTTTCTAGATATTTAGCAATACCTCCCTAAACCCCAGTTCTTAGGCTA
ATCTTGGCTTGGGTACTAGGGTTGTGTAAGATCAGACACCTTCAAACAGATACAGGCCAATGTGATTTCT
GGGCCAAAGTTAGACTACCAAGGCCTGGACATGTGGTCAGAGGACTCTGTTGCATTCTTAAGAGCTGTGA
CTGGGGGTTAAGCAACAGTAAAGACCCCCAGTAGAGCCAACCCTGCTGTCCTCAGGTTCTCTGCGCACAG
AGTTTCATTTTAAGTGGCAGTAGGAAATGTGTACTGATAGTCAACCACTCGTATTTCTGTCACTGCAGCC
ATCCATCAATCCATCCATCATCCCCATCGTTCATCCTTGTAGCCAGCCATCCATTACCCTCCAGCCGCTC
ACTCATCATCTTTCCCGACTATCGTGATTCTCCAGCTTCTCTGCCCCCTCTCCCTGTGGGGATTCAGTCT
TTCACCTATTGACTCCTCCTTACTAGGATTCTCTGTCATGGGCCAGGCCTTGGATTCCATGGGTGGCTAT
GGTACTTTTCTGAGTCAGGTTTCCCAAGCTGGTCTGTTGCTCTTGCTATTCTCAGGGAACTGGACTTTCA
AGCTGGAGAGTATCCAGGGCATGCATGGGCCTTTACTCCACTCTTGCTCTGAGAGCAGAGGGAAGTTGCT
AGAAACCAGCAACTCCTCCCCCCCCCCCCCGAAGTTCTGAAGGCCTGTGAGACAGGAGCAGGGCCCCCAC
TGCCCTCTTGTGGACACCTGGGCTCCAAGTATACCTGGTTGTAGAACTTTGTGTTCTAGGGGTGCCCATG
GAGGAGGCCGAGGCCTGTGTGGGAGTGGTCTCCATGGCCTGCTCCTGCTTCTTCCCAGATTTGCCTCTTA
TCCTGCTTCTGGTTTGTGATACTTGGGCTCAGGATGGGAAGGGAGACTTAGGTTAGAAAGGGGGCACCTG
GAGGGGCCTATGCCCTTGTCCATTGTGTGTAGTTGTCAGTGTCGGGCCTGGAAATTCTCCCGGGGGCTTG
GAGGGGACTCCCCTTGCTTTCCAGAAGCTGGGTGTGGGCTGTGAACTTCATCTTCCTCCAGGGTTCAGGT
CTGTGTGAGTGTGCAAATGTGAGTGTCTGTGCATGTATGCCCATGTGCATGTATGCAGAACAGGGTGTAT
GCCCATGTGCATGTGTGAAGAGCAGGGTGCTGCTGAGGGTTGTCTGTGCCATGCTATATGTCTTTCTCAT
GAGTCAGTGGTCACCCTGAATGCATGTTTCCATTCAGGGATGGCCTACTGAGGGTGCGTGGCATCTTCTT
CCCAGTGCCCCTGTGTTCATCCCTTCATTCTCATACCATCATCTCTATTGTGACCCCCACACGGCACCAG
CCTTGATGGTGCTACCCTTTTGCTCCATCTATCCCTGTCTTGTTTGGGTTAGAAGCTGCGGTCTAATAAA
CAGCCACACCACCCACCACTCAGAGTACTTGTGCAGCAACCCACTGCCCTGGGGACTCTCCCATGAGCTT
TGCCTTCTTGGCTGAGTCTGCTCGCCTTGGATTTCATCCCCAGTTTATTCTTACTTCCCATTCACTCATT
GCACATTCACAGGGCAGGTGCACACACTCTCATGTTTCCACCAACATGAACACACATAGATATATGCATG
CTCATAGGTATGCACAGGCACACACTTGCTCACAGGGACATAGATATAGTGTGTCCACATATGTACTTAT
ACCCATATACATACCTATAAACCATAGGTGCACACAAACTCACTCCTCTCTTGCTGCACACAGGTACACA
CATGAAGGCACATGGACCCATCCATAAGCACTCACCAATACATAGACATGCATACACATATACTCTAGGC
ATGAAGGGTCTTCAAAGTCTCCGAGGCCTTACAAGCTTAGGTGGTGGTGTTTCTCCCTCCCTGGGCCCTG
ACCCCTCCCTGTGTTCTGTAGACCCTAAGGATGATGGACAGGCACTGGATGGAAGTGCAGGGATACTTTG
GATGAGCACAGAGTTTATTTCAGGAGTAGGGACAGGCAGGGTGGCTCAGTAGCAGATGCCATCTCCCTCT
GACATGATCACAGACACGCTGACATTGGTGGGTTTACCCGACAGACGGTCGATGGTCTTCTGGGTGAAGT
TCATGGGCAAGGCCTCGTGGCCCACCATGCAGGAGTACTGGTCACCCTGTTTCCAGAGTTCAGCTGATAC
ACGCAACACGCTTGTCACCAGGTAGGTGGTGGCTCCCTCGCCTGGCTCCTTTAGGGGCTCAAACACTAGG
TAGCTTTCTGGGGACAGCTCCTCATTTCCATGCAGCCATCGCACCAGCACTTCTTTAGGGTTGAAAGCTC
GCACCAGGCATGTCAGGGACACGAGCTCATTCAGGGCCAGCTCCTCCGACGGCGGCGGTAGCAGGTGGAC
CTGGGGTGGGAAGGTGTTCACTGGAAGGTAGAAAGAAGAGTTATGGCTCAGACAAGGAGAGCAAGACCCC
TCTGCCCTTCCCTTCTGGGCAGTTCCTCAGATAGCTCCAATTTCCCTCTGTGATATAAGGACAGGAGCAG
TTAGTTGAGCATCTGTATTATAGGAAGAAAGCAGGCATGTGAGCAGGGAACGTCATACAATGTCCCGGGT
ATGCATCTGGGCTCACCTGTGATTTTGGCAATTGTGCCAGTTAAGGTGTCAGACTCAGGATGGGTAACTG
TGCACTTGAATGATGCGCCACTGTTCCAGCGCTCAGCACAGCCAGGCAGGACGCTGGACACACTGTAGCA
GCCGCAGGAATTCTGCACAGCTTTCTTCTGCACTGCATCCTTCCCAGTGGAGGGCTCCCAGGTGAAGACA
GCTCCCTCAGGATTTCTCAGGCCATTCAGAGTACATGTGAGGCTGGCATCTGAACCCAGGAGCAGGTCCT
CAAGAGCTGGCCGCTGCAGTGACAGGCTGGGATGGCAGGAAGGAGGACAAGGAGGACAAGGAGGAGGAGG
ACCTGTAACAGAGAAGTCCTAGCAAATCAGTATATTCTCCTTTTCTCCTTTGCTGTCCCCTTTTCTGGAT
GTTCTGAGGCCTCAGTTCCTTATGGCCTGTTTACGCTTCCCTTCCCCCACCCCCATGGGAGGTTTCTGAG
GGTCCCTGTGAGGGTGTGCCTCAGAGGGATATATGGATCTAGATAAGGTAGAACTTATCCCACCCCCAGC
TGACCCCCTAACGTTCTTTACCAGAGCACTTCACATCCAATTCTTGGACGGCGTTAGAGTCATGTTGCAC
GGAACATTTCACGGATTCTCCTTCTGGGCACTCGACAGCTGGCAGGGTCAACTGGCTGCTCATGGTGTAC
CCTCCCCCAGAGGCCAGGGCAGGTGGGAAGTTTACGGTGGTTATATCCTTCCCACTCTTTCCCCAGGTCA
CATTCATCGTGCCGGAAGGGAAGTAATCGTGAATCAGGCAGCCGATTATCACTGGGTCACTTGACAGAGC
TCGTGGGAGTGTCAGTGGGTAGATGGTGGGATTTCTCGCAGAC

Molecule Role : Vaximmutor

7. IgA Fc fragment

Gene Name : IgA Fc fragment
Sequence Strain (Species/Organism) : Macaca mulatta
NCBI Gene ID : 664734
NCBI Protein GI : 90265825
Protein Accession : NP_001035039
Taxonomy ID : 9544
Chromosome No : 19
Gene Starting Position : 60887587
Gene Ending Position : 60904465
Gene Strand (Orientation) : +
Protein Name : Fc fragment of IgA, receptor for
Protein pI : 7.75
Protein Weight : 30407.11
Protein Length : 287
Protein Note : Also known as CD89

DNA Sequence : Show Sequence

>gi|109156886:60887587-60904465 Macaca mulatta chromosome 19, Mmul_051212, whole genome shotgun sequence
GATGGACCCCAAAGAGACCACCCTCCTGTGTCTCGGTGAGTTTCAGAGTAAAAGTGGGTTAGAGGGGAAA
ACAGGGAAATCCCAAAATAATCCGGGTGTCTCTTGACAGTATGACTAGGAGATTTTAGTGGCTGCCAAGG
AGATTCTGACCTCCTTAGTGGAAAGGCAGTCTTTATCAATATGTCTATAACTTTGTCTCTGCCCAAGTCC
AACCTAGCTTGTGGGACTCAAGGGTTAATATTTTTATTAAACCTATAGTGTGTTATCTGGGATTAATGAT
GGTTCCAAGGTTCCCATCAAAGACAGACTTAGGGGCTGGAATCTGAAAGGTAAAAATAAAGAATGAGCCT
CAAAACTGTGATTGTTGTGGAATGAAAAAATATGATTGAACCCCATATAGAAATATGGTTACTAGTATTT
TGTTGAAGATTTTTGCATTTATGTTCAACAAAGACGTTATCCCGAAGTTTTCTGGTTTTGTTGCGTCTCT
GCCACGTTTTGTTATCAGGATGATGCTGGCCTCATAGAATGAGTTGGGGAGGAGTCCCTCCTCCTGGATT
TTTTCAATAGTTTCAGTAGGAATAATACTAGTTCTTCTTGGCCAGGTGCAGTGGCTCACGCCTATAATCC
CAGCACTTTGGGAGGCCAAGGCAGGTGGAACACACGGTCAGGAGATCACATCCTGCCTAACACAGTGAAA
CCCCGTCTACTAAAAATACAAAAAAATTAGCCAGATGTGGTGGCGGGCACCTGTAGTCCCAGCTACTCGG
GAGGCTGAGGCAGGAGAATGGCATGAACCTGGGAGGCAGAGCTTGCAGTGAGCTGAGATCGCACCACTGC
ACTTCAGCCTGGGCGACAGAGCGAGACTCTGTCTCAAAAAAAAAAAAATACTAGCTCTTCTTTATATATC
TAGTGGGACTGAGCTGTGTCTCCATCTGGTACTGGTCTTTTCCTGGTCTATCATTACAGAGGGTGATTTG
TCATAAAGATTGGAAATGGAAGCTTGATTTTTCATAAATCTCTCTCTTCCAGTGCTCTGTCTGGGCCAGA
GGATTCAGGCACAGGAAGGTAAGTGTCCTGTAAATCTCTCCCAGCCCCTTTAGACTCTCTTGGAAGCTCA
GGATAAAGAAATTGAGGAATAGCCTGAAGTACAGATTCTTATTTTAGTCCCCATTCCAGTTGTTTCTGCT
GTGCTTCTCTTGCATAATTTCTATCACACTTTGTTATAGCCAAATCCTTCAGACTCATTAATGCTCAGAC
CTGGATTTATAGTTAGTCCTTGCCTGTGTTAGACTGCCCATGAAGGATCTGTAATCTACTGAATGCTCAA
AACTGCAAGAATGAGGAAATCAGGAGTCATTTGCCCAACATCCTTCCTTATGCTTTGTTTTAGCAACCTA
CTTCCTCCTGTCACTTCATTTAAAGGGATACTGCCATAGTCTAATCCTACTGAACATTCTACTATTCTAT
AGTACTACTGCAGTACTAAGCATGCAGTAGTCTTAAGAGTACTACTGAATATTCTGCCACCCCAACTACT
ACTGCCTTAGCCTCCTAATGGGTGTAAGCCCCATGTCCATCCATGTCTGCTCTCTTCCAGCTCCTTCTAT
AGCCTGAATTATTTGTGTGTTGAACAATATTCATTCTTCCTATCCATGAGCATGGAATGTTTTTCCATCT
GTTTGTGTCATCTATGATTTCTTTGAGCAGCGTTTTGTAGTTCTCCTTGCAGATATCTTCCACCTCCCTG
GTTAGCTGTATTCCTAGGTATTTTATTCTTTTTGTGGTAATTGTGAATGGATTCTGTTCTTGATTTGGCT
CTTAGCTGAGACGTTTTTGGTGCATAGGAATGCTACTGATTTTTGTATATTGATTTTGTGTCCTGGAACT
TTGTCAGAGTCGTTTATCAGATTAAGAAGTGTTTGGGCAGAGATTGTGGTTTTCTAGGTATAGAATCACA
TCATCTGCAAACAGGGATGGTTTGACTTCCTTTCTTCCTATTTGGATGCCTTTCATTTCTTTCTCGCCTG
ATTGCTTTGGCTAGGACTTCCAGTACTATGTTGAATAGAAGTAGTGACAGAGGGTATCCATGTCTTGTGT
CAGTTTTCAAGGGGAATACTCCCAGCTTTTGCCCATTCAATATTATGTAGGCTGTGAGTTTGTCATAGAT
CTTCCTTATTATTTTGAAGTACGTTTCTTCAATGCCTAGTTTGTCGAGGTTTTTTAGCATAAAGGGATGT
TGGATTTTATCAAAAGCTCTATTGAGATGATTATATGTGTGTGGCCGGGGGATTGTTCTATGAATCACAT
TTAAGATTTGTGTATATTGAATCAACCTTGCATCCCAGAAATAAAGCCTACCTCATGGTGGTGGACTGGC
TTTCTGATGTGCTGCTGGATTGTTTGCTAGTATTTTCTTGAGGATTTTTGCATTTATGTTCAACAAGGAT
ATTGTCCTGAAGTTTTCTGGTTTTGTTGTGTCTCTGCCATGTTTTTGCATCTATGCGGGTCTCATAGAAT
GACTTGGGGAGGCATTCCTCTTCCTGAATTTTCTGGAAAGCTTCAGTAGATATAGTACCAGCTCTTCTCT
ATGTATCTGATGGGATTCAGCAGTGAGTTTGTCTGGTACTGGCCTTTTTCTTCTTTTGAAGAGGCCTTTT
TATTACTGATTCAATTTTGGAGTTCATTATTGGTCTGGTTCATGGAATCAGTTTGTTCTTGGTTCAATCT
CAGAAGGATGTATGTGTCCAGGAATCTCTCCATTTATTCTGGATTTTCTAGTTTGTGTGCACAGAGGTGT
TCCTAATATTCTCTGATGATTGTATTTCTGTGGGGTCAGTGGTAATATCCCCTTTGTTGTTTCTAATTGT
GTTTATCTGGATCATCTCTCTTTTCTTCTTAATTAGTCTAACTAGTCACCTGTCTTACTAATTTTTTTCA
AAAATCCAACTCCTGGATTTGCTGATCTTCTGAATGGTTTTTTGCATCTCAATCTCCTTCTGTTCAGCTC
TGGTTTTGGTTATTTCTCGTTTTCTACGAGCTTTGGGGTTGATTTCCTCTTGGTTCTCTCAGTTCCTCTC
GTTGTGATGTTAGGTTGTTAATTTGAACTTTTTCTAACTTTTTGACGTGGGAGTTTAGTACTATAAACTT
CCCCCTTAACACTGCCTTAGTTGTGTCCCAGAGATTCTGCTGTATTTACCCACAAATTCCAGAACAGACT
GTTTAATTTCCATGCATTGTACAGTTTTGAGTGGTTTTCTTAGTATCTATTCCTATTTTTATTCCACTGT
GCTCTGAGAATGTGCCTGGTATGATTTCACTATTCTGGATTTGTTAAGGATTGTTGTATGTCTGATTGCA
TGATTGACTTTAGAGTATGTGCCACGGGGCAATGAAAACAATGTAGATTCTGTTGTTTTGGGGGTGGAGA
GTTCTGTAGATGTCCATCAGGTCCCTTTGGTCCAGTGCTGAGTTCAGGTCCTGAATATCTTTGTTTGCCT
CAGTGATCTAACACTGTTGACGAGATGTTAAAGTCCCCCCCTATTATTGTGTGGTTGTCTAAGTCTCTTT
GTTGGTCTCTCAGAACACGCTTTATGAATCTGGGTGCTTCTGTGTTAGATGCATGATATTTAGGATAGTT
AGGTCTTCATGTTCTGTCTTTATTTTTTTCTTTTTCTTTTCCTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TGAGATGGAGTCTCACTCTGTTGCCCAGGCTAGAGTGCAGTGGTGCAATCTCGGCTCACTGCAAGCTTCA
CCTCCCGGGTTCACGCCATTCTCCTGCTTCAGCCTCCCGAGTAGCAGGGACTACAGGTGCCTGCCACCAC
GCCCGGCTAGTTTTCCAACATGGAAAACTATGTTTTCCATATTGCTTGCTTTCTCCCCATCTCTTTCGGG
GACCCCAATGGGTTGCCTATTTGGTCTCTTTACATAATCCCATGTTTCTTAGAGGTTTCAAATTTCATTC
ATTCTTTTGTATTCTTTTGTCTTCATTTTTGTCTGACTGAATTAGTTCAGAGAGCCAGTATTCATGCTCT
GAGATTCCTTCCTCGTTTTGCTTTATTCTGCCGTTAATACTTGTGATTGCATTATGAAATCTTGCAGTGT
GTTTTTCAGCTCTATCAGATCCGTTCGGTTCTTTCAAAATGACCGTTTCTTAGATTAGCCCCTGTGTCAT
TTTATCGTAATCTTTCGATTCCTCGCATTGGGTTTCAACTTTCTCCTGAATTTGATGACCTTGATTTCTA
CTCATATTCTGAATTCTATTTCTGTCATTTCAGCCACTTCCTCCTGGTAAAGAGCCCTTGCTGGGAAGCT
CATGTGGGAATTTGGAGGAAGGAAGACACTTGCTTTTTGAGTCTTGTGCTAATTCTTTCTCATCCGTGTG
GGCTAATGTTCTTTTAAGTGTGGTGCAATTGGAGTGTTTTTCTTTTTTCTTTTAACTGTGGTGTAATTTG
AGTACAGTCAGTAGACTTCTTTTCTGGGTGGTTTCAGAGGGCTGGGGCTTCGCACAGGGTCTTTACTGAT
AGCTAAATTCTTGTCCTTGGTATAACGGGGGGTATATTAGCAAGCATTTTTGGTGTTGAAGTTTGGGCTG
CAATCCAGTAAGTGATGCTTAAGCATAATGGCCAGTAGGTCATTCCTCATGACGGCCGCTGTGCTCCCTC
TCATGCTCTGAATGTGTGGGCTCCTCTCCCACTCAAGCACTGGCTGCAGATCTGGGCTCCGCACTCCCAG
GCTGCCCATCACAGCGCTGGGGTGAGCTCAGGTTTTATGTTCCCTCCGTGGCTTGGGGGCAGCAGGGGAA
GGGACCTCAGCAGTGGCTGTGGCAGATGGCCTTTCACTTGTCCCTTGGGACTCCACCCCAGAGAGATGTG
GAACCACTATCAGTAGTGTGATGAGCCAAGAGTGGGGCGACTGCGCTGTGGGCCCAAGCTAGGGGCCCTG
CCTAGTGATGAGCAGCGGGGACAGGTGGGTCACAGGGGTGACAGACTGGCCTCTTCTCCTTAGGGCAGCT
TGCGGGAGGTGTGGTTAAGGCACTCAGAGTCTTTGCTCCTTCCCCAGTCTGAGGGCAGCAAGGCCAGGAC
CACCGCAGTGGCAGCCGCAGAGGGGCTGTGAGTTGCCTCTGGGAGCTCCGCCACAGAGAAATGCAGACCC
ACAGCTCCCAGGCACGCTCCGCAGAGGGTGGGGCTGCTGTGCTGCGGGCTCAGGCTGGGGTTTGGTGAAG
AGCAGGGGGCTGAGGGCTCGCAGGGAGAGGAGACTGAGCTCCTCTCTTACGGTGACTGTGGTGTGCTAGA
GGCATGAATGAAGGCTGGGGCTCGGCGGCTCACACCTGTCATCCCAGCACTTTGGGAGGCCGAGGCGGGC
GGATCACGAGGTCAGGAGATCGAGGCCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAATACA
AAAAACTAAGCCGGGCGTGGTGGCAGGTGCTTGTAGTCNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNCTACAAA
TGCTCAGTAAAAAAAATACTAATAATAAAATAAAATAAAATAAAGCATGAATGAAGCTCCTAGGCTCCTT
GTTCTTCCTCAGACCACAGGCAGCAGGGGCAGAATCCTTGCCATGGCGGTGGCAGAGGGGCCGTCAGTTG
CCTCTGGGAGCCATTCCCCAGGGAAACACGGAGCCACCACCAGTGAGGATGCTGAGGGTAGGGCAGCTGC
TCTGCAGTCCCAAGCTGGGGGCTCTGCCTGGTAAAGTGGGGGTGGGGGCTCACGGGGAAGAGAGACTAGA
CTCCTCTCTGTCTGATGGCTGTGGCATAATGACCAGTCCCCAACACGTGAAAAAGAATTGTGGGAACTCA
GAAACCCAGTTTGTCCCCACCATGGACTCCTTGCACTGCGTTTCAAATTTCTCCTCAATCTCCATGAGCT
TCCCAGCCATCCAGATTCTGAATTCTATGTCCCTCGTTTCATTCATCTCAATCTAGCTAAGAACCAGATT
TCCAGGGGACTATCGAGTTGCCAGAGTTCTTGTGTTCCTTTTATTTTTTCCTTTTGTGTGACAAGAGTCT
TACTCTGTTACCCAGGCTGGGGTGCGGTGGCGTGATCTCAGCTCACGGCTGCAACTTTCACCTCCCAGGT
TCAAGCTATTCTCCTGTCTCAGCCTCCCAAGTAGCTGGGATTACAGCTGCGTGCCACCACACACAGCTAA
TTTTTGTATGTTTAGTAGAACCCAGGTTTTGTCAGGTTGGTCAGGCTGGTCTTGAACTCTTGACCTCCGG
TGATCCGCCCGCCTGGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCACCGTGCCCGGCCTTGGTGT
CGATTCTTTCTCTTGTGTGAGGGCTGGTGTTCCTTTAACTGTGATGTCAGTTGAATACAGTCACTTAGCT
TCATTTCTGGGTGTTTTCAGATGCCAGGACTCTGCACGGAATCTTTATTTGTGGCTGGATTTTTCACTTC
GTTGTCTACTGGCAAAATATTTCAGTCTTGTATTTTGACGTGTGATCCAGTAGGTGGCACTTAAAAGGGG
CTGGCCAGCATACAGGATCTTAGCCACAAGGCTGTTTTGTAGTTTTGTTTCGTTTTTTGTTTTGTTTTTT
GACACAGGGTCTTGCTCTGTCACCCAGGCTGGAGCGCAGTGGCACAGTCTCGGCTCACTGCAGCCTCCAT
CTATCAGGCTAAGTGATCCTCCTGCCTCAGCCTCCTAAGTAGCTGGGACTACAAGCACATACCACCATAC
CAAGAAAATGTTTGTAATTTTTTTTTTTTTTTTTTTTTAGAGATGGGGTTTCACCATGTCTGCCAGGCTG
GTCTCAAACTCCTGGGTTTAAGTGATCTGCCTCCCTTGGCCCCCCAACTCTTGTATTTTGACAAAGTTAG
CAGTAGTGCTCTGTGGTTGTGGGGAGGGGTGACTTCCTCACCTGGTCCATTCCTGGGCCTTGGAGGAGCC
TCCTACAATCACTAGCTCTGCACCCACCGTTTCCTTTGTTAGGATTGTTCTGCCCACGGGGTTCCTTCAG
GCAGTGCATGGTGGGAAGACAGGCTGTATCCTTCCCCAGCCAGCCTACGGAGGGAGGACCACCCCACTCC
TCTGCAGACTGATGAAATCACGTGTTTCATTCTTCTGAGTGTTCTGAGAATGAGGGCTCCTCACCGCTCA
GTCGCCACCCAAGCTGGTGAGTCCTTCTCAGCAAGGGCGGTTGGAACCACCTGATCTGCCATCTCAGTGC
TTCCCAGGGGAACCCAGAGCTGCTGGGGCATGGCAGCTCATGCCTGTAATCTCAGTACTTTGGGAGGCCA
AGGCGGGCAGATCACGAAGTCAGGAGATCGAGACCATCCTGGATAACATGGTGGAACCACATTTCTACTA
AAAATACAAAAATTATCCAGGCATGTGGCGGGCACCTGTAATCCCAGCTACTCGGGAGGCTGAGGCAGGA
GAATTGCTTGAACCCGGGAGGCGGAGTTTGCAGTGGGTCGAGATTGCGCCACTGCACTGCAGCCTGGGCG
ACAGAGCGAGACTCTGTCTCGAAAAATAATAACAAAAAAAAATAAAGATGGCAACCACAGACACTGGAGA
CGACTAGACGGGGAGGAAGAGAGGGGCTTGAAAAACTAACTGCCTACTGGGTACTACGCTCAGCACCTGG
GTGACAGGATCCACCGTACCCCAAACCTCAGCATCATAAATTATTTACATGTTTATTTTTATTTATTTAT
TTATTTTAATTGAGACAGAGTCTCACTCTGTGGCCCAGGCTGGAGTGCCATGGCGGGATCTCAGCTCACT
GCAAGCTCCGCCTCCTGGGTTCACGCCACTCTCCTGACTCATCCTCCCAAGTAGCTGGGACTACAGTCGC
CCACCCCCACGCCTGGCTAATTTTTTGTATTTTTAGTAGAGACGAGGTTTCACCATGTTAGCCAAGATGG
TCTCGATCTCCTGACCTCGTGTTCCACCCGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCA
CCACACCTGGCCTAAATTTTTCTTTAAATAAAGAATGACAGGTTCTTCATACCCTAATTTTCTTCCAGGG
AACTTTTCCACGCCTTTCATATCTACCAGGTCAAGTCCTGTGGTTCCCTGGGGTGGGTCTGTGAGAATCC
AGTGCCAGGCCATTCCTGACGCTTACCTGATCTGGCTGATGATGCTAAAAAACTCCACGTACGAGAAGAG
AGACGAAAAACTGGGGTTTTGGAATGATACTACGCCTGAGTTCGTCATTGACCACATGGACGCGAACAAA
GCAGGGCGCTATCAGTGCCGATATAGGATAGGGTTCTCCAGGTTCCGGTACAGTGACACCCTGGAGCTAG
TGGTGACAGGTAAGGAAACATCCAGGGTCCACAGCCCTGGTGTGATTTTTTTTCTTATTTTTAATAGAGT
ATTTTTCGATAAGTTTTAGATTTACAGAAAAAAGAAAAATTGAGATGACTGCTTCACAGAGTTCTCAGCT
ATCTGGCCACTTCCCCCAGAGTTAACATCTGACATTACTATGGCACATTTCTTTTTTTTTTTTTTTTTTA
ATTTTTTTTTTTTTTTTTTTGAGACGGAGTCTCACTCTGTCGCCCAGGCTGGAGTGCAGTGGCCGGATCT
CAGCTCACTGCAAGCTCCGCCTCCCGGGTTTACACCATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGAC
TACAGGTGCCCGCCACCTCGCCTGGCTAGTTTTTTGTATTTTTTAGTAGAGACGGGGTTTCACCGTGTTA
GCCAGGATGGTCTCGATCTCCTGACCTCGTGATCCGCCCGTCTCGGCCTCCCAAAGTGCTGGGATTACAG
GCGTGAGCCACCGCGCCNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNCACACACAC
ACACACACACACACAGAGGTTACACACACACACACACACACACAGAGGTTACACACACACACACACACAG
AGGTTACACACACACACAAACACACACACACAGAGGTTACACACACACACACACACACACAGAGGTTACA
CACACACACACACACACACAGAGGTTACACACACACACACACACACAGAGGTTACACACACACACAAACA
CACACAGAGGTTACACACACACACACACACAGAGGTTACACACACACACACACACAGAGGTTACACAAAC
ACACACACACACAGAGGTTACACACACACACACACAAACACACACACACACACACACACACACACAGGTT
TCACTTTGCATTCAGGTGTCATGTATCTTTAGCTTTCTCCCGGCTCTCACAGCTTCTCCGATGTTGCTGG
TTTTCCATGGCCTTGTCAGTTTTGAGAGTAGAAGTCCATCACTTTCATTGGCCGGGCGCGGTGGCTCAAG
CCTGTAATCCCAGCACTTTGGGAGGCCGAGACGGGCGGATCACGAGGTCAGGAGATCGAGACCATCCTGG
CTAACACGGTGAAACCCCGTCTCTACTAAAAAATACAAAAAAACTAGCCGGGCGAGGTGGCGGGCGCCTG
TAGTCCCAGCTACTCGGGAGTCTGAGGCAGGAGAATGGCGGGAACCCCGGAGGCGGAGCTTGCAGTGAGC
TGAGATCCGGCCACTACACTCCAGCCTGGGCGGCAGAGCCAGACTCCGTCTCAAAAAAAAAAAAAAAAGT
CCATCACTTTCAAGGGTACTCCCACTATTGGAAATTGTCCGATGTGTTGCTCATGACTAGACTGAGTTAT
GGGTTGTTGAAGACCACAGAAGCAAAGTGCCGTTTCATCTCCTCATAGCAAAGGTTTAAACTGTCCATGG
GAATATGACTGTTGATGCTGAACTGGCTGTTGTTGAAAGCCTGGCTGAAGTAGTGACTGTGACCAGGCAC
CGAGGCTCACGCCTGTAATCCCAGCGCTTTGAGAGGCCGGGCGCAGTGGCTCACGCCTGTAATCCCAGCA
CTTTGGGAGGCCGGGCGCAGTAATCCCAGCGCTTTGAGAGGCCAAGACAGGCGGATCACTTAAGCCCAGG
AGACCAGCCGAGGCAACATAGTAAGACCCCATCTGTACAAAAAAAACAAAAAATTAGCTGGGCATGGTGG
CACCCACCTGTAGTCTCAGCTACTTGAGAGGCTGAGATGGTAGGATCACTTGAGCCTGGGAGGTCGAGGC
TGCAGTGAGCCGCGATTATGCCACTGCCCTCAGCCTGGGCGACGGAGTGAGACCCTCTCTAAAATAAATA
AATAAATAAAATTTTAAAAAGAAAAAAGAGGCTGGGCACTGTGGTTCACGCCTGTAATCCCAGCACTTTG
GGAGGCTGAGGCGGGTGGATCACCTGAGGTCAGAGATTCAAGACCAGCCTGACCAACATGGTGAAACCTC
GTCTCTACTAAAAATACAAAAATTAGCTGGGCGTGGTGGGAGGTGCCTGTAATCCCAGCTACTCAGGAGG
CTGAGGCAGGAGAATCACTTGAACCTCGGAGGTGGAGGTTGTGGTGAGCCAAGATTGTGCCACTGCACTG
CAGCCTCGGTGACAGATCGAGACTCCATCTCAAAACACAATAATAGGCCGGGTGCGGTGGCTCACGCCTG
TAATCCCAGCACTTTGGGAGGCCAAGATGGGCAGATCACTTGAGGTCAGGAGTTCGAGACCAGCCTGACC
AACATGGAGAAACCCCATCTCTACTAAAAATACAAAAATTAGCTGGGCGTGGTGGTGCACACCTGTAATC
CCAGCTTCTCAGGAGGCTGAGGCAGGAGAATCACTTGAACCCAGGAGGCAGAGGTTGTAGTGAGCCGAGA
TCACACAATTGCTCTCCAGCTTGGGCAACAAGAGCAAAGCTCCGTCTCAAAAAATATATATAATAATAGC
AATAATCAGAAGAAGAAAAAAATAAAGGAGAAAAGGTCTTGCTAACAGCTCACTCTTCTCTCTCTTAGGC
TTGTATGGCAAACCTTCCCTCTCTGTGGATCGGGGTCCAGTGTTGATGCCGGGAGAGAATATTTCCGTCA
CGTGCAGCTCAGCACACATCCCATTTGATAGATTTTCACTGGCCAAGGAGGGAGAACTTTCTCTGCCACA
GCACCAAAGTGGGGAACACCCGGCCAACTTCTCTCTGGGTCCTGTGGACCTCAATGTCTCAGGGAGCTAC
AGGTGCTACGGCTGGTACAACAGGAGCCCCTACCTGTGGTCCTTCCCCAGTAATGCCCTGGAGCTTGTGG
TCACAGGTAGGTACCTCCCCATCCAGCCCTGTGTCCGGGTTGGCTGTCCAGGCCCTTGTCACTGGGCAGG
AATATGAATATGAAGAGGTGCACTGAGAATAATGTGAAGAGAGGCAAAGACTCACCCACTCCAGGACAGT
GGAGAAAGAAAGTCTTCCCATCACACTTTCCACCTTCACTTCCTCGCTAGAGTTCTCCAGACAGTGTTCA
TTGAAAACTTGTGGTCTATGGAGAAAAGAAGGACTGACTCATTTTATTTTATTTTATTTTCTGTGATGGA
GTCTTGTTCTGTCGCCAAGGCTGGAGTGCAGTGGCGCGATCTCGGCTCACTGCAAGCTTCGCCTCCCGGG
TTCAAGCAGTTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGACCATGCAGAGTTTCACCATGTTGTTCAGG
CTGGTCTCGATCTCATGACCTTGTGATCCACCCACCTCAGCTTCCCAAAGTGCTGGAATTACAGGCGTGA
GCCACCGTGCCCAGTCAAAAAAGGCTAACTTAGAGTCACAGGTTTATGGGCTATGTTGAGACAGTAGATA
CCAGGCTCAACCTTGTCTACCACACCTCTCCTTTCCAGTTGCAGCTGGAAATCCTCGAACTCACCAACCG
TACTGGAATTTACCATGAGTAATCAAATGGTCATTCATGGTGACCATTTAGTGACCAAATAGTGAGTGAG
GGGTCAAATAGTGACATATTTGGTGACCAAATAGTGAGTGAGAGGTCATAGGAAAGACTTTTAAAACCTC
TATCATGAGCCCCATTTTTATTTTATTCATTTATTTATTTTGAGACAGAATCTCGTTCTGTCGCCCAGGC
TGGAGTGCAGTGGCACAATCTCTGTTCACACTGCAACCTCCACCTCCCAGGTTGAAGCAATTCTCGTGCG
TCGGCCTCCTAAGTAACTGGGACCACAGGCGTGCACCACCGCACCAGGCTACTTTTTGTATTTTTAGTAG
AGATGGGGTTTTGCCATGTCGCCCAGGCTAGTCTCAAACTCCTGGCCTCAAGTGATCTGTCTGCCTCAGC
CTCACAACGTGCTGGGATTACAGGCGTGAGCCACCACGCCTGGTGGTGAAGACTCTAAAGGCTCTTCTCA
GACCAGCCTTTGTCCTGAGGGTCACATGCCCGTGTCCAGTTACCTCTCCAGCATCTTTTCAGGAGTTCCA
CGGACTCGCCCCTTCATTATCCAGGGTTGAGCTACAGATATTCTGATTAGGATTCCACCTAGTTCTGGTG
GTGGTGTAGAGATATGATTAGATATTTAGTGAAATCACCAAGTGAGGAGAGAATGAAAAGAAAACACAAC
TTGCCTGGCCGGGTGTGGTGGCGTGAGCCTGTGGTCCCAGCTACGCAGGAGGCTGAGGCAGGAGAATCGC
TTGAACCCAGGAGGCGTTGGTTGCACTGAGCCAAGATTGCGCCATTGCACTCCAGCCTGGGTGACAGAAT
GAGACTCCATCTCAAGAAAAAAAAAAAAAAACATGGCTGGGCACGGTGGCTCACGCCTGTAATCCCAGCA
CATTGGGAGGCTGAGACGGGCGGATCACTTGAGGTCGGGAGTTCGAGACCAGCCTGGCCAACATGGTGAA
ACCCCATCTCTACTAAAAATACAAAAATTAGCCAGGCATGGTGGCGGGCGCCTGTAATCCCAGCTACTTG
GGAGGCTGAGGCAGGAGAATCGTTTGACCAAGGAGGTGGAGGTAGTAGTGAGCCGAGATCGCGCCACTGC
ACTCCAGCCTGGGCGACAGAACAAGACTCCGTCTCCAAAAAAAAAAAAAAAACAACCTGCCCGTAATCAC
TCCCTTCCCAGTTTATGGAACTTCCCTGCCTGTGGACACAGTCCTGCTGACTGATCAATGTGGTGCTTGC
AAAGTGTGAGCCCATCGAGGAGATGCCTGAGGGAGTCACATTTTGGCAAGCGAATAGGGAAATGGGCTCC
CGTTTCAGGGCTCTGGGGTTGGGATGGAATGGAACACACCCGCCAACCATTCATCTCCCCGAATTGTGTC
TCCAGACTCCATAAACCGAGATTACACGACGCAGAACTTGATCCGCATGGCCATGGCAGGACTGGTCCTC
GTGGCTCTCTTGGCCATACTGGTTGAAAATTGGCACAGCCATAAGGCGCTGAACAAGGAAGCCTCGGCAG
ATGTGGCTGAACCGAGCTGGAGCCACCAGATGTGTCAGCCAGGATGGACCTTTGCACGAACACCAAGTGT
CTGCAAGTA

Protein Sequence : Show Sequence

>gi|90265825|ref|NP_001035039.1| immunoglobulin alpha Fc receptor precursor [Macaca mulatta]
MDPKQTTLLCLVLCLGQRIQAQEGNFSTPFISTRSSPVVPWGGSVRIQCQAIPDAYLIWLMMLKNSTYEK
RDEKLGFWNDTTPEFVIDHMDANKAGRYRCRYRIGFSRFRYSDTLELVVTGLYGKPSLSVDRGPVLMPGE
NISVTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSLGPVDLNVSGSYRCYGWYNRSPYLWSFPSNA
LELVVTDSINRDYTTQNLIRMAMAGLVLVALLAILVENWHSHKALNKEASADVAEPSWSHQMCQPGWTFA
RTPSVCK

Molecule Role : Vaximmutor
Related Vaccine(s): HIV-1 gp120 with mCT E112K

8. IgG

Gene Name : IgG
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 16059
Genbank Accession : AF010213
Taxonomy ID : 10090
Chromosome No : 12
Gene Starting Position : 881411
Gene Ending Position : 914690
Gene Strand (Orientation) : +
Protein Name : immunoglobulin heavy chain (V7183 family)
Protein Note : Also known as IgG; IgH; VI24H; VH7183; B9-scFv; IgVH1(VSG)

DNA Sequence : Show Sequence

>gi|94393741:881411-914690 Mus musculus strain 129/SvJ chromosome 12 unlocalized genomic contig, MGSCv37 alternate locus group 129/SvJ
CATGGACTTTGGGCTCAGCTGTGTTTTCCTTGTCCTCATTTTAAGAGGTAATTTGTAGAAATAAGATCCT
GCCAGTATTGTGTACAGGAGAAATAGAAAAATTTTTCTTTCCTCTATTTTGTTTTGTTTTGTTAGTGACA
GTTTACAAATAAGCATTCTCTGTTGTGAGGTGCCCAGTGTGAGGTGAAGATGGTGGAGTCTGTGGGAGGC
TTAGTGCAGCCTGTAGGGTCATTGAAACCCTCCTGTGCAGCCTCTGGATTCATTCTCACTGACTACTGAA
TGACCTGGATCCTTCAGGCTTCAAAGAAAAGGATGGAGAGGGTGACAATAAAATTTTTCCCACTCACACC
CACTTGCTGGCCCTGGCGTTCCCCTGTAATGAGGCACATAAAGTTTGCAAAACCAAGGGGCCTCTCTTCT
CAATGATGGCTGACTAGGACATCTTCTGATACATATGCAGCTAGAGACATGAGCTCCCGGGATACTGGTT
ACTTCATATTGTTGTTCCCCCACAACAGTTGCAGACCCTTTTATTTCTGTGGGTACTTTCACTAGCTCCT
CCATTGGGGGCCCTGTGTTCCATCCAATAGCTGACTGTGAGCATCCACTTCTGTAGTTGCTAGGCCCCGG
CATAGCCTCACAAGAGACAGCTATATCAGGGTCCTTTCAGCAAAATCTTGCTGGTGTATGCAATGGTGTC
AGAGTTTGGAGTCTGATTATGGGATGGATCCCCAGGTATGGCAAACTCTAGATGGTCCATCCTTTCCCAA
CAATAATTTTTAATGGTGGAGATAGCACCTACTATCCAGACACAATGAAGGGCCAATTCACTATCTCTAG
AGATGATGCCAAAAACACACTTTACCTGAAAATAAACAGTCTGAGGTCTGAGTACACAGCCATGTATACA
TATATTCCTAAGCTTGAGTAAGTGGACTTAAACTGATTCCATCACAACTTGCATGAGATGGATATTCCCC
AGTGTTAAGACCTGTCACCATCACTGTCAATCAGAAGACAAAGTTTATGCACAACAAAACAAAAAAACCA
AAAGCAGAGGCCTCCAATTACAAGTAATAGACCCAGACCCACAGTCTCTGAAAACTGACTGTACAGTTGG
ATCCAGTCTTTTACTTCTTTTCCCTGGATTTTATATTACTGAGGAAATGAGGAAAGCTCTACAATATCTG
TTCTCCATAGTGCTCAACACCTCCAAGCACAGGTTACCCATATTCATGCCTGCCTTCTGCTACACTTCTT
GTCTTGTAGACTACTTCAACCTATTTTGTACTCCAGTTAATGAAACTCAAGTCTAGCAGCCTGTCACTGT
TTATTCTAAAGTATTATGAACAGGTGACCTCCCATCCTTCCCCAACGCAATAATCATATTTAGGAATTTG
AGGTTTTATGAGATATGATCTCAGGGTAGAGAGAGAAAGCAAACTACATAGAAATATAGACTGACATAAA
TCAAGACTTGCATAAGCTAGTCCCCAAGTTCCATGTCCCTAAGTGGCAAGGACTATCTTCTGAGCCTAAT
GAGATGAGATCCAAATCAAACCTCCTGGGTCTTTTTAGATAAACATGTGAGATCAATAGACTAAATGCTT
TGGCTGGGCTTCCTTGCAATCCAATTCCCAAACAAAAATGGATCTGGCTCCACAGACACCACAAGAATAG
TCTTAAATAGTTCTTTAAGTAGAATGTCTGATCACTACGAGCCCAATTCCATCCTAAATACTCTTCTGGA
TTATACATAAATAAAAATTGAACATAGGGCATGGGGCACTGATCTCCCTGTGCTACATGAATGGGGGCTC
ATTTACTAAATGTTCCCATTTTTCTTTCTAGCGCTGCACAGTGCAAATCCTACAACTTCCTGTTTATCTA
CAATGTGAACTCCAAACAGTACAAGAAAAAACGTTCCTTATGTTCCTCTCCAGGTTCTCCAACAAGCACA
GAGCAACCTTCTGTCACCAGGACGGAAAACTGGAAACCTTGCTCACTGCTTCCTTTTATTCCCTCGGGAA
CCTCCCCCAATGCAAAGCAGCCCTCAGGCAGAGGATAAAAGCTCACACAAAGACGAGAAGCCCCATCCTC
TTCTCATAGAGCATCCATCAGAGCATGGCTGTCCTGGGGCTGCTTCTCTGCCTGGTGACTTTCCCAAGCT
GTAAGTGTTTCAGGGTTTCAGAAGAGGGACTAAGACATGTCAGCTAGAAGATGTGTGACTAATGGTGATG
TTGCTTGTCCCCAGGTGTCCTGTCCCAGGTGCAGCTGAAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCA
CAGAGCCTGTCCATCACATGCACCGTCTCAGGGTTCTCATTAACTAGCTATGGTGTACACTGGGTTCGCC
AGCCTCCAGGAAAGGGTCTGGAGTGGCTGGTAGTGATATGGAGTGATGGAAGCACAACCTATAATTCAGC
TCTCAAATCCAGACTGAGCATCAGCAAGGACAACTCCAAGAGCCAAGTTTTCTTAAAAATGAACAGTCTC
CAAACTGATGACACAGCCATGTACTACTGTGCCAGAAACACAGTGTGGGAAGTCCAATGTGAGCCTGCAC
AAATACTTCTCTGCAGGGATGATCACAACCAGCAGGGGGCGCTGATGACCCAAAGGGACTTCCCAGGATC
TCTTCTGGAATCTAGGGAGTTCTGGCCTGTGTCTATCAGCATGTGTTTCAATGTTAGAGTTGTGAGTTTT
CCTTCCAGCAACAGAGATATTTTAGAGCCCACTTTTCATGGTCATTCTACTAAATTTGTTCACATAGTGG
AAAGATTTGTTAAATGATTCTATAGTCTAATAGGGTCAAACAAAAACAAATAATTGAGTTCATATCTACC
AAAAAAAAAAAAATTCCCTCAAAGTGGACAACTGTGTAGGTGAGGAAAACCAGGGGGATTTGGGAATAGA
TTATTTCTCTCCCGACTGTGGTGTTAGTCACCTTTCAGCCATTTACTGTATTTAATTCATGTTTAAAGTT
AATTGTATTCATCTTCCCTAACATGAAGTTTTCAAACACATGTCCACAATTTAATGATGACACAGTTATC
ATTGTGAATGATAACTCATAAGATCTCTCTCCATATATGAAACACACGATATTCTGTTATTAGCTATAGC
CAACAAAGTTACATATCATTATTATTACTGAAATAATTCTTCCCATCTAACTGAATAGTTTTCTCACTCG
ACACTGCCTATGCTGCGATCAGCCTGCTCTAATTTTACCTTTGCTCAGAGCACTGCTTTCTGTTTCATTT
GATAAGATGGTGCCTGGTTGTCACTGAAAATGTGTCCTCCAGTTTCACAGTGATTAATGTGATTTTCAGT
ACATTGAGAACAGAGCCACAGCAAAAATGAGATGGAATGTCATCATTTTTACGCCAGGTGCTGCAGAAAT
AGCTAGGTGGTTAAGAGAGAATATTGAACTTTGAGGGGTTCAGATTAAATTCCTGATACCCACAATGTGC
ACCTCATAACCACATGTACATATAGAAAACTCAGTATAAATGTGGCCTCCGTGAGCACCACACTACTCCC
ACAAACACATATACACATAATTAAAAGTAAAGATTTTAGAAAAATGGCTAATCTAATGATAGGAAGTAGT
CAAAAAGAGAGTTCTTTTGTCATGTACATATGTGTAGCAGACTTAAATGTTAAACATTCAAGAATACATT
CCTCGATCCACATTAAAATTTTGCAAAGAGTAGCACAGACGGTGGCAATTGCTAAACTTATATCTAGAAA
CACAATTATGTGTGGTGATATTTAATTACACATTTATACCAGGACATATGACAATATGGAAACCAAACAT
GTTGTATCCACATGCTCTAAGGAAAACTAAATGGAGTGTGATAAAACCAAAGAAAATGTGAATATGAAAT
ATTTTTCCAACTCTGCATCTTAAAACGGTTTCTTTCATGTGTCATATCTGCTATGAGGACTTTCTTCTGC
CCATGTCCAACTCCAGAGCATGCCACAGCAGGAAGACCTACAGGTATTACTTCTCTGCACCCAGGAAAAC
CACCTCTGTCCTGACCCTGCAGCTCTCAGAAGAGCCCAGACCTTCATTCTCAGGCCCTCATCCAGTAATC
AGCACTGAATACAGAGCACTCACCATGGACTTTGGGCTCAGCTTGGTTTTCCTTGTCCTTATTTTAAAAG
GTAATTCATAGAGATAAGATTCTATCTGTTTTGTGTACATGAGAAACAGAAAAATTGTATTGTTTCTCTA
TTTTGTTTTGTTTTGTTAGTGACAGTTTCTGACTCAAGATTCTCTGTTTGAAGGTACCCAGTGTGAGGTG
AAGCTGGTGAAGTCTAAGGGGAGGCATAGTGCAGCCTAGAAGGTCCATGATACTCTACTGTGCAGCCTCG
GATTCACTGTAAGTGACGACTGGTTTGTCCGTGTTTGCCAGGCTCCAAAGAAGGGGCTGCAGTGGGGGAT
GGGAATAATTTTTCATGGTTGTGGTAGCCCCTCTTATGCAGACACCTTGAAGAAGTGGGTTGGACGTAAC
ATATTCAGAATCAATATTTAAAGATTCTAATCCTTGAAGATATCACTTTTGACCAAGTATATATGAACCA
TGTTACTGAGGTTTATGGAGGTTTGAGTATGTTAGGTCCATGGATAGGGAAAATATTAGGGGATTTTAGG
AGTAACTGAGGCTTGTTGTAGGAAGGACATCACTGTAGGGGTAGGCTCCGTGTTCCTATCTTCAAGCTCT
ACCCAGTGCAGAATAGAGCCCTCTTCTGCCGGCAAGTGGAAAGAGTTTCTCTTCCTGGCTGCCTTCAATC
CAAGTTGTAGAATATCAAATCTCCTAACACTATGACTGCGAGCATGCTGACATGCGTCCCACCATAAAAA
TAGACTGAACCTCTGAAGCTTTAAGCCAGCCTCTAGTAACTGTATTCTTTAATAAGACTGAACTTGGCTA
TGGTGTCTTTTCACAGTAAAATGGAAACATAGACAAGGTTCTAACTCTCTGTACTAGAGGACCATCTCTA
TGTCCTTGGTGTTGTATGTAAATTATTGAACAAATACTATAGACAAGTTGTATGGCCAAAAGTCCATCCC
CTTCAACAATCTACTATCTGGAACCATATAGATTAGATTCCTTTCCTGCACTCATTTCCCTTACTTGCTG
AGACATTTTGAAGACATGCTCAGAATCCCTGAACTTCCTGCTGAAAAAAAAATACCCCTCCAATTTGAAG
ACAGTTCTCTTCCAAAATTCATCATAAATACTGATCCACATGTCCAGGCATATCATGTAGTTTTAAAAAA
CAAACCAATCAATGCTAAAGTGGGTAAGTGCCTACATCATTGGTTTATGTCTGTTCATAACCTGGTATAT
AGCTAGAGACCAGGACTGCATGTTTCTCCTAGGCCACACCTCTCCCACAAATGCTGGCTCTGCCTCTCCA
GAATTCCAAGATCATGGATCTCTGGGTCCCCAAGGAACAATAAGTGTGCACTCTTGCCAGCCTGTACACT
ACTGCACTAGCTTCTCCCCCTGGAGCTTGGTCATTGCTCAATCTTCCCTTTCCAAAGCCTGGCCAAATTC
CTCCTACCTTTTGTTCTTTCAGTCAGGCCACCTAAGTCATCTTGAATGAAAAACAACACAAAATCTGAAC
TTAAAATCAACAAATAATACAAGTGCTGCGCACAAAATCAATCATTCTAAACTCATCAACTATTTTATGA
TGGAAATCTTCCAACATACAAGCTACCACCAGGTCTAAGAATTACTCATCTACATGTTGCTTCCTCTCAC
TCACAGCCTAACCATAAAAGGGCTGTTTCTTCCTCCCATGTCCCCTCTTTTGCCTTCAGAAGCAGAAGCT
CCACCTCCTCCTCTTTGCCCAGCAATTGGCTTCTTGTCGTCTTTATTATCATATTAATTACTTAGGGGAA
AATCCCGTGTAGTGGCTATTCCTGGTTGTCAACTTGACAATATTTGGAATGAACTACAATCCGGAATTGG
AAGGCTCACCAGTGACCCTTATCTGGAGGCTTGGAGATCCTTATCTGGATCTTGGTTTGAAGATCTTGAG
CCATAGGGGCTATGGATTCCAGAAGATTGAATCTCCGAGTTTAAGGAACACACCTTTAATCTGGGCTACG
CCTTTCATCTGGGATTAAAGGTGTGGCGGAACACACCTTTAATCTGGACTACACCTTCTGCTGGAGACAA
TATAAGGACATTGAAAGAAGGGAGTCTAGCTCTTGCTCTTGCTCCTTCGCCTGCTTGCTGCGTGAGACTG
AGTAACTGCTAGATCCTTGGACTTCCATTCACAGCTGCGACTGAACAATTGTTGGGAATTGGGCTGCCGA
CTCTAAGTCATCAATAAATTCCTTTACTATCTAGAGACTATCCATAGTTCTGTGACTCTAGAGAACCCTG
ACTAATACAGAAGTTGGTACCAGGAGTGGTTCTAGAGTAACAGAAGTACAAGGATGAATCTTTTAAAATA
CTGGAATTGGCTTGTTGATCCACCAGCACTTTCAACTATTGAAACCTCTCCAGATTCTCTCCCTCCTGGG
AGCTCAGAGAATTTTGAAGACCCATGGTTGAAACTATATTCCGAACTTAAAGAAGCAAATGCCCTTGATT
TTCTTAATGAATTAGGTGATTCAGTGCACAAAGCTTTCTACAAGATGGGGAAAAAATTGGAAAATGATTT
TACTGGCTGGCTGCTCTTAGTATCTGTGGAAAAAATGATGAATGAAAGGAAGGAGTTGTGTGATAAAATC
GAAAGGCTCCAGACACAAGTAAACGATCTAAAAGTTGCTAAGTGTGTCCTTGAGGAGAATCTTCTCTCTT
GTAGCAATAGAGCTCAAGTTGCAGAAAATCAAACAGAAACTCTCATTGTAAGGTTGGCTGAACTACAGCG
AAAATTCAAGTCTCAGCCTCAGAGTGTGTCAACAGTTAAAGTAAGGGCTCTAATTGGCAAAGAATGGGAT
CCTACAACATGGGACGGGGATGTGTGGGAAGACCATGTTGAAGCTGAGAATTTTGAATCTTCAGATTCTC
AAGGGTTTGCCCCACCTGAGGAAGTAGTACCCTCAGCCCCACCCCTTGAAATAATGCCTTCCCCACATGA
GGAAATTAATTTTGCAGAGTCTGATAAACCAGCAATGATTTTCACTACTGATGTTTCTCAAGGCCCACCA
ATAGTTTCTTCTAGACCTGTAACCAGACTCAAAGCAAAACAGGCTCCTAGAGGGGAGGTAGAAAGTGTAG
TCCATGAGGAAATTCGCTACACTACTAAGGAGCTTAATGAGTTTGCTAATTCATTCAAGCAGAAACCTGG
TGAATATGTGTGGGAATGGATTTTAAGGGTGTGGGATAAGGGTGGAAGGAACATAAGACTAGAGCAGGCT
GAGTTTATTGACATGGGTCCTCTGAGTAGAGATTCTAGGTTTAATACGGAAGCTCGCATAATTAAAAAAG
GTGTCAAAAGTTTGTTTGAATGGTTGGCTGAGGTGTTTATCAAAAGATGGCCTACTGGAAATGACTTGGA
GATGCCTGATATTCCGTGGCTTAGTGTTGATGAAGGGATTTTAAGACTTAGGGAAATTGCAATGCTAGAG
TGGATATATTGTGTAAAGCATAATTGTCCACAATGGGAAGGTCCAGAAGATATGCCTTTCACTAGCTCTA
TAAGACGCAAATTGGTGAGAGGGGCACCAGCACATTTGAAGGGTTTTGTTCTTTCCCTTTTCCTTGTACC
AGATCTTAGCATTGGAGATGCTTCTGCTCAATTAGATGAATTAAATTCACTGGGTTTAGTTGGATTCCGA
GGTAACAAGGGCCAGGTGGCAGCATTGAATCGCCGGAGACAAGGTGATTCTAGTTATTATAATGGACAGC
GTAGACAAAAGAATGTTTATAATAACATACCCAGCAATGGTCAGCACAGGAGAGGTGAAATTTATAATGG
CATGACTCGGTTGGACCTTTGGTACTGGCTAACCAATCATGGTGTTTCCAGGAATGAAATACATAGGAAG
CCTACTGCATATTTGTTTGATCTGTATAAGCAGAAAAATTCTCAAACAAATGAAAGAAAGGCTACATTAG
ATCATGGTAAACAGCAATCTCGGCCAGTGAATCAATTTCCAGACTTGAGACAGTTTGCAGATCCAGAACC
CCTTGAATGAAGGGGTGGCCAGGTTCCGCTGAGGAAGGATCTTGATAAGACACCCAAAGGTTTTGCTGTT
ACCCTTTCTCCAGTTCTTCCCCAGAGGGACCTAAGGCCTTTTACAAGGGTAACTGTACACTGGGGAAAAG
GAAATAATCAGACTTTTCAGGGTCTGCTGGATACTGGTTCTGAGTTGACACTGATTCCAGGGGATCCCAA
GAAACATTGTGGCCCTCCAGTTAAAGTAGAGGCTTATGGAGGGCAGGTGATTAATGGAGTTTTGACTGAT
GTCCGACTCACAATAGGTCCAGTAGGTCCCCAGACACATCCTGTGGTGATTTCCCCAGTTCCAGAATGTA
TAATTGGGATAGATATACTCAGAAATTGGCAGAATTCTCATATTGGTTCCCTGAACTGTAGAGTGAGGGC
TATTATGGTTGGAAAGGCCAAATGGAAACCTTTAGAGTTGCCTCTGCCAAAGAAAATAGTGAATCAAAAA
CAGTATCGTATTCCTGGAGGCATTGCAGAAATTACTGCCACTATCAAGGACTTGAAAGATGCAGGGGTGG
TGGTTCCCACCACATCTCCGTTTAACTCTCCTATCTGGCCAGTGCAGAAAACAGATGGATCATGGAGAAT
GACAGTTGATTATCGAAAACTAAATCAGGTAGTAACTCCAATTGCAGCTGCTGTACCAGATGTAGTTTCA
TTACTTGAGCAAATTAACACATCTCCTGGCACCTGGTATGCGGCTATTGATCTGGCAAATGCCTTCTTCT
CAGTACCTGTCCATAAGGACCACCAGAAGCAATTTGCTTTCAGTTGGCAAGGCCAACAGTATACTTTCAC
AGTTTTGCCTCAAGGATATATTAACTCTCCTGCCCTGTGTCATAATTTAGTTAGAAGGGATCTTGATCGT
TTGGATCTTCCACAAAATATCACATTGGTGCACTATATTGATGACATTATGCTGATTGGACCAAGTGAGC
AGGAAGTAGCAACCACTTTGGACTCATTGGTAACACATATGCGTATCAGAGGATGGGAAATAAATCCAAC
CAAAATTCAAGGACCATCTACCTCAGTGAAATTCTTAGGAGTCCAGTGGTGTGGAGCATGCAGAGATATT
CCTTCTAAGGTGAAAGATAAGTTATTGCACCTGGCCCCTCCTACAACCAAGAAAGAAGCACAACGTTTAG
TGGGTCTATTTGGATTCTGGAGACAACACATCCCTCACTTGGGTGTGTTACTTAGGCCTATTTACCAAGT
GACTCGGAAAGCTGCTAGCTTTGTGTGGGGCCTGGAACAGGAGAAGGCCCTTCAACAGGTCCAGGCTGCT
GTGCAGGCTGCACTACCACTTGGACCATATGACCCAGCAGACCCGATGGTACTTGAGGTGTCTGTGGCTG
ATAGAGATGCTGTTTGGAGCCTCTGGCAGGCCCCTGTAGGTGAATCACAGAAAAGACCTTTGGGATTTTG
GAGCAAAGCTCTACCATCATCTGCAGACAACTATTCTCCCTTTGAAAAACAGCTCTTGGCCTGCTATTGG
GCCTTAGTGGAAACTGAACGTTTGACAATAGGACACCAAGTTACTATGCGACCTGAACTACCCATCATGA
GCTGGGTACTATCAGACCCTGCAAGTCATAAAGTGGGACGCGCACAGCAGCAGTCTGTTATCAAATGGAA
GTGGTATATACGTGATCGGGCCAGAGCAGGTCCTGAAGGCACAAGCAAGTTACATGAAGAAGTTGCTCAA
ATGCCTATGGTTTCTACTCCTGTTACACTGCCATCTGCTGCCAAACATGTGCCTATAGCCTCATGGGGTG
TTCCCTATGATCGACTGACCGAAGAGGAAAAGACTAGAGCCTGGTTTACTGATGGCTCTGCACGTTATGC
AGGCACCACCCAGAAGTGGACAGACAGCTGCAGCATTACAACCCCTTTCTGGGACAACCCTGAAAGACAC
AGGTGAAGGGAAATCTTCACAGTGGGCAGAACTTCGGGCAGTACACATGGTATTACAGTTTGTTTGCAAG
AAGAAATGGCCAGATGTACGATTATTCACTGACTCATGGGCTGTAGCCAATGGATTGGCTGGATGGTCAG
GGACTTGGAAAGATCACAATTGGAAAATTGGTGAGAAAGACATCTGGGGAAGAAGTATGTGGATAGATCT
CTCCAAATGGGCAAAGGATGTGAAGATATTTGTGTCCCATGTAAATGCTCACCAAAAGGTGACTTCAGCT
GAGGAGGAGTTCAATAATCAAGTGGATAAGATGACCCGTTCTGTGGACAGTCAGCCTCTCTCCCCAGCCA
TCCCTGTCATTGCTCAATGGGCACATGAACAAAGTGGCCATGGTGGTCGAGATGGAGGTTATGCTTGGGC
TCAGCAACACGGGCTTCCACTCACCAAGGCTGACCTGGCTACAGCTGCTGCTGATTGCCAGATCTGCCAA
CAGCAGAAACCAACACTGAGTCCCAGATATGGCACCATTCCTCGAGGTGACCAGCCAGCAACCTGGTGGC
AGGTTGACTACATTGGACCACTTCCTTCGTGGAAAGGACAGCGTTTTGTTCTTACTGGAGTAGATACTTA
TTCTGGTTATGGATTTGCCTTTCCTGTACGTAATGCCTCTGCTAAAACCACCATTAACGGACTGACAGAA
TGCCTTATCTATCGTCATGGTATTCCACACAGTATTGCTTCTGACCAAGGAACTCATTTCACAGCCAGAG
AAGTACGACAGTGGGCCCACGATCATGGAATTCACTGGTCTTACCACATTCCCCATCATCCTGAAGCAGC
TGGTCTGATAGAAAGATGGAATGGCCTTCTGAAGACGCAGTTACAGCGCCAATTAGGTGGTAACAGCTTG
GAAGGCTGGGGTAGAGTTCTTCAGAAGGCAGTATATGCTTTGAATCAGCGCTCGATATATAGTACAGTTT
CACCCATAGCCAGGATTCATGGGTCCAGGAATCAAGGGGTGGAAAAAGGAATAGTTCCACTTACTATCAC
TCCTAGTGACCCTCTAGGAAAATTTTTGCTTCCTGTCCCCATAACTCTAGGTTCTGCTGGCTTAGAAGTT
TTGGCTCCAGAGAGGGGAGTGCTCCTACCAGGAGCTACAACAAACATTCCATTGAACTGGAAGCTCAGAC
TTCCCCCTGGTCATTTTGGGCTTCTAATGCCCTTAAACCAACAGGCTAAAAAAGGAGTAACAGTGTTAGG
AGGGGTGATAGATCCAGATTACCATGGGGAAATTGGATTACCTCTTCACAATGGTGGTAAGCAAGATTAT
GTCTGGAGTGTAGGAGATCCCTTAGGGCGTCTCTTAGTACTACCATGTCCTGTGATTAAAGTCAATGGGA
AACTACAACAGCCTAATCCAAGCAGGATGACAAAGGACACAGACCCATCAGGAATGAAGGTATGGGTCAA
TCCTCCAGGAAAAGAGCCAAGACCTGCTGAGGTGCTGACTGAAGGAGAAGGAAATATAGAATGGGTAGTA
GAGGAAGGTAGTTATAAATACCAATTAAGGCCACGTAACCAGTTGCAGAAACGAGGATTATAAAGTAATA
TGAATGCCCATTGTAAATTTACTAATGCGTTTGCGATTGTACGAGGGATAGTTATATCATGTTAGGCGTA
TTTACAAACTTGTTATTGTTTTATGTGAACATGAGATATTATTTGTGTCAAGTTGACAAGGGGTGGATTG
TAGTGGCTATTCCTGGTTGTCAACTTGACAATATTTGGAATGAACTACAATCCGGAATTGGAAGGCTCAC
CAGTGACCCTTATCTGGAGGCTTGGAGATCCTTATCTGGATCTTGGTTTGAAGATCTTGAGCCATAGTGG
CTATGGATTCCAGAAGATTGAATCTCCGAGTTTAAGGAACACACCTTTAATCTGGGCTACGCCTTTCATC
TGGGATTAAAGGTGTGGCGGAACACACCTTTAATCTGGACTACACCTTCTGCTGGAGACAATATAAGGAC
ATTGAAAGAAGGGAGTCTAGCTCTTGCTCTTGCTCCTTCGCCTGCTTGCTGCGTGAGACTGAGTAACTAC
TAGATCCTTGGACTTCCATTCACAGCTGCGACTGAACAATTGTTGGGAATTGGGCTGCCGACTCTAAGTC
ATCAATAAATTCCTTTACTATCTAGAGACTATCCATAGTTCTGTGACTCTAGAGAACCCTGACTAATACA
TCCCTACATACAGGAAACTTGATGTATAAGTAAAGAAAATAGTAAATCTAAAAATTTCCTTATCAAATAC
ATGCAAGAAATCCAAAATACCATGAAAAGACCTGATCTAAAAATAGTAGGAACTGAAGGTGAAGTGTCCC
AGCTCTGAAAACTAGAAAATGTTTTCAATATTTTTCCTAACAGTGAAGACATGGATCTAATGAGGCCACC
TCTTATAGCCATGCAAGACTGACAGTGGAGGGATAAGGACACCAATCCACCCACAAAACTTTTGACCCTA
AATCAGTTTTATCTAAAAGCAATGCAGGGGCACAAATGGAGCAGAGACTGGAGGAATGGTCAAACAATAA
CCTGTCATATCTGAGACCCACCTAATTGGCATACACCAGTCACTGACATTATTAATAATGTTCCATTATG
CTTACAGGCATTTCTCTAGCATTACTATTCTTGGAGAGACTTCACACAGCATCTTATTGAAACAGATGCA
GACACCCAGAACCAAACATTGGATGGAGATTGGGATCCTTAAAGAAGAGTTGGGAGGATAATTGAGAGAC
CTCAAAGGAATAGCAACCCCATAGAAAGACACGAACAGGGTCAGTAAACCTGGACCCATGGGGTATCTCA
GAGACTGATCACCAACCAAAAATCACAGAGGGCCTGGATTGATTCCCCTGGCACACATGTAGCAGAGGTC
TGCCTTGTCCTTCAGTAGGTGAAGATGAGCCTAAGGCTTCAGAGACTTGATATATCAGCATACAGCAACA
CCCAAGTGTGTCCCACTATCTCAGAGGTGAAGGGGTGGAGATGGGCAGAAGGGTCCTGATAGGGGACAAC
TGCAAAGAGGCAATATTTGGGACAGAAAGAAAGGAAGAGAGAGGAAGATAAAGAGAGAGATGAAGGAAGG
AAACAAACAAACCAAGATGAAGAGAGAGAAAAGGGGGAAAATAGCCTTGAATGGTTCAGGGATTCAAAGG
GACATACCTAAGCATGGTAAAACAATGCACATAATGGCAGCAAGTAGCTAACACTGAATTAAATAGAAAG
ACACATAAAGCAGTTCTACTAAAGTAAGAGACAGAGTTGCCCAATCTCACCCTATTTATTCAATAATAAT
GTACTTGAAGTTCTAGCTAGGGCTGTAAGACAACTCAAGGAGATCGGAGGATACAAATTAGAAAGAAAAA
TTCAAAGAATTGTAATTGGTAGATGATAGGATAATATACATAAATGACCTCAAAATTCTTCCAGAGAACT
CTGAAAGCTGATAAATACCTTCAGCAAAGTGGCTAGAAACAAAATTACTTCATAGAATTCAGGAGCTATC
CTTTATAGAAAAGTTAAAGTGGCTGAGAAAGAAATTAGGAAAATCACATTCTTTGCAATAACCAAAAATA
ATATGAATTAGCTTGGTGTGACTCTAATCTTGCAAGTGAAAGATGTGTGTGACAAGAGCTTCAGGACCCT
GAAGAAAGAAATCAAAGAACTCAAAGATGCAAAGTACTCTAATGCTCATGGATAGGCAGAATTAACATAA
TGAAAATGCCAAATTTAACAATTCAATCTACAGATTCAGTGGAATTCCCATTAAATATCCAACCCAATTT
ATTACATTCTTGAAAAAGCAAATCTCAACTTCATATAGAAAAACAAGAAATTGAGGGTAGCTAACAAAAT
CCTGAACAATGAAAACACTTCAGGAGAATTCACCATCCCCTACCTCAAGCTGTATTTTAGAGCAATAGTT
ATTAAAACTGCATGGTATTTGTATAGAAACAGATATGATGATCAATGTAATTGAATTGAATACACTGACA
TAAAACCACACTGTTATGGACACTTGATTTTTGACAAAGAACCCAATAATCATAATAAAAATCATAATAA
GAATGCATCCCCCAACAAATGGTCCTGATCTAAATGCAAATAGATTCATATCTATCATCCTGCACGAAAT
TCAAATCAAAGTGAATTGCAGACTTCGACCTAATACTGGATTAACTAAATCTAAATGAACAAAAAGTAGA
GAATAGTTTTGAACTCATTGATGCAGGATTCAATTTCCTGAACAGAACCACAATGGCTCAGGCTCTAGGA
TCATAAATTGGTAGATAGGATCTCATGAAACTGAAAAACTTCTGTAAGGCAAAGGCAATAAAACAAAATG
GCAACCTACAGATTGGAAAAAAAATAATCTTCAGTATCCCTAAATCCCATTGAAGGCCAATATGCAAAGT
ATATAAAGAACTCAAGATGTTATCCTCCACAAAACCAAATAAATCAATTAAAAATGAACTACAGAGCTAA
CAAGAGAATTCTCAACAGAGGAATCACCAATGACTGAGAATCACTTAAAGAAACATTCAATATTTGTAGT
CACCAGAGAATTGCAAATCAAAACTACCCTGAGATTCTACTTTATACCAATCATAATGGTCAAGATAAAA
ATTCAAATGACAGCGCATGTTGGTGAGGATGTGTATACTTTTGCATTGCTGGTGAGGAAAACAATCTGGC
AGCTCCTCAGAAAATTGTAAATAATTCTACCTGAAGATCCAGCCATACCACTCCTGTGCATATACATAAA
ATGTGCTCCACCATACCACTAGGAGATATGTGCCACTATGCCCATAGCAGCCTTATTTGTTAATAGCCAA
AAGATGGATACAACCCTGATGTGCCTCAAACAAAGATTGTATATAGAAAATATGGGTTCCCTTACACAAT
GGTATTCTACTCAGCAATTAAAACGTGAGAACATCATAAAGTTTTCAGGCAAACTGATCAAATGAAAAAG
TATAATCTTGAGTGAGGTAACAGAACCAAAATGACCTGCATGGGATGTACTCACTGGTAAGTGAATATTA
GACTAAAAGTATAGAATATCAATGATGAAAGCCACAGACCATAAAGAGTTTAATAAGATGGAAAGCTCAA
GTACGGATTCTTCAATCCAATATAGAAAGAGGGACAAAATAATCAGGGGAGGCAGAGGGAGAGAGAGACA
TTTGGTGGAAATGGGAGAAGAAGGGAGAAAGGCAGAAAGGATCAGGCGTTGGGGAACACTGGAAAGCAGC
CCAGGGGTCCTGGTAAATGGATTAAATATTCAGCTGAATGGAGGTGGGAGGCAGGGGGAAGCTCTGCAAA
GTCCAAGAGACCTGGGATGTGAGAGGCTCCCCAGATGATAATCTTAGCCTTCATGCCTAACAGTTGTAGA
TAAACCCTGAAGAGATCACTTCCAATAGATGCAGAGGGCCCTAAGTGGTTGGATGGAGTCCCCCAACTTA
CCTCAAAATTGTCAATACTCATAGAAATTAGGACAATGAAAATCAAAACACCCTGAGATTGTATCTTATG
TCTGTCACAATGGTTAAGACCAAAACCTCAAGTGATGGCTTGTGCTGGCAAAGATTCAGAATAGTAAAAG
TCTCCCCATGGCTTGTGGGAATGCAAACTCTTACAACCTCTTTGGAAGTATATTTGATTGTTACCTGGTA
TAAAATGGCAAAAAAAAAAAATGGTTGAAGGGGGACTAAAAAAGGAAGAAAGGGGAGAACTATGGGATGC
GAAACAAGAAAGTTTGTTGCAAAAGAAATATGTTTCCACTGCAAACCCTGAGTCTCAGACAGAAGGGGAC
CTGGAATTCTTCAGATACAAAGAATCTCTAAACCCTGAGGACATTCTATCACAAATAAGTAAAATTCAGA
AAATTCTGAGTGCTCCCATCACGGAGATGAATCTGCTATGAACAGCTCATAGGTGTGACCCTCTACAAAA
GCCATATTATTGAAAAGCCACATTGTGCCCAGACTTTGGAAAGACTGAGCTCATATCCTGAAATACAGTT
ATGTGTGGTTCTATTTAATTACACATTTACACTAAGAAAACATGGCAGTATGGGAATGAAGCTTGTTCTG
TACACATTAACAGAGGGAAACTAAACAAAGTATGGTGAATCCCTAACCAAAAGTAAAAAAAAAAAAAGAA
AGAAAAGAAAATAAAAGTGAAACTACAATATGTTTCAAATGCTGTAACTGAAATCTGGTTTTTTGATGCT
TATATCTGGTATCATCAGTGACTTCAGATTTAGTCCAACTCCAGAGCATGGTATAGCAGAAAGACATGCA
AATAAGCCTTCTCTCTGCCCATGAAAAACACCTCGGCCCTGACCCTGCAGCTCTGACAGAGGAGGCCAGT
CCTGGATTCGATTCCCAGTTCCTCACATTCAGTGATCAGCACTGAACACGGACCCCTCACCATGAACTTG
GGGCTCAGCTTGATTTTCCTTGTCCTTGTTTTAAAAGGTAATTTATTGAGAAGAGATGACATCTGTTGTA
TGCTCATGAGACAGAAAAATTGTTTGTTTTGTTAGTGACAGTTTTCCAACCAGTATTCTCTGTTTGCAGG
TGTCCAGTGTGAAGTGAAGCTGGTGGAGTCTGGGGGAGGCTTAGTGCAGCCTGGAGGGTCCCTGAAACTC
TCCTGTGCAACCTCTGGATTCACTTTCAGTGACTATTACATGTATTGGGTTCGCCAGACTCCAGAGAAGA
GGCTGGAGTGGGTCGCATACATTAGTAATGGTGGTGGTAGCACCTATTATCCAGACACTGTAAAGGGCCG
ATTCACCATCTCCAGAGACAATGCCAAGAACACCCTGTACCTGCAAATGAGCCGTCTGAAGTCTGAGGAC
ACAGCCATGTATTACTGTGCAAGACACACAATGAGGAAATGTTACTGTGAGCTCAAACTAAAACCTCCTG
CAGAGCACCCAGGACCAGCAGGGGGCGCAGAGAGCACATGGAGTTCTGATTCACAGAAGAGTTACAGCCT
GTACAATTAGACCCAATCTTCAACAAACCGTCAAAATATTCGATCCAAAATTGTTCCTGTCTAAAAGTAA
TTCAAGGACAAAATGGACCAGAGACTGAAGAAATGGCTGACCTGTGACCCTCCCAACTTTGGATCTATCT
CATAGGCAGGTACCAAACCTTGACATTTGTCACTGACACTGTATTGTGCTTGCAGACAGGAGCATAGCAT
GGCTGACCTCTAAGAGGCTCTGCAAGCACCTGAATGAGACAGATGTAAATAGAGTGTACAACTGGATTAA
GTTTGAAGACTGCAATGGAAGAGTTAGAGGAAGGAATGAAAAATCTGAAGGGGATCACAACCCCAGAAGA
AGACCAACAGTGCCAATTAAACTGGATGCCTGGGAACTCCCAGAGACTAAGCCACAAACCAAGAATCATG
CAGGCTGGTCTGAGAATCCTGGCACCCAAGTCTCAAGGAACTGCCTTTTCTTGGCTCAGATGGGAGAAGA
TGAGCCTAAAGCTTTAGACTTGACGCCCCAGGGATGGGCAATACAAAGTTGAGTTTCTTGGGAAAGTGAA
GAGGATGGTGGGAGGAGGAATAAATCTGGGAAGTGGGACTGGTTGGGGACAACATATTGGTCCTAAATTT
ATGAAATAATTATCTAATTGATAAAAAGAGTCCTTGGGGTAATGGAGGGCTAGACTCCTCTGTGCCTAGT
TTGTAACTCTACAGGGATCCTCTTTAAAAGAATAGGGTGCACATAGAGTATATGTGTGTGACACTAATAC
AGGGGTAAGTGTTTCTGTAAGAACTTTATGAATAAACTTTATTAAAACATCAAAAAGTATAGGTTGTAGC
AACCCTTGACCTGTACGAATGTTTATAAAACTTTCTATTTTCCTTAATTATATCTGTTTTGCATTTGTTT
ATTTATTTATTTACTTACTTACTTATTTATGATTTCACTGTGTCTTTCTGTAGTCCTGTATGTGTTTATT
TGTCTCTTTATTGCTCTGTTTCTGTTTCTTTCTCTCTGTCTAGTATTGTATCTCTCTGTGTCTCTATGTC
GCCGATTGTGTCTGTGTGTATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGCATATTGAAA
TGAGATCTCTTCTTCTATCAGTGTACATAATGACTTTGAAATAAAGTCCATCACTGGGCTTGGATATCAC
TATCTTGTTAGAATGGTTGCCCAAAGTGTTCCAACCATCACACTGTTTCTACATATAATAGATGGGTTTA
TTGATTTACTACCAAAACTACCCCATCTTAAGTTATGGATATTAAACACAGATCCTCATGGTGTGTTAAG
AACTTGAAGCACAGAGCTATATGTACAGCCCACTAAAAATGACTTAAATATAAGATAAACTCTGGCTTGA
ACAAAACACAGAGCATCACACGAGGCAGAAGTGAATCTCTATGAGGACCAGGATCACATCCCAAAGAACC
AAAGAACACTTGAGACTGTGGAACCCTAGAGTCAGGGCTGACACTCAGTAAGATTTACTTCATAGAGCAT
GATGTGGGATTCAAGAAGAAATCAGGCAGGGCCTGTGACCCATGAACCAGATGACTTCCAGTCTCTCCAT
CATCCTCACACAAACCATAGGCAACAGCTCAGCACTGACTCACCTGTGATGCTGGTGACAAAATGTGTGC
AAAGCCTCAGAACTGAGACGTGAGGCCAATGTTGCTACCGACACTCAGTGAGCTTCAATTTGCTGCAAAC
TGCTCCAAAACAACTCAAAGGGTAACTTCTTCTTTTTCTATTTGTACTTGTGATGCCTTGGTAGATATAG
TTCCCCAATAATTTAATAGGACAAATCATTTTTCCTTTTAACACATTAATCCCCTTTCCTTCCCCCAAGA
TTCTAAAATTTTTCTTTAACACTGATGTCTGAGAGATATGGCATAATAGATGTTTGTCTTATTCTGAGTT
GTTCCTTATCAAAAGAAATCAGCTGTGGCACTTTGAACCTAAATATAACAATATTTCACAAAGGCATTCT
GGGAATATATAGATGGTATTGCTACAAAAGAATAGGAGGATCTATGGCCATACCACCCTTAATGAACCAG
ATACTATCTAAAAGATTAGGACAGCTGGGCATGTTGGCACAGGCCTTTAATCCCAGCACTAAGGAGGCAG
AGGCAGGCAGATTTCTGATTCGAGGCCAGACTGGACTACAAAGTGAGTTCCAAGACAACCAGGGCTATAC
AGAGAAACCCTGTCTCGAAAAAACAAAACAAAACAAAACAAGAGTAGGAGGGTATTAGATGCGAGGTGAT
GATGGCCATTCAATCAAACCAGAATGTGACCTGAGAAAAGGTCTAAGTTTGTCAGCTTGTCCTGGAGATG
TGTTGCCTCTGATAAATGCAGAGCTGGAACTGCAATACATTGGATTCCTGTGAGTTACGGAGAAATAAAA
GGAATAGCCTCTGTTTCCTTTGGTTCATCAAGTTGGCAGTGAGCTAGAAGATGATACTGGGAACCATCAC
ATGTACTTCTACAGAGTTATTCTACATTCTACAAGTCAGTCTTGCTTGCTTTCGTTTCTGTGAGGAGCTA
AATACAGAATGTTTTCAATGTCTCATAATGTTCTGTGCACACCCATGGGTGCCTAGCCAAGGATAGAAAC
TTGTATCTGATAAGGAAAGAGGATGCTGCAGTGGCCACACTCTGAGATCACCTCCTGCCAAATTATACTA
GAGTGTTTTACATAGTCTTGAAAACACTAGGTCAAATATGTTGTCATCCAGATATGAAAACTCTGTGCAA
CAATTCAGAAATACAGTGGTCAGGACAACTGGTATGTAACACTTTAGTTCCAGCCCACATTAATCTCACA
TCTTTTCTGTGGTTTCAATAAAGAGCACACATGTTTGGAACACCATCTCCACTTTGTATGCTTATCCTTA
TGCATCAAACTTTTCCTGTAATTTCCTACCCCGCACAGGTTCCTGTCTTGATCTCTTTTTCTAATGAACA
GCAATACAGAAGTGTTGGCCAAATGAACACTTTCACCCCAAGTTGCTTTGCCATTGTGTTTCATCACAGC
ATTAGTAACTCCCAGTAAGGCTACTGGTTACCCTGCATCTTCTATGTAGATCTTTTGATGAAGTTCCAGG
CTTGGGGTCTTTATCTGACTGTTATCCTGGTTAATTCATGTCCACCAATAGAATATTGTTCTCATTTTCA
ATATCATATGAAGTTACCTGTTTATAGGATCTTCCTAAAGCAGAAAACTATATAAAATGTCTGCTTACTT
TAAGAAAAGTATGTGTCCTTGGAGGTAAATGGAGGAAAGGGTGGAGGATGTTGAGTAATGGAAGACTGGC
TAATACAGGAAGGTCACAGAATTGAATGATTTTAAAAATTTTAACTCCTCATCAATGAGGTACTTCAAGT
TGAGGCAGGAGTCCTTGATGCACAGGTGACCCAAAGGCCCCAGCCTCTGTTTCTTGGTCTGCTCCAGTCT
CCCGGCTCAGCACAGTTCACTGAGTGACAATCTTTAAGATAGTCTTTCAGGATACAGTTATCACAGTTTT
CAAACTCTCTTCATTGAAACAATATAATGAGTCAGAGTCCAGTGTGCCATTAATAGGCCCTATGCAATAG
GATTTTACTTCATCTGTGGAAAGAAACCACCATGGCCTCATCAAGGCCTCATTTGATGATTAGTGTAGAA
AGCGTCCCCAGAGCTTTGCTGGGATGAAAACCCTGGCAAGATGTTTAGGGCACTCTCCATCTGACAGGAC
AATTCTATCAAGGGTTGCTTCCATATAGAGAGAAATCTCCACATCTGCAGTATTTCCCGATTTATCAACA
GTTCTTTACCCCGTGTCATATGCATAAAATCTTTTCTCTGTAGAATTTTCAGTACTAAAAACTAACAAGG
ATGTTGGTCCTGATATCAGACATAATAAATAAATAAACATCAAATTATACCCTAAACATGTGGAGATGGT
TTTCTGTTATGAATTTATTGGCTCTCTAAAAAGTGTTAATTAAGCCAGGCGTGATGGCACATGCCTTTAA
TCCCAGCACTTGTGAGGCAGAGGCAGGCGAATTTCTGAGTTTGAGGCCAAACTGATCTACAGAGTGATTT
CCAGGACAGCCAGGGTTACACAAAAAAACCCTGTCTCCAAAAAGTAACAAAAAGAAAGTGTTAATTAACA
TCTACACTTTAAGATAATTTGGTGGCAAAGGTTAATAGTCTGAAATACTAGATATGAAAGTATGACACCT
AAATTGCATGCAGAGAATAAAGCTGAATTCCAATGAGATTCATGCCTTGTGAATCCATTCCAATCTGATC
TCAATCTTCAAACATGTTTGTGCATAATTTACATCTTAATCAGTTGCTGGAAATTAAAAGGACATAAGCT
AAACTTAAAACTCTTTCTATTTAATGTGTCAGAATAGAATATGTGCACTGAAGTTTTCATGTGCATAGGA
TATCATTGTTACAATGATGGTTCAAATACGCACCAGTAGCACAGGTGATGCTTGACATGAAAAAAACTGT
GACCAGAGCCCAGACGTTGATGTTGGCTGAAAGAGCCTAGTGTCTCACATTTGATCAAGCAAAGTGTTAT
TCAGAGAAGCAGTGCCAGATTTGGGATCCTTCTTAATGGATCAAGAACATGAGGAAGATTTGGAAGCCAG
ATTGATGAGATTACTAGAATCCTGGATCTGAACACACAACACACAATAGTAAGTTGAACTTTTCCACGCA
ATGCTAAAGATAAAGCATCCAGTATCATGTTATACAGGACCAAGGTGAGGATCAGTCTGTGGGTGAAGTA
CAATGAACTGGAAATTGTTTGGATTTTAAATGTTGGTTTTTAAATTATATATAAAATATATATATATATA
TATATATATACATATATATATATATATATATATATATATATATATCGGAACCAACATTTAAAATTTGGAT
TTTAAATGTTGGTTTTTAAATTATATATAAATTATATATATATATATATATATATATATATATATATATA
TATATATATATATATCGGAACCAACATTTAAATTCCTAATTCTTAAGGACTTCACTTTTGACCAAAAATA
TTTGAAATGGGTTATTTAGGTCTGTGGTGGTTTGAATATGCATAGCCTATAGGAAGTGGAAGTATGGCCA
TTTTGTAGTATGTGTAGCCTTGATGGAGGAAGTACATCACTATATGGTGTTGTGAGAGTTGAGATCCTAT
GTTCAAGTTCTGCCAAAAACAGAAGAGAGTCCCCTCCTGGATATTTGAAACAGATGCAGAGGCCCAAAGC
CAAACATTGGGTATATCTCAGGGTTTCTTATGGAAAAGTTGGCTGAAGGATTGAAGGCCTTAAAGGGGAT
AGGAACTTCACAGGAAAACCAACAGATTCATCTAACCTAGACTCTAGGGGTCTTTCAAAGGTTGAGTCAC
CATACAAAAAGGACACAATGGCTAGACCTAGGTCCCTGATACATATGTAGCAAATGTGCAGCTTAGACTC
CATGTGGATTCCCCAACGACTAGAGCAGGTATTGTCCCTGAAGTTATTGCTTGTCTGTAGAATACATTTC
CCAACATAATTGTCTTGTCTGGCCTCAGTAGGAGAGTATGTTCCAATCCTGGAGAGACTTGATATGCCAG
GATTGAGAGATTAAGGGTCTCCCACCATCTCAAAGTTCATGGGTATGACAGGGGAGGGGCAGTGCAGGTT
TTCCCCATCTCTGATTTCCAGCATTTGCACCCCCAATATTGAGGGGGAGGTCTAGCAATTGGAGGGGGGA
CAAACAGTATGAGAAAGCTAACTTTAGTGGTGTTGTCACAGTGTGGGGTATTGTGGGTGGGAGTGGAGAT
GAATCCTCCTCCTCCTCAGGAGGCTGTAGCAGGTGCTTGCCCTCTTTTGGGACAGTAGAGCTGTGGTCAG
TACTGGCCTGTTCCTGACAAATTTATTCTGTGCTGTGACCATTTATTCAAGGGAGGAAGATTTAAGACTT
GCTATGATAACCTGACGAATCTGGACAAACAAGAGACAGGAGGTAACACCTGAGTTACTCTTTTGCTTGC
TAGTACAGAAGAGCACTATAATCCACAAATTGGGGTCCCACATATTCTTGAGTGGGATCCAAGGTGCCAT
AATTTCAGCCACATTCCAAAGTCCCTCAAGGTCTGACAGTTTAGTCTTTAGGCTTCTCCTAACCAAATCA
TATTTGGAGTTCTTTAACATAAAAGGGTAGTTTCCCCATATCACTGCCAGCAAAACAGGTTGAATTTGGA
CAGACAAGCAAAACTATCACAAACAAGACAGACTATGTGTGCGATCCAAATGTCTTGTGATTAGAGGGGA
AGTTCTGCAGCTTATTAGGCTGTGTCCTTATGCCCACAAATGTCTTCAGATAGGAAAGGGCCATTGGGTG
CCAATCCTTAGTTCTTCTGTTTCCTGGGCTGTCAGTTTTTATGTGGAGAAGACATGAACCAAATGCAAAG
TCATGTATCCTACAAGAACTGACATACACAGACAAACAAGGAATAACAATGAGCTCTCTCATTCACCTAA
GGGGGTCTTATAACATAGAACAGAAAGGGGCCAACTTAGCAAGAATTGACCAAAAGGTGGTCACCTAGAC
CACACCACAATGCAGGAAGGATATCAATGAAGGAAGAACAAAGGAAAGGCCAAATCAAGTTTGTTGGCAC
ATGACATAAAACAGTGCTCAAAAAACAATAGATGCGAGCAAAATGAAGCATTGGAATCATATCGGGGTAC
ATAGGGGTCACTCTTACCCCTGTTCAAGTGCCAGATGTTGTTTTAGCCTTAGGCTCCCTGAGTTTGTCTT
TAGGGGAAATGGGTAAGAATACACAAAAATAATGTCACAGAATCTTAGAGGCAGATGAGAAGTCAAAGCA
GACTCATTTATTGCTATAGAAAAGAATGCCTTTATACCTTCTGTCCATAACACCTCTGCCCATATATGCT
CATCTCTGTGAGGCAATGGACTACCTGCAGACAGGCTGGTATCCAGTCAAGCTGAGGTCTGAACCACAAT
GGTCGTAACTCACCTAAAGGACGTGGTAGGCATGACGCGATAGGCGTTCCCTCATGCTCCTGGAACTCCG
GCCCCTGCCTAAGGTACCACCTCCCACAGCCCCCACAAGAGAAGCATGGTCAGTAGTCATGTAAGCAATG
GCCCAAGCTTCTGACCTTCAGCCTAAACTCCTCCCCAGTTACCTAGCAACAGTGAAGACCATAAAATGGG
ATGTTAGGCCCCCACCTCACTCTCTTACTCCTTTGTTCCTTTACCTCTCACTTCTCTCAATTCTCTCTCC
TCTTCCCTTTCTTTGTCTTCTTCTTTCCTTGTCTCTCTGTCTTTCTCTTTCTCTCTAGCCTTCTCTGCCT
CTCTCTCTCTCTCTGTCTCTCTGTCTCTCTCTTCTCTCTTTCCCTTGAATTTCTTTTTTTCTTTTTTCTT
TTTTTGATGAGCACAGTATAAATAGTTTATTGCATTGTTTCTGAATGTGGCTGTATTCTCTATTGTTCTC
TTTCTTATTTTTTTTCTTTTTTTGGTTGTTTTTGTTTTTATAGTCTCGCACAGAATTCTACATCTACCAA
ATCCCCATTGTGTACTTTAGTTTTGTCTTGTATTCAAAGGTTCTTTCAGAAAGAATCTTAAAGATGAAAT
TTGCCTTCCAACTTTTCAAAAATACATATAAAGATAGATGTTACATAGTTCACGGAATAGACACATATAC
GGAGATGCAGCAATATCTCCTTTGTGCCTCTTGTATATTCATGTTATTTCCTCAACTAAAAATACATAGC
CACAAAGACATACAATGAGCACTCCACTTAGGAAAATATGGCCATATTTTTTTACATTTTTATGATTTTA
TGATTAGGTATATTCTTCATTTACATTTCCAATGCTACCCCAAAAGTCCCCCAACCCTTCCCTCACTCCC
CTTCCCCACTCCCACTTGTTGGCCCTGGAGTTCCCCTGTACTGAGGCATATAAAGTTTGCAAGACCAATG
GGCCTCTCTTTCCACTGATGGCCCACAAGGTCATCTTCTGATACATATGCAGCTAGATACATATACATAC
ACGAGCTCCAGGGGGTACTGGTTAGTTCATATTGTTGTTCCACCTATAGGGTTGCAGATCCCTTCAGCTC
CTTGGGTACTTTCTCTAGCTCCTCCATTGAGGGCCCTGTGATCCATCCAATAGCTGACTGTGAGCATCCA
CTTCTGTGTTTGCTAGGCCCCATTATAGCCTTGCAAGACAGCTATATCAGGGTCCTTTCAGCAAAATCTT
GCTAGTGTGTGCAATGGTGTCAGCATTTGGGGGCTGATTATGGCATGGATCCCCGGATATGGCAGTCTCT
AGATGGTCCATCCTTTCATCTCAGCTCCAATCTTTGTCTCTGTAACTCTTTCCATGGGTGTTTTGTTCCC
AATTCTAAGAAGGAGCAAAGTGTCCACACATTTGTATTCATTACTCTTGAGTTTCATGTGTTTCCCTTGC
ATTTCTATAATAAACCATAAGGAGTCTCTGCTCTACCAAGACCCGCTGCACACTCTGGTCAGTGTTGGGA
ACTTTTCCCCTATTCCCTCTCTCCTATAACTCCGGGGCTACAGGGTGTCTCCTTTGGGTCCCGGTTGGGA
GCTGTCTCTTCTCAACCCCCTGACTCATGGGTCAGAGGCCTAAATCTCCACCCAAGGCTGTGTGAAAAGC
ACCGGGTGGTCTCCCCATATCTCCCTGTCCAGAGCACAGGAACTCTGGCCGGACATGGCATATTTTTCCT
CCCCAACTTCTTCCCCGGCCTCCTCAGGGCTGTCCCTTCATTTTGTTCCCCACACATCTCCACATGGCTG
CCACCATCCAATTGGCTGCTGAGGTCACACACTCTGTCTTTGTTCTTCTCTGAGTCTCATGCAGGTTTTG
TGTTAGTAAATGCAAAAGTGCCTGCTGTGCATGCATGAACCATTACAGGCTGCTAGGCAGAACATGCTGA
CTTGCTCCTGGATTATAAATCCATCACTGTGATAGCAGGACATATCCAGAAGACATTATTTAACAACACT
CCTCTTCGTGCTCAACCTCTCATGGTCTTTCTACCTCCTCTTTCTTAGTGTTCTCTGAGCCTACATGAAA
TGTGAACAAACCTGAAAAAAATCTCTGTGTCAAATACATAGTGTGGATTGGGAAGGAAAAACCCTGCACT
TGTGTGTGGGCAGGGAAATGCTGGTGCTTTAACAGGACAAGTGCGGTGTGGCTAGAGAAAGTGATGAGAA
GAAGGGAAGCATGAGAACTGGGTGGGTGGATCCCATGTCTACTGAAAATGCTATGTTGATGTCAAGATAT
TGTGTCTTGTTACAAAAATTCATTGAGTACCTAGGTTATTCTCAGTATATAAAAGGGGAGGAATGAAACT
AGAATTAAACACACACACACACACACACACACACACACACAAACACACACACACGAGTAGAGAAAAGAAA
TAGTCATGAGTTGCCTAGTGAATGAAGAGCGGAAAATGGTGCAGTTAATAGGGATCATAGAAAGAACTGG
GGGATGCACACGAATGGGTTTCCTGTAATTATGTCTTCATAGTAATCTCTGCTCAATAATCAGACAGTGA
CAATGTATGCCTCATTTACAAGCCCTGATGGCCTCTCAGAGGAAAGCATCTCTCTGAAATGAATAAAGTT
CAGAAATGTCCTAAGTGTCCCTGTCACAGGAAAGCAGTGTTGGTAACGTTTCCAGGAAGCTCAGTCTTTG
TCAAATATCCACAACAAGAAGAAGCCATGTCTAGACAGACAACAGACTGGGAAAGACTGAGCTCATGTAT
GGAAACACAACTATGTGTCATGCTTTTATTTTCACATTATACTGAGGGGATATGACATTATAGAAACACA
GTTTGTTCTTTGCATATGCTGAGAGAGGAACTAGATGAAGTGTGCTAATTCTTAGCAATAAAAAGATATA
CAAAGTGGTACTTTACTGTTTCAATTTTTGTAACTGGCATCATTGTCTTTGATATTTTATATCTTCCTTG
AGCACTGCCTTCTCTCAAGTGTCCAACTTCAGAGTATGCTATAGCAGGAAGACTACCAAATAAGATTAAT
TTTTTTGTACCCATGAAAAAATTATGTGCCCTGACCCCTGTTCTCTGAAAGAGGAGCCAAGTTCTGGATT
CCCAGATCCTCATATTCATTGATCAGCAGTGAACACAGATCATTCACCATGGACATGGGGCTCATCTGGA
TTCTCCTTATTGTTTTTAAAAAAGGATTTCATTGGGAAAAGCTGCCTCATATTTCTATGACCAGGAGAGG
AAGATACAGCTAGAGACACAAGCCCCACCATGTAAAATCTGTATGGTACTCTCGTTTTCATTTTACAACA
TTTTGCTTTTGCATTGCAAAGGAGCAATAAGGGTTCAGCAATCAGCACTGTAACTGTACTTTTAAAATTT
CCACCTCTACCCTCTGTGTCCTCTATCTAGTGATAGAAAGTGAAATAAGCACATAAAGCATGGGACAAGA
AGAACACACAGAGGAGCAGAGACTGGCTACAAGTGGCAGCCAGCATGGAGCTGGACAGAATTTAAAAAGA
TAAAGAGAAATGTCATGGCATGAAGCAGTGACTTTTTCTGTTCACAATGCCTGCAAAAACTTTATGGAGC
CTACTACTGCTGAGATATGCAGGTTTGGTTCCAGAGAGGATTTTCTGTTTTATTTAATTTGCTTTTAAAT
TTTTCTTCTTTGTATAGTCTGTATTTTTAAAAAGGGGTTGAATGAATACCTAAGCAGTTGGAAAATTTGT
GAGTAGAAACCGAGGGCCTGAGAAACAAATAAATCAAAATTTTGAAATGGCAAAAGAAAGGGTTCATTCT
ATTTTCTCTTTTCAGAAAAGGTTGCAAAGTTGGATGTGCAAATGGAGATGTTATGGGTGGACTTGGAACA
TCTTGGGAAGGAAGGAACCCAGGAAAAGAAAGAATGAAATGGCTCAGCCTCAATGACTGAGCAAGAGAGT
TAGAGTCACCCACAGGAGAAAAGAAGAAAATAAACAGCACTGGGGTGAATTTGGGTCAGAGAAAACCTTA
AAATGCCAGAGGACAATGTGATGAAAGAGACCATTTGAAAGAAAGGGTTAACCTCATTCCATCAGTCATG
CCAGAGTTAGAGAATGGGCAGTCTGGAGTTACAAGATCACGATTAGCCTTCCCAGTATGTATACAGCATA
TTCCTGATAATGAGATGAAGCAAAGTTTGACAAGGTAAGATTGTATCCTATAGTAATATATAGATCAAAG
GCATGTTGCAGTAAATCTCCAACAGAAATAAGCCCGGGCAATGAAAACACAACTCAATTAATATGAATAC
GTGCTGTGCACCTAGACTGGGCAGATCTACCACTCCACTACCATATGAGAGATCCCTTATAACTTGTGGT
TTCTCCAGGCCAGCTGCTTCTGCTCTACTTTCCTTCCTCCTCCTCCTATGTCATCCTCTCCCTCACTCTT
TCTCTCCCAAAACTTTCAGCTGCACCTTCCCCTCTTCATCCCCCAATCAGTGGCTCTAGCCTTTATTTAT
AAATTAAGGTAGGAAGAAGGTTTATAGGAAATTACCTGAGTGTTGACGTGTTGATAACCCCACACAAGAG
AACAAAATTAATATCAAATATGATTAGCTCCAGGGTTATATGCAACAAAGGCATGATAAAGTGGTCATGA
TTTCATATGAGATGTACTGGACTCATGTGAAAAAACGTTTAAATACATGGGCTTACTCAAAATATAGACT
CATACCCCCAAGATGGGAAGAGACTGGTAACATTTGTACTGGAGGCTGGTCTGCTGTGGCAGCCATTAAC
ACAGTGGAGGGAAGAGCCTCAAAGAGTGAAATAGAGGAAGGGGAACAAATACAGTAAACCACCAGTTACT
ACTTAAAGGGCAGTGTTCTGATGTCCTAGGGAGGGCACTCCAAAATACCAATGGCCTTATCCTTAAATTT
ATTGTTTAATGAGCCTACACTGATCTCAGTGGCCCACTACTAAGGAGAAATGACAGGCACTTGAACAGCT
GATATGAGAACAGCTGGAGGCACAGTATACAGAAGAGTTTACAAGCCTATGGAACTCCCCTGTATTTTTT
TATGATGAGGAAATCTGAAAAATGTAAAATGTTGAAAGATTTAAGAGCAGTTATTAGAGTAGATCAACCA
ATGAGTCTCTTGCAGCCTGGAATTCTTTTATCTTGTTTGTAACAACAATCAGGCTCCATAAATTATAAAC
TATAAAAATTTACTTTATAAATTATAAATATATATATATGTGTGTCTGTAGATAGATAGATAGATAAATA
GATAGATAGATAGATAGATAGATAGATAGATATATGGATTTGATGGTTGCAGCAAATTCTAATTGGTTCC
AACAACCCTACTCACATAATACATTCATACAGGTTTGATAGATGGAGCTAAGTTTTAAATAAATTATTTT
TCTCCCATGGCTTATATATACACCACCAAAATTCTCAAAAATTAAAATGTGATTGTGTTGTATTTTTCTT
TTACTGAATGACTATAAAAAGTTACAACATTCTCCATAAATTTACATGAAAAAATATTATGTAGTGCAGG
TAAAGAAAACAAATTGACCCAAGAATGGTGTATATTCATTACTAAGCAACTTTTTAGATTCACAAAGTGT
GGGTAAACAAGGTAATTTTTTCAATCAGTTTTTTTTAACTGGCAGGCAGCAATTCAGAGTTACAATGAGA
AGATTAATAATTTTATTGTGTATTTTAAAATAAATCTTACAAAAATATTAATAGAATCACAAATTTATAC
CTTTGTATAAAAACAATCAGTCATTTCTACTTTAAGAAACAGAACTCACATCTACTCATCAATCATTTTA
TTAAGTCATATTACAAAGCTGAGTGCTAACATGGGTATAAGAAAACCATAACCTTATTCACCAGCCCAGC
GTCAAAAAGAAAAAAACCAGTCATATCAGCTGCTGCTTCAAGAGTTCTTGTTCCTTGACATTAACAAAAT
CCCTAGCTTAACTATTAAATTTTTTTTCAAAACTTCTAATTGATCCCTTAGATAAATGTTTGTGCTAACC
ATCGGGACACATCCCATGAGTTCTGAAGCAGTGTGTTGTTCTTCATGCATGGCCCTTTTGTAGAGCTGTG
AGTGTAGGGGAAGAGGGGGGAGAGAGAGCCCGTGTCCAGCCAGAGATCCTGTGCTCTGGGCAGGCAGACA
CGGGAGGACAACGGAACACTTTTCACTCGGCCTTTGGTGGGCATCTGGCTGTGTGAAGTTACTGACCCCA
CATGGTGGGGGATGGACAAGGGGCAGCCCCTGGTACCAGGAGCCCCAGGGCTACACTCTCGGCCCCAGAT
ATACAAGAAGAGGGCAGAGGGAGAGAGGCTCCCACACAGGCGAGAGTCCTTAGTCTGGTCTGTGGCTGGA
GCAGGGGAATTCCTTCTGATTGGAGATTAGGCACAGCTGATTAGGGGAAAGCCTACCCCATCATCCAAGC
ACAATGGACTTTGAGGAACAGAGCCAGTCTAAGCTTTTATAGCTTTATGGTAGAAAGGCAGGGAGAAAGG
AGAGAATGTGGAGAGAGACAGAGAGAGACTGGCCATGGCCAAGAGGAGGGAAGGGGGAAGAGAGAGAAAC
AGGAAAAGCTAGAAAGTAAGATAAGAGAAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGCAAAGTG
GGGCCAAGCAGCCCCTTTTCTAGTGAGCTTGTCATCTCACAGTTGCTAGGTAACTGGGGAGGAGTTTAGT
CTGAAGGTCAGAAGCTTGGGACCTTGTGTATGTGACTACTAACCACAGCTTCTCCTGTCGGGACTGTGGG
AGCAGTAACTTTGACAGGAGACAGGGATCCAGGAGACATGAGGGAACACCTTCTGTCCCACATAGGTGGA
ATCGGTTGTACCAGGGTTCAGAACTCAACTCCACTGGAGACCAGCCTATGTGTGCATAGCCCATTGCCCT
ACAGCCTTTGACATTCTACAGAGTTCTGAGACTGGTAGAGATACAAAATAGCTAGGATTACACAGAGAAA
CACTGGCTTGACAATAAAACTTCCAAAACAAATATAAATGAATAAATACACAAATTGGAGCAAGTGAACT
TGCACTAAATCCATCAAAACTTGCACAGGATGGCTGTCTCCATAATGTTCAGATCTACTTCTATTAATGT
CATTAAGAAGACAAAGATTATGCACAAAAAGAAACAAAACAAGAAACCCAAAAGGTAAAGGCTCCAATTG
TAAGTAATAGACCCACAGTCTCTGAGGCCTGACTGTGCAGGTCCTCACCTTTGGTAATCAGCACTGAATG
CAGACCACTCCTCATGGACTTTGGGCTCAGGTTTGTTTTCCTTGTCCTTATTTTAAAAGGTAATTCATAG
AAATGAGATCCTGCCAGTATTGTGTACATGAGAAATAGAAAAATTGGTTTTCTTTGCTCTATTTTGTTTT
GTTTGGTTAATGACAGTTTCCAAATCAGCATTCTTTGCTTTGAGGTGCCCAGTGTGAGGTGAAGCTGGTA
GGGTCAGGGCAGCCTGGAGGGTCCCTGAAACACTCCTGTGCAGCCTCTGTAGTCACTGTGAGTGACTACT
GAATGACCTGGGTCCTTCAGGCTCTAAAGAAGGGGCTGGAGAGGGTGGAAATAATTTTTAATGGTGGAGG
TAGCACCTATTATCCAGACACCATGAAGGGCTGATTCACCATCTACAGAGATGATGCCAGAAACACACTT
TACCTGAAAATAAACAGTCTGAGGTCTGAGTACACAGCCATGTGTGTGTGTGTGTGTGTGTGTGTGTGTG
TGTGTGTGTGTGTGTGTGTGTGTGAGTGTGTATTCATATATATATATATAGTGTGTATGTATATTCATAT
ATATATGTATATTCATAAGGTTGAGTAAATGGACTTAAACTGATTCCATCACAACTTCCATGGGATGGAT
ATTTCCCAGTGTTAAGACCTGTCAACATCACTGTCATTCAGGAGACAATGATTATGCACAACAAAACAAG
AAACCCAAAAGCAGAGGACTCCAATTACAATAGACCCAGACCCACAGTCTCTGAAGATTGACTGTACAGT
TCAACCCAGCCCTGTACTTCTCTTCCCTAGAATTTACATTACTGAGTAACTGAGGAAAGCTCTACAATAT
CTGTTCTCTATAGTGGTCAACACCTCCAAACACAGGTTACCCATATTCATGCCTGCCTTCTGCTACACTT
CTTGCCATAATGTAGACTACTTCAGCCTATTTTGTACTCCAGTTAACGAAACTCAAGACTAGCTGCATGT
TAGTCCTTATTCTGAAATATTATGAACAGGTGACCTCCCATCATTCACCAATGCAATAATCATATTTAGG
AATATGAGGTTTTATGAGATATAAGCACAAGGGAGAGAAAGTAAGAAAACTACATAGATATATAGACTGA
CATAAATCAAGACTTGCATGAGCTAGTGCCCAAGTACCATGTCCCTAAGTGGCAAGGAGTATCTTTTGAG
CCTAGTGAGATGAGGTACAAATCGGACTCTTACATCTTTTTAGATAAACATGTGAGATCAATGGACTAAA
GGCGTGAGCTGGGCTTCCTTGCAATCCATTTTCCATACAAGATAACAATAGATCTGGCTCCACAGACACG
ATGAGAATAGTCTTAATTAGTTCTTTAAGTAGAATGACTGATCACTAAGAGCCCAATTCCATACTAAATA
CTCTTCTGGATTATGCACAGATAAAAATTGCACATAGGGCATGGGGCACTGATCTCCCTGCACTACATGA
ATGGGGGCTCATTTACTAAATGTTCCCATGTTTCTTCCTAGTGCTGCACAGAGCAAATCCTACAACTTCC
TGCTTGTCTACAATGTAAACTCCAGACAGTACCAGAAAATCATTCCTTATGTTCCTCTCCAGGTGCTTCA
ACAAGCACAGTGCAAATTTCTGTCACCCTG

Molecule Role : Vaximmutor
Additional Molecule Role : Vaximmutor

9. IgG Fc fragment

Gene Name : IgG Fc fragment
Sequence Strain (Species/Organism) : Macaca mulatta
NCBI Gene ID : 718859
NCBI Protein GI : 383873191
Locus Tag : EGK_10892
Genbank Accession : CM001271
Protein Accession : NP_001244449
Taxonomy ID : 9544
Chromosome No : 19
Gene Starting Position : 55776057
Gene Ending Position : 55793029
Gene Strand (Orientation) : +
Protein Name : 3
Protein pI : 6.71
Protein Weight : 38189.56
Protein Length : 365

DNA Sequence : Show Sequence

>gi|109156886:55776057-55793029 Macaca mulatta chromosome 19, Mmul_051212, whole genome shotgun sequence
AGAAGGATATTAAAGAGCACCTGCAGGACCTTTCTAACGGGATGTCGGGGGAAGGGCTTGAAGGAGGATC
TAGGGAGGCTTCCATAAGATTTTGATTAACATCCAGCGCTAGGGAAGGTCACAGGGATACAAAAGGGTAG
GAGGAGGATCCAGAGACCTGCATGTTGTGGACTTCGAAGGCATCCGGTTCCTTTCCCAGCTTTGTCAAGA
ATTCCCTGGGCGGCGGACACCCTCATAATAAAAAAAACGGGAACCACAGGGAAGGGGAATAGAAGAACCA
CAAGCGTTTTGAGAAACATACATAGGCTGGGCCTAGGGCCTGGGGTGTGCCCTGCAACTGGGGGGGGTGG
GGCTGGATGTTCTTGGAGTCAGGGAGCAGCAGCCTCCCACAGGATGTGAGAGAGGAACTGGGGTCTCCAG
TCACGGGAGCCAGGAGCCGGCCAGGGCCGCAGGCAGGAAGGGAGCGAGGCTGAAGGGAACGTGAGCCGAC
CAGGCCCCGATTGAGGGAGGAGGGAAGGGCCTGGACCCCTGGGCCTGAGGGAGGAGGGGCTGGGGGTCTG
GACAGTGCGTCTGAGGGAGGAGGGGCTGGGGGGGTCTCGACACTGGTTCTGAGGGAGGAGGGGCTGGGGG
CCTGGACGCCTGGGACGGAGGGAGGAGGCACTGGGGGTCTGGACACTGGGTCCGAGGGAGGAGGGGCTGG
GGGCCCGGACTCCTGGGTCCGAGGGAGGAAGGGTTGGGGGCCCGGACTCCTCGGTCGGAGGGTGGAGGGG
CTGGTGGCCCGGACTCCTGGGTCCGAGGGAGGAAGGGTTGGGGGCCCGGACTCCTGGGTCAGAGGGTGGA
GGGGCTGGTGGCCCGGACTCCTGGGTCCGAGGGAGGAAGGGTTGGGGGCCCGGACTCCTCGGTCGGAGGG
TAGAGGGGTTGGGGGCCCGGACTCCTCGGTCGGAGGGTGGAGGGGCTGGCGGCCCGGACTCCTGGGTCCG
AGGGAGGAAGGGTTGGGGGCCCGGACTCCTCGGTCGGAGGGTGGAGGGGCTGGTGGCCCGGACTCCTGGG
TCCGAGGGAGGAGGAGCTGGGGGCCCGGACTCCTCGGTCGGAGGGTGGAGGAGCTGGGGGCCCGGACTCC
TCGGTCGGAGGGTGGAGGGGCTGGGGGCCCGGACTTCTCGGTCGGAGGGTGGAGGGGCTGGGGGCCCGGA
CTCCTCGGTCGGAGGGTGGAGGGGCTGGGGGCCCGGACTTCTCGGTCGGAGGGTGGAGGGGTTGGGGGCC
CGGACTCCTGGGTCCGAGGGAGGAGGGGCTGGGGCCTGAGGGGGACGGAAGGGGCGTGGCCGAGCTCGGG
GCCGGGACTCTCAGCCTATCAAGTTTCTGTAATTAATTAACTAACTGAGATCCAGTTCAGGGGTGAAAGT
TCTTCAGGTAGGAGGAGGGCATTGTTGTCAGTCTGGACCGAGCCCGCAGAGCCCCTCCTCGGCGTCCTGG
TCCCGGCCCCTGCCCCGGTACCCCGGGAGGAAGGGCGGGGCCGGGGGTTTTTCGGGAGGAGTCACGTGCC
CCCTCCCGCCCCAGGTCGTCCTCTCAGCATGAGGGTCCCGCGGCCTCAGCCCTGGGCGCTGGGGCTCCTG
CTCTTTCTCCTGCCCGGGAGCCTGGGCGCAGGTGAGGGCCGCTGCGGGCCGGGGCCCTGCTGCAGGCGGG
CGGTGGGAGGCGGCCCCAGGCAGGCAGGGGCGAAGCCAGCGGGACCCGAGTTCCCCGCGAGTCCCGGGCG
CTGCCTTCTCCGCTCAGTTCACTTTCTCAGCGTCTCCTGCTGGGCCTGAGGCTGAGAACCACCTGTCGCT
TCTGTGTCTCTGTTTCCCTCTCTCTCTCTCTGGGTCTCTGTCCTCTCTCTCTCTCTGGGTCTCTGTCCTC
TCTCTCTCTCTGGGTCTCTGTCTCTGTCTCCCTCTCTCTCTCTGGGTCTCTGTCCCCTCCCTCTGAATCT
TCCCTCTCCATAATAGATTCTTCTCCCTCCCTGGATATCTGTCCCACTGCAATCTAGTTCCCCGCCCATG
TTCTCCCTTCAGCTCTGTCTCTGTCTGCAGAAAGTCACCTCTCCCTCCTGTACCACCTCACCGCGGTGTC
CTCGCCTGCCCCGGGGACGCCTGCCTTCTGGGTGTCCGGCTGGCTGGGCCCGCAGCAGTACCTGAGCTAC
GACAGCCTGAGGGGCCAGGCGGAGCCCTGTGGAGCTTGGGTCTGGGAAAACCAAGTGTCCTGGTATTGGG
AGAAAGAGACCACAGATCTGAGGATCAAGGAGAAGCTCTTTCTGGAAGCTTTCAAAGCTTTGGGGGGAAA
AGGTGAGATTCGAATCCGGAGGGGCAAGGGGCTGGGTCCATGCTCCTGGGCCCCACTTACATGTGTGTGG
GCGCCCCAGGCCCCTACACTCTGCAGGGCCTGCTGGGCTGTGAACTGAGCCCTGACAACACCTCGGTGCC
CACCGCCAAGTTCGCCCTGAACGGCGAGGAGTTCATGAATTTCGACCTCAAGCAGGGCACCTGGGGTGGG
GACTGGCCCGAGGCCCTGGCTATCAGTCAGCGGTGGCAGCAGCAGGACAAGGCGGCCAACAAGGAGCTCA
CCTTCCTGCTATTCTCTTGCCCACACCGGCTGCGGGAGCACCTGGAGAGGGGCCGTGGAAACCTGGAGTG
GAAGGGTGAGCCGGATCTGCAGCCACAGGCTGTTCTGTCCTCTCTGCCATCACGCCCACCTGCCTCAGTT
CCCCTGTCAGGACCCTCAGTCAGCCTCCCACTGCAGCCCACGCTCTGCCCCCATTCCTCAGGGGTTTTTC
TACATTCAGCCCTCCCATGGCTCCCCAGCGCCCCCCAAGACAAACTCTTGGCTTCCTTGCCTTTTTTTGT
TGAGACGAAGTTTCACTCTTGTTGCCCAGGCTGGAGTGCAATGGTGTGATCTCGGCTCACTGTAACCTCC
GCCTCCCGGGTTCAAGTGATTCTCCTGCCTCAGCCTCCCTAGTAACTGGATTACAGGCATGCATCACCAT
GCCTGGCTAATTTTGTATTTTTAGTAGAGGCGGGGTTTCTTCATGCTGGTCAGGCTGGTCTCAAATTCCC
AACCGCAGGTGATCCGCCCGTCTCAGCCTCCCAAAGTGCTGGGATTACAAGCGTGAGCCATCGCACCTGG
CTGTCTTTTTTTTTTTTTTTTTTTTTTTTTTTTGAGACAGATTCTCTGTCACCCCAGGCTGGAGTGTGGT
GGCACAATCTCAGCTCACTGCAGCCTGAACCTCCCAGGCTCAAGCAATCCTCCCACGTCAGCCTCCCAAG
TAGCTGCGACCACAGCATCGTCACACCTGGCTGACTTTAATTTTTATAGACACAGTGTCTCACTACGTTG
CCCAGGCTGGTCTTGAACTCCTAGGCTCAAGCAGTCTTACTGCTTTGGCCTCCTGAATAGCTGAGATTAC
AGGTGCATACCACCATAACTGGCTAATTTTTTTTTTAGTTTTCCGCACAGTCTGCCTCCCAGGCTAGTGT
GCAGCAGCGTGATCTCAGCTCGCTGCACACTCTGCCTCCTGGGTTTAAGCGATTCTCCTGCTGCAGCCTC
ATGAGTAGCTGGCACTACAGGCACATCCACCATCTCTGGCTAATTTTTGTAGTTTTAGTAGAGACAGGGT
TTCGTCATGTTAGCTAGGCTGGTCTCAAACTCTTGACCTCAAGTGATCCACTCACCTCAGCCTCCCAAAG
TGGTGGGATTACAGGCGTGAGCCACCGCATTTGACCATAACTGGCTAATTTTTAAAATTTGTTGTAGAGA
TGGCATCTCGCTGTGCTGCCCAGGCCAGACTCAAACTCCTGGCCTCAAGTGATTCTCCCACTTTGGCCTC
TCAGGGTGCTGGGATGACAGGTGTGAACCACTGTGCTTGGCCTTCCTTGCCTTAATGCCCTCGTCAGACC
CACGCAGCAGCACTTGTCTCTACACAGCTGTCAGAGTCTAGGCTCCAGCCACCCAACATGAGCAATCTTC
TCCCTCTGAGCATTTGTTCATCCAGTTCCCCCGGCCCCTCTCTGTTCCACCCTTCCCCCTCTCTGCATAT
ACTCCAGCCCTCCTTATTCTTCAAGGTCGGGGCTGGATATCACTTCCTCTGAGAAGCCTTCTCTCAGCTC
TGTAGGGCAGAGTTCACTGTTTCCTCCCCAGCGGCCCCAGATCCCCATTCATTCAGCTGTTGGCCAAGAG
CATTTGCACTGCCAGACACCGCTCTGGGACGCCGCTCTGGGCCTTGAGCAAAGAGGGAAGTGACACACGT
TCACCCTCTGTGGCTTCCAGGCTGCTGGACAAAGATAGATATCGGCTGGGGATTTGCACAGATGTTCATT
CCAAGTGCCACAAAGGAGAAGTTGAGACTTAACCAGGTAGTTTTTCTTTGATCGTCTTCTTTCTTTTTTA
AGTAGGGAAAATTTCCTTTTTTTTGAGATGGAGTCTCGCTCTTGTCGCCCAGGCTGGAGTGCAATGGCGC
AATCTCGGCTCACTGCAACCTCCGCCTCCCAGCTTCAAGTGATTTCTGCCTCAGCCTCCCGAGTTGCTGG
GACTACAGGCACGTACCACCATACCTGGCTAATTTTTGTATTTTTTTTAGTAGAGACAGGGTTTCACCAT
GTTGGCCGGGATGGTCTTGATCTCTTGACCTTGTCATCCGCCTGCCTCGGCTTCCCAAAGTGCTGGGATT
ACAGACATGAGCCACTGTGCCCGGCCTTTTTTTTTTTTTTTTTTTGAGACAGACTTTTGCATTGTTGCCC
AGGCTGCAGTGCAGTGGCACAGTCTTGGCTCACTGCAACCTCCACCTCCCAGGGTCAAGCAATTCTCCTA
CCTCAGCCTCCCGAGTAGCTGGGAATACGGGCACGCACCACCCTGCCTGGCTAACTTTTGTATTTTTAGT
AGAGACGGGTTTCACCATGCTGGCCAGGCTGGTCTCGAACACCTGATCTCGTGATCCGCCCACCTTGGCC
TCCCAAAGTGCTGGGATTATAGGCGTGAGCCACCACACCTGGCCTAAGTAGGGAAAGTTTCAAACCACAC
TTAAGTAGACACAATAGTATAAAAAGGACCAGGCATGGTGGCTCATGCCTGTAATCACAGCATTTTGGGA
GGCCAAGGCAGGTGGATTGCTTCATCCCAGGAGTTCAAGACCAGCCTGGGCAACATAGCAAGACCTCATC
TCTACTAAAAACTCAAAAAATTAGCCTGGCATGGTGGTATGTGCCTCTAGTCCCAGCCACTGGGGAGGCT
ATGGTGGGAGGATCACTTGAGCTCAGGAGTTTGAGGCAGTAGTGAACTGTGATTGCAATCCTGCACTCCA
GCCCAGACTACAGAGCCAGACCCTGTCTCAAAAAGAAAAAAAATATGATGGCCAGACGCGGTGGCTCATG
CCTGAATTCCAACACTTTGGGAGGCTGAGGTGGGCAGATCACTTAACAGGAGTTTGAGATAAGCCTGGCC
GACATAGTGAAACCCCATCTCTACTAAAAATACAAAAATTAGCCAGGTGCGGTGGTGGGCGCTTGTAATC
CCAGCTACCCTCCACTTCAAGTGATCCACCCTCCTTGGCCTCCCAAAGTGCAAGAGTCACGGTGCCCGGC
CAGAGTGTTTTGTTGATAAGTACTTTAGTATGTAACTCTACTAGGTAAGGGCATGTAAAAAAAATTAATA
CCAAAACCATTATCACACCTACGATCAATTAACTGTAACTCCTTAATGGCATCAGATGTCTAGTTTTTGT
TCACATTTTCCTGACTGTAAATTTTTTTTTTTTTTTTTTGAGACAGTCTCTTTCTCTGTCACCCAGGCTG
GAGTGCAGTGGCCGGATCTCAGCTCACTGCAAGCTCCGCCTCCCAGGTTTACGCCATTCTCCTGCCTCGG
CCTCCTGAGTAGCTGAGACTACAGGCGCCTGTCACCTTGCCCGGCTAGTTTTTTGTATTTTTTTTTTTTT
TGTTTGTTTGTTTTTTTTGAGACGGAGTCTGGCTCTGTCGCCCAGGCTGGAGTGCAGTGGCCGGATCTCA
GCTCACTGCAAGCTCTGCCCCCCGGGTTTACGCCATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGACTA
CAGGCGCCCGCCGCCTCGCCCGGCTAGTTTTTTGTATTTTTTAGTAGAGACGGGGTTTCACCGTGTTCGC
CAGGATGGTCTCGATCTCCTGACCTAGTGATCCGCCCGTCTCGGCCTCCCAAAGTGCTGGGATTACAGGC
TTGAGCCACCGCGCCCGGCCGTTTTTTGTATTTTTTTAGTAGAGACGGGGTTTCACCGTGTTAGCCAGGA
TGGTCTCGATCTCCTGACCTCGTGATCTCCCCGTCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNGCACACCACCATGCCTGGCTATTTTTTGTATCTTTAATAGAGACAGAGTTTCACCAT
GTTGGCCAGGCAGGTTTTGAACTCCCGACCCCAGGTGATCCACCTCCCTCGGCCTCCCAAAGTGTTGGGA
TTACAGGCATGAGCCACCGCGCTCAGCCGTATTTTTGTTTTCTTTTTTTTTTTTTGGAGACGGAGTCTCG
CTCTCTCGCCCAGGCTGGAGTGCAGGGGTGCCATCTCAGCTCACTGCAACCTCCACCTCCCGGGTTCAAG
CGATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACAGGCGCCTGCCACCACGCCTGGCTAATTTTT
GTATTTTTAGTAGAGATGGGGTTTCACGTGTTAGCCAGGATGGTCTCGATCTCTTGACTCGTGATCCGCC
CTCCTCGGCCTCCCAAAGTGCTGGAATTACAGGCATGAGCCACTGTGCCTGGCCATAATTTTTGTATTTT
TAGTAGAGACAAGGTTTCACCATGTTGGTCAGGCTGGTCTTGAACTCCTGACCTCATGATCCGCCTACCT
CGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCTACTGTGCCCGGCTGGATTCCAATTTTTTATCAGA
TAGGTGTTTTGCAAATATTCCTTACACTCTCTAAGTTGTCTTTTCATTGTTTTAACTGTGCCTTTCAGAA
AGAAAAAGTTTTTAACTTCGATAAAATAGTTTATTCTTTTTTTTTTTTTTTTTTAAATCATGGGTTATGC
TTTTGGTGTCTTATTTCAGAAGTAAGCACTAAACCCAAAATCAGCTAGATCTTCTCCTGTGTATTTTACG
AGTTTTAAAGTTTTGCATTTTATAGTTAGGTCTGTGATTCATTTTGAGGTAATTTGAGTTACTTGTGATC
TTGAGTGTCTTTTGATTTACAGGTTTCCCATTTTCTTTTTTTTTTTTCCCCTCGTAATTGTGGTTTGAAG
AAAGTCCGTTTATGTCCTATTGAGTTTCCCTCAGACTGGATTTTACCCTTTGCATCCTCTGATGTTGCTG
GACATAGTCCTCCTTCTCTTCTTTAAAGGAGCAGCTCGATCTGCAAGCTTGATCAGATTCTGGTTCAGTT
TTTATGGCAAGAAAAGTTTCGGCCGGGCGCCTGTAATCCCAGCACTTTGGGAGGCCGAGACGGGTGGATC
ACAAGGTCAGGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAAAATACAAAA
ATTAGCTGGGCGAGGTGGCGGGCGCCTGTAGTCCCAGCTATACTGGAGGCTGAGGCAGGAGAATGGCTTG
AACCCAGGAGGCGGAGCTTGCAGTGAGTGGAGATCGCGCCACTGCACTCCAGCCTGGGCGACAGGGCGAG
ACTCCGTCTCAAAAAAAAAAAAAAAAAAAAAAAAAAAACTTTCTGGGTAGTTGGTGGTTATGTCTGTGTG
CATAGGCTGCAAATATCTGCTCGCTTCTGTGCTGTTCTGCGGACCACTGGATTCGGGTGTTACAAAGTTC
TCTGTCAGGTTTTCTCCTGATGCTTTTAGCGGACAGCCATGGCCACTGCCTTAATCTTTTTTATTTATTT
ATTTATTTATTTTTGAGATGGAGTCTTGCTCTGTCGCCCAGGTTGGAGTGCAGTGGTGTGATCTCGGCTC
ACTGCAACCTCTGCCTTCCAGGTTCAGGCGATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGATTACAGG
CGCATGCCACTATGCCCGGCTAATTTTTGTATTTTTTTGGTAGAGATGGGGTTTCACCATGTTGGTCAGG
CTGGTCTTAAACTCCTGACCTTGTGATCCACCTGCCTCGGCCTCCCAAAATGCTGGGATTACAGGCATCA
GGCATGAGCCAGCGCGCCTGGCCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGAGAGGGAGTCTGC
CTCTGTCACCAGGCTGGAGTGCAGTGGGCATGATCTCGGTTGACTGCAACCTCCACCCCTCAGGTTCAAG
TGATCCTCCTGCCTCAGCCTCCTTAGTCGCTGGAATTACAGGTGCACACTACCACACCCAGCTACTTTTT
GTATTTTTAGTAGAGACGGGGTTTCACCATGTTGGCCAGGATGGATTTCTTTTTTTTTAGAGAGATGGAG
TTTCACTCTTATTGCCCAGGCTGTAATACAATGGCATGAACTCGGCTCACTGCAACCTCTGCCTCCTAGA
TTCAAGTAATCCTCCTGCCTCAGCCTCCAGGGTAGCTGGGACTACAGGCATGCGCCACCATGCACAGCTA
ATTTTTATATTTTTAGTAGAGACGGGGTTTCACCATGTTGGCGAAGCTGGTCTTGAACTCCTGACATCAG
GTGATCCGCCTGCCTCAGCCTCGCAGAGTGCNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNCACCGCGCCAGCCTTTTTCTTTTTTTTTTTTTTTAGACAGAGTCTTGCTCTGTC
GCCCGGGCTGGAATGCAATGGTGCAACCTCTGCCCACTGCAACCTTCGCATTCCGAGTTCAAGTGGTTCT
CCTGTCTCAGCCTCCTGAGTAACTGGGACTATAGGCGCCTGCCATCATGCCCAGCTAATTTTATGTATTT
TTAGTAGAGATGGGGTTTCACCATATTGGCTAAGCTGGTCTTGAACTCCTCACCTTGTGACCCACCCGCC
TCAGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCACTGTGCCTGGCCCCAAGTTTATAAATTTTAAT
TTATAAAGCTCAATTTTATCTTTGATTCTGTAGCTTTGTTGTGTATTCTCTTTAAGGAATCTTTCCTCCG
AGAAAGGTATTCACCTATGTCTTCTAGAAGCTTAGTTGATGAATAGCTTCCACATTTAGTGATACCATTG
ATTTTGAGTTAATTGCCTGTTATGATGAGGGTAGGAGTTGAGGTTCATATGTCCAGCCAGCATCATTTGT
TGCTAGACCATCATCCCCTCTCCCTCACTGGACTGCAGGGGAGTGTGTTTTGTGTGTAAGGTGTGGATCT
GCTTCTGACCCTCTCCTATTCTGCTGATTATTGGACTTAGTGTCAGTACCTCACTCTTGATTTGATGTAG
CTTTTTTTTTTTTTTTTCTTTTTTGAGATGGAGTCGCACTCTGTCGCCCAGGCTGGAGAGTAGTGGTGTG
ATCTCGGCTTACTGCAAGCTCCGACTCCCGCGTTCACGCCATTCTCCTGCCTCAGCCTCCCAAGTAGCTG
GTACTACAGGCGCCCGCCACCACACCCGGCTCATTTTTTTGTATTTTTAGTAGAGATGGAGTTTCACTGT
GTTAGCCAGGATGGTCTTGATCTCCTGACCTCCTGATCCGCCCACCTTGGCCTCCCAAAATGCTGGGATT
CCAGGTGTGAGCTACTGCACCCATCCTGAATCTATTTTTATGAGAGACATTGGCCTTAAGTTCTCTTTCT
TATAATGTCCTTTGTTGTCAAGATGATGCTGACCTCATAAAATATGCTGGGAGAGTGTTTCCTCTGTTTT
ATTGCCTGAAGAGTTTGCGTAGGAGTAGAATCATTTCTACATTGGAAGAATTCACTAATTGATGTCTTCC
GGACCTGGAATTTTAGTTTTCGGAAAGTTTTTTTTTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTATGT
CGCCCAGGGGGGGGGGCAGTGGCCGGATCTCAGCTCACTGCAAGCTCCGCCTCCCGGGTTTTTACCCCAT
TCTCCTGCCTCAGCCTCCCGAGTAGCCGGGACTACAGGTGCCCACCACCTCCCCTGGCTAGTTTTTTGTA
TTTTTTAGTAAAAACAGAGTTTCACTGTGTTAGCCAGGATGGTCTCGAACTCCTGACCTCGTGATCCGCC
CGTCTCGGCCTCCCAAAGTGCTGGGATTACAGGCTTGAACCACCGCGCCCGGCCAGTTTTCGGAAAGTTT
TAAACTATGGATTAAACATTTTATTTATTTATTTTTTTNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNCAGCTACTCGGGAGGCTGAGGCCGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCTG
AGATCCGGCCACTGCACTCCAGCCTGGGTGACAGAGCGAGACTCCGTCTCAAAAAAAAAAAAAAAAAATA
CTTACAGGACTGCTGACATTTTAAATTTCCTCTTGTGTCAGTTTAGAAGGTTGTATTTATCAAGAATGTG
TTCAGTTCATCTAAATTTTCAAATGTGTTAGTATGGAATTTTTCATAATTATCCTCTATCTTTTTTTTTC
CTTTCCCCAAGACGAAATCTCGCTCTGTCACTCAGGCTGGAGTGCAGTGGCACGATCCCAGCTCACTGCA
ACCTCTGCCTTCCAGGTTCAAGCGATTCTCCTGCCTCAGCCTCCTGAGTAGCTGGGACTACAGGTGCCCA
GCTAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCACGTTGGCCAGTCTGGTCTCAAACTCCTGACC
CCAGGTGATCCACCCACTTTGGCCTCCCAAAGTGTTGGGATTACAGGCGTGAGCCACCATGCCCAGCCCA
GGGAGGTGACATCTTGAGGGGACACCTTCAGGGTGGATAGGTTCAGTCTCTGTCACCTGGGAAGCGCCTC
CTCTTTTACCACCACATTATCCGGGGTTAGCACATTGCAAACATGGAGGCCTCTTTCTGTCATTACCCAG
CCCTGGCCCTGGGAGTGGTGGGCTCGGGGCTTAGACCTGTCTGCCTGGTTTCCTGCAGAGCCCCCCTCCA
TGCGCCTGAAGGCCCGACCCGGCAACCCTGGCTTTTCCGTGCTTACCTGCAGCGCCTTCTCCTTCTACCC
TCCGGAACTGCAACTGCGGTTCCTGCGGAATGGGATGGCCGCTGGCACCGGACAGGGCGACTTCGGCCCC
AACAGTGACGGCTCCTTCCACGCCTCGTCGTCACTAACAGTCAAAAGTGGCGATGAGCACCACTACTGCT
GCATCGTGCAGCACGCGGGGCTGGCGCAGCCCCTCAGGGTGGAGCTGGGTGAGGCCCCGCCCGGTGGTGA
TGCTCCTGGTTTCCCGTTGCCTTGTCTCACTGCTGCGCCGGTCCTTCCTGAGTCTGACCTTCCTCCCCGC
TGCTGCCATCTCCTTGAATCTGACTGCCTTGTGCCTCGCGCCTTTCAGTGCCCCCAAAGCCTGATGCCTT
GTCCTTCCCAAGGCCGACTGCCTTCCGTCCTGCTGCTTCTGGCCTCACTGAGTCTGAAGAGCTGTTAACC
ACCATGGCCAGTCCTCCCTGAGTCTGACCGTCTTCCATCCTGCTGCTGCTGCGGCTGCAGGTCTTCCTGG
AATCTGACCATTCGTTGTCTGCTATGCCCGTCCTCACCAAGACTGACCACTTGCTGCCTTGCTACTGCTG
GGGCCCATGAGGCTGACTTCCCACTGCTCTGCCTGCCTCTCCCCGCTGCGCCGGGACAGCCCCACCCTGC
CGCTGCTGGTCCATTGCCAGTGTGACCACGGCGGCCGCTCGTGCTGTGGCTGGTTCTTACATCCAGCCTG
GGGGCACCCTGCCGAGATCGCCCGCCTGGCCTTGCCTCTGTCCATCAGACACTTGGTGCTGGGATCTCCA
AGGCTGGGAGGGACTGGGACCCCCCACTGCTGTGTCCTGACTGGGTGGGGGTGGACGGGCTGCTCCACAT
CTCACAGCGTTCTCTGGCTGCAGAAACTCCAGCCAAGTCCTCGGTGCTCGTGGTGGGAATCGTCATCGGT
GTCTTGCTACTCACGGCAGCGGCTGTAGGAGGAGCTCTGTTGTGGAGAAGGATGAGGAGTGGGCTGCCAG
GTGTGGGCAGCGGGAGGAAGAGCCTTGGAGAGAGGGACAGAGACCCCAAGAGAGGGGCACACAGACCTGG
GAGGAGAGACCTGGTGTGGGGACAGACCCAAAGAGAGGAGGACAGAGACCAGAGAGAAGTGGAGACAGAA
ACCCAGAGACGGGGGAACAGAGGCACAGAGAGAGGGGACAGAGGAAGGGGGAGACAGAGACCCCGAGGAG
GGAGGCAAAGATGTAGAAAGAGGGGGGATGGAAAATTGGGAGAAGGGGAGACAGGCCCAGAAGGAAGGGG
TTAGAGACTGAGGGAGTGTGTGTGAGACACACACAGAAATGGGGGATGCCAGTCAGACCCAGAGCACCTC
AGAGATTCTGATGACCTCCCCCTCTCTCTCCACAGCCCCTTGGATCTCCCTCCGTGGAGATGACACCGGG
TCCCTCCTGCCCACCCCGGGGGAGGCCCAGGATGCTGATTCGAAGGATATAAATGTGATCCCAGCCACTG
CCTGACCATCTGCCATTCCGACTGCTAAAAGCGAATGTAGTCAGGCCCCTTTCATGCTGTGAGACCTCCT
GGAACACTGGCATCTCTGAGCCTCCAGAAGGGGTCCTGGGCCCTGTTGTCCTCCCTCTGGAGCCCCGTCC
TGTGGTCTGCCTCAGTTTCCCCTCCTAATACATATGGCTCTTTTCCACCTCGATAATATAACACGAGTTT
GGGCCCGAATCAGTGTGTTCTCATCATTTTTCAGGCAGGGGAGGTAAGGGAATAAATCAGGGGACTGAAT
GGCCGCTGAGGCTCAGATCTCTCCTACAGGTAA

Protein Sequence : Show Sequence

>gi|383873191|ref|NP_001244449.1| Fc fragment of IgG, receptor, transporter, alpha precursor [Macaca mulatta]
MRVPRPQPWALGLLLFLLPGSLGAESHLSLLYHLTAVSSPAPGTPAFWVSGWLGPQQYLSYDSLRGQAEP
CGAWVWENQVSWYWEKETTDLRIKEKLFLEAFKALGGKGPYTLQGLLGCELSPDNTSVPTAKFALNGEEF
MNFDLKQGTWGGDWPEALAISQRWQQQDKAANKELTFLLFSCPHRLREHLERGRGNLEWKEPPSMRLKAR
PGNPGFSVLTCSAFSFYPPELQLRFLRNGMAAGTGQGDFGPNSDGSFHASSSLTVKSGDEHHYCCIVQHA
GLAQPLRVELETPAKSSVLVVGIVIGVLLLTAAAVGGALLWRRMRSGLPAPWISLRGDDTGSLLPTPGEA
QDADSKDINVIPATA

Molecule Role : Vaximmutor
Related Vaccine(s): HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6) , HIV DNA vaccine SIVmac239 Gag-Pol-Nef and mock Env with rAd5 boost , HIV-1 gp120 with mCT E112K

10. IgG2b

Gene Name : IgG2b
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 16016
Genbank Accession : AC160982
Taxonomy ID : 10090
Chromosome No : 12
Gene Starting Position : 56717
Gene Ending Position : 60336
Gene Strand (Orientation) : -
Protein Name : immunoglobulin heavy constant gamma 2B
Protein Note : Also known as IgG2b; Igh-3; gamma2b

DNA Sequence : Show Sequence

>gi|121699722:56717-60336 Mus musculus immunoglobulin heavy chain complex (Igh) on chromosome 12
CCTAGGCTCCCTGCCCAATCATGTTTCTGTAGTCAGGGGAGATCTTCTGCTTCAGCTCCACCACTGAGGA
GAAGATCCACTTTACCTGTGGGGAAGTGAGAGTCAGAGACCACACCCATGCTCAGACCCTCCAATCCTGT
GGGGAAGACAGAGGCCTGTCTCTTCTTCAATTCCTTTCATACAGGTAGGAGACTGGGTATGGGAAGTGGT
CAAAGTGGAGATATTGTGGGAGTTGAGGTGGAGATGGTATGAGATTAGCTCACAGAGTACCTTGAGTTAT
GGTGAGGCGAACATCAAGGGGATTGTGTGTTAGACAGCATGAACCTCATTAAGGCTAGTGTGGAATGCAA
GGAGGTTTGGTCTCATAAGACAGTATGAGGATCACGCAGGACAGCAGTAGAGACAGAAGGGCAGACTGTA
TGGGACAAAATGTGGAGTCACATAGAGCAATGTGGGATGGCTCAGGGAATGGAGGAAACGGTGTGTGGTA
CAGAGTGGGGACAGCAAAGTAACATCCTACTACATCAGGGGAGGAGTGAGAGGACATTTTGTGGTCAGTG
TAGCTATCACAGCAGAGGGTGGGAGACAGTGCCAACCTTGAAGAGTGTGACAGAGGCGCTGTAGCACACG
CTGAGCAGGAAGAGGCTGATGAAGATGGTGATGGTCGTCCAGAGCCCGTCCAGCTCCCCATCCTTGGCCT
CAGCACAGATATCATCCAGGTCTAGCCCTGAACAGAGAGGACAGTCAGTGTTTGTCCCAACATGGTTGAT
GCTGGGAGAGATTCCCTGTGAGGCAGACATGTCTGCATGAAGTCAGAGGAGAGATCTCCAGCCTGACTGG
GACAGCAGACCCTCCCCGGGGCCTGCTTTCCTTCCTTTCCCTCTGGGACATCAGTCTCAGCTTCCTCCAC
CTGAGTCCAATAATGCCTTGGATGGACCTCAGAGTGACCTGGATTATTCAAGTGCCCTCTATGCTTGTCT
CATCTTTCATTCCTTCAGTACAGGAGAAGGTGGAGGGTCAGCAGGGCCTGTGACCCAGGTCAACAGTGGC
TATACAGCTGGACTGACCCTTTGCTATTCTTCAGTCATCAGCAGAGCCTGTGGCTTTTCTTGCCTGAACT
TGGGAACATCCCAGTGTGAAGTGATTCAGACCATTATGGCTATGGTTTGAATTATTCATGTGGGGTTGAA
GCATGACCCCGAGGTACCAGAGATGAATCTGGCTTCAGAGGTCTTGTTTTGAGCGGAGAATGGAGTGTCC
TCAGAAGAGGAAAGGTGTGTCTGATTGTGATGGCAGAAACGTGGGCATTGAATTTTTGGCCGTGTGTATG
GTGATACATTGCTGGATGTAGGTGCTGTGCTGGGCACAGAGGAGTTGTCCCAGTGTGTTAAATGCGTTTT
GTGCTCACGAGCATGAGGATACATGTGCTATATGGACTGGATGGTGTTCAGCAGGGTCAGGATTTAGCAT
GAGTGTGGCTATCTAATAGTCCCTCCCTTGGGGCATCAAGAGCCATGTGCCTCAGCCCCAGGTGGCACAG
GCAGGAGTGAGCCATTTGTATGGGTGTGCAGACCTCGTCTGTGAAAAGCTGCCTGAGTTGAGAGTATAGA
TGACAAAGGTCTATGGAATGCCCCTGGCCATGTGTCACTCCACAATAGACTCAGAAAAACCCCTAAGTAG
AGAAATGGGGCAGGGGGACAGGAACAGCCTAAGGGAGGTGGGTTTGTGTGCTTATCCATTTGAGGCTTCC
TAGGATTATCTCTATGTCTGGCAGCTGCTGGTTCATGGGAAGGCAAGGAAAAGGCACTGCCTAAAGCCAA
GCCCCAACAGTCCAAGGCAGAATGACTCATGACCTCTGAGTCATGCAGTGCAGAAACCTCATTCTCTTCC
TATAGACAAGGCTGTCCTCCAACCCTGGCCAGACCTATCAGCCCGTGAGCTATGCTCTATACCTTGGAAA
GAACCAGGACAGTTTTACATGGTACCAGGCTTTGCTGGATGCTTTATTTATACAAGGGATGCATGGATAT
GGGTGCCAGTGTCTCTTAGGACCTGAGAGCTTTGTGGGTGCTGAGCTCATTTACCCGGAGACCGGGAGAT
GGTCTTCTTCAGGTAGTAATTTTTCAGACCCTCGTGTCTCACGTTGCATGAGAAGGAATCTGTTTTCTCC
CACTTGCTTGTTTTTATATCGAGCTTGCTGTATATGAAGTAAGAACCGTCAGAGTCCAGGACTGGTGCGG
TGTCCTTGTAGTTCTCCTCTGTATGCCCATTGCTGGTCCACTCCACACTGATGTCTCCAGGGTTGAAGCC
CACGACCAGGCAAGTGAGACTGACATCTTTCCTGGACAACTGCTCTGCTGGTGGCGGCAAGATGTATACT
TGTGGAGCTCTGACTAGCCCTGTGGGGTTAGAAACATACATAGAGGTCATGGCTGAAGTGGAAGGCTGTC
CACATAGACATTTATTCTTATGCCCATCCCAGCCCCCATGCAGTTGTCCTGCAGGTCCCACCTTTAATTT
TTGAGATGGTTCTCTCGATGGGTGATGGGAGGTCTTTGTTGTTGACCTTGCATTTGAACTCCTTGCCACT
CATCCAGTCCTGGTGCTGGATGGGGAGGGCACTGACCACCCGGATAGTACTGTTGTAATCCTCTCTATGG
GTTTGTGTCTGAGCTGTGTGTACTTCCACGTTGTTCACAAACCAGCTGATCCGGACGTCTGGGTCATCCT
CGCTCACATCCACCACCACACACGTGACCTTGGGTGTCAGGGAGATCATGAGTACATCCTTGATATTTGG
AGGGAAGATGAAGACGGATGGTCCACCCTCGAGGTTAGGAGCTGATGAGAAGAGATGGAAATGGATTTGT
ACATGGCTTATCCTCCATTACAGGGATTTTTACAGCACTTACCATTCTCCTGGGAGTGGAGCTCTGGTAG
TGACTTACCTGGGCATTTGTGACACTCCTTGCATGGAGGACAGGGGTTGATTGTTGAAATGGGCCCGCTG
GGCTCTGCAGAGAGAAGGCTGGATGTTACTGGTTTTTGAAGGAGAGAAGCACCAAACCAGAGAGAGGAAA
GTTTGTCCCTGGTATGGGCTTAGTCCAGGATGATCCTGGAAATGACAAGCACACCTATCCCAGAGGATCA
TGTCCTTGAGTGTAGGTGGTCATAGCTAGATGTTCCCAGGAGGGAGGCAGAGACAGTATCTCCCTCTTCC
CTGGGCTAAGGTCACCTCCTTGGTGATGGATCCCAGCCTGGCTGGTTTAGATAGGCTAATACCTTTGCCT
CAACTCTGGTGAATCCCTCCTCCCCTGAATGTCCTCTCACCAAGTTTTTTGTCCACCGTGGTGCTGCTGG
CTGGGTGAGCAACGCTGCAGGTGACGGTCTGACTTGGCCAGGTGCTGGAGGGGACAGTCACTGAGCTGCT
CATAGTGTAGAGTCCAGACTGCAGGAGAGCTGGGAAGGTGTGCACACTGCTGGACAGGGATCCAGAGTTC
CAAGTCACAGTCACTGACTCAGGGAAGTAGCCCTTGACCAGGCATCCCAGAGTCACAGAGGAACCAGTTG
TATCTCCACACCCAGGGGCCAGTGGATAGACTGATGGGGGTGTTGTTTTG

Molecule Role : Vaximmutor

11. Ighg1

Gene Name : Ighg1
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 16017
Genbank Accession : AC160982
Molecule Role : Vaximmutor

12. Ighv1-9

Gene Name : Ighv1-9
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 668478
Genbank Accession : AC073561
Taxonomy ID : 10090
Chromosome No : 12
Gene Starting Position : 114583568
Gene Ending Position : 114583861
Protein Name : immunoglobulin heavy variable V1-9
Protein Note : Also known as Igg2a; Gm16697

DNA Sequence : Show Sequence

>gi|372099098:114583568-114583861 Mus musculus strain C57BL/6J chromosome 12, GRCm38 C57BL/6J
GTCTTGCACAGTAATAGATGGCAGAGTCCTCAGTTGTCAGGCTGCTGAGTTGCATGTAGGCTGTGTTGGA
GGATGTATCTGCAGTGAATGTGGCCTTGCCCTTGAACTTCTCATTGTAGTTAGTACTACCACTTCCAGGT
AAAATCTCTCCAATCCACTCAAGGCCATGTCCAGGCCTCTGCTTTACCCACTCTATCCAGTAGCCAGTGA
ATGTGTAGCCAGTAGCCTTGCAGGAAAGCTTCACTGAGGCCCCAGGCTTCATCAGCTCAGCTCCAGACTG
CTGCAGCTGAACCT

Molecule Role : Vaximmutor

13. IL-6

Gene Name : IL-6
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 16193
NCBI Protein GI : 13624311
Genbank Accession : AC112933
Protein Accession : NP_112445
Taxonomy ID : 10090
Chromosome No : 5
Gene Starting Position : 30013160
Gene Ending Position : 30019967
Gene Strand (Orientation) : +
Protein Name : interleukin 6
Protein pI : 7.5
Protein Weight : 23291.86
Protein Length : 211
Protein Note : Also known as Il-6

DNA Sequence : Show Sequence

>gi|372099105:30013160-30019967 Mus musculus strain C57BL/6J chromosome 5, GRCm38 C57BL/6J
ACCAAGAACGATAGTCAATTCCAGAAACCGCTATGAAGTTCCTCTCTGCAAGTAAGTGAAGGCAGTTCCT
TGCCCTCTGGCGGAGCTATTGAGACTGTGAGAGAGGAGTGTGAGGCAGAGAGCCAGCATTGTGGGTTGGC
CAGCAGCCATCAGCTAGCAGCAGGCGCCCAACTGTGCTATCTGCTCACTTGCCGGTTTTCCCTTTTCTCC
ACGCAGGAGACTTCCATCCAGTTGCCTTCTTGGGACTGATGCTGGTGACAACCACGGCCTTCCCTACTTC
ACAAGTCCGGAGAGGAGACTTCACAGAGGATACCACTCCCAACAGACCTGTCTATACCACTTCACAAGTC
GGAGGCTTAATTACACATGTTCTCTGGGAAATCGTGGAAATGAGAAAAGAGGTGGGTAGGCTGTGAAACT
GATGAAGACCCAGTGTGGGCGTCCATTCATTCTCTTTGCTCTTGAATTAGAAATTCTCTGCTGGGATCTA
GGGCCCTTAGGATTTGAAGCTAAAGGTCAGACTAGACTGTGTTCTCTCTTTCTCACCTCTTTGCTGGTTT
TGAGTGGAGGTTGGGAAGGGGTTCCTTTCCTGTCTGGAAGATACAGAATGTGACTGCATTTCTAGAAAAT
TCACAGTGGGCCATTCTCTGTTCCAATTTAGCTATTGCTTCTTAGGTGGGGATTCCTTTTCCCTCATTAT
TCCTTTTTCCTTATCTCTTTGCCTTCATTTATCCCTTGAAGTCTACAAGGACCAGAAAGTGCTTTTTGGC
TGAATGTAGTAAGTTCTGTGTGTGTGAAATCAGGATGCTCTAGGGTCAGCCCAGATAAGATGCATATTGT
ATAGAGCCCAATAAAGTGCTAACACACACACACACACACACACACACACACAACCTAGATTAGGCTGGGC
ATGGTGGTGGATGCCTCCCAGCACTTGGGAGGCACACGCAGGAAGATCTCTGTGAGTTAGAGGCCAGCTT
GGTCTACATATTGAGTTCCAGGATATCCAAGACTACATTGAGAGATCCTTTCTCAAAAAAAAAAAAAAAA
AAAAAAAAACAACAACAACAAACAAACAAACAAACAAGAAAAAAAAAACCCAACCAACCCTACCTAGATT
AAAATATCTCCCATCTTTAAATGAAAAGTATTTTGACTCTGCTTGACAGAAAGGAAAAAAAAAATCACAA
ACAAGATTAATAGCCTAGGTCTGGGTGTGTAGAACCAACTTTGTAATCTTGGGAAAATCCTCAACTATTT
AGTACTCTTTATCTGCATAATTATGGAGTTACAGATAATGGCACAGACCCTTCCAGATGGAATATTCTGT
GACTTAAATTTATTTGCCCCAAGATATCATCAAAATTTCTGTCCTTTACCAAGTTCCTACTCTATGCTGG
GCAGTTTTTATCGTTGAATCCTTGAGACAAATGTATAAGAGGGACATCAATAATTCTTTATTGAAACATA
GGAAATACTTAGGAGAGTAACAAGCTTAAAGCCAAGGGACTGAGCCTAAGGGTGCATTTTTATTTATTGG
GCTGCTTAGTAGGGTTCTAAGAAGGTATAGCTTCCCTTTTCTGTGTCCTGGCTATGAAAGAGCATGACTT
GGCCCTCTAGTGGTGCTTGTTGTAAGAGGTGTTTAAGTGATTGCTCTGGTAATCTTTTGCAGTTGTGCAA
TGGCAATTCTGATTGTATGAACAACGATGATGCACTTGCAGAAAACAATCTGAAACTTCCAGAGATACAA
AGAAATGATGGATGCTACCAAACTGGATATAATCAGGTAGAAACTTGTCACGTTTACTTTCAACAATTCT
TCAAGGTTCTCTCTTGCACGTGATACCTGCATTTGTACAGTCCCAGTCAGGCAACAAAGATGGGGGGATA
CATCCAATACCACTTGGATGTAACTGGCCTGCAGTAGCTTGAATACAAAAGGAGATTGAGAGGTACCTCA
GCAGCTGCTAGGGTGAGGGAAAGTTTACCAACCAGTGCTATAAATGTTCACTCAATCTATGTCCATCAGG
AGCTAAATGTTTAAAGTCTCTATTCTCATCTTGGCTTTGAGGTGTTAGATGATTAAAAAAAAAACATTTT
TTTTGTCTAAAAAAGTGGAAGAGTAGATATAAAACATGTTATGTAAACGTCATGAGGAAAGTAACTTACA
GATTTAATTAAAAAGCAGTTTATTTAAACAGGTAAAGGCCCACTATGCTGGGATTCTTCACCACTGTTAA
ATGTTAGAAGTCATAGCAAGTTTAGCTAGTTCATGAGCCATCTCTTCTCTGGCTGCCCCTGGAAGGATCC
AGGCCTACACTCCCTACTGAGAACACTCTTCACACCCCTCTCCTTCCAGCCGGTGAGATAGTCTACATCA
GGTCTCAGGACAAGTCAGACAAGAACAAGAGTACAGGAAGGGCACTGCAGGATAGAAGGGAAGGAGTGAG
GGTCAGAAGTGGATTCCCACTGCCACACTCTGGGGTAGGGGGTGGGGGGATATTAAGTGGTGCCTCTCTC
TACTTGTCCAGATAATTCAGGAGGTCAGCTGATGCTGCCTGTTGTCTAATTCTGTAGAAGATACTGAACA
GCAGGAATCTTTTTTTCAATTTTTTATTAGATATTTTCTTCATTTACATTTCAAATGCTATCCCCACAGT
CCCCTATACCCTCCCCCCCCTCCCCGCTCCCTTACCCACCAACTCCCACTTCTTGGCCCTGGCATTCCCC
TGTACTGGGGCATATAAAGTTTGCAAGACCAAGGGGCCTCTATTCCCAATGATGGCTGACTAGGCCATCT
TCTGCTACATATGCAGCTAGAGATATGAGCTCTGGGGGTACTGGTTAGTTCATATTGTTGTTCCACCTAT
AGGGTTGCAGACCCCTTCAGCTCCTTGGGTACTTTCTCTAGCTCCTCCATTGGGGGCCCTGTGTTCCATC
CAATAGAAGACTGTGAGCATCCACTTTTTGCCAGGCATTGGCCTAGCCTCACACGAGACAGCTATATCAG
GGTCCTTTCAGCAAAATCTTGCTGGTATATGCAATACTGTCTGGGTTTGGTGGCTGATTATGGGATGGAT
CCCTAGGTGGGGTAGTCTCTGGATCTTCCATCCTTTTGTCTTAGCTCCAAACTTTGTCTCTGTAACTCCT
TCCATGGGTATTTTGTTCCCCATTCTAAGGAGGAATGAAGTATCCACATGTTGGTCTTCCTTCTTCTTGA
TTTTCTTGTGTTTTGGAAATTGTACCTTGGGTATTCTAAGTTTCTGGGCTAATATCCACTTATCAGTGAG
TGCATATCAAGTGACTTCTTTTGTGATTGGGTTACCTCACTAAGGATCATACTCTCCAGATACATCCATT
TGACCAAGAATTTCATAAATCCATTGTTTTTAATAGCTGAATAGTACTCCATTTGTAAATGTACCACATT
TTCTGTATCCATTCCTCTGTTGAGGGACATCTGGGTTCTTTCCAGCTTCTGGCTATTATGAATAAGGCTG
CTATGAACATAGTGGAGCATATGTCCTTATTACCAGTTGGAACATCTTCTGCGTATATGCCCAGAAGAGG
TATTGCTGGATCTTCCGGTAGTACTATGTCTAATTTTTTGAGGAACAGCCAGACTGATTTCCAGAGTGGT
TATACAAGCTTGCAATCCCAACAGCAATGGAGGAGTGTTCCTCTTTCTCCACATCCTTACCAGCATCTGC
TGTCACCTGAATTTTTGATCTTAGCCATTCTGACTGGTGTGAGGTGGAATCTCAGGGTTGTTTTGATTTG
CATTTCCCTGATGATTAAGGATGTTGAACATTTTTTCAAGTGCTTCTCAGCCATTCAGTATTCCTCAGTT
GAGAATTCTTTGTTTAGCTTTGTACCCCATTTTTAATGGGGTTATTTGAATTTCTGGAGTTCAGCTTCTT
GAGCTCTTTGTATATATTGGATATTAGTCCCCTATCAGATTTAGGATTGGTAAAAATCCTTTCCCAATCT
GTTGGTGGCCTTTTTGTCTTATTGACAGTGTCTTTTCCCTTACAGAAGCTTTGCAATTTTATGAGGTCCC
ATTTGTCGATTCTCGATTTTACTGTACAAGCCATTGCTGTTCTGTTCAGGAATTTTTCCCCTGTTCCCAT
ATCTACGAGGGTTTTTTTCCCACTTTCTCCTCTATAAATTTCAGTGTCTCTGGTTTTATGTGGAGTTCTT
TGATCCACTTAGACTTGAGCTTTGTACAAGGAGATAAGAATGGATCAATTCGGGCTGGAGAGATGGCTCA
GTGGTTAAGAGCACTGACTGCTCTTTCAGAAGTCCTGAGTTCAAATCCCAGCAACCACATGGTGGTTCAT
AACCATCTATAATAAGATCTGATGTCCTTTTCTGGTGTGTCTGAAGACAGCTACAGTGTACTTACATGTA
ATAAATAAATAAAACTAGATTATTTAAAAAAAAAAAAAAAGAATGGATCAATTCACACTCTTCTACATGA
TAACCACCAGTTGAGCCCGCACCAATTGTTGAAAATGCTCTCTTTTTCCCACTGGATGGTTTTAGCTCCC
TTGTCAAAGATCAAGTGACCATAAGTGTGTGGGTTCATTTCTGTGTCTTCAATTGTGTTCCATTGATCTA
CCTGTCTGTTGCTGTATCAATACCATGCAGTTTTTTTTATCACAATTGCTCTGTAGTACAGCTTGAGGTC
AGGCATGGTGAGTCCACCAGAGGTTCTTTTATTGTTGAGAATAGTTTTTGCTATCCTAGTTTTTTTTTTT
TTTTTTTTTTGAACAGCAGGAATCTTATTCTCAAATTGAATCTATTCCTAGAAAGAACTGACTTCCTTTT
CCATTTTACTTATAGGAAATTTGCCTATTGAAAATTTCCTCTGGTCTTCTGGAGTACCATAGCTACCTGG
AGTACATGAAGAACAACTTAAAAGATAACAAGAAAGACAAAGCCAGAGTCCTTCAGAGAGATACAGAAAC
TCTAATTCATATCTTCAACCAAGAGGTGAGTGCTTCCCCATCTCTCATGCAGTGTGGGAAAGAGGACACC
CGGCACCTCAGGGTAGCGGCACTTTTTCCAGACAGCTGCTCAGAAGGGAGAGAGTCTGAACAACAGTTCT
TGATTATAAGGCCTTGCTTTGTTTTACTTTGGGGTTTTGTTTGAGGTTCTCTTTTGCAAAGAACATCAAT
ACCTGCTTTAAACTGTATTAATAGAATGTTACTAATTGCGTAAGAGGTATGAAAACTATGACAGCCATAC
ATAGTCACCCATTATGAGAGCACAGAGACAAAAGTGACTTTAATATTTAATCCTTGGCAAGTGACATTTT
TGTAACCAGAGTTCTAATGCAGAGAAGTAGCCAAAAGCTAAAATGTCAGGGAAGGAAGGGATCAAGGGCT
TCTGGCTACCATTAGCCAGAAGAATGGTAGATATGGAGGATTAATGACTCAGAGTGTGGGCGAACAAAGC
CAGATGCAATAAGAAGGGCCTGGAATGAAACCCTCTTGCTAAGGCTGCTTTTGCCACTTGTAGTTTCTTG
CCTTAAACCAGAGAGTTTCCCAATTTAATGTGCACAGGAACCACTTAGGGTCTTGTTCCAGCAGGGTCTT
ACTTAGGAGGTCTAGGAAGGGAACTAAGATTCATTTTTGTAAACAGCTGCTTGTTTATGACCCTGCTATA
TAGTATTCAGGCTCCTAAGTAGTGGGGCAAGCCTTCCAGTTAGTCTTCCCCATGCCAGTGGGCCCATGGA
AGGGTGTTTCCAGACTTCTTCATGCTACCACACTAAGAGACTCTCAACAGAGTCTGAATGGAAACCACGA
AGGAACACATTTGTTTTAGATTCCTCTGTGCCACCTTTACTGATGGGAGCTTCTGTTTTCCAGTAGAATA
CAGTATGTTAGCATGGATGCTTGGATAACAGACAAATAAGATGGTGGTGCTGACCTCTGGACGCTTACTC
TCTAGTGGCAGACAGAACAGTAAGGTTAGAATTCTGTTGCTATTAAAAAACTAATAATAATCACCTTGAA
AAAGAATGGAGTTGTTAGGCATGGGTCTCTCTCGAGTAAGCTTGGAACAAAAGCATCTCCCCTGGCTTGG
GTGAGTCAAAGCAGATGGACTTAGCTCGTCTCATTCATTCTAAATTAGAACTTCTTCCCACAGCCCAGAA
CACGCCACAAGAAAAAAAAAATGTGCAATATTTAACCAGTCTTTGTTTTTTCCTCCTTTAGGTAAAAGAT
TTACATAAAATAGTCCTTCCTACCCCAATTTCCAATGCTCTCCTAACAGATAAGCTGGAGTCACAGAAGG
AGTGGCTAAGGACCAAGACCATCCAATTCATCTTGAAATCACTTGAAGAATTTCTAAAAGTCACTTTGAG
ATCTACTCGGCAAACCTAGTGCGTTATGCCTAAGCATATCAGTTTGTGGACATTCCTCACTGTGGTCAGA
AAATATATCCTGTTGTCAGGTATCTGACTTATGTTGTTCTCTACGAAGAACTGACAATATGAATGTTGGG
ACACTATTTTAATTATTTTTAATTTATTGATAATTTAAATAAGTAAACTTTAAGTTAATTTATGATTGAT
ATTTATTATTTTTATGAAGTGTCACTTGAAATGTTATATGTTATAGTTTTGAAATGATAACCTAAAAATC
TATTTGATATAAATATTCTGTTACCTAGCCAGATGGTTTCTTGGAATGTATAAGTTTACCTCAATGAATT
GCTAATTTAAATATGTTTTTAAAGAAATCTTTGTGATGTATTTTTATAATGTTTAGACTGTCTTCAAACA
AATAAATTATATTATATT

Protein Sequence : Show Sequence

>gi|13624311|ref|NP_112445.1| interleukin-6 precursor [Mus musculus]
MKFLSARDFHPVAFLGLMLVTTTAFPTSQVRRGDFTEDTTPNRPVYTTSQVGGLITHVLWEIVEMRKELC
NGNSDCMNNDDALAENNLKLPEIQRNDGCYQTGYNQEICLLKISSGLLEYHSYLEYMKNNLKDNKKDKAR
VLQRDTETLIHIFNQEVKDLHKIVLPTPISNALLTDKLESQKEWLRTKTIQFILKSLEEFLKVTLRSTRQ
T

Molecule Role : Vaximmutor
Related Vaccine(s): HIV priming with DNA vaccine expressing HIV gp160 protein and boosted with Ad5/35 vector expressing the same protein

14. Il12a

Gene Name : Il12a
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 16159
NCBI Protein GI : 226874945
Genbank Accession : AC121306
Protein Accession : NP_001152896
Taxonomy ID : 10090
Chromosome No : 3
Gene Starting Position : 68690643
Gene Ending Position : 68698546
Gene Strand (Orientation) : +
Protein Name : transcript variant 1
Protein pI : 8.33
Protein Weight : 25111.9
Protein Length : 236
Protein Note : Also known as p35; Ll12a; Il-12a; IL-12p35; MGC151228; MGC151232

DNA Sequence : Show Sequence

>gi|372099107:68690643-68698546 Mus musculus strain C57BL/6J chromosome 3, GRCm38 C57BL/6J
CTGCCACCTACTCCCTTGGATCTGAGCTGGACCCTTGCATCTGGCGTCTACACTGCTGCTGAAATCTTCT
CACCGTGCACATCCAAGGATATCTCTATGGTAAAAGTCCAGAAAGGCTAAAGATGTTGTCCACAATCTCT
CGGCAATGACCAGATATATCCCCACCAGTATCACAACTTGCAACGCGCTCCGTTCCCATCTGCCCTCTGC
CTCCCTACTGTGTTGATTCCCATTTCCAAAACTAGCTCAGAATGCATCCCACTGGCAGCCAGGCAATGCC
TTCTTGCAGATCTGGAGGCTTCAGGAGCCTTTGCTGCCTCTTAGGCTCCTGCAGAGAGATGGCCTTGCTC
TCTCTGGGCCCTTTTCCCCCAAGATGCTGTGCAGTCGTCTCACTAAATCAAAACTGCCAGAACTGAGTTT
TAAGCGATATATAGCCACCACATCTATTTTGTTCCTTTATACTTTCAAAGTAGGACAGATTCGCAAAATA
CATTGAGTCAGACTCAGTGTCCACGATGGAGAGACGAGTGGGTAGCTTGTGCTTCTTTAGAAGGGGCACT
GGGCAGCGTGTTAGGGCTAGGGGGTAGTGGGGCAGGACAGACCTGTCCCGGGACAAGAGTGGCTACTCGC
AGGCCGGTTTTGCTTTCGCTCTGAGTGTGGTGGGCGGTGGGACGGTCCCGAATCTCCTCAAACGGGCACT
CCGAGAGTTAATTCGAAAGCGCCACCAGCCTTGGGGGCGATCGACGCACTTGTCCTTGAGATGTAGAGAC
AGAGAGAGAAAGCAAGAGACACAGTCCTGGGAAAGTCCTGCCGGCTATCCAGACAATTATAAAAATGTGT
CTCCCAAGGTCAGCGTTCCAACAGCCTCACCCTCGGCATCCAGCAGCTCCTCTCAGTGCCGGTCCAGCAT
GTGTCAATCACGCTGTAAGTACCTGAGGGCCGGGACCAGGGTGACTTGATGAGAGGAGAAGGCTTGAGAA
AGAACAGACAGAAGCCCTGGACCCATTAAGGGAGACTAAAGGGCTGCCAGCAACTGCAGGCCAAGGGAAG
GAAGAGGGGAAAGATGGTCGTGCTAGATTGCGCTGCACCGAGCATGGTCTCATTATAGAACAACCCTGGG
GGCTACGGCTATGCCCGTTTCACAGAAGAGAACTAAAGCCCAGCCTTGAAACCAATGTAAGGAAAATGCA
GGTCTCAGGCAGTCCCCAAACAAGATCTGGGAGGTCTTGCTTCATCTGTCAGCCCCGGGGAAGGGCTTAA
ATTATGTGTGGAGGGAGGTCAGTACCCAGAATGGATGGAAAAAATTGCCAGAATGGCTGAAGAAAGAGGC
AGGTCAAAACCAAGTTGACAAGCTCCACCTGCCCTTTGTTTCCCTTCCAGACCTCCTCTTTTTGGCCACC
CTTGCCCTCCTAAACCACCTCAGTTTGGCCAGGGTCATTCCAGTCTCTGGACCTGCCAGGTGTCTTAGCC
AGTCCCGAAACCTGCTGAAGACCACAGATGACATGGTGAAGACGGTGAGTTTCTCCTGTCCTTCTGGCTT
CAAAGTTCCGCTGTTGACATGACTTCTAACCTATCTGGTATCTGCTGGGAAGTTTATGGTATCTGGCAGG
AACCGTAGAGGGTTTCAAGACTTCTAAATATAATCTAAAGGAAACTGTGTCTCTAGAGAAAGGAAGAATG
GTAATAAATTGTAACGGCATCGGTTTAGGCTGTGTCTACACAGAGGAAAGTGGGGACTTGCAATGTCCCT
CCCAGCCTGCCTGCCTGTGTGACACAGTGTCAGGTGCTCCCTGCTTCTGCTTCAGGGCAGGTGGAACAGG
GAGACAGTCTCTAGGTACACTCTCTGTGCTTCACAAGCCATAGAGATGAATTAGATTGTCTCTCCCCCTG
CTCACCAGTGTCCAGCACTGTGATGCAGTCCCTTGTCGGATGGACACATGTCAGGGAGGACTCAGACATC
AGATAGCAAGCAGGTCCAGCCTCCAGTTTTCTGGGGCAAGTGTGATCCAGTTTTAGTCACGGCTCCACTC
ATTTTTCTCAGGTTTCATGTTTGAATGCAAAATAGCCTTTTCCGTTGTAAAATTGCCACGGTTTCCTCTC
GCTTTGGGGACAAAGCTACAGCAAAATGCTAATGTGTTTGAGATATCCTGCAGCTGCTAGGGCTGGAGAT
CCAGTAGAATTCTGGCTTAATTATGAATGGGTCTCCCGGGTTCTATCCCCCAACAGAGCGTGCGTTCATA
AGCACCTGGGAACAGAGGAGGGAAGGAGGGAAACTCTGTCTTCCTGTTTTGTTTTTAAATCTTTCTTGAG
GATCTTCTAGCTTGTTGTCTTATGGCTATCCCAACATAAGCTCCGCTCCACAAGCCCTTCTTGGTGAATT
TTCTTTCTTTCCTTCCCGTCTTGCATAACGTGCTGCTGGCTGTTCCTCCAAGCTCAGTCTTAATTGAGTG
GGGTTCCCAGGAGGGAGAGATGGCTCTGTGGTTAAGAGAGCTGGCTGCTCTTCCAGAGGTCCAGAGTTTC
CACACCCTCATGGTGGCTCACAATCATGGTAACTCTGATCATAGGGAACCTGTCGTTTTCTCTGTGCCTC
TGTGGGCACTGAGCACATGCCACACAGACATCCATGCAGGCAGAACACTCTTGGCCATGAAACCTTAAAA
TGAAGGAGAAACCTTACGAGAGGTTCCCTAAGGAATCCCTGCAGAAGGGAGAGATTGTTTTCCTAAGATG
AGGTTTGGTGTGGAGGGGATGAGGTATTCAAAGTTAACTAGCCGCTCCTCACTCCTCTGCTGCCAAATAC
CAGCACTGGGCTTCGAGACACAATAGAATTCGACCTTGTTTTCGTTTGGGTCACTATTGCTCTCTAGTTG
AACACGGAATCCACGGGGGCACATTGCTGTCTGTCCTTTGTCACACCCCAGGACCACAGCTGCATGGAAA
AGTCATCGCAGGCTTCAGTCAGAGAGCTGTTGACTTCCTAATATGTTGTGTAATTCTGTTCAGTGGTGCT
TTCCAGCACACCAGGGAATAAGAGACAGTCCCCGCGTATGTAAATTAAAGCTCAACTAGTATTTAGGGCT
TGCAAGTTTGTTACAGCCATCAAGCTGTGACTTTAACAGTTTCCTCTTTAGAAGTTAAACTTGAAAAAAA
ATAGAGGGAGAGAGAGATTCACAGGGCACAGCTGCTTGGAAAAAGGAAAAGCCACAGGACTCACCAGAAG
CAAGCAGCACAGTGTGGCACTGATGCTGATGAGTACAGCCTGCTGCACCCCAGTGTTCACATGGTGAAAA
AAATACCCTGCTGGCGGACAGCCTAGGCAAAGGGGGAGGAGAGTAGGGAGAGCGTGCGGGAGGTTGGGTT
TCTTAGCTTATGAAGAGCCTGAGTTTCCTACAGGCCAAAGAGATGACGGTTCAGAGTGGCCAGCCTAGGC
TCTGCTGATCCACTGCGATGCAGGTCTCAGAGGGAACCAGCTGTCTTGCTGAGAGATTCACCTCAGCTTC
TCCTTATGTTTTTCCCAGGCCAGAGAAAAACTGAAACATTATTCCTGCACTGCTGAAGACATCGATCATG
AAGACATCACACGGGACCAAACCAGCACATTGAAGACCTGTTTACCACTGGAACTACACAAGGTATGGAG
GACCCCCACCCAAAAAACAACAACAACAACAACAAAAAACACAATTAAGAGCCGTGCAGCCAACCTCAGC
TGTCTCCAGATACTTACTTGTAGCTATCAAACGTGAGAGTTTTGAAGAAAAAAAAAAAAGTCAACAACCA
TACAAATACTTCTACAAGCTGAAGGATATACTCGGTAACTAGGAGGTGGCTATGGTGGTATAGACCTTTA
ATTCCAGCACTTGATGGATAGAGGAAGGCCGGCTCCTGTTAAGTTAGAGGCCAGTCAGGGATACACAGCA
AGATTTCATCTTTAAAAAGAAAGGGGGTGGTGTGGCGGGTGAAGCTTACTTATTGAAGTGCTCATGTCAC
AAGCCTGGGGACCTAAGTTCCCATCCCCAGCACCCATGTAGGAGCTGGGTGTGATGGTTTCACATGCAGA
GACAGGAGGATACCTGGGCCAGCTAGTCTAGCCGAATCCATGAGCTGCAGGCCCAGTGAGAGAACCTGTA
TCAGAAAACAAGAAAGTCAGGAGAGCGGCTGAGAAAGACCCCAAAGATCATCCTCCGATTTCCACGAGTA
CATGCACCTGCACACACGTGCACACAGGAATCCTATACATAGCCACCCAAAAGCAGTTATGATGGTGAAG
TTTCTTTTACTGGAATGAAAAGTTAGTTTGAGAAAAAAATATCAGAGAGATTTATATTAAGAGTGAATGG
GTGGGGGGTATGCATGCCTTTAATCTCAGCACTTGATAGGCAGAGGCAGATGGATCTCTGTGAGTTCAAG
GCCGGCCTGGTCTACAGAGTAAGTTCCAGGACAGCCAGTGCTACAATAGAAACAGGTGATGGTGATGATG
GTGATGATGGCGGTGATGATGATGATGATGACGAAGACAAACTCCTCGGTTTATGATTTTCTTCTAGAAC
GAGAGTTGCCTGGCTACTAGAGAGACTTCTTCCACAACAGTAAGTAAGCACTCTAAGGGTTCCTTCCCCA
TGACGGATTCATAACACTGATGCCTGGTCATTCTTTCTCTAGAGAGGGAGCTGCCTGCCCCCACAGAAGA
CGTCTTTGATGATGGTAAGCCACATCACTTTTCTGAAATGCAGCAGGGTCCTGTAGTTCCAGCCCATCTC
AATGATTCCTTGCCCATTGTGTCCTGCGCTCTAGACCCTGTGCCTTGGTAGCATCTATGAGGACTTGAAG
ATGTACCAGACAGAGTTCCAGGCCATCAACGCAGCACTTCAGAATCACAACCATCAGCAGATCATTCTAG
ACAAGGGCATGCTGGTGGCCATCGATGAGCTGATGCAGGTAAGCCTTCCTCCTATCAGCCAGCGCTCCTT
TTCCATGGTGAAGAGAGGTCCTTTATTAGATATGATAAAATCAGCACAGCTTGGGTTGGGAGAGACCTGA
ACACCCCCACCCCACCCCACACCCTCATCCCCCAACCATGAAAGGCCTTGCAAGGTTACATTTGCTTAGA
GAGCCTTGAGGGGGCCTCTACAATAAGGGCAAATGCAAGCAGCCTTCTACTTGTTGACTCATGATACAAA
TCAGGCACTTTTCAAATGCTTCTTCTCATACCATCCCCACAACAAGCAAATAAGGTCTCTACAGAGGAGG
AAACTGAAGCTTAAGAGGATGAACGAGGGTTCCCTACAAAAGGGTTTTTTGTTGTTTGGTTTGGTTTGGT
TTGGTTTGGTTTGGTTTGGTTTTTCCGAGACAGGGTTTCTCTGTATAGCCCTGGCTGTCCTGGAACTCAC
TTTGTAGATCAGGCTGGCCTCGAACTCAGAACTCCACCTGCCTCTGCCTCCCAAGTGCTGGGATTAAAGG
TGTGCGCCACCATTGCCCAGCTTATTGTTGTTTTAAATACATTCTTTTCTTAAAGGTTCAAGATTAGGAC
TGGAGAGACAGTCCGATGATTAAGAGGACTTGAGTTTGGCCTGGGGCTCCTATGTAACAAACAGGGTGTG
GTCCTGAACTGCTCTCTAACTCCAGAGAGTGGAGACAGGAGGCCTATGGAGGCTTTCTTGCTGCAAGTTT
AGCCATGAAATCTCCAGGTTCAGGGAGAAAGCATGCCTCAAAGAAATAAGATGGAGAGTCACGTGATCTC
TTCTCTGGCTTCTGCATGGTGTAGGCACAGATATGCACATGTTTGAGTGCATACAATACAGGCAAACATA
CACGTGTCCTTTTTAAAATGTATAGGATGGACATTCTAGGGGCTGCACACATATTCAAATATTACTAGGG
GAAGCACTTGGGGCTGGTGTCCAAGTATAATCTATTTTGAACCAAAATGTGACCAAAATGAAAAGTGGTC
TTACATCTAGGTAATTACAGTGTTAGGTATCCGTGGGAACTTTGCTGTACCACCAGTAACACAAAGCACA
GGAGTGTGCACACCAGAGACAAGCACCTTGGCAACCAAGGCGTGGGATGAACATATGTTCAGAAGTCACT
GCCTGGAAAGCAATTGTTTTTCATTTCATACATACTGTCTTGCACAGGGTTTCTATGTCTTAGATAAAAT
ATCATGACGGAAAGCAAGTTGGGGAGGAAAGGGTTTATTTCATCTTGTAGAGTGTAGTGAGTCTATTACC
CAGGGAAGTGGAGGCAGAAGCTGATGCTGGAGAGGACTCCTGGTGACTGGAGTGCTCCACATGACTTGCT
CAGTGTGCTTTGTATAGCACCCAGGACCACCAGGCTAGGGTGAGCTGGTGCCTCCCACATCAACTGTCAA
TCAAGAAAATCACCAGAGGCTTGCCCACTGGCCAATCTGGCTGGAGGTGTTTTTCTCAATGACCACAGGC
TTGTGTAGAGTTAACATAAAAGCACCCAGGACATTACATATTGCCAGATGACTCCTTTGAAAGACAGTGA
AGTTTATGCAGGTCAAACAACCTATCATGTAGAGATTTGTAATGGATATTGCATGAACAAGGCCAGAAGT
CAGGTGATTTGGATAGTAGGAAGAGGTCTACCAGGGACCAGCCAACTATGCTGACAGGGTTAACTCTTGT
CAGCCTGTTTGTAAAATAAGATGACTTTAAATAGCCTATGTCTCTCTTGAGATTTTTGTGAGGAGCAAGC
AAAAATCTTAAACATCACAGAAACCTAAGTTCTTATTCTATGTTATGAAATCAAAGGATCGAGTGGGGAA
ACACGGTACTGGCTTGTTTATCTACCACAAATAGCGTTTCTATCAGAGATAGGTCTGTTGTTGATAATAA
GCTCTAATCCATAGATCCTACTTACCCTCCAACTCCCTCCTCTAAAAGAACAGGACTTCTTAACATAATT
TATAAAAATTAATTAGCTATTGCTGCAGGTGCTACCTCATAGACTCACACCTTCTGAGAGATCAGCTCTA
ATGACAATTTCTTTCTGGAAAATTTAGGGGTCTTGTCAGAGATCATTAAAAACATAGGTATATGCTCACA
AAAGAGTATTTCTTCCCTCTTTTCCTGCAGGAACACAGCAGGAGTAGATGTGAAATGGGTCTAGGAGTGT
GATGAGGGGCTAGGTTGCAGGCCCTGGACTTTGCATTGACTGTCTCCCATTTTGCAGACAAACATTCTAA
TTTTTAAATTGTGCATATGCTATGCTTGGTGTTTCTTTCTAGTCTCTGAATCATAATGGCGAGACTCTGC
GCCAGAAACCTCCTGTGGGAGAAGCAGACCCTTACAGAGTGAAAATGAAGCTCTGCATCCTGCTTCACGC
CTTCAGCACCCGCGTCGTGACCATCAACAGGGTGATGGGCTATCTGAGCTCCGCCTGAAAGGCTCAAGGC
CCTCTGCCACAGCGCCCTCCTCACACAGATAGGAAACAAAGAAAGATTCATAAGAGTCAGGTGGTCTTGG
CCTGGTGGGCCTTAAGCTCCTTCAGGAATCTGTTCTCCCATCACATCTCATCTCCCCAAAGGTGGCACAG
CTACCTCAGCATGGTCCCCTCCATCGCTTCTCTCATATTCACTATACAAGTTGTTTGTAAGTTTTCATCA
AAATATTGTTAAGGGGCGAAGACGTCCTCCCCTCAATGTGTTAGCAGAAGAGCAAGAACTGATAAGCTAT
TGTTTTTGTGCCAAAGTGTTTATGAAAACACTCAGTCACCCCTTATTTAAAAATATTTATTGCTATATTT
TATACTCATGAAAGTACATGAGCCTATTTATATTTATTTATTTTCTATTTATTATAATATTTCTTATCAG
ATGAATTTGAAACATTTTGAAACATACCTTATTTTGTGGTTCTAATAAAGTAATGTTATCACTT

Protein Sequence : Show Sequence

>gi|226874945|ref|NP_001152896.1| interleukin-12 subunit alpha isoform 1 [Mus musculus]
MVSVPTASPSASSSSSQCRSSMCQSRYLLFLATLALLNHLSLARVIPVSGPARCLSQSRNLLKTTDDMVK
TAREKLKHYSCTAEDIDHEDITRDQTSTLKTCLPLELHKNESCLATRETSSTTRGSCLPPQKTSLMMTLC
LGSIYEDLKMYQTEFQAINAALQNHNHQQIILDKGMLVAIDELMQSLNHNGETLRQKPPVGEADPYRVKM
KLCILLHAFSTRVVTINRVMGYLSSA

Molecule Role : Vaximmutor

15. Il2

Gene Name : Il2
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 16183
NCBI Protein GI : 7110653
Locus Tag : DN-144H19.3
Genbank Accession : AF195954
Protein Accession : NP_032392
Taxonomy ID : 10090
Chromosome No : 3
Gene Starting Position : 37120712
Gene Ending Position : 37125953
Gene Strand (Orientation) : -
Protein Name : interleukin 2
Protein pI : 4.63
Protein Weight : 18506.61
Protein Length : 169
Protein Note : Also known as Il-2

DNA Sequence : Show Sequence

>gi|372099107:37120712-37125953 Mus musculus strain C57BL/6J chromosome 3, GRCm38 C57BL/6J
ATTTTTTTTTAGAGGAGAGCTTTATTTCTTGAAAACACTGATTAACATAGAGTTCACAGGAATAACTGAG
AAGTTATTTTAGCGCTTACTTTGTGCTGTCCTAAAAATGACAGACATCTGAGCTTATTTATATTTGAATC
ATCTAAATACTTTTATTAATGAGTCTACCTACACATGATATTTAACAATTCAATATAATAAATAATTTCA
GATAAATAGTTTAAAACATTTTTGAGCCCTTGGGGCTTACAAAAAGAATCTTTAAAGATCCATATTTATC
ATCTGAAGACTAGTAGTTACAAAAGATAGTAAACAATACATCCAAAAATAAATTAAAGTTAAATATTTAA
ATAAATAGAGAGCCTTATGTGTTGTAAGCAGGAGGTACATAGTTATTGAGGGCTTGTTGAGATGATGCTT
TGACAGAAGGCTATCCATCTCCTCAGAAAGTCCACCACAGTTGCTGACTCATCATCGAATTGGCACTCAA
ATGTGTTGTCAGAGCCCTAAAAAAGAATATAAAATTGTAGGCTAAGGTAGCTTACTTTGCATATAATTAT
TCTTCACGGAAGCTTTTAGGCATTTATTTTAACACTGGTTAAATATATTGAACATTCACATTTCTGAAAT
GATCACAATTATTGGGTTATGTTTTATTATGATATCAAATGGTAAAGCATAAAAAATAAAGCTCTCCAGA
GTTGATTACCAACGAGCATTTGATGGGAACACTGAACACTTCTGTAGAATTCAGTTGCTTGACCACTTTT
TCTCTGGTAAGTGTACACAGCTATGCATCAATTTAGGCTTCAGGAATGGAGAAATGATACTTGTTATATG
TTCTTTGCTAAATCTTAAGAGTCTATTATTCAATTCTTTCCCCCCCAAGTCAGAATGGGAACAACCCAGA
GTAGGTTAGGACAAGCATCTATTGGGGGAAATTTGGAGAATTTTGTTATAGATATACCTACCCTGATACC
AGTGTAGATGAATCACAAAGTTTGTACATGTATAAATATTATAAATTTGTTCTGTGGATTAGCTTTTTGA
AAGCTAACCCTCTTTGCTAAAGGAGATATTTTAATTCTGTTTTTAGGTGACAAGCTGAGAAGGAAATATT
TTGACAAATTTATGGGATGGCTTTTCCAAATCTGACTAATTCCTTGTAAGTCAAATGAGGCAGATTATTC
CTTTTAAATAAATACTCCTTTTCAAATAAGCTGCTGTGGTCTTATATACCCTCTTTACATAGCTACTTCA
ATATTCTAATGTCTTGAATTTTTCATTTTTAAAAATATGTGGCCCTTGAAACATTTTTCTAGTTCTCATG
TAGCTCTAAAGTTTGTACCATTCATTAGGGGTGAACTTTCTGATGTTGGCCATAGATTTTAGAGCATCCA
TCTTTGCATACGTAAGTACTCGATTTTAGAGCATCCATCTTAGCATACGTAAGTACTCACACCTTTCAAC
GTCTAGATGATGTGTATTTCAGCCTGCTTTAAAAACCTCAAATGGAAGCTGGGCAGTGGTGGTGCAGGCC
TTTAATCCCAGCACTTGGGAGGCAGAGGCAGGCGGATTTCTGAGTTCGAGGCCAGCCTGGTCTACAGAGT
GAGTTCCAGGACAGCCAGGGCTACACAGAGAAATCCTGTCTCAAAAAAACAAACAAACAAACAAACAAGA
AACAAACAAACAAAAAAAACAAAAACAAACAAAACAAAACCTCAAATGGAAACAGTGCACTGAAATGTGA
CTTTGGTTTGGAAAGGACTAGCCCACACCCTCTTGGAGGCTTGCTGCTACTGTCTCACCAGAGTCCATGA
TTCTTGTGCATTTAAAAACAAAGCTCTGCAGTGGGCTCTCCCCGTCCTGCTCTGTCCATTTTAATGGCTG
CCATTTTTGGAGAGAAATGTCTGTTTTTCTACCAATACCAGCACAACTTCTCTGGAAAAACTTTTCAGAT
AATTTTTTCTGATCTGATGAATGTAACACCAGCAAGAGTTGCTTGTTTCTTGTGGAATTCTACTCCGTGC
TTTCTCTCACATCCAGTTCTATGCTGGTGTGGAGGGAGCAGAGTGTTCATGTTCCCAGTTTCCTTGCAGG
TGATGGTAGGTGGAAATTCTAGCATCATCCTACAGTGGAAGGATTCACTTGCACAGTGACTTTAAACTTT
GGCTGACTAAATGCACAGAACCCATCAAAGACCAGAAATGGCAAGCCACTTAAAAATGCATTTCTTCTCT
ATTTTATTTCCAGATTAGCAAATAAAGCAACACCTTACCTTTAGTTTTACAACAGTTACTCTGATATTGC
TGATGAAATTCTCAGCATCTTCCAATTGAAAGCTTTTGCTTTGAGTCAAATCCAGAACATGCCGCAGAGG
TCCAAGTTCATCTTCTAGGCACTGAAGATCTTTCAATTCTGTGGCCTAGAGGAGTAATAAGCTTAACCAT
CAGCTCAGCTCACCACATACTGAAGAGCCAGAAAGTTAGTCTGCAGTCTCTCTAATCAAGAGAAGGCAGC
ACATAGCTTTTACCACTCCCTGTCCTCTGTAAAGGGGGACTGAGGTAATCGATGCCATAAATCTAGAAGA
GCAAGAGCTCACAACCATAAGGGTCACCTTGACTGTTAGGCCACTCTAGTGAGCTCTTCTGGCTTCATTA
GACTTTGTAAAAAGTCTGTGTTTCTCTACCAATGCATAGCACAAGTTCAGACTATTGTTCCAATCTACAA
AGAAATCTGCAAGGTTCACATTCTAATATCTAATCGCAGAGTTGAGAATCACAGAAGGGTAAGGGACAGG
AATCCTTGGATGCCAACTGTCATAGGCCTAAATCTTACAGATTAGGTTATCATGGCCCTGACTGAGGGGT
GTCAAGATAGCCAGGAAGACACATGTAATATTTTTTAAATTTATACTTCTCTGCAATTACTAAAGATGAG
TTTTTTAAAAACCCATATGTCAAGCTAGGAAGATGGCTTTTAAGGTAAAGGTACCTGCCACCAAACTTGA
TGATTTGAGTTCAATTGCAGTGACCCACCCACATTGTGGAAAGAATGGCCCAACTTTCATATTTCGTCTT
CTGACCTCCACAGTTACACTGTGATACACATGCACCTCCACACATACATACATACATACATACATACATA
CATACATACATACATACATACATACATAAAATGTAAAATCTATTTGTCCCAATGAAAAAAGTCATAACAT
TTTGGCAGAACACTTGGGAGAATTTTTCTGATCCATGTATGAAATAATGTTTAAATACATCATGCATACT
TACATACATATACAGGGAAAAAGGATATTGTCTAGCTCTATAGTACACTATGATTTCCATAAAGTCAGCT
GCTTTAAGTCTACAGTGAACTGTGTTATCTCCATTTTACCAAGTCTCACAATCAGTGTCTTTCCCACAAC
CACATGAACGGGGAGCAAGGGTGGCCCGGTCGGTCGGTCGCTCCTTTCATTAACCACAGCCTTTGAATTA
CATGCTTCTATTGTTTTTAAAATCTTACATACCGAATGCAGGTTAAATGAAAACATCAGCAGAATTTACC
ACATTACTCTTGTTTTCAATAATTATTTTAAAACTTAGATTTCTAGGAATTTCACCACTCTCTAAATTAA
CATGATCTCTGTTGTTTCTCTAACAATCCTTAGAGGAAGAGGTTTGACAAGATAACACGTAGTTCCTGAT
TGGTCTGCTATTGACCTTCCAACTTGTTATGGTGTGTCTTGGGTATTCAGTGTGGAGCTCCTTCCCTCAC
AGAACTCTCCAGTTTGTTACTGTGGGAGCTGAACATTATGTGACTGTAATTAAGCTGGAAGAGCAACTGG
GGCCTTTCTTTTTCATCTCCTGTAGAACAGCTAGAGGCAAAGTTCCCCTGACTCAATAGGAATGGGTCAA
CAGCTGCCTCTTTGTCCCCTTAGATCCCATTTTGCTCTAGGCTTGGATTTACTTGGGACAAGCTCTTTCT
AGGACCAAAGTTATCCATTCTCTTTTGACTTTCGGGACTAGAGCAAATTTCTACCCTTGCTGGAGTTCTA
AGAGCTTGTGTAAGCTGTTTTGTATCACACAACATTCTGCCTCCAAAGGAGACCAAAAAACCTTTCAATA
TTGAGAGATAGTATCATGTAGTAATATTACAGCTCTCTAGTTCCACTAGTTAAAAGAGACTGTATAAATC
CAAAATTGTTTTATACATCTCGGACTTCTTCTCTAGCACTAATAGTGTGTTTATGTGCTGTTGGCCAGAC
ACTGTTCTGAAACCTGACAAGTGATAAGCATAGCAATGATCATTTATGTAAGTGGGTGAATGAGCATAGA
CAACTTCCTGAGGCCATGAGAGCTAGGCCCTAGCAGGGCTGGACTCCACTGCAGATCATTGGCCCTAGAA
TCTTAACATTGGTTATGCTGCTCCTCAAAAATGCAGTCATAGGAATCATTCTTAAAACAGTAAAGTGTGT
GTAAAATGAGACCCTCTCAAGTCAATTTTTACATTTAAGAAGCTGAAATAATGCACCTCTCTCAAATATC
TGTAGGACAAGCATAAAACAGAAATCAACAGTCTTTAAATTATCCCAGCATCAAAATGCAATCATCTTGC
ATTTTCTTCTCATTCCCTTTCCCAACACATAAATACACAGGAAAAATGTAAAGAAAACCATTTAAAAGAA
GTACCATTGTCAAGATTTTTTTACAGAGAGATATCAGAGAAACTTATTTTCTTCAGATGAGGTACTATTC
ATCTGGTCACATGTTATTTACACGTTATACACATGTATGTTACTTTGAATTCATTAGAGCACCAGTTAAA
CACAGAAACTCACTCACCTGCTTGGGCAAGTAAAATTTGAAGGTGAGCATCCTGGGGAGTTTCAGGTTCC
TGTAATTCTGAGAAAGCGTAACACATTATTATTAAAGGTTATTAAACACAGCCTTTGGCAAGAAAGCTAA
AGGTATTGCCTATAGATGGGATGGCTGTGCACTTACCTCCATCCTGCTCAGGAGCTCCTGTAGGTCCATC
AACAGCTGCTCCAGGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGTGCTTCCGCTGTAGAGC
TTGAAGTGGAGCTTGAAGTGGGTGCGCTGTTGACAAGGAGCACAAGTGTCAATGTGACACAGGATGCGAG
CTGCATGCTGTACATGCCTGCAGGACTTGAGGTCACTGTGAGGAGTGATTAGCAAGGGTGAT

Protein Sequence : Show Sequence

>gi|7110653|ref|NP_032392.1| interleukin-2 precursor [Mus musculus]
MYSMQLASCVTLTLVLLVNSAPTSSSTSSSTAEAQQQQQQQQQQQQHLEQLLMDLQELLSRMENYRNLKL
PRMLTFKFYLPKQATELKDLQCLEDELGPLRHVLDLTQSKSFQLEDAENFISNIRVTVVKLKGSDNTFEC
QFDDESATVVDFLRRWIAFCQSIISTSPQ

Molecule Role : Vaximmutor

16. IL2

Gene Name : IL2
Sequence Strain (Species/Organism) : Papio anubis
NCBI Gene ID : 100126754
NCBI Protein GI : 162951936
Genbank Accession : AHZZ02027629
Protein Accession : NP_001106124
Taxonomy ID : 9555
Chromosome No : 5
Gene Starting Position : 117784284
Gene Ending Position : 117788978
Gene Strand (Orientation) : -
Protein Name : interleukin 2
Protein pI : 7.38
Protein Weight : 17215.83
Protein Length : 154
Protein Note : Also known as IL-2

DNA Sequence : Show Sequence

>NC_018156.2:117784284-117788978 Papio anubis isolate 1X1155 chromosome 5, Panu_3.0, whole genome shotgun sequence
ATCAGGTCAGTGTTGAGATGATGCTTTGACAAAAGGTAATCCATCTGTTCAGAAATTCTACAATGGTTGC
TGTCTCATCAGCATATTCACACATCAGTGTTGTTTCAGATCCCTATAAAAGAAACATGTTAATTTTTTAA
AGTGCAGAGTAGTTTACCTTATATATAGTATTCCCAATTGAAGTCTTATAGGCCTGTTGCCTTTATTTTC
AAGCTTACCAAACATATTAATTATTCACATTTTCTTGAAATGATCAAAATGAATGCCAAAATTACATATT
TTGTTATGATACCAAATGATAGTAACATGGAAGCTGAGATTTTCCTCATTTGTTAATTCAGTCAATGAAC
ACAAAAATTTTTTCCCTGAATTGGGTGCAAATAAACATTTAAATAAAAACAGATCGAGACAAATATTAAA
TGCTGGATATGAAATAAACTTGATCGCTTTTCCTCTGAGTATGTACCTATATTTGTTTAAGTTAAATGTA
TGAATTGATATGCACATTATACTTTTCTAAATCTTGATTAGAGTCTCCTATTTTTCTACTTAAGTGAATC
TCCTTATATTTTCCCCAAAGCAGAATAGAACTAGCCTAGAGTAAGCGAGGACATGTTTCTGTTTGGGAGA
AATTTGTGTGAAGAACATCTTCATAAATACTTATACCTACCCCTACCCTATCATAGTATCAATACAGGTG
AATTTAACAACTTTTGAAAGTTTAAACATTGGAAATTTTGTTCTATGGACTGGCTTTTTAGAAACTAGGC
TCCTCTGCTGAAAGAAGCGATTTAAACGCTTCCTCTAGTTGATAAGCTAAGGAGGAAATATTTTGATATA
AAGTAATACTTAAAAGACAGCTTTTCAAATTTGAAGTTATTCCTACCCTGGGAACAAAAAGCAAGTGAGA
TAGAGTGTTCCCTTTAAATAAGTATTCTCTTTAAATAAACTGTTACAGTGTTCTGTACCCTCTTAAGCAT
AATTATTTAAATATTGTAATATCTTGGGTTTTTTTATTTTAAAAAGTGTTTGGCTTTTGAAACACAGTTT
TCAGATTTTTGCATGGTTTTGTCTTAAATTTGTATCAAGAGTTAAGAATGAGTTTCTATTTTAGAGTAAA
ACTCTTGCCATAGATAAGGAACTGAATCTGTCAGTGTCTAGATGACATGGATCTCAATGTATTTTTTTTA
ATTCAGCTGAAACAGTCCACTAATAAGTGATTCATTTGGACACAACTGGAGTTACTTTTAGAAATGTCTT
TCTATTATTGTACTTATGCTGCTTATTTAGGATAGCTATTAACTCATGAATTTTATACCTTAGCAGATGG
GATATAAAAAGAGAGAAGGGAATGTCTTTTACATCACCTGAGTCCCTTGCATATTTTATGCATCCTGTGC
ATTTAAAAATACTTGATTCTGAAAGTGGGATTGCCTCTAAAAAGGTTGTTGTTTGTTTAGTCCACTGGCC
ATTGTAATGGCTCCAGGTTTTTTTTTTTTTTTTAAGACAAATCTCTTATGGGTAGTCCTTCTATCAAATG
ATAAGGAAACACCATTTGAAAAGGCATTTCAGGTAATCAGTATTGACTATTCCAGTAAATGATCTGAAGG
AATTGAAAAATATATAATAAAATCTGCCTGCTTTCTGTGAAACTCAATTCAGTACCTTCTCTCACTCCCA
GTTTTGTGTTAATGTGAAAAGTGATGGAGTTTGGGATGAGGCTTGTCCATTAGTAGATGGTAGGTGCAAA
CTCTGTAGCTTATACTTCCCAGTTAGTTTATCATCTAACATTAGAAACGATTCATGTTCACAGTGTACTT
AAAATGTAGGCTAATTACATGCATGGGTACTTTACAAATACCAAAAATGTTATGTCACTTTGAAATGTGG
TACTTTTCCCCTTCCATTTTTTTTTTTTTTATTTCCAGGAGAGCAAATAAAGTAATGCCTTACCTTTAGT
TCCAGAACTATTACGTTGATATTGCTGATTAAGTCCTTGGTATCTCTTAAGTGAAAGTTTTTGCTTTGAG
CTAAATTTAGCACTTCCTCCAGAGGTTTAAGTTCTTCTTCTAGACACTGAAGATGTTTCAATTCTGTGGC
CTAGAATAATAATTATCATCAGCTCAGTTTCCACAGAGGTCAGAATCAGAAATTAATTTCTAATTTATTT
TATTTGGAGTAGCAGTATGTAGTTTTTACCATTCTCTCTGTTCTCAGTATCACTGTAAAGATGGACCAGT
AGAGTTTACATTATAAAACTGGAAAAACTAGGGCTCAAGTACCTATGACTAGCGTTAAGTGATAGTTGAC
TCACTGGTTTTAGCTTAATTTGGCTTTGCAAAATGTTAGCATTTCTGCATCTAAATGCAAATTACAGATG
TAGGCTGATTACTTTTCCAGTCTGCATAGAAAATCATTAGAACCAGATCAGTTAGAATGTGGAAATATAA
AAATCACATTCTATGATTATAATATTTGATAATCTAAGAGTTAAGAATCACAGAATGTTAAGAGACAGAA
GGAACTCTTGGATGCCATCTATCACAATCCTGACATTTTACACTAGGTAACAATAATCATGTAGTAGTGG
CTCTCGATATAGCCTGGAGCAAGACACATTTAAGTGTGTCTAAATTTTTACTTTTCTACAATCACTACAT
TAAGATGCATTTCAAAAATATTTGTCCCAATAAAATAAAAGATTATAGTACTTTGGAAGGACTTTTGAAC
AGGCCTCCTGGTTCTATATTATATATAATATTTCGTATTTCTATGGTATATTATAATTTAAAAGAATTTT
CTCCAAAATAAGCCCATTTACATCTCACGTCATCTTTTGAAGTAGGCAGTGAAGGATCATCTCCATTTTT
AAAATAAGGATGCCAAATCTCAGAATTTGACCACATAAGTAGGTAGAGCCAGAATTAGATTTCAGTTCTT
TCTCATTATAGCATTAACATAGCATCCTTGGAATCAAATATTTTTATTAGTTTCTAAAATTTTTTGTAAA
TGTGCAATGAGGGTTAAACAAATGAATAGAGTTTATCATTACTTTTGTTTTCAAACTGTTAGATTTCAGT
GAATTCTACCACCCCCTAAATTATGCACATAATATCGTCTTTCTAACAATCTTTAGTGGGAAAGGTAGGA
CAAGACAATACCGATCCCCTGATATGTCCATCTATTGTGCTTTCAATTCGCCACTACAAATTCTACAAAT
TCTACAAATTCGGGGTTAAGTTTTTGGCATGAACAATGAGGAGAAATTTTCTTCAGGAAACAGCATCTAG
TGTCTTTATGTTGCTGGAGTTGCATCACGTGGCTCTGTTTAAACTAGAGTAACATCTGTAAGCTGTCTTC
TTTACATCTTTCAGAAGAGTAGTTTGAAGCAGATTTCCCTTGAATTAATAGAATTTGAGTCAATGGGATT
GCATCTGTGTCCCCTTAAATCCTATTATTTTCTGGGTTTGGATTCACCCTGGCACAAGCCCTTTCTGGCA
CCAAATTTTGTTCATTCTCTCTTAACTGGCACAGCTACTAGGTAGCTTTGCACACCTAATGTAACCTAGG
AACTTGGATGATTATGCTTATGCTGTATCTGAATCCAAAAACCACCTAATGAAGCTTTTAATCTTGGGAA
ATAAGTCATATAACATTATAAGTCTCAAGTTCTATTGGTAAAAAGATAAAAATCCAAAATTTCACTTTGT
ATTTCTCAGTAAGAATTTTATCTTTAATACTACTAATAATAGCTAATGCTTATATGGTATTTACCTTATG
CCAGACACGGTTCTGAGTGCTTTACATTTACTTACTAATTCTCACAAAAGTGTATTAAGTATATACAGTT
ATTCATTTAAGTAGACATGAAACTGAATCACAAAGAGAGCAGGTAATTTGCCAAAGGTCATGAAAGCTGG
GACATGGCAGAGCTGAGATTTCACTTGAGATATCTGGCCCCAGAGTCTGTGCTATTAGTTAGTGTTATGC
TGCCTCTTACTTAGGAACCTTTCCTAAAACAAGAAAAGGTTTTTTAAGTTGGGCTTCTTGGAAATAGATT
TTGGTATTTTACATACTAAAATGGCATAATCAAATATTTTAGAGTTTTACATTTTTAAATGAAACCATAA
GTCAACATTTTTGTTTAAAATTGTCTTATCAATAAAGTGAGAATATTATTTTTATGTTTTCTTCCCACCC
CCACCAATACACAAATATATGTAAAAAATATAGGTAAAACTATTTTAATAGATGCTTCATTATCAAACTT
GGGTTTTCAAAAAACAGAAATTAAAGTTACTCTTTACCTTAGATAAGCTGCTATTAATCCCATCTGTGCA
ATTTTTCATATTACTTTGAATTTTATTAAAACAAATTGAACATAAAAAATTGTACTTACCTTCTTGGGCA
TGTAAAACTTAAATGTGAGCATCCTGGTGAGTTTGGGATTCTTGTAATTCTAAGAAAGTATAATACATTG
TTAATTAAGAAATGATCTCCAGCTAGATTACTAAATGTAATAATTTTAGTAAGAAAGAAATATACTTACA
TTAATTCCATTCAAAATCATCTGTAAATCCAGCAGTAAATGCTCCAGTTGTAGCTGTGTTTTCTTTGTAG
AACTTGAAGTAGGTGCACTGTTTGTGACAAGTGCAAGACTTAGTGCAATGCAAGACAGGAGTTGCATCCT
GTACA

Protein Sequence : Show Sequence

>NP_001106124.1 interleukin-2 precursor [Papio anubis]
MYRMQLLSCIALSLALVTNSAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA
TELKHLQCLEEELRPLEEVLNLAQSKNFHLRDTKDLISNINVIVLELKGSETTLMCEYADETATIVEFLN
RWITFCQSIISTLT

Molecule Role : Protective antigen

17. IL2

Gene Name : IL2
Sequence Strain (Species/Organism) : Macaca mulatta
NCBI Gene ID : 708017
NCBI Protein GI : 114052044
Genbank Accession : JSUE03034369
Protein Accession : NP_001040595
Taxonomy ID : 9544
Chromosome No : 5
Gene Starting Position : 121451956
Gene Ending Position : 121456685
Gene Strand (Orientation) : -
Protein Name : interleukin 2
Protein pI : 7.38
Protein Weight : 17187.82
Protein Length : 154
Protein Note : Also known as IL-2

DNA Sequence : Show Sequence

>NC_027897.1:121451956-121456685 Macaca mulatta isolate 17573 chromosome 5, Mmul_8.0.1, whole genome shotgun sequence
CCTGGTATGTTTTAAGTGGGAAGCACTTAATTATCAGGTCAGTGTTGAGATGATGCTTTGACAAAAGGTA
ATCCATCTGTTCAGAAATTCTACAATGGTTGCTGTCTCATCAGCATATTCACACATCAGTGTTGTTTCAG
ATCCCTATAAAAGAAACATGTTAATTTTTTAAAGTACAGAGTAGTTTACCTTATATATAGTTATTCCCAA
TTGAAGTCTTATAGGCCTATTGCCTTTATTTTCAAGCTTACCAAACATATTAATTATTCACATTTTCTTG
AAATGATCAAAATGAATGCCAAAATTACATATTTTGTTATGATACCAAATGATAGTAACATGGAAGCTGA
GATTTTCCTCATTTGTTAATTCAGTCAATGAACACAAAATTTTTTTCCCTGAATTGGGTGCAAATAAACA
TTTAAATAAAAACAGATCTAGACAAATATTAAATGCTGGATGTGAAATAAACTTGATCGCTTTTCCTCTG
AATATGTACCTATATTTGTTTAAGTTAAATGTATGAATTGATATGCACATTATACTTCTTTTCTAAATCT
TGATTAGAGTCTCCTATTTTTCTACTTAAGTGAATCTCCTTATATTTTCCCCAAAGCAGAATAGAACTAG
CCTAGAGTAAGCGAGGACATGCTTCTGTTTGGGAGAAATTTGTGTGAAGAACATCTTCATAAATACTTAT
ACCTACCCCTACCCTATCATAGTATCAATACAGGTGAATTTAACAACTTTTGAAAGTTTAAACATTGGAA
ATTTTGTTCTGTGGACTGGCTTTTTAGAAACTAGGCTCCTCTGCTGAAAGAAGCGATTTAAACGCTTCCT
CTAGTTGATAAGCTAAGGAGGAAATATTTTGATATAAAGTAATACTTAAAAGACAGCTTTTCAAATTTGA
AGTTATTCCTACCCTGGGAACAAAAAGCAAGTGAGATAGAGTGTTCCTTTTAAATAAGTATTCTCTTTAA
ATAAACTGTTACAGTGTTCTGTACCCTCTTAAGCATAATTATTTAAATATTGTAATATCTTGGGGTTTTT
TTATTGTAAAAAGTGTTTGGCTTTTGAAACACAGTTTTCAGATTTTTGCATGGTTTTGTCTTAAATTTGT
ATCAAGAGTTAAGAATGAGTTTTCTGATGTTAACTATTTTAGAGTAAAGCTCTTGCCATAGATAAGGAAC
TGAATCTGTCAGTGTCTAGATGACATTGATCTCAATGTATTTTTTAAATTCAACTGAAACAGTCCACTAA
TAAGTGATTCATTTGGACACAACTGGAGTTACTTTTAGAAATGTCTTTCTATTATTATACTTATGCTGCT
TATTTAGGATAGCTATTAACTCATGAATTTTATACCTTAACAGATGGGATATAAAAAGAGAGAAGGGAAT
GTCTTTTACATCACCTGAGTCCCTTGCATATTTTATGCTTCCTGTGCATTTAAAAATACTTGATTCTGAA
AGTGGGATTGCCTCTAAAAAGGTTGTTGTTTGTTTAGTCCACTGGCCATTGTAATGGCTCCAGGTTTTTT
TTTTTAAGACAAATCTCTTATGGGTAGTCCTTCTATCAAATGATAAGGAAACACCATTTGAAAAGCATTT
CAGGTAATCAGTATTGACTATTCCAGTAAATGATCTGAAGGAATTGAAAAATATATAATAAAATCTGCCT
GCTTTCTGTGAAACTCAATTCAGTACCTTCTCTCACTCCCAGTTTTGTGTTAATGTGAAAAGTGATGGAG
TTTGGGATGAGGCTTGTCCATTAGTAGATGGTAGGTGCAAACTCTGTAGCTTATACTTCCCAGTTAGTTT
ATCATCTAACATTAGAAACGATTCACGTTCACAGTGTACTTAAAATGTAGGCTAATTACATGCATGGGTA
CGTTACAAATACCAAAAATTTTATGTCACTTTGAAATGTGGTACTTTTCCCCTTCCATTTTTTTTTTTTT
TATTTCCAGGAGAGCAAATAAAGTAATGCCTTACCTTTAGTTCCAGAACTATTACGTTGATATTGCTGAT
TAAGTCCTTGGTATCTCTTAAGTGAAAGTTTTTGCTTTGAGCTAAATTTAGCACTTCCTCCAGAGGTTTG
AGTTCTTCTTCTAGACACTGAAGATGTTTCAATTCTGTGGCCTAGAATAATAATTATCATCAGCTCAGTT
TCCACAGAGGTCAGAATCAGAAATTAATTTCTAATTTATTTTATTTGGAGTAGCAGTATGTAGTTTTTAC
CATTCTCTCTGTTCTCAGTATCACTGTAAAGATGGACCAGTAGAGTTTACATTATAAAACTGGAAAAACT
GGGGCTCAAGTACCTATGACTAGCGTTAAGTGATAGTTGACTCACTGGTTTTGGATTAATTTGGCTTTGC
AAAATGTTAGCATTTCTGCATCTAAATGCAAATTACAGATGTAGGCTGATTACTTTTCCAGTCTGCATAG
AAAATCATTAGAACCAGATCAGTTAGAATATGGAAATATAAAAATCACATTCTATGATTATAATATTTGA
TAATCTAAGAGTTAAGAATCACAGAATGTTAAGAGACAGAAGGAACTATTGGATGCCATCTATCACAATC
CTGACATTTTACACTAGGTAACAATAATCATGTAGTAGTGGCTCTCGATATAGCCTGGAGCAAGACACAT
TTAAGTGTGTCTAAATTTTTACTTTTCTACAATCACTACATTAAGATGCATTTCAAAAATATTTGTCCCA
ATAAAATAAAAGATTATAGTACTTTGGAAGGACTTTTGAACAGGCCTCCTGGTTCTATATTATATATAAT
ATTTCGTATTTCTATGGTATATTATAATTTAAAAGAATTTTCTCCAAAATAGGCCCATTTACGTCTCACA
TCATCTTTTGAAGTAGGCAGTGAGGGATCATCTCCATTTTTAAAATAAGGATGCCAAATCTCAGAATTTG
ACCACATAAGTAGGTAGAGCCAGAATTAGATTTCAGTTCTTTCTCATTATAGCATTAACATAGCATCCTT
GGAATCAAATATTTTTATTAGTTTCTAAAATTTTTTGTAAATGTGCAATGAGGGTTAAACAAATGAATAG
AGTTTATCATTACTTTTGTTTTCAAACTGTTAGATTTCAGTGAATTCTACCACCCCCTAAATTATGCACA
TAATATCGTCTTTCTAACAATCTTTAGTGGGAAAGGTAGGACAAGACAATACCGATCCCCTGATATGTCC
ATCTATTGTGCTTTCAATTCGCCACTACAAATTCTACAAATTCGGGGTTAAGTTTTTGGCATGAACAATG
AGGAGAAATTTTCTTCAGGAAACAGCATCTAGTGTCTTTATGTTGCTGGAGTTGCATTACGTGGCTCTGT
TTAAACTAGAGTAACATCTGTAAGCTGTCTCCTTTACATCTTTCAGAAGAGTAGTTTGAAGCAGATTTCC
CTTGAATTAATAGAATTTGAGTCAATGGGATTGCATCTGTGTCCCCTTAAATCCTATTATTTTCTGGCCT
TGGATTCACCCTGGCACAAGCCCTTTCTGGCACCAAATTTTGTTCATTCTCTCTTAACTGGCACAGCTAC
TAGGTGGCTTTGCATACCTAATGTAACCTAGGAACTTGGATGATTATGCTTATGCTGTATCTGAATCCAA
AAACCACCTAATGAAGCTTTTAATCTTGGGAAATAAGTCATATAACATTATAAGTCTCAAGTTCTATTGG
TAAAAAGATAAAAATCCAAAATTTCACTTTGTATTTCTCAGTAAGAATTTTATCTTTAATACTACTAATA
ATAGCTAATGCTTATATGGTATTTACCTTATGCCAGACACGGTTCTGAGTGCTTTACATTTACTTACTAA
TTCTCACAAAAGTGTATTAAGTATATACAGTTATTCATTTAAGTAGACATGAAACTGAATCACAAAGAGA
GCAGGTAATTTGCCAAAGGTCATGAAAGCTAGGACATGGCAGAGCTGAGATTTCACTTGAGATATCTGGC
CCCAGAGTCTGTGCTATTAGTTAGTGTTATGCTGCCTCTTACTTAGGAACCTTTCCTAAAACAAGAAAAG
ATTTTTTAAGTTGGGCTTCTTGGAAATAGATTTTGGTATTTTACATACTAAAGTGGCATAATCAAATATT
TTAGAGTTTTACATTTTTAAATGAAACCATAAGTCAACATTTTTGTTTAAAATTGTCTTATCAATAAAGT
GAGAATATTATTTTTATGTTTTCTTCCCACCCCCACCAATACACAAATATATGTAAAAAATATAGGTAAA
ACTATTTTAATAGAGGCTTCATTATCAAACTTGGGTTTTCAAAAAAACAGAAATTAAAGTTACTCTTTAC
CTTAGATAAGCTGCTATTAATCCCATCTGTGCAATTTTTCATATTACTTTGAATTTTATTAAAACAGAAA
TTGAACATAAAAAATTGTACTTACCTTCTTGGGCATGTAAAACTTAAATGTGAGCATCCTGGTGAGTTTG
GGATTCTTGTAATTCTAAGAAAGTATAATACATTGTTAATTAAGAAATGATCTCCAGCTAGATTACTAAA
TGTAATAATTTTAGTAAGAAAGAAATATACTTACATTAATTCCATTCAAAATCATCTGTAAATCCAGCAG
TAAATGCTCCAGTTGTAGCTGTGTTTTCTTTGTAGAACTTGAAGTAGGTGCACTGTTTGTGACAAGTGCA
AGACTTAGTGCAATGCAAGACAGGAGTTGCATCCTGTACA

Protein Sequence : Show Sequence

>NP_001040595.1 interleukin-2 precursor [Macaca mulatta]
MYRMQLLSCIALSLALVTNSAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKA
TELKHLQCLEEELKPLEEVLNLAQSKNFHLRDTKDLISNINVIVLELKGSETTLMCEYADETATIVEFLN
RWITFCQSIISTLT

Molecule Role : Protective antigen

18. IL4

Gene Name : IL4
Sequence Strain (Species/Organism) : Macaca mulatta
NCBI Gene ID : 574281
NCBI Protein GI : 74136371
Locus Tag : EGK_16838
Genbank Accession : CM001258
Protein Accession : NP_001028076
Taxonomy ID : 9544
Chromosome No : 6
Gene Starting Position : 129082063
Gene Ending Position : 129090398
Gene Strand (Orientation) : +
Protein Name : interleukin 4
Protein pI : 9.44
Protein Weight : 17265.73
Protein Length : 153

DNA Sequence : Show Sequence

>gi|109157119:129082063-129090398 Macaca mulatta chromosome 6, Mmul_051212, whole genome shotgun sequence
AATGGGTCTCACCTCCCAACTGCTTCCCCCTCTGTTCTTCCTGCTAGCATGTGCCGGCAACTTTGCCCAC
GGACACAACTGCCATATCGCCTTACGGGAGATCATCGAAACTCTGAACAGCCTCACAGAGCAGAAGGTGA
GTACCTATCTGGCACCATCTCTCCAGATGTTCTGGTGATGCTGTCAGTATTTCTAGGCCATGAAAACGTT
AACAGTTGCTAGAGAAGTTGGAACTGGTGGTTGGTGGCAGCCCGGGGCACACAGCCAGGCTTCCCCTGTC
ACTCTTTTTTCTGAGGGTTTGTAGGAAGTTTCCTCAGTTGGAGGGAGTGAGAGATGCTCATCAAGGACTG
CTCTGTCCAGTTGGAGGTTAACTCTGTCTCTTGCTCTCTCATTTCTGCCTGGACCAAGACTCTGTGCACC
AAGTTGACCATAACGGACATCCTTGCTGCCTCCAAGGTAAGAAGCCGTCCCACGGTCTGTTTTAGCACAT
GGGGAGATCCATCCCCAAGTGTCTGAATAAGAAACTTGTCTAATGGAAAACAAGCGGGCCCAAATTAACT
CTAAGGTGTTAGATGTTTTCAAAGAACGAGAAGTCTGATTTTTACTCTTAAGTGTGTTTTGGTCTTTCTG
GTTTCACTTGATTTAGATGTGTAATAGAAAGCTTACATGCTATAGTCCTGACTCAGATCCTGGTCAAAGA
AAAGCCCTCTTGGGTTTTACTTAGCTTTGGCATAGTGCCTGGAACGTAGGAGGCACTCAATAAATGCCTG
TTGAATGGGAGAATTTTTCTGGCCCATACATTTCTGAAAAACCAAATACTCTCACAGAAACAGATATTGA
GATGACAGGTTGAGGGAGCTTTCATTTTGTCTAAGAGACTTCCTATGGCAACAGAAAAGGTATCACCAGA
GCCCCTCCTCTTCCACAGCCTGGCCACCTAACAGCCCTCTGGGTTCCAGGGCTGGCGGTCCAGGGCTCCT
CAGCTTGCTCTGGCGGGTCGAATTCCCGTCCAGCTCGGTCCGGAACCATCCTGCTGGGCAGCGTCCAGCA
CATCCCTGCTTCCGGTTGCCTGGGCACCTCGCCTCTCTGCCTCCTGTGCTGCCTCACCCCCACCCCTCTA
TCTGTAGTGGGAGGAGATAGATTTGACAGCTGATAGTGCATTTTCTCTGACAAACACATGACTACAGCCG
TATCAATAGTTTTGTGCATTTCAGTTCCTGTTTTCATGGAAACACACAGCTGAGAATGAAAGCCCCAAAG
CCTCAATTTCACAGTGGTCTCCTAACTACTGCTTTCCATGCGAACTAGGGGGATGATTTGGCCAGCAGTG
AAGCCCTGTGTGTTGGGCAGGGTCACGCCCTGGCACCCAGGCCATAGAACAGGGCCCATCCTGCTTCATG
AGGGAAACTGCTCTTCGGGCCTTTATCTGGACTATCTCATTCATTAAACGTTATCCCAGGAGTTCAATAC
AGGATGAGATTCCTGAAGGGTAAATCCACACTTTGTTTTTTTTTTCTTTTGAGATAGGGTCTTGCTCTGT
CACCCAGGCTAGAGTGCAGTGGTGCGATTTCAGCTCACAGCAGCCTCCACCTCCCAGGCTCAAGCTAACC
TCCCACCTCAGCCTCCCAAGTAACTGGGATGACAGGTCTGCGCCACCACGCCTGGCTAACTTTTGTATTT
TTGTTGTAAAGATGGGGTCTTGCCATTTCATTTTGCCCAGGCTTGTCTTGAACTTCTGAGCTCAAGCAAT
CCATCCACCTCGGCCTCCCAAAGTGCTGGGATTAGCCACTGCACCTGGACAACAGTTTGTGTGTGTGTGT
GTGTGTGTGTGTGTGTGTATACACAAAATTTCTAAGTCCTTCCAACCGAGATGGCTCCTACTAGAAGCCA
AGAGTCCACCGGGTTGAGCACTGGGTCTCTGGAGGCCTGTGGCACTGCTGAGAAGGCTCTAACAAAGCCA
AGGGAAGGGCCACCTCACTAGAAGTCAGGCCTGGAGGAAGGGTGAGGGTTGAGGGCCTGGAGGTGAGACT
GCCTATGGTTTTAGACCCCGCTCTGCCACTGACAGCTGTGTGGCTGGCCTTCGGCACATCTTCACACCTC
TCTGCACCTCAGTTTCCACGTGTGAAGATACGAAAGTGATTCTGAAGGTGATTGCAAGGTTGATTGGAAT
CCAGTTCTTGAGTTAGTGGAAAGGGTTATTGTGAGATGATATAACCCTGATTAAAAGCAAGGACACGTTG
CAGAGAAGCGATGATTCTAAGAAGGAGGTGCCCAGGTTGGAAAGGATCAAACCCTCCAGGATGCTGAGCC
TGGGGCTATCCATCTGGGCTGTTTCTGGAAGACCTCCAGGCGCAGGCGAGGACACCACTGCCCTCCCGTC
CTTAACTCCCCTCTTCACTCAGTCCTCACTCACCTCCCTCTCACACACACAGACATCTCCTAGAACAATC
CCCACTGCCTGCCTTTACTCTTACCTGTCTCATTCGCCTTCCCCGAACTTCATCCTCCTGGAGTTCTCAA
TCTCACTCTTCTACTCTTTTCTTCCCCTTGAAGATTCAGCACTGCTTACTTACATGTTAAGATATTTCAG
AACAGTGAAATGTTGCTATTTTCAAAAACCTACAAAGGTGGTATGCAGAGGAAAAGGTACTTCTTTGTGT
TCCCAAAGAAAACATCTTTCCAAAATCCAGCCTATTGATTTTATTTCTTCGGGGGGAACAAGAATTTTAG
TATCTCTAAGTTGGGTAGCATTCTACTCTTGGCAGTTGCTGGAAAGAAGGCACTGATCTAGGTCCTGGGC
TTCATAGGTAACACCTGTTGGGGTGTCTATGAAGTCAAGGCTGTCTGAGGAACAGCAAAGTGGGAAGAAG
CAAGCTGGCTGGTCGATGAAGGGTTTCTTGGGTGGACAAGTAGATGGAGCTATTTCCTACTTACCAAAGA
GAGCTAAAGTTCATAATTCTACAGAGAGTTCCATAATGAACCTCAAATATCTCTGTTTTTTGAAGGAGTT
TCTCATATAGAGCACTAGCTGACTACCCTGGGCAGGATGGGAGATAATGAATGCAGTGCCAGTCGGGCTG
GATTTGTATGGTCCTCAGTGAGGCTGGTCAAGAACCAAGTCAGAACTCTCACAGAGTCACTGCCACAGAA
GAAATCTCCTAAGTGGCTGTTTCCTGACATTCCCGGGAGGGACAGACCTCCTTCTCAGTCACTCCCTAAG
CAGTTCTGAACGGTGAGGTCAGCCAGGCTGTCAAAGTGCACTCCCTGAGCCACTGGCAGACACACTCAGC
AGCCGGAGCTAGACAGGCAGGTAGAAGGAGTCCAGGGTCACAGCAGGGATGGAGTGTCGCCCCCTCGCTG
CGATACCAGAGCAACTAAAACGTAAAGGCCGCACTAAAGCTGCCCTTAGGATGTATTCTTTTAAAGTTTT
TCCATTTAATGCAGACTCTTTTCAATTCTTATTTTATCCTTGTTTCCTTTAGAAAGTCCTTTGAAAAATA
TCTTTAGAGGATTTTTTCCTATACTATGTGGCCATATATGGGTCAAAATTAAGTTTAATTTCCAGGGTCC
AAGCCAGCATTTCAGAAAAATCTCACCAAGGTTTGTGGGAAAAGAAGCAAAGGCTTTTTGGCCTTCTTGA
AGCTCACTGTTCCCTCTGCAGCAGCATGCATGTCTGCCCACCTCCAGACACTCAGGTAGCATGTGCTGCC
CCCCACCAGCCCCTGTGTCCCCTCCACCTCGACTCGCCCACAAAGCACAGAGAGGTCTGTTTCTTGGCTC
CAAGAGCCCAAAAATACTGACACACTCTTGTATTTCCAACTAGAATCAGGAACCAGGAGTGACTCTCAGT
CAGTTCATTAAGTAAATGTCTTTCCAACCGCTCTGCCCATGGGATGTCACGCCCCACAGAGGAAAGGGGA
AGCTTCCGTAGCCTGGGATTCTGGTGCCTCAATCTGGGTCTAGATCTTCCTGAAAAAAAAACGTTAAAAT
ATGAACTGCATTCCTAGAATGTAGCCTATATAAATAAGAGATGAACACAAAGATTTATATAGTTTACTCA
CTGCCACTTATTTACAGAAAGAGAAAGCTGCTGTAAATAAGGCAAATTACAATTGTAAAGGGGCCTGACA
AATGACAGCACCACTATGCAATACGTTTCTATGCAGCTCTCAAACCCATGTTCTCAAATACCACCGAAGG
GCTTAGGAAATGCTTATAGTATATGCAAAGGGTAAAAAAGTTACAAAACAGTATCAACAGTTGATCCCTA
TTTTAAAAAGTGTTTTTTAAAGTGTGATGATATTTACCAAAATATTAACAGCAGTAGTTACCTCTGGCTG
ATGGGATGAGTGAATGTACTTTTGTTGAATATATAATTACCTTTATAGTAAATACACGTTACCTTGATCA
TCAGAAAAAAAAATGTAACCGTAAGAACTTGAAAGCTGCTTGGACAGTGCTGCTGATAGAAATCCCTGAG
GATCTTGTCACTGTTCTGATTCAGAGGGTCTGGGTGGGGCAGGGGTGGTCTGAGATTCTGTATTCTAAGA
AGCTCCCAGTGATGTCCATGATTCTGGTCATGGACCACACTTTTGAGTAGCAAGGGACCAGAGCATGTCG
GGGGAGAGGCTGGGGATAGCTTTATCTCAACTGGATAAAGGAACTAGGCTCAAGCTAAGAACCCTCTCCA
AGTTCTGCATCTTTGTTCTTCAGTGAAAAATGAGAGGACAGACCAGTTCAGACCGAGACAAAATCCCTCT
CCTGGGTTCCCAATGACTTGTCTCCCTGTGTGTCCATTCCCTTCTCTAAGGTTAAGGGCCCCAGGAAGAG
CCATGTGGCCAGACCCTCACAGTTGCCAGCATTTCAGGGAGATTCTCACTCTGCACCATTTGGGGCCAAA
AGGCCCCTTACAGAAACTCTGCCCAACGCTCAGCTCAATGGCACCTGCTCCCAGAGCCTCCCCTGATCTC
CCAGGACACCTTTCCCCAATCTGTACACTTATCTCTTGCTGCCTGGGGTAATGTCTTAGCTCCTCACTTG
GACCATGTGCTGCTCTCCTCTCCCATGGGGAGGACCAAACGGATAGTGCTGCCCAAAGCAGCAGAGTCCA
GGCCAAAGGATGTGCCCTCATTTATTCAACAGGCATGCAGGATTTCCAGGGAAAGCTGGATTTTAAAACC
TTTGGGAACGAGAGCAGAACCTGACTGAGAGCTCATGTGGGCACTGTCCATAGCAGAATAGCTCATGGGG
TATAGAGATACGGACGCGGAACGTGGGCTGTAGCGATAGATAGTCCTGCATTCTAGTCCCCACTGTGCCC
TTTCCTTGCGGGGTGGCTTTATTCAGGTACCCTTTCAGCAAAATCCTCCAAGAGAAAAGAAACTGGGGGG
TTCTGGGGAGAAGGCTGCTGCGTTTGCAATTGGGAGAGGTTGTTGACAGAGGTTTGTGTCTGTGGCAAGC
AGCCTTCCTTCAGTGGAATACTTGAAGACAGGTCTGTAGTTGAGCAAACTCACCTCCATTTGTCCCTCTG
GAAAGAAGAAATCAAGAGGAAAAAATCTCTTTCCCATCCTCCAAATGGAGCTGGCACATGGCTATCTATG
GCATTTGTCTTTCCAGAACACAACTGAGAAGGAAACCTTCTGCAGGGCTGCGACTGTGCTCCGGCAGTTC
TACAGCCACCATGAGAAGGACACTCGCTGCCTGGGTGCGACTGCACAGCAGTTTCACAGGCACAAGCAGC
TGATCCGATTCCTGAAACGGCTCGACAGGAACCTCTGGGGCCTGGCGGGCTTGGTAAGCTGCACTGTATT
CCTAGCAAGCTGGCAGCATGGCTCCTGGTGGACAGCAGCCTCACTTCTAAACACTCCTCCTTAGGAGCTG
CAGCACCCTTGGTCAACCCATTCATTCATTCACTCATTCACTAAGTATTTGTTGAAGTTCCGTAAGTGCT
GGGTGCGGTTCTAGGTGCTGAGGACGTGTCACTAAAGACACGCAGGCCAAGTCCCTGTTCTCGTGGGATG
TTCTAGTGGGAGAGTCAGAAAAACAAACATGTAAAATGATGCCCAGTAGTGATACGTGCTACAAAGAAAA
ACATAGGAATAAAGAATGTAAGGGTCATGGGGGAGGGGGCTGACTTAGGAGCTGGTGACATTATCTGAGC
AGATATTTGAATTAAGTGAGGGAGCAGGCCACATGACTAACTGGGGAGAGACCATTCCAGGCAGAAGGAG
GAGCTATGCAAAGGCCTTAGGATGGAAATGAACTTCCTGTATTTGAAGACCAGTAGGAAGGCCAGTGTGG
CTGGATCACAGTGAGTGAGGGGGAGTTTCTAGGACAGCAGATCACACAAGGCCTTGAGATTCCACCACGA
GTATGGCAGGGAACACCTGCAGAGCTCTGGGCAGGGCAAAGACTGTACGATCTGATTTACGTGATTTAAA
AGGGTCAGTCTGGCTACTGTGTGGTAAATAGGCTGAAAGGGGGAGGCATAGAAGCAAGATGGCCTGTTGG
GAGGCAGTAAACCAGGCTAGAGATGATGGTGGCATGGACAGGATGGGAACAGTGGATAGATTTGGGATAT
GACTAAAAATAAAACCAGAAAGATTTGCTGACAGATCAGTTGTAAGGGGTAAGATACAGGGGAGGAAAAG
ATGACCTCTTCGTTCCTGCCTAAACCCGTCTGGCGATGGTTGGTACCGTTTATAGAGCGATGGAAGACTG
GGGGCAAGGCAGGGCTGGAGGTTAAGCAGAAGATCAAGAGTTCAATTTTGTACGTTGTACATGTAAGGTG
GCTGTTGGACAGCCAAGTGAAGATGTTGAGAAGATGGTTAGAAGAGTCTGGAACTTAGAGGAGAGGTCAG
AACTTGCAGTACAAAAAGGAGAGTCCTTAGATAGATGCTATTGAAAGTCTGAATGACAGAAAGGGAGAGA
TCAAAGGACTGAGCCTGAGATCAACACATGGAGGTCAGGAGAGGAGGATCCAGTAAAGGCGCCTGAGACT
CCTCAGACCAGTGAGGCAGGAGAACACTGGAGAGTGGGCGGTATCCCAGGAGGCCAGTGAGGACACTCAC
GGAGGGAGGGTCGACTGTTTCAAATGTACTGAAAGGTCAGGTCAGGTAAGGACTGAGAAAGGCCCCTGGG
TTTGACTGATGGAGGTCATGGGTGAGGCTGATGTAAATGGAGAAGCAGGAAGGAAAGTCCAGCTGGAGTG
GGCTCACCGAGGATGGGGCGGTGAGAGAAGCCAAAGAAGGAACAGTGAGGGCAGAACACTCTTTGAAGGT
GTTTAGCTATAAGGCTGCAGAGAAACTGAACCATGGCTGCAGGGCGGTTATGGAGTGAGGGAAGCTCTTT
TAAGGTGGGGTGTATACCCAGCATGCTAATGCACCTGGGGGAACGGTCTGGTGGAGTAGGGAGAACTGAA
GAGAGGAGAAGGAGGAGGAATCATTAGAGGGCAGAAGTCCTTGTGGCCCAGAGTGGGTGTTATCTAATAT
CGAGTGGAGGAATTAATTGGCTTTAGAAGAGAACAAGGACATGTATCCCTTCTTTGGGCCTATCACCTTG
TAGACAATGGGATAGGTCATGGGATAGGAACTTGGCACAACACATGTTCTCTTTTAATTCTCTCCATTAT
CTTATGAAGCAGGCAAGTAGGCAAACAATTGTCCCGACTTTAAAAATAAACTGAAGCTTTTATAAATTAA
GTAGTACGTTCTCAGCAATACAATTAATAAATGGTAGAGCTGAGATTCAAACTGAAGCAGTGGCCTGGGG
GTAGCATCTGGAACCCTTCCCACCTTTAGGGCTGCTGTGCTGCAGTGCTGCTGTTTAATGACAGGAGGGC
CACATGACTGAATCTCTCTCAGCAGTCCAGGCAGCCATGCAGAAGGCCCAGTAGAGCACGGGCAGGTCTG
AGCCAGCACCTTCAAGTTCTACCCTCTGAGCAAGCACCTAGCTGTGACACACCTCTCCAGAGACTGCACT
CCCCGCCGCCCTGCCCACCGCAAAAGCAGATAGGTAATGGTATACAGTAACCATTTCTAGAAGTGTAAGT
AGTATGCACCCAAAACAGGCAACACCTGCTGGCCTAGTGATAGAGACGACTCCCAGTCAGGCTAGACTGG
AGGCCTTGGTTTGGTAAGTGTTCAGGTGGCAAGTACCAGAGTAGGCTTGATCAAGTAGACAGGCAGGCAA
GACAAATGCTTACCAATGCAAGCTAATTAAATGCTTCTTTTGTAGAACTCCTGTCCTGTGAAGGAAGCCA
GCCAGAGTACGTTGGAAGACTTCTTGGAAAGGCTAAAGACGATCATGAAAGAGAAATATTCAAAGTGTCG
GAGCTG

Protein Sequence : Show Sequence

>gi|74136371|ref|NP_001028076.1| interleukin-4 precursor [Macaca mulatta]
MGLTSQLLPPLFFLLACAGNFAHGHNCHIALREIIETLNSLTEQKTLCTKLTITDILAASKNTTEKETFC
RAATVLRQFYSHHEKDTRCLGATAQQFHRHKQLIRFLKRLDRNLWGLAGLNSCPVKEASQSTLEDFLERL
KTIMKEKYSKCRS

Molecule Role : Vaximmutor
Related Vaccine(s): HIV DNA vaccine VlJns-tPA-gp120 , HIV-1 gp120 with mCT E112K

19. Il4 (interleukin 4)

Gene Name : Il4 (interleukin 4)
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 16189
NCBI Protein GI : 10946584
Locus Tag : RP23-188H3.4
Genbank Accession : NM_021283.1
Protein Accession : NM_021283.1
Taxonomy ID : 10090
Gene Strand (Orientation) : ?
Protein Name : IL-4, Interleukin 4

DNA Sequence : Show Sequence

>gi|10946583|ref|NM_021283.1| Mus musculus interleukin 4 (Il4), mRNA
GGATCCCCGGGCAGAGCTGGGGGGGGATTTGTTAGCATCTCTTGATAAACTTAATTGTCTCTCGTCACTG
ACGGCACAGAGCTATTGATGGGTCTCAACCCCCAGCTAGTTGTCATCCTGCTCTTCTTTCTCGAATGTAC
CAGGAGCCATATCCACGGATGCGACAAAAATCACTTGAGAGAGATCATCGGCATTTTGAACGAGGTCACA
GGAGAAGGGACGCCATGCACGGAGATGGATGTGCCAAACGTCCTCACAGCAACGAAGAACACCACAGAGA
GTGAGCTCGTCTGTAGGGCTTCCAAGGTGCTTCGCATATTTTATTTAAAACATGGGAAAACTCCATGCTT
GAAGAAGAACTCTAGTGTTCTCATGGAGCTGCAGAGACTCTTTCGGGCTTTTCGATGCCTGGATTCATCG
ATAAGCTGCACCATGAATGAGTCCAAGTCCACATCACTGAAAGACTTCCTGGAAAGCCTAAAGAGCATCA
TGCAAATGGATTACTCGTAGTACTGAGCCACCATGCTTTAACTTATGAATTTTTAATGGTTTTATTTTAA
TATTTATATATTTATAATTCATAAAATAAAATATTTGTATAATGT

Protein Sequence : Show Sequence

>gi|10946584|ref|NP_067258.1| interleukin 4 [Mus musculus]
MGLNPQLVVILLFFLECTRSHIHGCDKNHLREIIGILNEVTGEGTPCTEMDVPNVLTATKNTTESELVCR
ASKVLRIFYLKHGKTPCLKKNSSVLMELQRLFRAFRCLDSSISCTMNESKSTSLKDFLESLKSIMQMDYS

Molecule Role : Vaximmutor
Molecule Role Annotation : IL-4 plays an important role in Th2 immune response.

20. Il5

Gene Name : Il5
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 16191
NCBI Protein GI : 6754336
Locus Tag : RP23-239O19.2
Genbank Accession : AC084392
Protein Accession : NP_034688
Taxonomy ID : 10090
Chromosome No : 11
Gene Starting Position : 53720793
Gene Ending Position : 53725102
Gene Strand (Orientation) : +
Protein Name : interleukin 5
Protein pI : 8.9
Protein Weight : 14616.09
Protein Length : 133
Protein Note : Also known as Il-5

DNA Sequence : Show Sequence

>gi|372099099:53720793-53725102 Mus musculus strain C57BL/6J chromosome 11, GRCm38 C57BL/6J
GCGCTCTTCCTTTGCTGAAGGCCAGCGCTGAAGACTTCAGAGTCATGAGAAGGATGCTTCTGCACTTGAG
TGTTCTGACTCTCAGCTGTGTCTGGGCCACTGCCATGGAGATTCCCATGAGCACAGTGGTGAAAGAGACC
TTGACACAGCTGTCCGCTCACCGAGCTCTGTTGACAAGCAATGAGGTAAAGTATAACTTATTCCTTCAGC
TTTGTTTTTAAGATCAGGACCTTGCTATACCGCTCTGACTGGCCTCAAACTTGCTATGTAGGGTAGGCTG
TCCTAACCCCTACCAGATCTCCTTACCTATGTCTCCCAAATACTAGGATTACAGACACATTACCTTGCCT
GACGCTATGGTTCTTCAGAATGCATAAATAGCTGCATTTGGCCTTTAATCCCAGAACTTGGGAGGCAGGG
TCAGGTGGATCTCTGTGAGTTCAAGGCCAGACTTGTCTACGTGGCCAGTTACAGGACAGCCAGAGCTAAA
GCAAGACCCTGATTCAAAATAATTTTTTTTCAAAACAAAAAAAAAAAACCCAAACCATTTGTGGCAATTC
ATTTCTAAACATAAAGATCTGCTTTAAATAGTGCAATTATGGCTTGTTCCCTTGCCTTCTTGCTCCCGTT
CTGTCCTCTTGTCCCACTCTCTCCCCATTCCACCCCCACCATGTGCTCATGGCCCGCATCTCTACTTCTC
TACTCTCTTTCTCTCCCTCTCCCCTCCTTCTTCCTTTCCCTCTCTCTCTCCCTCTTCTTCTCCTCCTCTC
TTTCTCTCTCTCTCCCTCTCTCTCTCTCTTTCTCTCTCTCTCTGCTTTTTTCTATCTCTACTACCCTCTC
AACTCCCCTCTCCATGCCCTGAATAAGCTCTATTCTATACTAAAAAAAAAAAGTGCAATTATGAATGTGT
TAGTGTTAATGCACAGGTGATAACCCTATCACCAGCAAGCATTGCATTAAAAAAGGCAACGGACTCTCTT
TAGGATGACCCTATGATGTTCTTTCCTTTGCAGACGATGAGGCTTCCTGTCCCTACTCATAAAAATGTAA
GTTATTCTTTACTGCCGTGCTTGCATGAGTAAGTCAGCTTCGCATACTAAGCTATAAGTCATCTGCATCT
AGCTTTCTGGTGTTGTGTGTGTCTGGGATGGGGACCTCTCTAGGTCTCAAGCTCCTGGGTTCAAGTGATT
CTCTTGCCTTGATAGAGCAGCTGGGACACAGGCCTGTGCCACCACACCCAGCAGAGCTTTTGATTTCAGT
TAAACTGTTTGACTTTCTTGGAAAAGAAAATTTATGTAGGTAGATATGAAAGTTTGTGCTTATAAATAAA
AAGAATATGAGAGTGGCAAATTATGTAATCCCAGTACTTGGGAGCCAAAGGCAGGGGTAGTCTGAGTCTA
GGGCCAGCTTAGATACATTGCCCTGTATGTATCAAAAGTAAATCCTATAAATAAATAAACAAAAACATTA
GAGGGCTGGAGATATAAGCTCTGTTGATAGATGGCCTAATATGCTGGGTTGACTCTTAGCACCCCATAAA
CTAAACATGGAAGTACCTGGCTGTAATCTCATGATGGTGAAATGGAGGCGGGAAGATCATAGGTTCAAGG
TCATCCTCAGCTACATTTTTGAGCTAGAGGCCAGCCTGGGCTATGAGACACGCAAAAACCACCAGCCAAT
TAATATTAGGAATGGCTTTGAGCTAGATCTGTTATGTAAGTGGCCAGCTGGAGCTGTCAGTCATACATCT
CACAGCCTCACAAGATTCTTTGCATGGCGAGAGGTCCTGCTGGGCTCCCTTTGGCTCTGTCCATGGCTCT
CTTCATCCTAGTGCCTCTCTTTGTTTTCCTTGTCTTATTTCTTACTGCTGAGGATCAAGCCCAGGGCCTT
CAGTGTGTGAAGTGAGCACTCTACCACTGAATTCCAGAGCCCGCCCACTCTAATGCCTTTCTGAAAGTAT
TAAGAGTTTAGGGTTATATATTCCTTTTGTTTATTTTATGTGTATGAGCATTTTGCCTGCATATATATAT
ATATATATATATATATATGTGTGTGTGTGTGTGTGTGTGTGTGTATATATATATGTATGTATGTATGTAT
GTATGTATGTATGTATATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTTCCACGTATGTGTCTATGTG
TCTGGTGTTCCTGAAGGCTAAAAGAAGGGCATCAGATCACCTGGGGCTGGATATGCAGATGGTTGTGAGC
CAACCATCTGGATGCTGGGAACTGCATCAAGTGTTCTTAACCACTGAGCCATCTCTCCCGCTCAGAGGGT
TATATTCTTAGGTAATGATAGAAAGACATAAAAATATCATGAATGCCTTTATTAATAATTTCTAAACAGT
TTAATGAATATGACTATGTAGTGATATTGTATACATTTCAATATTATCTTATTCTAGCGTAAAGTACATT
ATTTAACTTTTTCTAAATAGAAGAAAATTCATCAGCCTAAATTTCAAAAGAAAATATTAATATGGGTGTG
GTACCACTCACCTTTAATCCAGATGGTTGTGAGCCACCACAAGGGTGCTGGTAACTGAACCCAGGTCCTC
TGGAAGAGGACCCAGTGATCTTAACCACTGAGCCATCTCCCCAGCCCCAATCCTAACTTTGGGTTCATTT
TTTTGAAATGATCTCATGTAGCACTAGCTGGCCTCAAACTCTATGTATCAGAGGCTGGCCTTCAACTCCT
GATCCTCTTACCTCAACTTCCTGAATGCTGGCATTACAGATAAGCACCATCACATCTTGTATTGTCTGGG
GTTTTTTATTGATGCATTTAAATTGCATGTATTTATTGCATATGGCATGATATTTCAAAATATGTGTACG
TTGTGGGCAGTCTGATCTATTTGCTTCTTGATAATCTTCTTTCAGCACCAGCTATGCATTGGAGAAATCT
TTCAGGGGCTAGACATACTGAAGAATCAAACTGTCCGTGGGGGTACTGTGGAAATGCTATTCCAAAACCT
GTCATTAATAAAGAAATACATTGACCGCCAAAAAGTAAGTTCCCCAGGGACCCTGTGAATCCGGCTGCAG
CTGGTTCTCCAGGAGCCAACCTGACAGTCTGTTCTTTTCACAGGAGAAGTGTGGCGAGGAGAGACGGAGG
ACGAGGCAGTTCCTGGATTACCTGCAAGAGTTCCTTGGTGTGATGAGTACAGAGTGGGCAATGGAAGGCT
GAGGCTGAGCTGCTCCATGGTGACAGGACTTCACAATTTAAGTTAAATTGTCAACAGATGCAAAAACCCC
ACAAAACTGTGCAAATGCAAGGGATACCATATGCTGTTTCCATTTATATTTATGTCCTGTAGTCAGTTAA
ACCTATCTATGTCCATATATGCAAAGTGTTTAACCTTTTTGTATACGCATAAAAGAAATTCCTGTAGCGC
AGGCTGGCCTCAAACTGGTAATGTAGCCAAGGATAACCTTGAATTTCTGATCCTCCTGCCTCCTCTTCCT
GAAGGCTGAGGTTACAGACATGCACCATTGCCACTAGTTCATGAAGTGCTGGAGATGGAACCCAAGGCTT
TGTGCATGTTACCAACTGAGTTATACTCCCTCCCCCTCATCCTCTTCGTTGCATCAGGGTCTCAAGTATT
CCAGGCTGACTTTGAACTCAGTGTGTAGCCAAGGGTGACCCTGAACTCTTGGTCCAGATGGACGCAGGAG
GATCACATACCCAACCTTAGCATCCTTTCTCCTAGCCCCTTTAGATAGATGATACTTAATGACTCTCTTG
CTGAGGGATGCCACACCGGGGCTTCCTGCTCCTATCTAACTTCAATTTAATACCCACTAGTCAATCTCTC
CTCAACTCCCTGCTACTCTCCCCAAACTCTAGTAAGCCCACTTCTATTTCTTGGGGAGAGAGAAGGTTGA
CTTTTCTTATGTCCTATGTATGAATCAGACTGTGCCATGACTGTGCCTCTGTGCCTGGAGCAGCTGGATT
TTGGAAAAGAAAAGGGACATCTCCTTGCAGTGTGAATGAGAGCCAGCCACATGCTGGGCCTTACTTCTCC
GTGTAACTGAACTTAAGAAGCAAAGTAAATACCACAACCTTACTACCCCATGCCAACAGAAAGCATAAAA
TGGTTGGGATGTTATTCAGGTATCAGGGTCACTGGAGAAGCCTCCCCCAGTTTACTCCAGGAAAAACAGA
TGTATGCTTTTATTTAATTCTGTAAGATGTTCATATTATTTATGATGGATTCAGTAAGTTAATATTTATT
ACAACGTATATAATATTCTAATAAAGCAGAAGGGACAACT

Protein Sequence : Show Sequence

>gi|6754336|ref|NP_034688.1| interleukin-5 precursor [Mus musculus]
MRRMLLHLSVLTLSCVWATAMEIPMSTVVKETLTQLSAHRALLTSNETMRLPVPTHKNHQLCIGEIFQGL
DILKNQTVRGGTVEMLFQNLSLIKKYIDRQKEKCGEERRRTRQFLDYLQEFLGVMSTEWAMEG

21. TNF

Gene Name : TNF
Sequence Strain (Species/Organism) : Macaca mulatta
NCBI Gene ID : 715467
NCBI Protein GI : 114051684
Locus Tag : EGK_14705
Genbank Accession : AB128049
Protein Accession : NP_001040614
Taxonomy ID : 9544
Chromosome No : 4
Gene Starting Position : 32435034
Gene Ending Position : 32437640
Gene Strand (Orientation) : +
Protein Name : transcript variant X1
Protein pI : 6.12
Protein Weight : 24042.53
Protein Length : 233
Protein Note : Also known as TNF-ALPHA

DNA Sequence : Show Sequence

>NC_027896.1:32435034-32437640 Macaca mulatta isolate 17573 chromosome 4, Mmul_8.0.1, whole genome shotgun sequence
CATGAGCACGGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAGGAAGACAGCGGGG
CCCCAGGGCTCCAGGCGGTGCTGGTTCCTCAGCCTCTTCTCCTTCCTGCTCGTGGCAGGCGCCACCACGC
TCTTCTGTCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGGGAAGAGGTGAGTGCCTCGCCAGCCTTCAT
CCACTCTCCCACCCAAGAGGGGGAGAGAGATGGGATGGGCGAAAGATGTGTGCTGACAGGGAGGGATGGA
GAGAAAAACAACGTGGAGGAAGACGAGGATGCAGAAAGAGATGTGGCAAGAGATGGAGAACAGAGAGAGA
AAGATGGAGAGGCAGAATGTCTGGCACATGGAAGGTGCTCACTAAGTGTGTATGGAGTGAATGAATGAAT
GAATGAACAATCAGATAGTAAATAAGATATGGAGACAGATGTGGGGTGTGAGCAGAGAGATGGGGGAAGA
AACAAGTGATATGAATAAAGATGGTGAGACAGAGAGTGGGAAATATGGCAGCTAAGGAGAGAGATGAGGG
AGATAAGGAGAGATGAGGGAGATAAGGAGAGATGAAGATAGGATGTCTGGCACACAGAAGACACTCAGTG
AAAGAGTTGTTGAATGCATGGAGGGTGAATATACAGATGAATGGAGAGAGAAAACCGGACAACTCAGGGC
TAAGAGCGCAGGTCAGACAGGCAGCCAGCTGTTCCTCCTTTAAGGGTGATTCCCTTGATGTTAACCATTC
TCCTTCTCCCCAACAGTTCCCCAAGGACCCCTCTCTAATCAGCCCTCTGGCTCAGGCAGTCAGTAAGTGT
CTCTAAACCTTTTTCCTAATTCTGGGTTTGGGTTGGGGTGTAGGGTTAGTACTGGTACGAAAGCAGTGGG
GGAAATTTAAAGTTTTGGTCTTGGGGGAGGGCGGATGGGGTGAAAGTAAGGGGATGGGGGGTATTTTCTA
GGAAGTTTAAGGGTCTCACCTTTTTCTTTTCTCTCTCCTCTTCAGGATCATCTTCTCGAACCCCAAGTGA
CAAGCCTGTAGCCCATGTTGTAGGTAAGAGCTCTGATGATGTGTCTTGGAACTTGGAGGGCTAGGATTTG
GGGGTTGAAGCCCGGCTGAGGGTAGGCAGACCTTGGAGACAGTGTGAGAAGGACTGGCTGAGCTCAAGGG
AAGGGTGGAGGAACTGCACAGCCCTTAGGGGGATACTCAGAACGTCATGGCCAGGTGGGATGTGGGATGA
CAGACAGAGGGAACAGGAACCGGATGTGGGGTGGGCAGAGCTCGAGGGCCAGGATGTGGAGAGTGAACCG
ACATGGCCACACTGACTCCCCTCTCTCTCTCTCCCTCCCTCCAGCAAACCCTCAAGCTGAGGGGCAGCTC
CAGTGGCTGAACCGCCGGGCCAATGCCCTCCTGGCCAATGGCGTGGAGCTGACAGATAACCAGCTGGTGG
TGCCATCAGAAGGCCTGTACCTCATCTACTCCCAGGTCCTCTTCAAGGGCCAAGGCTGCCCCTCCAACCA
TGTGCTCCTCACCCACACCATCAGCCGCATCGCCGTCTCCTACCAGACCAAGGTCAACCTCCTCTCTGCC
ATCAAGAGCCCCTGCCAGAGGGAGACTCCAGAGGGGGCTGAGGCCAAGCCCTGGTACGAGCCCATCTACC
TAGGAGGGGTCTTTCAGCTGGAGAAGGGTGATCGACTCAGCGCTGAGATCAATCTGCCCGACTATCTCGA
CTTTGCCGAGTCTGGGCAGGTCTACTTTGGGATCATTGCCCTGTGAGGAGGACGAACATCCATCCTTCCC
AAACCCCTCCCCCGCCCCAATCCCTTTATTATCCCCTCCTTCAGACACCCTCATCCTCTTCTGGCTCAAA
AAGAGAATTGGGGACTTAGGGCCAGACCCCAAGCTTAGAACTTTAAGCAACGCCACCACCACTTCGAAGC
CTGGGGTTCAGGAATGTGTGGCCTGCACAGTGAAGTGCTGGCAACCACTGAGAATTTAAACTGGGGCCTC
CAGCACTCACTGGGGCCTACAGCTTCCATCCCTGAACTCAGTCTGTGACATCTGGAATCTGGAGACCAGG
GAGCCTTTGGTTCTGGCCGGAACGCTGCAAGACTTGAGAAGACATCACCTAGAAGTTGACACAAGTGGAC
CTCGGGCCTTCCTCTCTCCAGATGTTTCCAGACTTCCTTGAGACATGGAGCCTGGCCCTCCCCATGGAGC
CAGCCCCCTCTATTTATGTTTGTACTTGTGATTATTTATTATTTATTATTTATTTATTTATTTACCGATT
AATGTATTTATTTGGGAGGTCGGGGGATCCCAGGGGACCCAATGTGGGAGCTGCCTTGGCTCAGACATGT
TTTCTGTGAAAACGGAGCTGAACAATAGGCTGTTCCCACATAGCCTCCTGGCCTCTGTGCCTTCTTTTGA
TTATGTTTTTTAAAATATTTATCTGATTAAGTTGTCCGAACAATGCAGATTTGGTGACTGACTGTCACTC
ATTGCTGAGCCTCTGCTCCCCAGGGGAGTTGTGTCTGTAATCGCCCTACTATTCAGTGGCGAGAAATAAA
GTTTGCTTAGAAAAGAA

Protein Sequence : Show Sequence

>NP_001040614.1 tumor necrosis factor [Macaca mulatta]
MSTESMIRDVELAEEALPRKTAGPQGSRRCWFLSLFSFLLVAGATTLFCLLHFGVIGPQREEFPKDPSLI
SPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELTDNQLVVPSEGLYLIYSQVLF
KGQGCPSNHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSA
EINLPDYLDFAESGQVYFGIIAL

Molecule Role : Protective antigen
Related Vaccine(s): HIV DNA vaccine VlJns-tPA-gp120

22. TNF-a from Papio anubis

Gene Name : TNF-a from Papio anubis
Sequence Strain (Species/Organism) : Papio anubis
NCBI Gene ID : 100126739
NCBI Protein GI : 162951924
Genbank Accession : AHZZ02024393
Protein Accession : NP_001106118
Taxonomy ID : 9555
Chromosome No : 4
Gene Starting Position : 31002321
Gene Ending Position : 31004098
Gene Strand (Orientation) : +
Protein Name : tumor necrosis factor
Protein pI : 6.93
Protein Weight : 24148.68
Protein Length : 233
Protein Note : Also known as TNFa; TNFSF2

DNA Sequence : Show Sequence

>NC_018155.2:31002321-31004098 Papio anubis isolate 1X1155 chromosome 4, Panu_3.0, whole genome shotgun sequence
CATGAGCACGGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAGGAAGACAGCGGGG
CCCCAGGGCTCCAGGCGGTGCTGGTTCCTCAGCCTCTTCTCCTTCCTGCTCGTGGCAGGCGCCACCACGC
TCTTCTGTCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGGGAAGAGGTGAGTGCCTCGCCAGCCTTCAT
CCACTCTCCCACCCAAGAGAGGGAGAGAGATGGGATGGGCGAAAGATGTGTGCTGACAGGGAGGGATGGA
GAGAAAAACAACGTGGAGAAAGACTTGGATGCAGAAAGAGATGTGGCAAGAGATGGAGAAGAGAGAGAGA
GAAAGATGGAGAGGCAGGATGTCTGGCACATGGAAGGTGCTCACTAACTGTGTATGGAGTGAATGAATGA
ATGAATGAACAATCAGATAGTAAATAAGATATGGAGACAGATGTGGGGTGTGAGCAGAGAGATGGGGGAA
GAAACAAGTGATATGAATAAAGATGGTGAGACAGAGAGTGGGAAATATGGCAGCTAAAGAAAGAGATGAG
GGAGATAAGGAGAGATGAAGATAGGATGTCTGGCACACAGAAGACACTCAGTGAAAGAGTTGTTGAATGC
ATAGAGGGTGAATACACAGATGAATGGAGAGAGAAAACCGGACAACTCAGGGCTAAGAGCGCAGGCCAGA
CAGGCAGCCAGCTGTTCCTCCTTTAAGGGTGATTCCCTTGATGTTAACCATTCTCCTTCTCCCCAACAGT
TCCCCAAGGACCCCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGTAAGTGTCTCCAAACTTTTTTCCT
AATTCTGGGTTTGGGTTGGGGTGTAGGGTTAGTAGTGGTACGAAAGCAGTGGGGGAAATTTAAAGTTTTG
GTCTTGGGGGAGGGCAGATGGGGTGAAAGTAAGGGGATGGGGGGTATTTTCTAGGAAGTTTAAGGGTCTC
ACCTTTTTCTTTTCTCTCTCCTCTTCAGGATCATCTTCTCGAACCCCAAGTGACAAGCCTGTAGCCCATG
TTGTAGGTAAGAGCTCTGATGACGTGTCTTGGAACTTGGAGGGCTAGGATTTGGGGGTTGAAGCCCGGCT
GAGGGTAGGCAGACCTTGGAGACAGTGTGAGAAGGACTGGCTGAGCTCAAGGGAAGGGTGGAGGAACTGC
ACAGCCCTTAGGGGGATACTCAGAACGTCATGGCCAGGTGGGATGTGGGATGACAGACAGAGGGAACAGG
AACCGGATGTGGGGTGGGCAGAGCTCGAGGGCCAGGATGTGGAGAGTGAACCGACATGGCCACACTGACT
CCCCTCTCTCTCTCTCCCTCCCTCCAGCAAACCCTCAAGCTGAGGGGCAGCTCCAGTGGCTGAACCGCCG
GGCCAATGCCCTCCTGGCCAATGGCGTAGAGCTGACAGATAACCAGCTGGTGGTGCCATCAGAAGGCCTG
TACCTCATCTACTCCCAGGTCCTCTTCAAGGGCCAAGGCTGCCCCTCCAACCATGTGCTCCTCACCCACA
CCATCAGCCGCATCGCCGTCTCCTACCAGACCAAGGTCAACCTCCTCTCTGCCATCAAGAGCCCCTGCCA
GAGGGAGACTCCAGAGGGGGCTGAGGCCAAGCCCTGGTATGAGCCCATCTACCTAGGAGGGGTCTTTCAG
CTGGAGAAGGGTGATCGACTCAGCGCTGAGATCAATCTGCCCGACTATCTCGACTTTGCCGAGTCTGGGC
AGGTCTACTTTGGGATCATTGCCCTGTG

Protein Sequence : Show Sequence

>NP_001106118.1 tumor necrosis factor precursor [Papio anubis]
MSTESMIRDVELAEEALPRKTAGPQGSRRRWFLRLFSFLLVAGATTLFCLLHFGVIGPQREEFPKDPSLI
SPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVEPTDNQLVVPSEGLYLIYSQVLF
KGQGCPSNHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSA
EINLPDYLDFAESGQVYFGIIAL

Molecule Role : Protective antigen
Related Vaccine(s): HIV-2 DNA vaccine

23. TNF-alpha

Gene Name : TNF-alpha
Sequence Strain (Species/Organism) : Mus musculus
NCBI Gene ID : 21926
NCBI Protein GI : 7305585
Genbank Accession : AB039224
Protein Accession : NP_038721
Taxonomy ID : 10090
Chromosome No : 17
Gene Starting Position : 35199389
Gene Ending Position : 35201995
Gene Strand (Orientation) : -
Protein Name : tumor necrosis factor
Protein pI : 4.75
Protein Weight : 24010.47
Protein Length : 235
Protein Note : Also known as DIF; Tnfa; TNFSF2; Tnfsf1a; TNFalpha; TNF-alpha; MGC151434

DNA Sequence : Show Sequence

>gi|372099093:35199389-35201995 Mus musculus strain C57BL/6J chromosome 17, GRCm38 C57BL/6J
CTTTATTTCTCTCAATGACCCGTAGGGCGATTACAGTCACGGCTCCCGTGGGGAGCAGAGGTTCAGTGAT
GTAGCGACAGCCTGGTCACCAAATCAGCGTTATTAAGACAATTGGGTTAGATAAATATTTTGTTTTAAAC
ATAAGCAAAAGAGGAGGCAACAAGGTAGAGAGGCCAGGTGGGGACAGCTCAGCTCCGTTTTCACAGAAAA
CATGTCTGTCTGAAGACAGCTTCCCACACTGGGTCCTCCAGGACACCCCGGCCTTCCAAATAAATACATT
CATAAGCAAATAAATAAATAATAAATAAATAATAAATAATAAGTGCAAATATAAATAGAGGGGGGCTGGC
TCTGTGAGGAAGGCTGTGCATTGCACCTCAGGGAAGAATCTGGAAAGGTCTGAAGGTAGGAAGGCCTGAG
ATCTTATCCAGCCTCATTCTGAGACAGAGGCAACCTGACCACTCTCCCTTTGCAGAACTCAGGAATGGAC
ATTCGAGGCTCCAGTGAATTCGGAAAGCCCATTTGAGTCCTTGATGGTGGTGCATGAGAGGCCCACAGTC
CAGGTCACTGTCCCAGCATCTTGTGTTTCTGAGTAGTTGTTGAAAGCTCTGAGCACAGAGTTGGACCCTG
AGCCATAATCCCCTTTCTAAGTTAGAAGGATACAGACTGGGGGCTCTGAGGAGTAGACAATAAAGGGGTC
AGAGTAAAGGGGTCAGAGTGGGGGCTGGGTAGAGAATGGATGAACACCCATTCCCTTCACAGAGCAATGA
CTCCAAAGTAGACCTGCCCGGACTCCGCAAAGTCTAAGTACTTGGGCAGATTGACCTCAGCGCTGAGTTG
GTCCCCCTTCTCCAGCTGGAAGACTCCTCCCAGGTATATGGGCTCATACCAGGGTTTGAGCTCAGCCCCC
TCAGGGGTGTCCTTGGGGCAGGGGCTCTTGACGGCAGAGAGGAGGTTGACTTTCTCCTGGTATGAGATAG
CAAATCGGCTGACGGTGTGGGTGAGGAGCACGTAGTCGGGGCAGCCTTGTCCCTTGAAGAGAACCTGGGA
GTAGACAAGGTACAACCCATCGGCTGGCACCACTAGTTGGTTGTCTTTGAGATCCATGCCGTTGGCCAGG
AGGGCGTTGGCGCGCTGGCTCAGCCACTCCAGCTGCTCCTCCACTTGGTGGTTTGCTGAGGGGGGGGGGG
AGGATTGAGTCAGTGTCACCCTCTTAGTTCACACTCCACATCCTGAGCCTCAGCAGCTACCCACACTTCA
CTTCCGGTTCCTGCACCCTCTGTCTTTCCACATCCCATTGGCTATGAGGTCCCGGGTGGCCCCCTGATGC
CTTGCTTTTGAGTCACTGCTCTGACTCTCACGTGCTGTCTCTAAGAGCTCTGTCTTTTCTCAGCCTGGCT
CGACACCCCTCAACCCGCCCCCCAAAATCATGCCCCTTCATTCTCAAGGCACATGTAAAGAAATCTTACC
TACGACGTGGGCTACAGGCTTGTCACTCGAATTTTGAGAAGATGATCCTGGAGGGGAAGAGACAAAGGCA
AGGATGAGCCTTTTAGGCTTCCCAGCAAGCATCTATGCACTTAGACCCCTTTCCTCCCAAACCAAAGCTT
TAAGTTCTCCCCCCACCCCATCTCATCCCATGCCTAACTGCCCTTCCTCCATCTTAAATTAAGAGAGAGG
TGTGGGAACACTTACTGAGTGTGAGGGTCTGGGCCATAGAACTGATGAGAGGGAGGCCATTTGGGAACTT
CTGTGTAGGAAAAGGAGGTTAGTTAAGACAGACTCACCCCAAAGGAGAAGCCTCCCGGCTGATTGCCCCG
CTTACAGTTCCTCTTTGCCCCACCCCACCCCCCAGCTTTGTGTTTTTCTTCTTCATTCATTCATCTGTCC
AACCCACGGCTTCTTTCTGCGGTGCCCTCTGTGCTTGATCTCCCGTTATCTCCCCTTCATCTTCCTCCTT
ATCTCTCATGCCTCTCTCATTTCTGTCTCTGAGTTTTATCTCTTGCTTATCCCCTCTTCCCCTGGCCACA
TCTTTCCAGATCTCTCCACGTGTGAACACACTTGTTCGTTCATTCATCTCTCTGTGCATCCGACGAAGGA
TGTTTAGTCAGCTGGACGCATGGGTCCGAGGTCCTGACTCTGTCCCCTCCACACTCTCCTCCACCTTGCC
CTGCCCATTAGCCCACTTCTTTCCCTCACACTGTCCTTCTTGCCCTCCTAACCCGTTTTGCTTGTGAGCG
AGAATAAGGGTTGCCCAGACACTCACCTCATCCCTTTGGGGACCGATCACCCCGAAGTTCAGTAGACAGA
AGAGCGTGGTGGCCCCTGCCACAAGCAGGAATGAGAAGAGGCTGAGACATAGGCACCGCCTGGAGTTCTG
GAAGCCCCCCATCTTTTGGGGGAGTGCCTCTTCTGCCAGTTCCACGTCGCGGATCATGCTTTCTGTGCTC
ATGGTGTCTTTTCTGGAGGGAGATGTGGCGCCTTGGGCCAGTGAGTGAAAGGGACAGAACCTGCCTGGTT
GGCTGCTTGCTTTTCTGGGAGCTATTTCCAAGATGTTCTGGAGTTTCTGTTCTCCCTCCTGGCTAGTCCC
TTGCTGTCCTCGCTGAG

Protein Sequence : Show Sequence

>gi|7305585|ref|NP_038721.1| tumor necrosis factor [Mus musculus]
MSTESMIRDVELAEEALPQKMGGFQNSRRCLCLSLFSFLLVAGATTLFCLLNFGVIGPQRDEKFPNGLPL
ISSMAQTLTLRSSSQNSSDKPVAHVVANHQVEEQLEWLSQRANALLANGMDLKDNQLVVPADGLYLVYSQ
VLFKGQGCPDYVLLTHTVSRFAISYQEKVNLLSAVKSPCPKDTPEGAELKPWYEPIYLGGVFQLEKGDQL
SAEVNLPKYLDFAESGQVYFGVIAL

Molecule Role : Vaximmutor

IV. Vaccine Information

1. Adenoviral vector Ad5 expressing SIV gag protein

a. Vaccine Ontology ID:

VO_0000788

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Antigen

SIVmac239 gag protein (Shiver et al., 2002)

e. Gene Engineering of Gag protein from SIV-mnd 2

Type: Recombinant vector construction
Description:
Detailed Gene Information: Click here.

f. Vector:

Adenoviral vector (Ad5)

g. Preparation

The adenoviral vector was based on a serotype 5 adenovirus that is incompetent to replicate with deletion of the E1 and E3 viral genes, and was propagated subsequently in E1-expressing 293 cells. Recombinant adenovirus expressing the codon-optimized SIV gag gene was then prepared. The recombinant adenovirus (Ad5-SIVgag) was grown in large quantities by multiple rounds of amplification in 293 cells. The virus was purified by caesium chloride gradient centrifugation (Shiver et al., 2002).

h. Immunization Route

Intramuscular injection (i.m.)

i. Monkey Response

Host Strain: rhesus monkey (Macaca mulatta)
Vaccination Protocol: In this study, 21 rhesus monkeys were divided into 6 groups, including an unimmunized control cohort. Each of the test vectors expressed the identical SIVmac239 gag gene that had been codon optimized for expression in mammalian cells. In the first study, the two viral vector vaccines were administered, followed by a booster dose; preparations of DNA plasmid vector vaccine were delivered thrice, followed by a booster (Shiver et al., 2002).
Immune Response: In general, all of the monkeys developed p11CM-specific cellular immune responses after the initial immunization series. The p11CM (residues 181–189) is an immunodominant SIV gag epitope that is presented by the Mamu-A*01 MHC protein and is capable of binding T-cell receptors in the model monkeys. Administration of the third dose of the Ad5 vector resulted in an additional increase of p11CM-specific CD8+ T cells at the time of virus challenge. After the booster inoculation, these animals exhibited peak levels of p11CM-specific CD8+ T cells (Shiver et al., 2002).
Challenge Protocol: At 12 weeks after the final immunization, all monkeys were challenged i.v. with the pathogenic HIV–SIV hybrid virus (SHIV) 89.6P16. The challenge of the control and immunized animals within the context of each of the two independent studies occurred concurrently (Shiver et al., 2002).
Efficacy: Each of the animals in both control groups exhibited acute CD4+ T-cell lymphopenia and peak viral loads of viral RNA copies at about 3 weeks after challenge. With the exception of one animal, all of the control monkeys experienced dramatic loss of CD4+ T cells. During the acute phase of the infection, most monkeys immunized with either the DNA or MVA vectors exhibit an acute CD4+ T-cell lymphopenia. By about 70 d after challenge, many of the immunized monkeys exhibit some evidence of a positive immunization benefit, as manifested by control of viremia and recovery of CD4+ T-cell counts. However, the animals immunized with Ad5 vector exhibited the most pronounced attenuation of the infection with a pathogenic HIV–SIV hybrid virus (SHIV) (Shiver et al., 2002).

2. ALVAC-HIV-2

a. Vaccine Ontology ID:

VO_0004727

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Baboon

e. Gene Engineering of env

Type: Recombinant vector construction
Description: Live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).
Detailed Gene Information: Click here.

f. Gene Engineering of gag

Type: Recombinant vector construction
Description: Live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).
Detailed Gene Information: Click here.

g. Preparation

A live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).

h. Immunization Route

Intramuscular injection (i.m.)

i. Monkey Response

Vaccination Protocol: Five monkeys were immunized either three times with ALVAC HIV-2 alone or twice with ALVAC HIV-2 and once with purified native HIV-2 gp125 (Walther-Jallow et al., 2001).
Vaccine Immune Response Type: VO_0003057
Challenge Protocol: The monkeys were then challenged with HIV-2 given intravenously and finally with pathogenic SIVsm given intrarectally (Walther-Jallow et al., 2001).
Efficacy: After challenge with SIVsm, three of five monkeys were completely protected against SIVsm infection. Vaccination with an ALVAC HIV-2 vaccine followed by exposure to live HIV-2 could induce cross-protection against mucosal infection with SIVsm and seemed to be more efficient than immunization with a live HIV-2 vaccine only (Walther-Jallow et al., 2001).

3. ALVAC-HIV-2- env/gag/pol

a. Vaccine Ontology ID:

VO_0004737

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Baboon

e. Gene Engineering of env

Type: Recombinant vector construction
Description: Live attenuated human immunodeficiency virus type 2 (HIV-2) vaccine alone versus boosting with live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).
Detailed Gene Information: Click here.

f. Gene Engineering of gag

Type: Recombinant vector construction
Description: Live attenuated human immunodeficiency virus type 2 (HIV-2) vaccine alone versus boosting with live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).
Detailed Gene Information: Click here.

g. Preparation

A live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).

h. Immunization Route

Intramuscular injection (i.m.)

i. Monkey Response

Vaccination Protocol: Six monkeys were first inoculated intravenously with live HIV-2(SBL-6669) (Walther-Jallow et al., 2001).
Vaccine Immune Response Type: VO_0003057
Challenge Protocol: 7 to 10 months after vaccination, the monkeys were challenged intrarectally with 10 MID(50) of cell-free simian immunodeficiency virus (SIV) strain SIVsm (Walther-Jallow et al., 2001).
Efficacy: Vaccination with an ALVAC HIV-2 vaccine followed by exposure to live HIV-2 could induce cross-protection against mucosal infection with SIVsm and seemed to be more efficient than immunization with a live HIV-2 vaccine only (Walther-Jallow et al., 2001).

4. ALVAC-SIV/gp120

a. Vaccine Ontology ID:

VO_0004638

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Baboon

e. Immunization Route

Intramuscular injection (i.m.)

5. CVB4/p24(73(3))

a. Vaccine Ontology ID:

VO_0004719

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Baboon

e. Preparation

A live coxsackievirus B4 recombinant, CVB4/p24(73(3)), that expresses seventy-three amino acids of the gag p24 sequence (HXB2) (Gu et al., 2010).

f. Immunization Route

Intramuscular injection (i.m.)

g. Mouse Response

Vaccination Protocol: Immunization was by intraperitoneal (IP) injection or by oral gavage. Mice were immunized with either CVB4/p24(733) or the parental CVB4. PBS-treated mice served as controls (Gu et al., 2010).
Vaccine Immune Response Type: VO_0003057
Challenge Protocol: Mice immunized with the avirulent CVB4 variant are protected when subsequently challenged with a virulent variant (Gu et al., 2010).
Efficacy: Results showed that oral immunization with CVB4/p24(73(3)) induced gag p24-specific immune responses in vector-immune mice (Gu et al., 2010).

6. DNA and poxvirus priming-boosting SHIV vaccine

a. Vaccine Ontology ID:

VO_0000825

b. Type:

DNA vaccine

c. Antigen

SHIV89.6P env and SIVmac239 gag (Santra et al., 2004)

d. Gene Engineering of env

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

e. Gene Engineering of Gag protein from SIV-mnd 2

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Vector:

pV1R plasmid and recombinant fowlpox virus

g. Preparation

The recombinant vaccinia viruses (rVac) expressing SHIV89.6P env and SIVmac239 gag were constructed by inserting these genes in the HindIII M region of TBC-Wy, Therion strain of vaccinia. rFPV viruses expressing these same genes were constructed by inserting the genes in the BamJHI region of POXVAC-TC (Schering-Plough) strain of FPV (Santra et al., 2004).

h. Description

An HIV vaccine should elicit a cytotoxic T lymphocyte (CTL) response, but the characteristics of effective vaccine-induced CTL response remain unclear. The SHIV/rhesus monkey model has been used to in the course of assessing the relative immunogenicity of vaccine regimens that include a cytokine-augmented plasmid DNA prime and a boost with DNA or recombinant pox vectors. This study indicates that the steady-state memory, rather than the peak effector vaccine-elicited CTL responses, may be the critical immune correlate of protection for a CTL-based HIV vaccine (Santra et al., 2004).

i. Monkey Response

Host Strain: rhesus monkey (Macaca mulatta)
Vaccination Protocol: Nonrecombinant wildtype vaccinia virus was designated VV-WT, wild-type fowlpox virus was designated FPV-WT, and wild-type MVA was designated MVA-WT. These wild-type viruses were used as control vector immunogens (Santra et al., 2004). One group of monkeys were vaccinated by separate i.m. injections of HIV-1. Half the dose was delivered to each quadriceps muscle. Seven of the 28 monkeys were vaccinated by both i.d. and i.m. injections of rFPV expressing HIV-1 89.6P Env and the same virus expressing SIV mac239 Gag. Seven monkeys received rMVA-HIV-189.6P Env and rMVA-SIVmac239 Gag, and another seven monkeys received rVac-HIV-1 89.6P Env and rVac-SIVmac239 Gag administered both i.d. and i.m. Another 28 monkeys received sham plasmid DNA and empty pox vectors (Santra et al., 2004).
Persistence: Persistence levels were measured 2 weeks after challenge with results mentioned in Challenge Protocol section (Santra et al., 2004).
Immune Response: Recombinant vaccinia virus, MVA, and fowlpox were comparable in their immunogenicity. Magnitude of peak vaccine-elicited CTL responses in pox virus-boosted monkeys is substantially greater than that seen in monkeys immunized with plasmid DNA alone, but magnitudes of recombinant pox boosted CTL responses decayed rapidly and were comparable to those of the DNA-alone vaccinated monkeys by the time of viral challenge. Clinical protection seen in all groups of experimentally vaccinated monkeys is similar, indicating that steady-state memory, rather than peak effector vaccine-elicited T lymphocyte responses, may be the critical immune correlate of protection for a CTL-based HIV vaccine (Santra et al., 2004).
Challenge Protocol: Eighteen weeks after the final immunization, all animals were challenged with cell-free SHIV-89.6P i.v. (Santra et al., 2004).
Efficacy: Control monkeys developed tetramer-binding CD8 T lymphocyte responses that were maximal 2 weeks after viral challenge and no detectable p41A-specific CD8 T cells. In contrast, all four groups of vaccinated monkeys developed robust secondary p11C-specific CTL responses that were comparable in magnitude. Animals boosted with plasmid DNA had Gag p11C-specific CD8 T cell responses similar in magnitude to that seen in the recombinant pox virus-boosted animals. Magnitudes of the postchallenge IFN ELISPOT responses to both vaccine antigens were comparable in all four experimentally vaccinated groups of monkeys. Therefore, although the pre-challenge peak vaccine-elicited immune responses were greater in the groups of monkeys boosted with recombinant pox vectors, the pre-challenge plateau and post-challenge peak secondary responses were equivalent in magnitude in all four experimental groups of animals (Santra et al., 2004).
Host Gene Response of IFNG
- Gene Response: There was a greater contraction of the vaccine-elicited IFN-γ-secreting T cell responses in the groups of monkeys boosted with recombinant pox vectors than in the group of animals boosted with plasmid DNA. Although the pre-challenge peak vaccine-elicited immune responses were greater in the groups of monkeys boosted with recombinant pox vectors, the pre-challenge plateau and post-challenge peak secondary responses were equivalent in magnitude in all four experimental groups of animals (Santra et al., 2004).
- Detailed Gene Information: Click here.

7. DNA vaccine expressing multiple HIV epitopes

a. Vaccine Ontology ID:

VO_0000817

b. Type:

DNA vaccine

c. Antigen

The antigens are named MultiHIV-A (based on the subtype A consensus sequence), MultiHIV-B (subtype B consensus sequence), MultiHIV-C, and MultiHIV-FGH (based on ancestral sequence for subtypes F, G, and H). The MultiHIV DNAs encode polypeptides consisting of a fusion of the full-length regulatory proteins Rev, Nef and Tat as well structural proteins p17 and p24 (Malm et al., 2005).

d. Gene Engineering of rev from HIV 1

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

e. Gene Engineering of Nef

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Gene Engineering of Tat

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

g. Gene Engineering of Gag from HIV 1

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

h. Gene Engineering of env

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

i. Gene Engineering of pol

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

j. Vector:

Auxo-GTU vector system (Malm et al., 2005)

k. Preparation

A vaccine platform was constructed with an HIV-1 subtype B DNA immunogen expressing full-length consensus sequences from HIV-1 rev, nef, tat, and gag with additional cellular epitope clusters from the env and pol regions. Furthermore, this platform has been extended to three additional plasmids expressing the same immunogens but originating from subtypes A or C consensus or FGH ancestral sequences (Malm et al., 2005).

l. Description

A significant limitation for HIV vaccine development is that there are no small animals in which actual productive HIV-1 infection can be established. DNA immunization with candidate vaccines comprising multiple genes of clades A, B, C, F, G, and H create strong cellular responses in BALB/c mice, especially after gene gun immunization (Malm et al., 2005).

m. Mouse Response

Host Strain: C57BL/6, BALB/c
Vaccination Protocol: C57BL/6 mice were divided into groups g.g. immunized or i.m. inoculated. Mice were bled 2 weeks after the last immunization, and individual blood and spleen samples were collected post-challenge and used fresh in ELISPOT assays (Malm et al., 2005).
BALB/c were immunized by MultiHIV/MultiClade DNA. Initially the immune response was evaluated after 3 immunizations by g.g. Equal amounts of clade A, B, C, and FGH MultiHIV plasmids were mixed together and coated onto the gold particles to construct the subtype cocktail MultiHIV DNA immunogen (MultiHIVmix). Mice were sacrificed 10 days after the last immunization and individual spleens were collected and the cells preserved at –70°C until used. In a second set of experiments a short-term immunization schedule was used to address three different administration routes; g.g., i.m., and i.d. Mice were immunized 3 times with MultiHIVmix DNA (Malm et al., 2005).
Immune Response: Though the immune response detected was quite low, the majority of g.g. immunized animals responded with specific IFN production. Interestingly, the gag specific response in the same gene gun immunized animals was weaker than the envelope responses and also drastically weaker than the responses seen before the experimental challenge (Malm et al., 2005). The CTL response, following i.d. injection, was detected five weeks after the first immunization and persisted up to 12 weeks later. In contrast, i.m. immunization induced detectable IFNy only at week 17 (Malm et al., 2005).
Side Effects: no side effects occurred (Malm et al., 2005)
Challenge Protocol: C57BL/6 mice transgenic for HLA-A201 were given an experimental challenge after a short-term immunization schedule. Amphotropic murine leukemia virus was used to prepare pseudovirus with HIV-1 isolate. Challenged animals were given i.p. injections of sHIV-1/MuLV infected cells (Malm et al., 2005).
Efficacy: The vaccine-induced immunity has in vivo efficacy. Here a mouse model showed that the HIV-1 GTU-MultiHIVmix vaccine induces virus-specific CD8 T cellular immunity and protects against experimental HIV-1 challenge (Malm et al., 2005).
Description: The cocktail of MultiHIV protected 19/24 animals against an experimental HIV-1 challenge. This experiment also demonstrates cross-clade protection, as the subtypes A and B viruses used for challenge were derived from different subtypes than the sequences found in the clade A or B specific MultiHIV constructs. Furthermore, it demonstrates that consensus approach used in Multi-HIVmix vaccine is functional and causes protection against naturally occurring isolates. Gene gun immunization was superior to intramuscular immunization in terms of both the T cell immunity induced, as well as higher frequency of protection. Data generated in this work support the hypothesis that DNA representing several HIV-1 subtypes and several genes are immunogenic and protective (Malm et al., 2005).
Host Gene Response of Ifng (Interferon gamma)
- Gene Response: IFN-gamma levels in mice immunized by gene gun or intramuscular delivery with HIV-1 subtype B DNA immunogen showed strong up regulation in response to an H-2d restricted gag peptide (AMQMLKETI) and even stronger up-regulation in response to an env epitope (RGPGRAFVTI) (Malm et al., 2005).
- Detailed Gene Information: Click here.

8. Gag-VRPs

a. Vaccine Ontology ID:

VO_0000822

b. Antigen

HIV matrix-capsid portion of Gag, envelope gp160, secreted gp140, cloned SIVsm H-4i, SIVsm E660 (Davis et al., 2002)

c. Vector:

VEE replicon particles (VRPs)

d. Preparation

Gag-VRPs is a cocktail vaccine of V3014-packaged VRPs expressing the SIVsm H-4i nonmyristylated matrix-capsid region, full-length gp160, and a secreted form of gp160 (gp140). Structural proteins for packaging of replicon RNA into VRPs are expressed from separate helper RNAs. VRPs expressing either the matrix-capsid portion of Gag, the full-length envelope gp160, or the secreted gp140 of cloned SIVsm H-4i were mixed in a cocktail and used to immunize macaques (Davis et al., 2002).

e. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: VRPs with wild-type glycoprotein spikes were inoculated into the footpads of mice (Davis et al., 2002).
Persistence: At 11 months post-boosting with the downstream vector, serum antibody levels against HIV MA/CA were undiminished, and MA/CA specific CTLp were detectable in all mice tested. These findings suggest that VEE vectors can be optimized to elicit strong, balanced and long-lived immune responses to foreign viral proteins (Caley et al., 1999).
Immune Response: In BALB/c mice, the two vectors elicited cellular immune responses to MA/CA as determined by bulk CTL assays and precursor frequency analysis, but the humoral response induced by the downstream vector was significantly stronger. These findings suggest that VEE vectors can be optimized to elicit strong, balanced and long-lived immune responses to foreign viral proteins (Caley et al., 1999).

f. Monkey Response

Host Strain: rhesus monkey (Macaca mulatta)
Vaccination Protocol: A cocktail vaccine of V3014-packaged VRPs expressing the SIVsm H-4i nonmyristylated matrix-capsid region, full-length gp160, and a secreted form of gp160 (gp140) was used to immunize rhesus macaques. Animals were given each VRP subcutaneously in the arm and later were challenged by the intrarectal (IR) route. Control animals received an equivalent dose of HA-VRPs (Davis et al., 2002).
Immune Response: Both humoral and cellular immune responses were induced. On the day of challenge, all vaccinated animals had neutralizing antibody to the homologous SIVsm H-4, most had CTL specific for Gag, Env, or both. The animals were followed for a period of 40 weeks postchallenge, and although vaccination did not prevent infection by the high dose IR challenge, several protective effects of vaccination were seen. Peak virus titers in plasma were reduced, and the range of peak titers was much smaller for the controls, suggesting that a clear protective effect against the acute phase of infection was induced in some of the vaccinated animals (Davis et al., 2002).
Side Effects: No side effects were encountered (Davis et al., 2002).
Challenge Protocol: Animals were given a dose of VRP subcutaneously in the arm and 1 month later were challenged by the intrarectal (IR) route. Control animals received an equivalent dose of HA-VRPs. The challenge virus was the highly virulent swarm SIVsm E660 (Davis et al., 2002).
Efficacy: Animals were followed for a period of 40 weeks postchallenge, and although vaccination did not prevent infection by the high dose IR challenge, several protective effects of vaccination were seen. Four of six vaccinated animals, as compared to one of six controls, showed virus loads below 1,700 copies per ml at the “set point” (23 weeks postchallenge). By 41 weeks postchallenge, when the experiment was terminated, there was a significant decrease in the mean plasma virus load in the vaccinated animals compared to that in the controls. Most vaccinated animals showed virus loads below the “set point” (23 weeks postchallenge). By 41 weeks postchallenge, when the experiment was terminated, there was a significant decrease in the mean plasma virus load in the vaccinated animals compared to that in the controls. Finally, the CD4C cells of the vaccinated animals were preserved and even increased postchallenge compared to those of the controls. In fact, in the vaccinated animals, there is a clear correlation between increased CD4C cells and lowered viral load (Davis et al., 2002).

9. gp120 recominant with GMDP adjuvant

a. Vaccine Ontology ID:

VO_0004233

b. Type:

Subunit vaccine

c. Status:

Research

d. Antigen

Recombinant HIV gp120 derived from CHO cells (Bomford et al., 1992).

e. Adjuvant:

VO ID: VO_0001295

f. Immunization Route

subcutaneous injection

g. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Mice were subcutaneously immunized with antigen and adjuvant (Bomford et al., 1992).
Immune Response: Mice immunized with gp120 and GMDP in combination with pluronic emulsion resulted in a secondary antibody response (Bomford et al., 1992).

10. gp120 recominant with MDP adjuvant

a. Vaccine Ontology ID:

VO_0004234

b. Type:

Subunit vaccine

c. Status:

Research

d. Antigen

Recombinant HIV gp120 derived from CHO cells (Bomford et al., 1992).

e. Adjuvant:

VO ID: VO_0000187

f. Immunization Route

subcutaneous injection

g. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Mice were subcutaneously immunized with antigen and adjuvant (Bomford et al., 1992).
Immune Response: Mice immunized with gp120 adjuvanted with MPD plus pleuronic emulsion resulted in a secondary antibody response (Bomford et al., 1992).

11. gp140, Gag and Tat Protein Vaccine with MF59

a. Vaccine Ontology ID:

VO_0004238

b. Type:

Subunit vaccine

c. Status:

Research

d. Antigen

gp140, Gag and Tat recombinant proteins (Bråve et al., 2007).

e. Adjuvant:

VO ID: VO_0001301

f. Immunization Route

Intramuscular injection (i.m.)

g. Mouse Response

Host Strain: C57Bl/6
Vaccination Protocol: The protein vaccine component consisted of 20 μg ro-gp140 delivered in the right tibialis muscle and 20 μg rGag and 5 μg rTat delivered in the left tibialis muscle. The proteins were formulated in 50% MF59 solution. Mock treatment consisted of MF59 adjuvant alone or empty DNA plasmid alone (Bråve et al., 2007).
Challenge Protocol: Briefly, 3 weeks after the final immunization (week 12), the animals were injected intraperitoneally with 1 million syngeneic splenocytes infected with HIV-1/MuLV of subtype B (LAI) (Bråve et al., 2007).
Efficacy: 83% of mice were tested negative for HIV-1 after challenge (Bråve et al., 2007).

12. HIV DNA and adenoviral vector Ad5 expressing SIV gag protein

a. Vaccine Ontology ID:

VO_0000786

b. Type:

DNA vaccine

c. Status:

Research

d. Antigen

SIVmac239 gag protein (Shiver et al., 2002)

e. Gene Engineering of Gag protein from SIV-mnd 2

Type: Recombinant vector construction
Description:
Detailed Gene Information: Click here.

f. Gene Engineering of Gag protein from SIV-mnd 2

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

g. Adjuvant:

VO ID: VO_0001318

h. Vector:

V1R plasmid and adenoviral vector (Ad5)

i. Preparation

The V1R DNA vector expressed the identical SIVmac239 gag gene that had been codon optimized for expression in mammalian cells (Shiver et al., 2002). The plasmid DNA vector was formulated in a solution containing a nonionic blocked copolymer adjuvant (CRL1005) (Shiver et al., 2002).
The adenoviral vector was based on a serotype 5 adenovirus that is incompetent to replicate with deletion of the E1 and E3 viral genes, and was propagated subsequently in E1-expressing 293 cells. Recombinant adenovirus expressing the codon-optimized SIV gag gene was then prepared. The recombinant adenovirus (Ad5-SIVgag) was grown in large quantities by multiple rounds of amplification in 293 cells. The virus was purified by caesium chloride gradient centrifugation (Shiver et al., 2002).

j. Immunization Route

Intramuscular injection (i.m.)

k. Virulence

No virulence has been reported associated with this vaccine (Shiver et al., 2002).

l. Description

Immunization and viral challenge studies were conducted in rhesus macaques (Macaca mulatta). Each of the test vectors expressed the identical SIVmac239 gag gene that had been codon optimized for expression in mammalian cells. The plasmid DNA vector was formulated in either PBS solution, a solution containing adjuvant, or a solution containing MPL/alum. All immunized animals were genotyped for the MHC class I Mamu-A*01 allele, allowing analysis of the responses of T cells (CD8+) to the test vaccines (Shiver et al., 2002).

m. Monkey Response

Host Strain: rhesus monkey (Macaca mulatta)
Vaccination Protocol: This study used 14 monkeys, 3 each in the immunized groups and 8 in the unimmunized control group. Each of the test vectors expressed the identical SIVmac239 gag gene that had been codon optimized for expression in mammalian cells. The DNA vector priming inoculations were administered, followed by viral vector boost inoculations (Shiver et al., 2002).
Immune Response: In general, all of the monkeys developed p11CM-specific cellular immune responses after the initial immunization series. The p11CM (residues 181–189) is an immunodominant SIV gag epitope that is presented by the Mamu-A*01 MHC protein and is capable of binding T-cell receptors in the model monkeys. Administration of the third dose of the Ad5 vector resulted in an additional increase of p11CM-specific CD8+ T cells at the time of virus challenge. After the booster inoculation, these animals exhibited peak levels of p11CM-specific CD8+ T cells (Shiver et al., 2002).
Side Effects: None of the vaccinated monkeys have yet exhibited any signs of immunodeficiency or suffered any consistent weight loss (Shiver et al., 2002).
Challenge Protocol: At 6 weeks after the final immunization, all monkeys were challenged i.v. with the pathogenic HIV–SIV hybrid virus (SHIV) 89.6P16. The challenge of the control and immunized animals within the context of each of the two independent studies occurred concurrently (Shiver et al., 2002).
Efficacy: Each of the animals in both control groups exhibited acute CD4+ T-cell lymphopenia and peak viral loads of viral RNA copies at about 3 weeks after challenge. All of the control monkeys experienced dramatic loss of CD4+ T cells. During the acute phase of the infection, most monkeys immunized with either the DNA or MVA vectors or with the DNA/CRL1005–MVA vector prime–boost combination exhibit an acute CD4+ T-cell lymphopenia. By about 70 d after challenge, many of the immunized monkeys exhibit some evidence of a positive immunization benefit, as manifested by control of viremia and recovery of CD4+ T-cell counts. However, the animals immunized with Ad5 vector exhibited the most pronounced attenuation of the infection with a pathogenic HIV–SIV hybrid virus (SHIV) (Shiver et al., 2002).
Host Gene Response of IFNG
- Gene Response: Levels of interferon-gamma in monkeys stimulated intramuscularly with either the p11CM peptide or a pool of peptides derived from SIV gag were significantly upregulated and correlated well with the tetramer-staining results after the final boost. Intracellular IFN-[gamma]-staining assays confirmed that these responses were primarily mediated by CD8+ T cells (Shiver et al., 2002).
- Detailed Gene Information: Click here.

13. HIV DNA vaccine Ad26/Ad5HVR48 encoding HIV or SIV env or gag

a. Vaccine Ontology ID:

VO_0004342

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Human

e. Gene Engineering of env

Type: Recombinant vector construction
Description: This recombinant vector vaccine expressed env from HIV-1 (Barouch et al., 2012).
Detailed Gene Information: Click here.

f. Gene Engineering of Gag from HIV 1

Type: DNA vaccine construction
Description: This recombinant vector vaccine expressed gag from HIV-1 (Barouch et al., 2012).
Detailed Gene Information: Click here.

g. Gene Engineering of env from SIV

Type: Recombinant vector construction
Description: This recombinant vector vaccine expressed env from SIV (Barouch et al., 2012).
Detailed Gene Information: Click here.

h. Gene Engineering of Gag protein from SIV-mnd 2

Type: DNA vaccine construction
Description: This recombinant vector vaccine expressed gag from SIV (Barouch et al., 2012).
Detailed Gene Information: Click here.

i. Immunization Route

Intramuscular injection (i.m.)

j. Macaque Response

Vaccine Immune Response Type: VO_0000286
Efficacy: After the high-dose vaginal SHIV-162P3 challenge, 7/8 control animals were infected. Similarly, 7/8 animals in the vaccine-only group (group V) were infected. In the microbicide-only group (group M), 4/8 animals were infected. In the combination group (group V+M), only 2/7 animals were infected. The intervention efficacy in group V+M was 67%. In summary, the data supports that vaccines and microbicides used in combination may confer protection against sexual HIV-1 transmission to women by the vaginal route (Barouch et al., 2012).

14. HIV DNA vaccine pCMN160

a. Vaccine Ontology ID:

VO_0004345

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Chimpanzee

e. Antigen

env and rev of HIV-1 strain MN and gag/pol from HIV-1 III8 (Boyer et al., 1997)

f. Gene Engineering of env

Type: DNA vaccine construction
Description: This DNA vaccine encoded env (Boyer et al., 1997).
Detailed Gene Information: Click here.

g. Gene Engineering of rev MN isolate

Type: DNA vaccine construction
Description: This DNA vaccine encoded rev (Boyer et al., 1997).
Detailed Gene Information: Click here.

h. Gene Engineering of gag-pol

Type: DNA vaccine construction
Description: This DNA vaccine encoded gag/pol from HIV-1 III8 (Boyer et al., 1997).
Detailed Gene Information: Click here.

i. Vector:

pCMN160 (Boyer et al., 1997)

j. Immunization Route

Intramuscular injection (i.m.)

k. Chimpanzee Response

Vaccine Immune Response Type: VO_0000286
Efficacy: Animals were challenged with a heterologous chimpanzee titered stock of HIV-1 SF2 virus. Polymerase chain reaction coupled with reverse transcription results indicated infection in the control animal, whereas those animals vaccinated with the DNA constructs were protected from the establishment of infection (Boyer et al., 1997).

15. HIV DNA vaccine pHIS-SHIV-B

a. Vaccine Ontology ID:

VO_0004348

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Monkey

e. Antigen

full-length unmutated SIVmac239 Gag and Pol, HIV-1AD8, Tat, Rev, and Vpu, and the 5′ third of HIV-1AD8 Env (Dale et al., 2004)

f. Gene Engineering of env

Type: DNA vaccine construction
Description: The DNA vaccine strain, pHIS-SHIV-B, encoded full-length unmutated SIVmac239 Gag and Pol, HIV-1AD8, Tat, Rev, and Vpu, and the 5′ third of HIV-1AD8 Env (Dale et al., 2004).
Detailed Gene Information: Click here.

g. Gene Engineering of Gag protein from SIV-mnd 2

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

h. Gene Engineering of Pol SIV

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

i. Gene Engineering of Tat

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

j. Gene Engineering of rev from HIV 1

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

k. Gene Engineering of vpu

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

l. Vector:

pHIS-64 (Dale et al., 2004)

m. Immunization Route

Intramuscular injection (i.m.)

n. Macaque Response

Vaccine Immune Response Type: VO_0000286
Efficacy: DNA vaccination alone primed for protection almost as effectively as the DNA/fowlpox virus regimen (Dale et al., 2004).
Host Gene Response of IFNG from Macaca nemestrina
- Gene Response: SIV Gag-specific CD8 T cells expressing IFN-γ were dramatically boosted after challenge. Mean Gag-specific CD8 T cells peaked 3 weeks following challenge at 11.7% of all CD8 T cells in these outbred pigtail macaques immunized with the 2DNA/FPV regimen. The other vaccine groups had lower mean postchallenge CD8 T-cell responses, with peak responses at week 2 following challenge numbering 3.8% in the 3DNA group, 1.1% responses in the 1DNA/FPV group, and 2.0% in the 2DNA/FPV-IFN-γ-immunized animals (Dale et al., 2004).
- Detailed Gene Information: Click here.

16. HIV DNA vaccine SHIV-89.6 DNA (DNA/89.6)

a. Vaccine Ontology ID:

VO_0004344

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Macaque

e. Gene Engineering of gag

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Gene Engineering of pol

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

g. Gene Engineering of env

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

h. Gene Engineering of tat

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

i. Gene Engineering of rev

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

j. Gene Engineering of vif

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

k. Gene Engineering of vpr

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

l. Gene Engineering of vpu

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

m. Vector:

pGA (Robinson et al., 2006)

n. Immunization Route

Intramuscular injection (i.m.)

o. Macaque Response

Vaccine Immune Response Type: VO_0000286
Immune Response: Co-delivery of GM-CSF and vaccine DNAs enhanced the temporal appearance of neutralizing Ab and broadened the specificity of the neutralizing activity to include SHIV-89.6P (Robinson et al., 2006).
Efficacy: The GM-CSF-adjuvanted group showed a trend towards better control of the challenge infection and had better control of re-emergent virus (P < 0.01) than the non-adjuvanted group. After 52 weeks, the non-GM-CSF group continued to show some peaks of re-emergent virus whereas the GM-CSF group continued to maintain control below our level of detection (Robinson et al., 2006).

17. HIV DNA vaccine SIVmac239 Gag-Pol-Nef and mock Env with rAd5 boost

a. Vaccine Ontology ID:

VO_0004349

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Macaque

e. Gene Engineering of Gag protein from SIV-mnd 2

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Gene Engineering of Pol SIV

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

g. Gene Engineering of Nef SIV

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

h. Gene Engineering of env

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

i. Vector:

pVR1012 prime, rAd5 boost (Mascola et al., 2005)

j. Immunization Route

Intramuscular injection (i.m.)

k. Macaque Response

Vaccine Immune Response Type: VO_0000286
Immune Response: DNA priming-rAd5 boosting immunization platform can elicit potent anti-HIV-1 cellular immune responses and anti-HIV-1 neutralizing antibodies (Mascola et al., 2005).
Efficacy: In a challenge study, all monkeys were immunized with DNA plasmids at 0, 4, and 8 weeks and boosted with rAd5 at week 26. Serial plasma dilutions were tested against four of the more neutralization-sensitive viruses, and the plasma dilution that produced 50% virus neutralization, which is required to protect 50% of the cells from virus-induced killing, was determined. The data clearly demonstrates that both the vaccine platform and these immunogens elicit IgG-mediated virus neutralization (Mascola et al., 2005).

18. HIV DNA vaccine VlJns-tPA-gp120

a. Vaccine Ontology ID:

VO_0004351

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Rhesus monkey

e. Gene Engineering of gp120

Type: DNA vaccine construction
Description: This vaccine encoded gp120 from HIV IIIB (Lekutis et al., 1997).
Detailed Gene Information: Click here.

f. Vector:

VlJns (Lekutis et al., 1997)

g. Immunization Route

Intramuscular injection (i.m.)

h. Monkey Response

Vaccine Immune Response Type: VO_0000286
Immune Response: The secretion of IFN-y stimulated CD4+ Th cell lines and rgp120-stimulated PBL from the vaccinated monkeys suggest that an HIV-1 env plasmid DNA vaccine elicits a Thl-like immune response in primates as well as in rodents (Lekutis et al., 1997)
Efficacy: The secondary immune response that arose after repeated plasmid DNA administration was Thl-like, suggesting that the nature of the DNA vaccine-elicited Th cell response was maturation dependent. Evidence from vaccinated nonhuman primates suggests that a vigorous Th cell response, including viral Ag-specific IFN-y production, may be a correlate of protection from HIV- 1 and Simian Human Immunodeficiency Virus infection (Lekutis et al., 1997)

19. HIV priming with DNA vaccine expressing HIV gp160 protein and boosted with Ad5/35 vector expressing the same protein

a. Vaccine Ontology ID:

VO_0000789

b. Type:

DNA vaccine

c. Antigen

HIV Env gp160 protein (Xin et al., 2005)

d. Gene Engineering of env

Type: Recombinant vector construction
Description: An Ad5/35 vector was used to express HIV Env gp160 protein (Ad5/35-HIV) (Xin et al., 2005).
Detailed Gene Information: Click here.

e. Gene Engineering of env

Type: DNA vaccine construction
Description: The DNA vaccine contained env and rev from HIV-1 IIIB (Xin et al., 2005).
Detailed Gene Information: Click here.

f. Gene Engineering of rev from HIV 1

Type: DNA vaccine construction
Description: The DNA vaccine contained env and rev from HIV-1 IIIB (Xin et al., 2005).
Detailed Gene Information: Click here.

g. Vector:

pCAGGS and a replication-defective chimeric Ad5 vector with the Ad35 fiber (Ad5/35)

h. Preparation

A replication-defective chimeric Ad5 vector with the Ad35 fiber (Ad5/35) was prepared and used to express HIV Env gp160 protein. The product is named Ad5/35-HIV (Xin et al., 2005).

i. Virulence

This novel Ad5/35 vector showed minimal hepatotoxicity after intramuscular administration with the novel Ad5/35 vector (Xin et al., 2005).

j. Description

Replication-defective Ad5 HIV recombinants and replication-defective MVA elicit potent CD8+ T-cell responses and provide a high degree of protection in NHPs. The Ad5 (subgroup C) has well-defined biological properties and has been widely used as a vector for gene therapy and vaccine. The replication-defective Ad5 vector can easily be produced in high titers and is highly effective in boosting HIV-specific immunity. However, this virus uses CAR as its primary attachment receptor, which confers tropism for liver parenchymal cells. This raises important safety concerns. Thus, a replication-defective chimeric Ad5 vector with Ad type 35 fiber (Ad5/35) has been developed, which not only induces strong antigen-specific humoral and cellular immune responses and exhibits minimal hepatotoxicity in both mice and NHPs, but is also significantly less susceptible to the pre-existing Ad5 immunity than a comparable Ad5 vector (Xin et al., 2005).

k. Monkey Response

Host Strain: rhesus monkey (Macaca mulatta)
Vaccination Protocol: 10^11 vp of Ad5/35-HIV vector was injected i.m. into two rhesus monkeys (2 years old, male) at weeks 0 and 8 (Xin et al., 2005).
Immune Response: A detectable HIV-specific serum Ab response developed within 2 weeks of the first immunization. At 4 weeks post boosting, titers in excess of 1:50 000 were achieved. Similar results were observed in neutralizing Ab. A increase in the number of HIV-specific IFN-gamma-secreting T cells was also detected in the peripheral blood mononuclear cells (PBMCs). Boosting with Ad5/35-HIV vector further increased this T-cell response (Xin et al., 2005).
Side Effects: Liver infection with Ad5 vector was 20- to 40-fold stronger than that with Ad5/35 vector. Ad5-Luc vector was two- and four-fold higher, respectively, than that of the monkeys that received the Ad5/35-Luc vector. The Ad5/35 recombinants exhibits minimal hepatotoxicity in non-human primates but is also significantly less susceptible to the pre-existing Ad5 immunity than a comparable Ad5 vector (Xin et al., 2005).

l. Mouse Response

Vaccination Protocol: Mice were injected i.m. with Ad5-Luc or Ad5/35-Luc. Luciferase expression was monitored using an in vivo imaging system (IVIS). The expression of HIV gp160 was confirmed by Western blotting. Mice were immunized with Ad5/35-HIV vector, and the HIV-specific CMI was periodically monitored by the intracellular cytokine staining (ICS) assay (Xin et al., 2005).
Immune Response: The animals immunized with Ad5/35-HIV vector developed a high-titered anti-gp160 antibody (Ab) response. The magnitude of this response was not significantly altered by preimmunization with the DNA-HIV vaccine. DNA-HIV vaccination alone generated a low level of HIV-specific serum Ab. HIV-specific neutralizing Ab was only detectable in the Ad5/35-HIV vaccinated mice and DNA prime/Ad5/35-HIV boosted mice. HIV-specific cellular immune responses persisted through 7 months after final immunization (Xin et al., 2005).
Side Effects: The hepatotoxicity caused by the Ad5 vector was circumvented by the use of an Ad5/35 vector (Xin et al., 2005).
Challenge Protocol: Immunized mice were challenged with vPE16 2 weeks after final immunization. Vaccinated mice were challenged with vPE16 7 weeks after final immunization. The strain vPE16 is HIVBH8 gp160-expressing replication-competent vaccinia virus (WR strain, vPE16; HIVBH8 gp160 has 97.32% amino-acid homology with HIVIIIB gp160) (Xin et al., 2005).
Efficacy: The animals that were vaccinated with the Ad5/35 vector alone or in combination with the DNA-HIV vaccine were completely protected from infection; however, the DNA-HIV vaccination alone had little impact on the susceptibility to infection by vPE16. DNA-HIV vaccination by itself was not protective, but the combination of DNA-HIV priming and Ad5/35-HIV boosting yielded a prolonged and complete protection (Xin et al., 2005).

20. HIV recombinant gp160 Protein Vaccine

a. Vaccine Ontology ID:

VO_0004274

b. Type:

Subunit vaccine

c. Status:

Research

d. Antigen

Recombinant gp160 (Barrett et al., 1989).

e. Adjuvant:

VO ID: VO_0001291
Description: 0.2% Al(OH)3 and 0.25% deoxycholate (Barrett et al., 1989).

f. Immunization Route

subcutaneous injection

g. Mouse Response

Vaccination Protocol: The potency of the vaccine was determined by injecting mice with serial dilutions of gp160 alone or adjuvanted with different formulations. Groups of 10 mice were injected subcutaneously with 1 ml of fourfold dilutions of the test substance. A total of 50 mice were injected in each test (Barrett et al., 1989).
Immune Response: The highest potency in mice was obtained using a preparation with 0.2% Al(OH)3 and 0.25% deoxycholate (Barrett et al., 1989).

21. HIV recombinant vector vaccine MVA-gag encoding gag

a. Vaccine Ontology ID:

VO_0004347

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Macaque

e. Gene Engineering of Gag from HIV 1

Type: Recombinant vector construction
Description: This recombinant vector vaccine expressed gag from HIV-1 (Casimiro et al., 2003).
Detailed Gene Information: Click here.

f. Vector:

pSC59 (Casimiro et al., 2003).

g. Immunization Route

Intramuscular injection (i.m.)

h. Monkey Response

Vaccine Immune Response Type: VO_0000286
Immune Response: Immunization of macaques with MVA-gag resulted in relatively weak antigen-specific T-cell responses; the levels did not exceed 150 spot-forming cells (SFC)/106 PBMCs after three doses and were significantly less than those observed in the Ad5-gag vaccinees. Only one of six MVA-gag vaccinees elicited any detectable Gag-specific antibody response (140 mMU/ml at 4 weeks post-dose 3 for monkey V215) (Casimiro et al., 2003).
Efficacy: The study reports that SIV Gag delivered by DNA, MVA, or adenovirus type 5 vectors is able to inhibit viral replication and disease progression in rhesus macaques following challenge with the SHIV89.6P virus. However, only 50% of the animals that received MVA alone or in combination with DNA were able to effectively control viremia (Casimiro et al., 2003).

22. HIV recombinant vector vaccine MVA.HIVA encoding env and rev

a. Vaccine Ontology ID:

VO_0004350

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Human

e. Gene Engineering of env

Type: Recombinant vector construction
Description: This DNA vaccine encoded env from HIV-1 (Peters et al., 2007).
Detailed Gene Information: Click here.

f. Gene Engineering of rev from HIV 1

Type: Recombinant vector construction
Description: This DNA vaccine expressed rev from HIV-1 (Peters et al., 2007).
Detailed Gene Information: Click here.

g. Immunization Route

Intramuscular injection (i.m.)

23. HIV-1 gp120 with mCT E112K

a. Vaccine Ontology ID:

VO_0004268

b. Type:

Subunit vaccine

c. Status:

Research

d. Antigen

HIV-1LAIEnv gp120 (Yoshino et al., 2004).

e. Adjuvant:

VO ID: VO_0001347

f. Immunization Route

intranasal immunization

g. Monkey Response

Host Strain: rhesus macaques
Vaccination Protocol: Rhesus macaques were divided into four groups and nasally immunized with vaccine containing: 1) 100 µg of gp120 alone, 2) 100 µg of gp120 plus 10 µg of nCT, 3) 100 µg of gp120 plus 25 µg of mCT E112K, or 4) 100 µg of gp120 plus 100 µg of mCT E112K. Macaques were anesthetized with ketamine and placed in dorsal recumbancy with head tilted back so that the nares were pointed upward. Vaccine solution (0.5 ml) was instilled dropwise into each nostril without inserting the syringe into the nasal cavity. Macaques were kept in that position for 10 min and then placed in lateral recumbancy until they recovered from anesthesia, as described previously (16). Nasal immunization was conducted on days 0, 7, 14, 28, 42, and 56 (Yoshino et al., 2004).
Immune Response: Macaques given nasal gp120 with either mCT E112K or nCT showed elevated gp120-specific IgG and IgA Ab responses with virus-neutralizing activity in both their plasma and mucosal external secretions, as well as higher numbers of gp120-specific IgA Ab-forming cells in their mucosal and peripheral lymphoid tissues and of IL-4-producing Th2-type CD4-positive (CD4(+)) T cells than did controls. Even though significant mucosal adjuvanticity was seen with both mCT E112K and nCT, neuronal damage was observed only in the nCT-treated, but not in the control or mCT E112K-treated groups (Yoshino et al., 2004).
Host Gene Response of IgA Fc fragment
- Gene Response: Macaques given nasal gp120 with either mCT E112K or nCT showed significantly elevated IgA Ab responses with virus-neutralizing activity in both their plasma and mucosal external secretions, as well as higher numbers of gp120-specific IgA Ab-forming cells in their mucosal and peripheral lymphoid tissues compared to controls, who were vaccinated without the adjuvant (Yoshino et al., 2004).
- Detailed Gene Information: Click here.
Host Gene Response of IgG Fc fragment
- Gene Response: Macaques given nasal gp120 with either mCT E112K or nCT showed significantly elevated gp120-specific IgG responses with virus-neutralizing activity in both their plasma and mucosal external secretions compared to controls, who were vaccinated without the adjuvant (Yoshino et al., 2004).
- Detailed Gene Information: Click here.
Host Gene Response of IL4
- Gene Response: Vaccinated animals that received the adjuvant had a greater increase in IL-4-producing Th2-type CD4-positive (CD4(+)) T cells in mesenteric lymph nodes (MLNs) than did controls vaccinated without the adjuvant, which did not produce IL-4 (Yoshino et al., 2004),
- Detailed Gene Information: Click here.

24. HIV-2 DNA vaccine

a. Vaccine Ontology ID:

VO_0004259

b. Type:

DNA vaccine

c. Status:

Research

d. Antigen

The DNA vaccine constructs were developed based on the gene sequences of the gp140 envelope, p55 Gag, Nef, and Tat proteins from the HIV-2UC2 isolate (GenBank accession number U38293) (Locher et al., 2004).

e. Gene Engineering of gag

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Gene Engineering of nef

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

g. Gene Engineering of tat

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

h. Gene Engineering of env

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

i. Adjuvant:

VO ID: VO_0001337

j. Adjuvant:

VO ID: VO_0001294

k. Vector:

pND-14 (Locher et al., 2004)

l. Immunization Route

Intramuscular injection (i.m.)

m. Baboon Response

Vaccination Protocol: Each baboon was immunized four times with the experimental or control DNA constructs formulated with Vaxfectin. The time intervals were chosen to permit maturation of the immune response (Locher et al., 2004).
Challenge Protocol: One month after the fourth immunization, the baboons were challenged twice (6 h apart) by the intravaginal route using 50 baboon infectious dosages (30,000 tissue culture infectious dosages) of HIV-2UC2/9429 for a total of 100 baboon infectious dosages. This virus isolate is a more virulent variant of the HIV-2UC2 isolate and was recovered from a baboon with an AIDS-like disease (Locher et al., 2004).
Efficacy: At 2 weeks post-HIV-2 challenge, viral loads ranged from 100 (below the threshold of detection) to 81,000 viral RNA copies in the plasma, with the lowest average viral loads in the group of baboons that received the HIV-2 DNA without the genetic adjuvants (a mean of 852 copies/ml), followed by the group of baboons the received the HIV-2 DNA and the genetic adjuvants (a mean of 2499 copies/ml) (Locher et al., 2004).

25. Inactivated HIV-2 Vaccine with PMMA

a. Vaccine Ontology ID:

VO_0004242

b. Type:

Inactivated or "killed" vaccine

c. Status:

Research

d. Adjuvant:

VO ID: VO_0001308

e. Immunization Route

subcutaneous injection

f. Mouse Response

Host Strain: NMRI
Vaccination Protocol: Mice received 0.5 ml of the specified vaccine preparations subcutaneously under the abdominal skin on day 0 (Stieneker et al., 1991).
Immune Response: Mice immunized with PMMA adjuvant had higher antibody counts than mice immunized with an alum adjuvant (Stieneker et al., 1991).

26. L. T -HIV-1 Gag

a. Vaccine Ontology ID:

VO_0004629

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Baboon

e. Gene Engineering of Gag from HIV 1

Type: Recombinant vector construction
Description: A non-pathogenic Leishmania tarentolae was used to express full-length HIV-1 Gag protein (Breton et al., 2007).
Detailed Gene Information: Click here.

f. Vector:

(Breton et al., 2007)

g. Preparation

A non-pathogenic protozoan parasitic vector, Leishmania tarentolae, which shares common target cells with HIV-1, was used to express full-length HIV-1 Gag protein (Breton et al., 2007).

h. Immunization Route

Intramuscular injection (i.m.)

i. Mouse Response

Host Strain: Balb/c
Vaccine Immune Response Type: VO_0003057
Immune Response: Immunization of BALB/c mice with recombinant L. tarentolae led to the expansion of HIV-1 Gag-specific T cells and stimulated CD8(+) T cells to produce gamma interferon in response to specific viral Gag epitopes. A booster immunization with recombinant L. tarentolae elicited effector memory HIV-1 Gag-specific CD4(+) T lymphocytes and increased antibody titres against HIV-1 Gag (Breton et al., 2007).
Efficacy: Immunization of human tonsillar tissue cultured ex vivo with Gag-expressing L. tarentolae vaccine vector elicited a 75% decrease in virus replication following exposure of the immunized tonsils to HIV-1 infection (Breton et al., 2007).

27. MVA expressing HIV Gag, Pol and Env proteins

a. Vaccine Ontology ID:

VO_0000824

b. Type:

Recombinant vector vaccine

c. Antigen

HIV Gag, Pol, and Env proteins (Liu et al., 2006)

d. Vector:

modified vaccinia Ankara (MVA)

e. Preparation

An rMVA vaccine that expresses HIV Gag, Pol, and Env proteins was constructed (Liu et al., 2006).

f. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Female BALB/c mice were used for immunizations. All were conducted on anesthetized mice. Immunizations with MVAs were accomplished by inoculating the desired amount of MVA into a single quadriceps muscle. Immunizations with DNA were accomplished by injecting the desired amount of DNA into the quadriceps, half in each leg (Liu et al., 2006).
Persistence: Temporal CD8 responses were conducted in BALB/c mice using MVA. Responses were steady for >10 weeks (>6 weeks post-MVA) (Liu et al., 2006).
Immune Response: CD8 T cells were boosted more effectively than CD4 T cells with the ratio of elicited CD8 to CD4 cells for the immunodominant CD8 epitope in Gag increasing with boosts. The most effective boost for CD8 T cells resulted in the greatest skewing of the CD8 to CD4 T cell ratio. This could represent better access of CD8 than CD4 T cells to APCs (Liu et al., 2006). The dose–response studies showed good increases for antigen expression with increasing MVA dose. A 1000-fold increase in the dose of MVA resulted in a 300-fold increase in the frequency of antigen-expressing cells. In contrast, dose–response studies for in vivo immunogenicity showed <10-fold increases in elicited T cells and Ab for 100–1000-fold increases in the dose of inoculated MVA. Shallow dose–response curves for immunogenicity were observed post priming as well as post boosting of an MVA or a DNA prime (Liu et al., 2006).
Side Effects: No adverse effects were encountered (Liu et al., 2006).

28. NYVAC-HIV-1

a. Vaccine Ontology ID:

VO_0004774

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Baboon

e. Preparation

Attenuated poxvirus-HIV-1 recombinants followed by protein boosting (Patterson et al., 2000).

f. Immunization Route

Intramuscular injection (i.m.)

g. Macaque Response

Vaccination Protocol: Twenty-four macaques were primed with NYVAC (a genetically attenuated Copenhagen vaccinia strain) recombinants with HIV-1 and HIV-2 env and gag-pol or NYVAC vector alone and boosted with homologous, oligomeric gp160 proteins or adjuvant only (Patterson et al., 2000).
Vaccine Immune Response Type: VO_0000287
Challenge Protocol: One half of each immunization and control group were intravenously challenged with SHIV(HXB2) the other half was challenged with HIV-2SBL6669 (Patterson et al., 2000).
Efficacy: Virological assessments verified that both NYVAC-HIV-1 and NYVAC-HIV-2 immunization significantly reduced viral burdens and partially protected against HIV-2 challenge, although cross-protection was not at the level that had been previously reported. Humoral antibody and/or CTL and CD8AA were associated with protection against homologous HIV-2 challenge, while cellular immune responses seemed more important for cross-protection. No significant protection was observed in the SHIV-challenged macaques (Patterson et al., 2000).

29. NYVAC-HIV-2

a. Vaccine Ontology ID:

VO_0004775

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Baboon

e. Preparation

Attenuated poxvirus-HIV-1 recombinants followed by protein boosting (Patterson et al., 2000).

f. Immunization Route

Intramuscular injection (i.m.)

g. Macaque Response

Vaccination Protocol: Twenty-four macaques were primed with NYVAC (a genetically attenuated Copenhagen vaccinia strain) recombinants with HIV-1 and HIV-2 env and gag-pol or NYVAC vector alone and boosted with homologous, oligomeric gp160 proteins or adjuvant only (Patterson et al., 2000).
Vaccine Immune Response Type: VO_0003057
Challenge Protocol: One half of each immunization and control group were intravenously challenged with SHIV(HXB2) the other half was challenged with HIV-2SBL6669 (Patterson et al., 2000).
Efficacy: Virological assessments verified that both NYVAC-HIV-1 and NYVAC-HIV-2 immunization significantly reduced viral burdens and partially protected against HIV-2 challenge, although cross-protection was not at the level that had been previously reported. Humoral antibody and/or CTL and CD8AA were associated with protection against homologous HIV-2 challenge, while cellular immune responses seemed more important for cross-protection. No significant protection was observed in the SHIV-challenged macaques, although NYVAC-HIV-1 immunization resulted in significantly lower viral burdens compared with controls (Patterson et al., 2000).

30. NYVAC-SIV

a. Vaccine Ontology ID:

VO_0004779

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Baboon

e. Preparation

The gag, pol, and env genes of SIV(K6W) were expressed in the NYVAC vector (Benson et al., 1998).

f. Immunization Route

Intramuscular injection (i.m.)

g. Macaque Response

Vaccination Protocol: The macaques were immunized with NYVAC-SIV and NYVAC-IL-12 or NYVAC-SIV alone (Benson et al., 1998).
Vaccine Immune Response Type: VO_0003057
Challenge Protocol: At the end of the immunization regimen, half of the animals were challenged with SIV(mac251) by the intravenous route and the other half were exposed to SIV(mac251) intrarectally (Benson et al., 1998).
Efficacy: Significantly, five of the eleven vaccinees exposed mucosally to SIV(mac251) showed a transient peak of viremia 1 week after viral challenge and subsequently appeared to clear viral infection. In contrast, all 12 animals inoculated intravenously became infected, but 5 to 6 months after viral challenge, 4 animals were able to control viral expression and appeared to progress to disease more slowly than control animals. Protection did not appear to be associated with any of the measured immunological parameters. Further modulation of immune responses by coadministration of NYVAC-cytokine recombinants did not appear to influence the outcome of viral challenge (Benson et al., 1998).

31. rBCG-SIVgag and rDIsSIVgag Prime-boost SHIV vaccine

a. Vaccine Ontology ID:

VO_0004600

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

cynomologus macaque

e. Antigen

gag from simian immunodeficiency viruses

f. Gene Engineering of gag

Type: Recombinant vector construction
Description: The SHIV gag gene was inserted to a recombinant BCG vector and a replication-deficient vaccinia virus strain (DIs) vaccine vector (Ami et al., 2005).
Detailed Gene Information: Click here.

g. Vector:

Mycobacterium bovis bacillus Calmette-Guérin (BCG)-Tokyo and a replication-deficient vaccinia virus strain (DIs) (Ami et al., 2005)

h. Immunization Route

Intramuscular injection (i.m.)

i. Macaque Response

Host Strain: cynomologus macaque
Vaccination Protocol: cynomologus macaques were primed with rBCG-SIVgag, and then boosted with rDIsSIVgag (Ami et al., 2005).
Vaccine Immune Response Type: VO_0003057
Challenge Protocol: Ten weeks after the second booster immunization, the macaques were challenged by intrarectal inoculation with 2 × 10^3 TCID50 or 50 50% monkey infectious doses (MID50) of SHIV KS661c, an SHIV-89.6 variant clone (Ami et al., 2005).
Efficacy: For the prime-boost vaccination group, plasma viremia levels remained undetectable and CD4+ T-cell counts stayed above 500 cells/μl for the entire year of testing (Ami et al., 2005).

32. Recombinant HIV gp120 with adjuvant NanoEmulsion

a. Vaccine Ontology ID:

VO_0000819

b. Type:

Subunit vaccine

c. Antigen

HIV glycoprotein 120, which has a role in facilitating coreceptor interaction and in mediating virus binding to cellular CD4 (Bielinska et al., 2008).

d. Adjuvant:

VO ID: VO_0001319
Description: An oil-in-water nanoemulsion (NE) was used as the mucosal adjuvant for this vaccine (Bielinska et al., 2008).

e. Preparation

The gp120 and NE vaccines were prepared by mixing NE with gp120 protein solution, using pyrogen-free saline as a diluent (Bielinska et al., 2008).

f. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: BALB/c mice were immunized with two or three intranasal administrations of gp120/NE formulation at 3 weeks apart. The immunizations of 10 microliters were performed by slowly applying gp120/NE mixes to the nares.Control mice were immunized with gp120 in saline, with NE alone or saline. Intramuscular immunization was performed with two doses, 3 weeks apart, of 20 micrograms of gp120 injected in 50 microliters of either saline or 1% NE (Bielinska et al., 2008).
Immune Response: Immunized mice demonstrated robust serum anti-gp120 IgG, as well as bronchial, vaginal, and serum anti-gp120 IgA . The analysis of gp120-specific CTL proliferation, INF- induction, and prevalence of anti-gp120 IgG2 subclass antibodies indicated that nasal vaccination in NE also induced systemic, Th1-polarized cellular immune responses (Bielinska et al., 2008).

g. Guinea pig Response

Host Strain: Hartley
Vaccination Protocol: Hartley guinea pigs were immunized intranasally with two administrations (50 microliters per nare) of gp120/NE mix at 3 weeks apart (Bielinska et al., 2008).
Immune Response: Immunization produced significant levels of serum anti-gp120 IgG antibodies in all animals, as was seen with the mice. The analysis of gp120-specific CTL proliferation, INF gamma induction, and prevalence of anti-gp120 IgG2 subclass antibodies indicated that nasal vaccination in NE also induced systemic, Th1-polarized cellular immune responses (Bielinska et al., 2008).

33. rgp120 HIV Vaccine with immunoliposomes

a. Vaccine Ontology ID:

VO_0004264

b. Type:

Subunit vaccine

c. Status:

Research

d. Antigen

rgp120 (Ozpolat et al., 1998).

e. Adjuvant:

VO ID: VO_0001343

f. Immunization Route

subcutaneous injection

g. Mouse Response

Host Strain: C3H/HeN
Vaccination Protocol: Groups of five mice were immunized subcutaneously three times at 14-day intervals. The immunoliposomes were suspended in PBS and each mouse received 0.1 ml per injection. Each injection contained 380 μg of PC, 193 μg of CH, 10 pg of PE-B, 2.0 μg of MAb, and 10 μg of rgpl20 (Ozpolat et al., 1998).
Immune Response: Mice vaccinated with immunoliposomes were found to have a strong delayed-type hypersensitivity (DTH) response to the weakly immunogenic gp120 that was dependent on the presence of the MAbs. However, this vaccination protocol did not induce humoral immunity (Ozpolat et al., 1998).

34. rMVA-SIV-CD40L

a. Vaccine Ontology ID:

VO_0004792

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Baboon

e. Preparation

Co-expressed the CD40L with our DNA/SIV vaccine such that the CD40L is anchored on the membrane of SIV virus-like particle (VLP) (Kwa et al., 2014).

f. Immunization Route

Intramuscular injection (i.m.)

g. Macaque Response

Vaccination Protocol: The macaques were divided into 3 groups and group 1 was vaccinated with a DNA/MVA SIV vaccine, group 2 was vaccinated with the DNA/MVA SIV vaccine with CD40L in the DNA, and the third group was an unvaccinated control (Kwa et al., 2014).
Vaccine Immune Response Type: VO_0003057
Challenge Protocol: The macaques were intrarectally challenged with SIVE660 at a dose of 5000 TCID to test the level of protection of the vaccines (Kwa et al., 2014).
Efficacy: CD40L adjuvant enhanced the functional quality of anti-Env antibody response and breadth of anti-SIV CD8 and CD4 T cell responses, significantly delayed the acquisition of heterologous mucosal SIV infection and improved viral control. Notably, the CD40L adjuvant enhanced the control of viral replication in the gut at the site of challenge that was associated with lower mucosal CD8 immune activation, one of the strong predictors of disease progression (Kwa et al., 2014).

35. rMVTT-SIV-gpe

a. Vaccine Ontology ID:

VO_0004760

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Baboon

e. Gene Engineering of env from SIV

Type: Recombinant vector construction
Description: A recombinant modified replicating vaccinia virus Tiantan strain (MVTTSIVgpe) and a recombinant, nonreplicating adenovirus type 5 strain (Ad5SIVgpe) expressing the SIVmac239 Gag, Pol, and Env structural proteins were generated (Sun et al., 2013).
Detailed Gene Information: Click here.

f. Gene Engineering of Pol SIV

Type: Recombinant vector construction
Description: A recombinant modified replicating vaccinia virus Tiantan strain (MVTTSIVgpe) and a recombinant, nonreplicating adenovirus type 5 strain (Ad5SIVgpe) expressing the SIVmac239 Gag, Pol, and Env structural proteins were generated (Sun et al., 2013).
Detailed Gene Information: Click here.

g. Gene Engineering of Pol SIV

Type: Recombinant vector construction
Description: A recombinant modified replicating vaccinia virus Tiantan strain (MVTTSIVgpe) and a recombinant, nonreplicating adenovirus type 5 strain (Ad5SIVgpe) expressing the SIVmac239 Gag, Pol, and Env structural proteins were generated (Sun et al., 2013).
Detailed Gene Information: Click here.

h. Preparation

(Sun et al., 2013) a modified replicating vaccinia virus Tiantan strain (MVTT(SIVgpe))

i. Immunization Route

Intramuscular injection (i.m.)

j. Monkey Response

Vaccination Protocol: Eight monkeys were divided into two groups: (i) four monkeys received the MVTTioin+Adim testing regimen as in study I, and (ii) four monkeys received an empty MVTT control vector (10^9 PFU) through intraoral (0.5 ml) and intranasal (0.5 ml) routes and an empty Ad5 control vector (10^11 vp in 1 ml of PBS) through intramuscular injection (Sun et al., 2013).
Vaccine Immune Response Type: VO_0003057
Challenge Protocol: At either week 30 after the initial vaccination or week 24 after the final vaccination, each animal was challenged intrarectally with 5 × 10^5 50% tissue culture infective doses (TCID50) of Chinese rhesus monkey-adapted and neutralization-resistant SIVmac239. In all cases, the challenge virus stock was administered in 1 ml of PBS (Sun et al., 2013).
Efficacy: The reductions in peak and set-point viral loads were significant in most animals, with one other animal being protected fully from high-dose intrarectal inoculation of SIV(mac239). Furthermore, the animals vaccinated with this regimen were healthy, while ~75% of control animals developed simian AIDS. The protective effects correlated with the vaccine-elicited SIV-specific CD8(+) T cell responses against Gag and Pol (Sun et al., 2013).

36. SHIV DNA vaccine encoding env and gag

a. Vaccine Ontology ID:

VO_0004596

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Rhesus macaques

e. Gene Engineering of env

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Gene Engineering of env

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

g. Gene Engineering of env

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

h. Gene Engineering of env

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

i. Gene Engineering of gag from HIV-1 vector pNL4-3

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

j. Vector:

pSW3891 (Pal et al., 2006)

k. Immunization Route

Gene gun

l. Macaque Response

Vaccine Immune Response Type: VO_0003057
Efficacy: The immune response elicited by the multivalent DNA prime/protein boost vaccine was able to protect macaques from rectal challenge with SHIV-Ba-L isolate. This polyvalent vaccine formulation was able to confer protection in four out of six animals against SHIV-Ba-L and significantly reduced plasma viremia in the two remaining animals (Pal et al., 2006).

37. SHIV(Ba-L) DNA vaccine encoding env and gag

a. Vaccine Ontology ID:

VO_0004597

b. Type:

DNA vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Macaques

e. Gene Engineering of env

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Gene Engineering of env

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

g. Gene Engineering of env

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

h. Gene Engineering of env

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

i. Gene Engineering of env

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

j. Gene Engineering of gag from HIV-1 vector pNL4-3

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

k. Vector:

pSW3891 (Pal et al., 2005)

l. Immunization Route

Intramuscular injection (i.m.)

m. Macaque Response

Vaccine Immune Response Type: VO_0003057
Efficacy: one of six immunized animals was completely protected whereas all six naïve animals were infected. These results demonstrate that a vaccine based on priming with a polyvalent DNA vaccine from multiple HIV-1 subtypes followed by boosting with homologous Env proteins elicits anti-HIV-1 immune responses capable of controlling rectal transmission of SHIV(Ba-L) (Pal et al., 2005).

38. V3 VLPs with Gamma inulin adjuvant

a. Vaccine Ontology ID:

VO_0004232

b. Type:

Subunit vaccine

c. Status:

Research

d. Antigen

gp120 V3 loop (Harris et al., 1996).

e. Adjuvant:

VO ID: VO_0001292

f. Immunization Route

Intramuscular injection (i.m.)

g. Mouse Response

Host Strain: BABL/c
Vaccination Protocol: Mice were immunized with 10 μg of V3-VLPs without adjuvant in the muscle of the left leg. At the same time, the mice were immunized in the right leg with the other immunogens (Harris et al., 1996).
Immune Response: Mice immunized with V3 VLPs adjuvanted with gamma inulin showed good CTL responses (Harris et al., 1996).

39. YF17D- HIV-1 p24

a. Vaccine Ontology ID:

VO_0004690

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Mouse

e. Preparation

HIV-1 p24 (clade B consensus), was inserted near the 5' end of YF17D, in frame and upstream of the polyprotein (YF-5'/p24) (Franco et al., 2010).

f. Immunization Route

Intramuscular injection (i.m.)

g. Mouse Response

Vaccination Protocol: Mice were immunized two times subcutaneously at the base of the tail with PBS or 10^6 pfu of YF17D, YF-E/p24/NS1, or YF-5′/p24 in 100 μl on days 0 and 14 (Franco et al., 2010).
Vaccine Immune Response Type: VO_0003057
Challenge Protocol: Three weeks after the second immunization, half of the mice in each group were challenged intranasally with 5 × 10^5 pfu of Gag-expressing recombinant vaccinia virus (Vac-gag). The remaining animals in the groups were challenged intranasally with the same dose of wild-type vaccinia virus (Vac-wt) (Franco et al., 2010).
Efficacy: The protective efficacy of the YF17D recombinants, particularly YF-E/p24/NS1, in mice challenged with a vaccinia expressing HIV-1 Gag was demonstrated (Franco et al., 2010).

V. References

1. Aggarwal et al., 2005: Aggarwal P, Kumar S, Vajpayee M, Seth P. Adjuvant action of murine IL-2/Ig plasmid after intramuscular immunization with Indian HIV-1 subtype C recombinant env.gp 120 construct. Viral immunology. 2005; 18(4); 649-656. [PubMed: 16359231].

2. Ami et al., 2005: Ami Y, Izumi Y, Matsuo K, Someya K, Kanekiyo M, Horibata S, Yoshino N, Sakai K, Shinohara K, Matsumoto S, Yamada T, Yamazaki S, Yamamoto N, Honda M. Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. Journal of virology. 2005; 79(20); 12871-12879. [PubMed: 16188989].

3. Ara et al., 2001: Ara Y, Saito T, Takagi T, Hagiwara E, Miyagi Y, Sugiyama M, Kawamoto S, Ishii N, Yoshida T, Hanashi D, Koshino T, Okada H, Okuda K. Zymosan enhances the immune response to DNA vaccine for human immunodeficiency virus type-1 through the activation of complement system. Immunology. 2001; 103(1); 98-9105. [PubMed: 11380697].

4. Ayyavoo et al., 2002: Ayyavoo V, Muthumani K, Kudchodkar S, Zhang D, Ramanathan P, Dayes NS, Kim JJ, Sin JI, Montaner LJ, Weiner DB. HIV-1 viral protein R compromises cellular immune function in vivo. International immunology. 2002 Jan; 14(1); 13-22. [PubMed: 11751747].

5. Bagley et al., 2003: Bagley KC, Shata MT, Onyabe DY, DeVico AL, Fouts TR, Lewis GK, Hone DM. Immunogenicity of DNA vaccines that direct the coincident expression of the 120 kDa glycoprotein of human immunodeficiency virus and the catalytic domain of cholera toxin. Vaccine. 2003; 21(23); 3335-3341. [PubMed: 12804865].

6. Barouch et al., 2012: Barouch DH, Klasse PJ, Dufour J, Veazey RS, Moore JP. Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(22); 8694-8698. [PubMed: 22586094].

7. Barrett et al., 1989: Barrett N, Mitterer A, Mundt W, Eibl J, Eibl M, Gallo RC, Moss B, Dorner F. Large-scale production and purification of a vaccinia recombinant-derived HIV-1 gp160 and analysis of its immunogenicity. AIDS research and human retroviruses. 1989; 5(2); 159-171. [PubMed: 2713166].

8. Benson et al., 1998: Benson J, Chougnet C, Robert-Guroff M, Montefiori D, Markham P, Shearer G, Gallo RC, Cranage M, Paoletti E, Limbach K, Venzon D, Tartaglia J, Franchini G. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. Journal of virology. 1998; 72(5); 4170-4182. [PubMed: 9557706].

9. Bielinska et al., 2008: Bielinska AU, Janczak KW, Landers JJ, Markovitz DM, Montefiori DC, Baker JR Jr. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS research and human retroviruses. 2008; 24(2); 271-281. [PubMed: 18260780].

10. Bomford et al., 1992: Bomford R, Stapleton M, Winsor S, McKnight A, Andronova T. The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants. AIDS research and human retroviruses. 1992; 8(10); 1765-1771. [PubMed: 1457190].

11. Bower et al., 2004: Bower JF, Yang X, Sodroski J, Ross TM. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. Journal of virology. 2004; 78(9); 4710-4719. [PubMed: 15078953].

12. Boyer et al., 1997: Boyer JD, Ugen KE, Wang B, Agadjanyan M, Gilbert L, Bagarazzi ML, Chattergoon M, Frost P, Javadian A, Williams WV, Refaeli Y, Ciccarelli RB, McCallus D, Coney L, Weiner DB. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nature medicine. 1997; 3(5); 526-532. [PubMed: 9142121].

13. Bråve et al., 2007: Bråve A, Hinkula J, Cafaro A, Eriksson LE, Srivastava IK, Magnani M, Ensoli B, Barnett SW, Wahren B, Rollman E. Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge. Vaccine. 2007; 25(39-40); 6882-6890. [PubMed: 17707956].

14. BrÃ¥ve et al., 2005: BrÃ¥ve A, Ljungberg K, Boberg A, Rollman E, Isaguliants M, Lundgren B, Blomberg P, Hinkula J, Wahren B. Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Molecular therapy : the journal of the American Society of Gene Therapy. 2005; 12(6); 1197-1205. [PubMed: 16112909].

15. Breton et al., 2007: Breton M, Zhao C, Ouellette M, Tremblay MJ, Papadopoulou B. A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection. The Journal of general virology. 2007; 88(Pt 1); 217-225. [PubMed: 17170454].

16. Buchbinder et al., 1994: Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD. Long-term HIV-1 infection without immunologic progression. AIDS (London, England). 1994 Aug; 8(8); 1123-8. [PubMed: 7986410].

17. Calarota et al., 1998: Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson AC, SandstrÃ¶m E, Wahren B. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet. 1998; 351(9112); 1320-1325. [PubMed: 9643795].

18. Calarota et al., 2008: Calarota SA, Dai A, Trocio JN, Weiner DB, Lori F, Lisziewicz J. IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine. Vaccine. 2008; 26(40); 5188-5195. [PubMed: 18462844].

19. Caley et al., 1999: Caley IJ, Betts MR, Davis NL, Swanstrom R, Frelinger JA, Johnston RE. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy. Vaccine. 1999 Aug 6; 17(23-24); 3124-35. [PubMed: 10462249].

20. Caputo et al., 2003: Caputo A, Gavioli R, Altavilla G, Brocca-Cofano E, Boarini C, Betti M, Castaldello A, Lorenzini F, Micheletti F, Cafaro A, Sparnacci K, Laus M, Tondelli L, Ensoli B. Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat. Vaccine. 2003; 21(11-12); 1103-1111. [PubMed: 12559787].

21. Casimiro et al., 2003: Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, Tang A, Chen M, Huang L, Harris V, Freed DC, Wilson KA, Dubey S, Zhu DM, Nawrocki D, Mach H, Troutman R, Isopi L, Williams D, Hurni W, Xu Z, Smith JG, Wang S, Liu X, Guan L, Long R, Trigona W, Heidecker GJ, Perry HC, Persaud N, Toner TJ, Su Q, Liang X, Youil R, Chastain M, Bett AJ, Volkin DB, Emini EA, Shiver JW. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. Journal of virology. 2003; 77(11); 6305-6313. [PubMed: 12743287].

22. Chan et al., 1997: Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 1997 Apr 18; 89(2); 263-73. [PubMed: 9108481].

23. Chen et al., 2005: Chen X, Rock MT, Hammonds J, Tartaglia J, Shintani A, Currier J, Slike B, Crowe JE Jr, Marovich M, Spearman P. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses. Journal of virology. 2005 May; 79(9); 5537-47. [PubMed: 15827168].

24. Chin'ombe et al., 2009: Chin'ombe N, Bourn WR, Williamson AL, Shephard EG. Oral vaccination with a recombinant Salmonella vaccine vector provokes systemic HIV-1 subtype C Gag-specific CD4+ Th1 and Th2 cell immune responses in mice. Virology journal. 2009; 6; 87. [PubMed: 19555490].

25. Coakley et al., 2005: Coakley E, Petropoulos CJ, Whitcomb JM. Assessing chemokine co-receptor usage in HIV. Current opinion in infectious diseases. 2005 Feb; 18(1); 9-15. [PubMed: 15647694].

26. Coffin et al., 1986: Coffin J, Haase A, Levy JA, Montagnier L, Oroszlan S, Teich N, Temin H, Toyoshima K, Varmus H, Vogt P. What to call the AIDS virus?. Nature. 1986 May 1-7; 321(6065); 10. [PubMed: 3010128].

27. Cristillo et al., 2011: Cristillo AD, Ferrari MG, Hudacik L, Lewis B, Galmin L, Bowen B, Thompson D, Petrovsky N, Markham P, Pal R. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. The Journal of general virology. 2011; 92(Pt 1); 128-140. [PubMed: 21169215].

28. Dale et al., 2004: Dale CJ, De Rose R, Stratov I, Chea S, Montefiori DC, Thomson S, Ramshaw IA, Coupar BE, Boyle DB, Law M, Kent SJ. Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. Journal of virology. 2004; 78(24); 13819-13828. [PubMed: 15564490].

29. Davis et al., 2002: Davis NL, West A, Reap E, MacDonald G, Collier M, Dryga S, Maughan M, Connell M, Walker C, McGrath K, Cecil C, Ping LH, Frelinger J, Olmsted R, Keith P, Swanstrom R, Williamson C, Johnson P, Montefiori D, Johnston RE. Alphavirus replicon particles as candidate HIV vaccines. IUBMB life. 2002 Apr-May; 53(4-5); 209-11. [PubMed: 12120997].

30. Deng et al., 1996: Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996 Jun 20; 381(6584); 661-6. [PubMed: 8649511].

31. Denis-Mize et al., 2000: Denis-Mize KS, Dupuis M, MacKichan ML, Singh M, Doe B, O'Hagan D, Ulmer JB, Donnelly JJ, McDonald DM, Ott G. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene therapy. 2000; 7(24); 2105-2112. [PubMed: 11223992].

32. Duerr et al., 2012: Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, Del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, Robertson MN. Extended Follow-up Confirms Early Vaccine-Enhanced Risk of HIV Acquisition and Demonstrates Waning Effect Over Time Among Participants in a Randomized Trial of Recombinant Adenovirus HIV Vaccine (Step Study). The Journal of infectious diseases. 2012; 206(2); 258-266. [PubMed: 22561365].

33. Durier et al., 2006: Durier C, Launay O, Meiffredy V, Saidi Y, Salmon D, Levy Y, Guillet JG, Pialoux G, Aboulker JP. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. AIDS (London, England). 2006 Apr 24; 20(7); 1039-49. [PubMed: 16603857].

34. Flatz et al., 2012: Flatz L, Cheng C, Wang L, Foulds KE, Ko SY, Kong WP, Roychoudhuri R, Shi W, Bao S, Todd JP, Asmal M, Shen L, Donaldson M, Schmidt SD, Gall JG, Pinschewer DD, Letvin NL, Rao S, Mascola JR, Roederer M, Nabel GJ. Gene-Based Vaccination with a Mismatched Envelope Protects against Simian Immunodeficiency Virus Infection in Nonhuman Primates. Journal of virology. 2012; 86(15); 7760-7770. [PubMed: 22593152].

35. Franco et al., 2010: Franco D, Li W, Qing F, Stoyanov CT, Moran T, Rice CM, Ho DD. Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development. Vaccine. 2010; 28(35); 5676-5685. [PubMed: 20600494].

36. Gu et al., 2010: Gu R, Shampang A, Nashar T, Patil M, Fuller DH, Ramsingh AI. Oral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses. PloS one. 2010; 5(9); . [PubMed: 20824074].

37. Gudmundsdotter et al., 2009: Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, Robb M, Cox J, Michael N, Marovich M, Biberfeld G, SandstrÃ¶m E, Wahren B. Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine. 2009; 27(33); 4468-4474. [PubMed: 19450644].

38. Hammer et al., 2009: Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men [http://www.clinicaltrials.gov/ct2/show/NCT00865566?term=Ad5+DNA&rank=3]

39. Hanke et al., 2002: Hanke T, McMichael AJ, Samuel RV, Powell LA, McLoughlin L, Crome SJ, Edlin A. Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Vaccine. 2002; 21(1-2); 108-114. [PubMed: 12443668].

40. Harris et al., 1996: Harris SJ, Woodrow SA, Gearing AJ, Adams SE, Kingsman AJ, Layton GT. The effects of adjuvants on CTL induction by V3:Ty-virus-like particles (V3-VLPs) in mice. Vaccine. 1996; 14(10); 971-976. [PubMed: 8873390].

41. Harro et al., 2009: Harro CD, Robertson MN, Lally MA, O'Neill LD, Edupuganti S, Goepfert PA, Mulligan MJ, Priddy FH, Dubey SA, Kierstead LS, Sun X, Casimiro DR, DiNubile MJ, Shiver JW, Leavitt RY, Mehrotra DV. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS research and human retroviruses. 2009; 25(1); 103-114. [PubMed: 19108693].

42. Hawkins et al., 2003: Hawkins WG, Trcka J, Segal N, Blachere NE, Gold JS, Moroi Y, Bowne WB, Lewis JJ, Wolchok JD, Houghton AN. The role of lipopolysaccharide in T-cell responses following DNA vaccination. Vaccine. 2003; 21(13-14); 1548-1553. [PubMed: 12615452].

43. Hejdeman et al., 2004: Hejdeman B, BostrÃ¶m AC, Matsuda R, Calarota S, Lenkei R, Fredriksson EL, SandstrÃ¶m E, Bratt G, Wahren B. DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy. AIDS research and human retroviruses. 2004; 20(8); 860-870. [PubMed: 15320990].

44. Hirao et al., 2008: Hirao LA, Wu L, Khan AS, Hokey DA, Yan J, Dai A, Betts MR, Draghia-Akli R, Weiner DB. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine. 2008; 26(25); 3112-3120. [PubMed: 18430495].

45. Johnson et al., 2012: Johnson MJ, Petrovas C, Yamamoto T, Lindsay RW, LorÃ© K, Gall JG, Gostick E, Lefebvre F, Cameron MJ, Price DA, Haddad E, Sekaly RP, Seder RA, Koup RA. Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity. Journal of immunology (Baltimore, Md. : 1950). 2012; 188(12); 6109-6118. [PubMed: 22586038].

46. Kaneko et al., 2000: Kaneko H, Bednarek I, Wierzbicki A, Kiszka I, Dmochowski M, Wasik TJ, Kaneko Y, Kozbor D. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology. 2000; 267(1); 8-16. [PubMed: 10648178].

47. Kang et al., 2003: Kang KK, Choi SM, Choi JH, Lee DS, Kim CY, Ahn BO, Kim BM, Kim WB. Safety evaluation of GX-12, a new HIV therapeutic vaccine: investigation of integration into the host genome and expression in the reproductive organs. Intervirology. 2003; 46(5); 270-276. [PubMed: 14555847].

48. Kent et al., 2007: Kent S, De Rose R, Rollman E. Drug evaluation: DNA/MVA prime-boost HIV vaccine. Current opinion in investigational drugs (London, England : 2000). 2007 Feb; 8(2); 159-67. [PubMed: 17328232].

49. Kim et al., 1998: Kim JJ, Trivedi NN, Nottingham LK, Morrison L, Tsai A, Hu Y, Mahalingam S, Dang K, Ahn L, Doyle NK, Wilson DM, Chattergoon MA, Chalian AA, Boyer JD, Agadjanyan MG, Weiner DB. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. European journal of immunology. 1998; 28(3); 1089-1103. [PubMed: 9541605].

50. Kim et al., 2000: Kim JJ, Yang JS, VanCott TC, Lee DJ, Manson KH, Wyand MS, Boyer JD, Ugen KE, Weiner DB. Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants. Journal of virology. 2000; 74(7); 3427-3429. [PubMed: 10708463].

51. Kim et al., 2001: Kim JJ, Yang JS, Manson KH, Weiner DB. Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvants. Vaccine. 2001; 19(17-19); 2496-2505. [PubMed: 11257383].

52. Knight et al., 1990: Knight SC, Macatonia SE, Patterson S. HIV I infection of dendritic cells. International reviews of immunology. 1990; 6(2-3); 163-75. [PubMed: 2152500].

53. Kutzler et al., 2005: Kutzler MA, Robinson TM, Chattergoon MA, Choo DK, Choo AY, Choe PY, Ramanathan MP, Parkinson R, Kudchodkar S, Tamura Y, Sidhu M, Roopchand V, Kim JJ, Pavlakis GN, Felber BK, Waldmann TA, Boyer JD, Weiner DB. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. Journal of immunology (Baltimore, Md. : 1950). 2005; 175(1); 112-123. [PubMed: 15972637].

54. Kwa et al., 2014: Kwa S, Lai L, Gangadhara S, Siddiqui M, Pillai VB, Labranche C, Yu T, Moss B, Montefiori DC, Robinson HL, Kozlowski PA, Amara RR. CD40L-adjuvanted DNA/MVA SIV239 vaccine enhances SIV-specific humoral and cellular immunity, and improves protection against a heterologous SIVE660 mucosal challenge. Journal of virology. 2014; ; . [PubMed: 24920805].

55. Leclerc et al., 1997: Leclerc C, DÃ©riaud E, Rojas M, Whalen RG. The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Cellular immunology. 1997; 179(2); 97-9106. [PubMed: 9268493].

56. Lekutis et al., 1997: Lekutis C, Shiver JW, Liu MA, Letvin NL. HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFN-gamma and TNF-alpha. Journal of immunology (Baltimore, Md. : 1950). 1997; 158(9); 4471-4477. [PubMed: 9127013].

57. Lena et al., 2002: Lena P, Villinger F, Giavedoni L, Miller CJ, Rhodes G, Luciw P. Co-immunization of rhesus macaques with plasmid vectors expressing IFN-gamma, GM-CSF, and SIV antigens enhances anti-viral humoral immunity but does not affect viremia after challenge with highly pathogenic virus. Vaccine. 2002; 20 Suppl 4; A69-79. [PubMed: 12477432].

58. Li et al., 2008: Li W, Li S, Hu Y, Tang B, Cui L, He W. Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting. Vaccine. 2008; 26(26); 3282-3290. [PubMed: 18472194].

59. Liu et al., 2004: Liu YZ, Zhou L, Wang Q, Ye SQ, Li HX, Zeng Y. [Immune response induced by HIV DNA vaccine combined with recombinant adeno-associated virus]. Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology. 2004 Sep; 18(3); 251-4. [PubMed: 15640860].

60. Liu et al., 2006: Liu J, Wyatt LS, Amara RR, Moss B, Robinson HL. Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine. Vaccine. 2006 Apr 12; 24(16); 3332-9. [PubMed: 16472543].

61. Locher et al., 2004: Locher CP, Witt SA, Ashlock BM, Polacino P, Hu SL, Shiboski S, Schmidt AM, Agy MB, Anderson DM, Staprans SI, zur Megede J, Levy JA. Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection. Vaccine. 2004; 22(17-18); 2261-2272. [PubMed: 15149785].

62. Lu et al., 2000: Lu Y, Friedman R, Kushner N, Doling A, Thomas L, Touzjian N, Starnbach M, Lieberman J. Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity. Proceedings of the National Academy of Sciences of the United States of America. 2000 Jul 5; 97(14); 8027-32. [PubMed: 10884430].

63. MacGregor et al., 1998: MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, Coney LR, Ginsberg RS, Weiner DB. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. The Journal of infectious diseases. 1998; 178(1); 92-9100. [PubMed: 9652427].

64. MacGregor et al., 2005: MacGregor RR, Boyer JD, Ugen KE, Tebas P, Higgins TJ, Baine Y, Ciccarelli RB, Ginsberg RS, Weiner DB. Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips". Vaccine. 2005; 23(17-18); 2066-2073. [PubMed: 15755572].

65. Malm et al., 2005: Malm M, Rollman E, Ustav M, Hinkula J, Krohn K, Wahren B, Blazevic V. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH. Viral immunology. 2005; 18(4); 678-88. [PubMed: 16359234].

66. Mascola et al., 2005: Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, Vancott TC, Huang Y, Chakrabarti BK, Kong WP, Yang ZY, Xu L, Montefiori DC, Nabel GJ, Letvin NL. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. Journal of virology. 2005; 79(2); 771-779. [PubMed: 15613305].

67. McElrath et al., 2008: McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008; 372(9653); 1894-1905. [PubMed: 19012957].

68. McEvers et al., 2005: McEvers K, Elrefaei M, Norris P, Deeks S, Martin J, Lu Y, Cao H. Modified anthrax fusion proteins deliver HIV antigens through MHC Class I and II pathways. Vaccine. 2005 Jul 14; 23(32); 4128-35. [PubMed: 15964481].

69. Moore et al., 2002: Moore AC, Kong WP, Chakrabarti BK, Nabel GJ. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. Journal of virology. 2002; 76(1); 243-250. [PubMed: 11739689].

70. O'Hagan et al., 2001: O'Hagan D, Singh M, Ugozzoli M, Wild C, Barnett S, Chen M, Schaefer M, Doe B, Otten GR, Ulmer JB. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. Journal of virology. 2001; 75(19); 9037-9043. [PubMed: 11533167].

71. Otero et al., 2004: Otero M, Calarota SA, Felber B, Laddy D, Pavlakis G, Boyer JD, Weiner DB. Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine. 2004; 22(13-14); 1782-1790. [PubMed: 15068862].

72. Otten et al., 2005: Otten GR, Schaefer M, Doe B, Liu H, Srivastava I, Megede J, Kazzaz J, Lian Y, Singh M, Ugozzoli M, Montefiori D, Lewis M, Driver DA, Dubensky T, Polo JM, Donnelly J, O'Hagan DT, Barnett S, Ulmer JB. Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. Journal of virology. 2005 Jul; 79(13); 8189-200. [PubMed: 15956564].

73. Ozpolat et al., 1998: Ozpolat B, Rao XM, Powell MF, Lachman LB. Immunoliposomes containing antibodies to costimulatory molecules as adjuvants for HIV subunit vaccines. AIDS research and human retroviruses. 1998; 14(5); 409-417. [PubMed: 9546800].

74. Pal et al., 2005: Pal R, Wang S, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, Hudacik L, Rose N, Cristillo A, Mboudjeka I, Shen S, Wu-Chou TH, Montefiori D, Mascola J, Lu S, Markham P. Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. Journal of medical primatology. 2005; 34(5-6); 226-236. [PubMed: 16128917].

75. Pal et al., 2006: Pal R, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, Hudacik L, Rose N, Mboudjeka I, Shen S, Wu-Chou TH, Montefiori D, Mascola J, Markham P, Lu S. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology. 2006; 348(2); 341-353. [PubMed: 16460776].

76. Palella et al., 1998: Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. The New England journal of medicine. 1998 Mar 26; 338(13); 853-60. [PubMed: 9516219].

77. Parker, 2007: Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults [http://clinicaltrials.gov/ct2/show/NCT00528489]

78. Patterson et al., 2000: Patterson LJ, Peng B, Abimiku AG, Aldrich K, Murty L, Markham PD, Kalyanaraman VS, Alvord WG, Tartaglia J, Franchini G, Robert-Guroff M. Cross-protection in NYVAC-HIV-1-immunized/HIV-2-challenged but not in NYVAC-HIV-2-immunized/SHIV-challenged rhesus macaques. AIDS (London, England). 2000; 14(16); 2445-2455. [PubMed: 11101054].

79. Pegu et al., 2013: Pegu P, Vaccari M, Gordon S, Keele BF, Doster M, Guan Y, Ferrari G, Pal R, Ferrari MG, Whitney S, Hudacik L, Billings E, Rao M, Montefiori D, Tomaras G, Alam SM, Fenizia C, Lifson JD, Stablein D, Tartaglia J, Michael N, Kim J, Venzon D, Franchini G. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. Journal of virology. 2013; 87(3); 1708-1719. [PubMed: 23175374].

80. Peters et al., 2007: Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, Schmidt C, Gilmour J, Bogoshi M, Omosa-Manyonyi G, Dally L, Klavinskis L, Farah B, Tarragona T, Bart PA, Robinson A, Pieterse C, Stevens W, Thomas R, Barin B, McMichael AJ, McIntyre JA, Pantaleo G, Hanke T, Bwayo J. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine. 2007; 25(11); 2120-2127. [PubMed: 17250931].

81. Qiu et al., 1999: Qiu JT, Song R, Dettenhofer M, Tian C, August T, Felber BK, Pavlakis GN, Yu XF. Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses. Journal of virology. 1999; 73(11); 9145-9152. [PubMed: 10516021].

82. Rerks-Ngarm et al., 2009: Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. The New England journal of medicine. 2009; 361(23); 2209-2220. [PubMed: 19843557].

83. Reynolds et al., 2012: Reynolds MR, Weiler AM, Piaskowski SM, Piatak M Jr, Robertson HT, Allison DB, Bett AJ, Casimiro DR, Shiver JW, Wilson NA, Lifson JD, Koff WC, Watkins DI. A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. Vaccine. 2012; 30(30); 4465-4475. [PubMed: 22569124].

84. Robinson et al., 2006: Robinson HL, Montefiori DC, Villinger F, Robinson JE, Sharma S, Wyatt LS, Earl PL, McClure HM, Moss B, Amara RR. Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. Virology. 2006; 352(2); 285-294. [PubMed: 16740288].

85. Santra et al., 2004: Santra S, Barouch DH, Korioth-Schmitz B, Lord CI, Krivulka GR, Yu F, Beddall MH, Gorgone DA, Lifton MA, Miura A, Philippon V, Manson K, Markham PD, Parrish J, Kuroda MJ, Schmitz JE, Gelman RS, Shiver JW, Montefiori DC, Panicali D, Letvin NL. Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proceedings of the National Academy of Sciences of the United States of America. 2004 Jul 27; 101(30); 11088-93. [PubMed: 15258286].

86. Sheets et al., 2006: Sheets RL, Stein J, Manetz TS, Duffy C, Nason M, Andrews C, Kong WP, Nabel GJ, Gomez PL. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicological sciences : an official journal of the Society of Toxicology. 2006; 91(2); 610-619. [PubMed: 16569729].

87. Shiver et al., 2002: Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002 Jan 17; 415(6869); 331-5. [PubMed: 11797011].

88. Sizemore et al., 1995: Sizemore DR, Branstrom AA, Sadoff JC. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science (New York, N.Y.). 1995; 270(5234); 299-302. [PubMed: 7569980].

89. Song et al., 2006: Song R, Liu S, Adams RJ, Leong KW. Enhancing efficacy of HIV gag DNA vaccine by local delivery of GM-CSF in murine and macaque models. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research. 2006; 26(6); 380-389. [PubMed: 16734558].

90. Stieneker et al., 1991: Stieneker F, Kreuter J, Löwer J. High antibody titres in mice with polymethylmethacrylate nanoparticles as adjuvant for HIV vaccines. AIDS (London, England). 1991; 5(4); 431-435. [PubMed: 2059385].

91. Sun et al., 2013: Sun C, Chen Z, Tang X, Zhang Y, Feng L, Du Y, Xiao L, Liu L, Zhu W, Chen L, Zhang L. Mucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys. Journal of virology. 2013; 87(10); 5669-5677. [PubMed: 23487457].

92. Takehisa et al., 2001: Takehisa J, Harada Y, Ndembi N, Mboudjeka I, Taniguchi Y, Ngansop C, Kuate S, Zekeng L, Ibuki K, Shimada T, Bikandou B, Yamaguchi-Kabata Y, Miura T, Ikeda M, Ichimura H, Kaptue L, Hayami M. Natural infection of wild-born mandrills (Mandrillus sphinx) with two different types of simian immunodeficiency virus. AIDS research and human retroviruses. 2001 Aug 10; 17(12); 1143-54. [PubMed: 11522184].

93. Tatalick et al., 2005: Tatalick LM, Gerard CJ, Takeya R, Price DN, Thorne BA, Wyatt LM, Anklesaria P. Safety characterization of HeLa-based cell substrates used in the manufacture of a recombinant adeno-associated virus-HIV vaccine. Vaccine. 2005 Apr 8; 23(20); 2628-38. [PubMed: 15780446].

94. Vecino et al., 2002: Vecino WH, Morin PM, Agha R, Jacobs WR Jr, Fennelly GJ. Mucosal DNA vaccination with highly attenuated Shigella is superior to attenuated Salmonella and comparable to intramuscular DNA vaccination for T cells against HIV. Immunology letters. 2002; 82(3); 197-204. [PubMed: 12036602].

95. Vinner et al., 1999: Vinner L, Nielsen HV, Bryder K, Corbet S, Nielsen C, Fomsgaard A. Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons. Vaccine. 1999; 17(17); 2166-2175. [PubMed: 10367950].

96. Walther-Jallow et al., 2001: Walther-Jallow L, Nilsson C, Söderlund J, ten Haaft P, Mäkitalo B, Biberfeld P, Böttiger P, Heeney J, Biberfeld G, Thorstensson R. Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys. The Journal of general virology. 2001; 82(Pt 7); 1601-1612. [PubMed: 11413371].

97. Wang et al., 1993: Wang B, Ugen KE, Srikantan V, Agadjanyan MG, Dang K, Refaeli Y, Sato AI, Boyer J, Williams WV, Weiner DB. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90(9); 4156-4160. [PubMed: 8483929].

98. Wang et al., 1993: Wang B, Boyer J, Srikantan V, Coney L, Carrano R, Phan C, Merva M, Dang K, Agadjanan M, Gilbert L. DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates. DNA and cell biology. 1993; 12(9); 799-805. [PubMed: 8216851].

99. Wang et al., 2006: Wang S, Farfan-Arribas DJ, Shen S, Chou TH, Hirsch A, He F, Lu S. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine. 2006; 24(21); 4531-4540. [PubMed: 16140431].

100. Weber et al., 2001: Weber R, Bossart W, Cone R, Luethy R, Moelling K. Phase I clinical trial with HIV-1 gp160 plasmid vaccine in HIV-1-infected asymptomatic subjects. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2001; 20(11); 800-803. [PubMed: 11783696].

101. Xin et al., 2005: Xin KQ, Jounai N, Someya K, Honma K, Mizuguchi H, Naganawa S, Kitamura K, Hayakawa T, Saha S, Takeshita F, Okuda K, Honda M, Klinman DM, Okuda K. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene therapy. 2005 Dec; 12(24); 1769-77. [PubMed: 16079886].

102. Yoshino et al., 2004: Yoshino N, Lü FX, Fujihashi K, Hagiwara Y, Kataoka K, Lu D, Hirst L, Honda M, van Ginkel FW, Takeda Y, Miller CJ, Kiyono H, McGhee JR. A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates. Journal of immunology (Baltimore, Md. : 1950). 2004; 173(11); 6850-6857. [PubMed: 15557179].

103. Zhang et al., 2009: Zhang H, Hong H, Li D, Ma S, Di Y, Stoten A, Haig N, Di Gleria K, Yu Z, Xu XN, McMichael A, Jiang S. Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells. The Journal of biological chemistry. 2009; 284(14); 9184-9191. [PubMed: 19193636].